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The research conducted within this thesis investigated the application of adaptive 
designs within phase III cancer trials, in particular, the use of multi-arm multi-stage 
designs (MAMS) were investigated. The application of adaptive designs in phase III 
randomised controlled trials are becoming common. These designs have the ability 
to reduce the number of patients required, be efficient in reducing the time needed 
and effective in having the ability to answer many questions within one trial.  
A literature review found that adaptive designs were regularly implemented but the 
reporting of these methods were poor. I proposed there should be an adaptive 
design extension to the CONSORT 2010 guidelines and subsequently this has been 
published.  
A scoping exercise of cancer trials conducted within the Warwick Clinical Trials Unit 
found that adaptive methods were regularly implemented without classifying them 
as adaptive designs. This scoping exercise was extended to identify exemplar trials 
that have implemented adaptive design methodology and to understand the design, 
conduct and reporting of these trials.  
MAMS designs within three common cancer sites (breast, colon and lung) were 
investigated using a superiority hypothesis, primarily focusing on the longer term 
outcome of overall survival. Simulations were used to demonstrate how MAMS 
designs can be extended for use with a non-inferiority (NI) hypothesis. A MAMS 
design was then applied to a trial investigating the optimal duration of Herceptin 
therapy for patients diagnosed with early breast cancer. A MAMS design with a NI 
hypothesis appeared feasible from a statistical viewpoint however the operational 
aspects must be considered to ensure the trials’ success.  
My research showed that implementing a MAMS design within cancer trials can be 
more efficient and effective. It is anticipated that the use of adaptive designs within 
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Prior to introducing a new medical intervention, a sequence of processes must 
take place to ensure the safety and efficacy of these interventions. This is a vital 
process as these interventions can be beneficial as well as detrimental. A few 
examples of interventions could be new or existing drugs, surgical procedures, 
treatment of behaviour or preventive care (World Health Organisation 2019). The 
process of evaluating these new interventions is commonly through clinical trials. 
The World Health Organisation (WHO) has defined clinical trials to be, “Any 
research study that prospectively assigns human participants or groups of humans 
to one or more health related interventions to evaluate the effects on health 
outcomes.” (World Health Organisation 2019). The most commonly accepted 
method of treatment evaluation that results in a change to clinical practice are 
known as a randomised controlled trial (RCT) and comes under the umbrella of 
phase III clinical trials (Akobeng 2005). The use of random allocation within phase 
III RCTs ensures that selection bias is reduced when assigning patients to 
treatment groups. Furthermore, the use of stratification ensures that treatment 
groups are equally divided between prognostic groups (Sacks et al. 1982).   
The first RCT recorded by the Medical Research Council (MRC) in the UK was 
performed in 1950 comparing the use of streptomycin in treating tuberculosis 
(Long et al. 1950). The first recorded RCT in the field of Oncology began in 1955 in 
the US and compared two chemotherapy regimens in patients diagnosed with 
acute leukaemia (Frei et al. 1958). Since then, phase III RCTs within the field of 
Oncology have continued to develop and have proved effective in evaluating 
treatments (Gehan 1979, Booth et al. 2008). However, clinical research continues 
to explore and evaluate new treatments and methods that will help to prevent, 
diagnose or treat cancer (Comprehensive Cancer Centers 2017). The research 
conducted within this thesis will primarily focus on statistical methods and trials 
related to the therapeutic area of cancer.  
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 Bayesian and frequentist philosophies 
The application of statistics in clinical trials can be categorised under two principle 
philosophies; Bayesian or frequentist (Berry et al. 2010). Some of the key 
differences between these methods are: 
1. The probability of parameters: The Bayesian approach believes that all 
unknowns have some form of a probability distribution compared to the 
frequentist approach where probabilities are defined based on data. 
Bayesian methods use prior and posterior distributions. Information 
parameterised before the data is collected is the prior distribution and 
information parameterised once data is observed is the posterior 
distribution.     
2. Available evidence: Frequentist methods are explicit to particular 
experiments compared to Bayesian methods which utilise all available 
information related to the parameters of interest.  
3. Conditioning on the observed: Bayesian methods focus only on observed 
results compared to frequentist methods that use probabilities of data to 
predict possibilities that may have not been directly observed.  
4. Strictness: Frequentist approach have more stricter criteria to complete an 
experiment in comparison to Bayesian methods (Berry et al. 2010). For 
example, before starting a trial, the frequentist approach requires a sample 
size compared to a Bayesian approach where sample size may not be 
required at the beginning. 
5. Randomisation: The role of randomisation is of utmost importance in 
phase III trials. Randomisation reduces selection bias and allows the 
balancing of pre-specified covariates. The Bayesian approach does not 
depend on randomisation and can use subjective probability compared to 
the frequentist approach where randomisation offers inference on clinical 
trial results (Berchialla et al. 2019). 
The key differences between these philosophies have been highlighted here as 
Bayesian methods are used in adaptive trials, particularly in early phase trials, but 
the focus of this thesis is on phase III clinical trials, where more frequentist 
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methods are applied. Therefore, the review of adaptive design methods in chapter 
two will focus on the frequentist approaches but will highlight some of the 
Bayesian adaptive methods for completeness.   
 Survival Analysis 
The term ‘Survival Analysis’ can be defined as the analysis of data in the form of 
different timepoints where there is a defined starting point measured up until the 
incidence of a certain event (Collett 2015). The rate of survival at different 
timepoints can be shown either through life-tables or more graphically through a 
survival curve. The limitations of these methods are that the survival time cannot 
be measured until an event has occurred therefore the output can only be 
produced once all patients have had an event. Hence, the concept of censoring, 
allows the use of partial information so patients can be censored either during the 
trial because they may have withdrawn or were lost to follow up or at the end of 
the trial.  
In the context of a RCT of a control versus a new treatment with a time-to-event 
(TTE) endpoint, Kaplan-Meier curves can be estimated and compared using a log-
rank test to test whether there is a difference between two survival curves and 
are useful only when the predictor is categorical variable, i.e. treatment A vs 
treatment B. The Cox proportional hazards model can incorporate categorical as 
well as continuous variables and can include more than one predictor variable. The 
hazard ratio (HR) can be used to measure the frequency of an event in one 
treatment arm compared to another. A HR greater than (or less than) one would 
indicate that survival was better (or worse) in one of the treatment arms. A HR 
equal to one would indicate that there is no difference between the arms.  
1.3.1 HR calculation 
In survival analysis, the hazard rate is the probability of an event occurring at time 
𝑡𝑡 given that it survives until time 𝑡𝑡 or later. Therefore, the HR is the ratio of the 
hazard rates for the experimental treatment against a control. The HR can be 
obtained using a TTE survival rate at time 𝑡𝑡 for the control and the experimental 
TTE survival rate by the following formula:  
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log (𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑡𝑡𝐸𝐸𝐸𝐸 𝑇𝑇𝑇𝑇𝐸𝐸 𝑠𝑠𝑠𝑠𝐸𝐸𝑠𝑠𝐸𝐸𝑠𝑠𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸𝑡𝑡𝐸𝐸 𝐸𝐸𝑡𝑡 𝑡𝑡𝐸𝐸𝐸𝐸𝐸𝐸 𝑡𝑡)
log (𝐶𝐶𝐶𝐶𝐸𝐸𝑡𝑡𝐸𝐸𝐶𝐶𝐸𝐸 𝑇𝑇𝑇𝑇𝐸𝐸 𝑠𝑠𝑠𝑠𝐸𝐸𝑠𝑠𝐸𝐸𝑠𝑠𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸𝑡𝑡𝐸𝐸 𝐸𝐸𝑡𝑡 𝑡𝑡𝐸𝐸𝐸𝐸𝐸𝐸 𝑡𝑡)
= 𝐻𝐻𝐸𝐸𝐻𝐻𝐸𝐸𝐸𝐸𝐻𝐻 𝐸𝐸𝐸𝐸𝑡𝑡𝐸𝐸𝐶𝐶 
For sample size calculations, the hypothesised HR can be calculated using the TTE 
survival rate at time 𝑡𝑡 for the control and the experimental TTE survival rate 
determined based on the absolute difference wanting to detect. For example, to 
demonstrate an improvement in treatment (superiority) of at least 7.5% from the 
control arm with a five-year survival rate of 85% for breast cancer, the HR is 




Similarly, the following formula can be used when only the median of the TTE 
outcomes are available: 
𝐶𝐶𝐶𝐶𝐸𝐸𝑡𝑡𝐸𝐸𝐶𝐶𝐸𝐸 𝐸𝐸𝐸𝐸𝐻𝐻𝐸𝐸𝐸𝐸𝐸𝐸 𝑇𝑇𝑇𝑇𝐸𝐸 𝐶𝐶𝑠𝑠𝑡𝑡𝑜𝑜𝐶𝐶𝐸𝐸𝐸𝐸
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑡𝑡𝐸𝐸𝐸𝐸 𝐸𝐸𝐸𝐸𝐻𝐻𝐸𝐸𝐸𝐸𝐸𝐸 𝑇𝑇𝑇𝑇𝐸𝐸
= 𝐻𝐻𝐸𝐸𝐻𝐻𝐸𝐸𝐸𝐸𝐻𝐻 𝐸𝐸𝐸𝐸𝑡𝑡𝐸𝐸𝐶𝐶 
For example, to demonstrate that an absolute improvement in median OS for the 
experimental arm of at least 30% from a median OS on the control arm of 21.6 




Therefore, a HR of 0.769 is the same as saying that there will be approximately 
23% relative reduction in events in the experimental arm.  
1.3.2 Parametric models  
Parametric models are often used to simulate and analyse survival data (Machin 
2006). The more popular distributions that are used are the exponential, Weibull 
and gamma distributions.  
The exponential distribution can be used when the hazard rate is constant in a 
treatment group and is of the form, 𝑆𝑆(𝑡𝑡) = 𝐸𝐸𝐸𝐸𝐸𝐸−𝜆𝜆𝜆𝜆, where 𝑆𝑆(𝑡𝑡) is the survival 
function at time 𝑡𝑡 and 𝜆𝜆 is the constant hazard. The shape of this distribution for 




Figure 1.1: Exponential distribution when λ = 0.1, λ = 0.2 and λ = 0.3.  
The Weibull distribution is used when either the hazard rate is constant or 
increasing. The Weibull distribution is a modification of the Exponential 
distribution and of the form 𝑆𝑆(𝑡𝑡) = exp[−(𝜆𝜆𝑡𝑡)𝑘𝑘], where the shape of this 
distribution is dependent on the constant k.  An illustration of this distribution for 
λ = 0.1 and different values of k can be seen in Figure 1.2.  
 
Figure 1.2: Weibull distributions when λ = 0.1 and k = 0.5, k = 1 and k = 5. 
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Similarly, the gamma distribution is a special case of the exponential distribution 
(Cox et al. 2007). The survival function is of the form 𝑆𝑆(𝑡𝑡) = 1 − 𝐼𝐼𝑘𝑘(𝜆𝜆𝑡𝑡), where 
𝐼𝐼𝑘𝑘(𝜆𝜆𝑡𝑡) is an incomplete gamma integral (Kiche et al. 2019). An example of the 
gamma distribution with different values for the constant k can be seen in Figure 
1.3. 
 
Figure 1.3: Gamma distribution when λ = 0.1 and k = 0.5, k = 0.75 and k = 2. 
Further information on other popular distributions that could be used for 
analysing survival data such as the log-normal or log-logistic distributions can be 
found in the book ‘Survival Analysis: A practical approach’ by Machin et al (Machin 
2006).  
1.3.3 Time-to-event outcomes within cancer 
Survival analysis methods are frequently used in the context of cancer trials due 
to many outcomes being the time to an event of interest. There are many types of 
‘time-to-event’ outcomes within cancer which are of special interest and can be 
used to assess the impact of a treatment (US Food and Drug Administration 2007). 
Few of these common events of interest are defined and discussed below (Hudis 
et al. 2007): 
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- Overall survival (OS) - defined as the time from randomisation till death 
due to any cause. Patients are censored at the date last known to be alive. 
Considered one of the easiest endpoints to assess however can extend the 
duration of a trial due to the potential length of follow-up required.  
- Disease-free survival (DFS) – defined as the time from randomisation till 
disease recurrence or death due to any cause. DFS is considered a 
surrogate endpoint especially where death could be a prolonged and 
unrealistic endpoint. Furthermore, using DFS can accelerate the time it can 
take for a potential new drug or regimen to be approved. This is also known 
as relapse-free survival (RFS) or recurrence-free survival (RecFS). 
- Progression-free survival (PFS) – defined as the time from randomisation 
till tumour progression, which can be clearly outlined in the trial protocol 
as this varies from trial to trial, or death. The definition of PFS has an 
outcome of death and hence can be considered a surrogate endpoint for 
OS.  
- Failure-free survival (FFS) - defined as the time from when primary 
treatment for the cancer ceases till the time a patient experiences specified 
events, also known as event-free survival.  
- Metastasis-free survival (MFS) – defined as the time from when primary 
treatment of cancer ceases till the cancer spreads to other parts of the 




1.3.4 Example – survival curves showing DFS 
Figure 1.4 displays survival curves showing DFS (previously defined in section 
1.3.3) for breast cancer patients that received Herceptin (trastuzumab) for one-
year compared against observation only. Patients that received Herceptin for one 
year had a two-year DFS rate of 85.8%, patients on observation only had a two-
year DFS rate of 77.4%. The HR for a risk of an event in the one-year Herceptin 
group compared to the observation group was 0.54 (95% CI: 0.43 to 0.67); this can 
be interpreted as just under half as many patients in the one-year Herceptin group 
would experience an event compared to the observation arm. A p-value < 0.0001 
obtained from comparing the trial arms by the log-rank test shows there is a 
statistically significant difference between the two treatment arms.  
 
Figure 1.4: Survival curves showing DFS, breast cancer patients that received one year 
Herceptin compared against patients on observation only. Example taken from HERA 
trial  (Piccart-Gebhart et al. 2005) . Hazard ratio with 95% CI and p-value shown. DFS – 
Disease free survival, CI – Confidence Interval. 
 
 Hypothesis testing options 
The choice of hypothesis to implement within phase III trials is dependent on the 
objective of the study. It could be to demonstrate that a new treatment is better 
compared to the current standard treatment or a placebo, which is classified as a 
superiority hypothesis. Alternatively, the objective of a study could be to 
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determine if a new treatment is the same (equivalent) or no worse (non-
inferiority) to a current standard treatment. Each of these hypotheses vary in 
terms of their design, analysis and interpretation; the hypotheses associated with 
each trial design are shown in Table 1.1.  
Hypothesis testing 
options Null Hypotheses Alternative Hypotheses 
Superiority No difference between treatments Difference between treatments 
Equivalence Treatments are not equivalent Treatments are equivalent 
Non-Inferiority New treatment is inferior to current treatment 
New treatment is not inferior to 
current treatment 
Table 1.1: The null and alternative hypotheses for the different hypothesis testing 
options (Walker et al. 2011). 
1.4.1 Superiority hypothesis 
A two-sided superiority hypothesis to compare two treatments in a phase III 
cancer trial can be defined as follows: 
𝐻𝐻0: 𝛿𝛿 = 1 
𝐻𝐻1: 𝛿𝛿 ≠ 1 
where 𝛿𝛿 can be defined as the HR. The null hypothesis, 𝐻𝐻0, specifies that there is 
no difference between treatments and the alternative hypothesis, 𝐻𝐻1, specifies 
that there is a difference without indicating which direction i.e. the experimental 
arm could be better or worse than the control arm. The one-sided superiority 
alternative hypothesis specifies the direction for the alternative hypothesis (Bland 
et al. 1994), such that the experimental treatment is hypothesised to be better 
than the control by an amount 𝛿𝛿1. Hence a one-sided superiority hypothesis with 
a critical HR, 𝛿𝛿1,  to compare two treatments in a phase III cancer trial can be 
defined as follows:  
𝐻𝐻0: 𝛿𝛿 ≥ 𝛿𝛿1 
𝐻𝐻1: 𝛿𝛿 < 𝛿𝛿1 
The null hypothesis indicates that the experimental arm is either the same or 
worse than the control arm. Comparatively, the alternative hypothesis indicates 
that the experimental arm is better than the control arm.  
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For this thesis, implementing a superiority hypothesis refers to a trial involving a 
one-sided significance level with a pre-specified absolute or relative margin, e.g. 
3% absolute difference. The first step in analysing a trial with a superiority 
hypothesis is to perform a statistical significance test (p-value), to assess the 
assumption that there is no difference between treatments (null hypothesis). In 
most cases, a p-value < 0.05 means that the data suggests that there is a difference 
between the two treatments (alternative hypothesis) hence rejecting the null 
hypothesis (Table 1.1). If the data suggests that there is a difference between 
treatments then it is important to measure the size of the difference and if it is 
clinically relevant (CPMP 2001). Thereafter, a confidence interval (CI) is generated 
(usually at the 95% CI), which gives a range of values for which the true value will 
most probably be within. For example, using a time-to-event outcome within a 
cancer setting, a new treatment is considered superior to the control treatment if 
the HR and its respective CI is below the pre-specified margin as shown in Figure 
1.5  (Dunn et al. 2018).   
The potential results obtained from a one-sided superiority trial with a pre-
specified margin can be seen in Figure 1.5 and are as follows: 
1. HR favours the new treatment however the lower bound of the CI is 
greater than the critical HR and the upper bound of the CI is less than one 
suggesting that superiority of the experimental arm is demonstrated but it 
is not conclusive (Superior, not clinically meaningful); 
2. HR favours the control treatment and the lower bound of the CI above one 
therefore suggesting that the new treatment is inferior to the control 
(Inferior, clinically meaningful); 
3. HR favours the new treatment and the upper bound of the CI is below the 
critical HR therefore it is conclusive that superiority of the experimental 
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arm above the specified margin is demonstrated (Superior, clinically 
meaningful); 
4. HR favours the new treatment however the lower bound of the CI is less 
than the critical HR and the upper bound of the CI is above one therefore 
neither superiority nor NI of the experimental arm are demonstrated 
(Inconclusive); 
5. HR favours the new treatment however the upper bound of the CI is less 
than one and greater than the critical HR which indicates that superiority 
of the experimental arm is demonstrated but it is not conclusive (Superior, 
not clinically meaningful).   
 
 
Figure 1.5: Potential results of using a superiority hypothesis comparing two drugs 
shown with HR and CI. HR = Hazard ratio; CI = Confidence interval. 
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1.4.2 Equivalence hypothesis 
An equivalence hypothesis aims to determine that one treatment is ‘similar’ to 
another; this can be defined as follows: 
𝐻𝐻0: 𝛿𝛿 ≥ 𝛿𝛿𝑈𝑈 𝐶𝐶𝐸𝐸 𝛿𝛿 ≤ 𝛿𝛿𝐿𝐿  
𝐻𝐻1: 𝛿𝛿𝐿𝐿 < 𝛿𝛿 < 𝛿𝛿𝑈𝑈 
where 𝛿𝛿𝑈𝑈 is defined as the upper critical HR and 𝛿𝛿𝐿𝐿 is defined as the lower critical 
HR.  
For this hypothesis testing option, the null hypothesis would be that treatments 
are not equivalent, and the alternative hypothesis would be that the new 
treatment is equivalent to the current treatment (Table 1.1). Therefore, a p-value 
< 0.05 would suggest that treatments are equivalent. To assess the size of the 
difference between the two treatment within this setting, an equivalence margin 
is defined. The two treatments are classed as equivalent if the CI of the new 
treatment lies within the pre-specified margins. For example, using a time-to-
event outcome within a cancer setting, a new treatment is considered equivalent 
to the control treatment if the HR and CI is between the two pre-specified margins 
(Figure 1.6). 
 The potential results obtained from using an equivalence hypothesis can be seen 
in Figure 1.6 and are as follows: 
1. HR favours the control treatment however the lower bound of the CI is 
greater than one and the upper bound of the CI is less than upper 
critical HR indicating that the new treatment is inferior to the control 
but is not conclusive as the HR and 95% CI are below the upper critical 




2. HR equals one indicating that there is an equal effect between the new 
and control treatment however the lower bound of the CI is below the 
lower critical HR and upper bound of the CI is above the upper critical 
HR resulting in an inconclusive trial (Equivalent, not clinically 
meaningful); 
3. HR and the lower bound of the CI is above one and within the upper 
critical HR. However, the upper bound of the CI is greater than the 
upper critical HR therefore suggesting that the new treatment is 
inferior to the control but this is not conclusive as the HR and 95% CI 
are not greater than the upper critical HR (Inferior, not clinically 
meaningful); 
4. HR favours the control treatment and the lower and upper bounds of 
the CI are between the lower and upper critical HR therefore 
equivalence is demonstrated (Equivalent, clinically meaningful); 
5. HR favours the new treatment however the lower bound of the CI is 
less than the lower critical HR and the upper bound of the CI is less than 
one therefore superiority is demonstrated but it is not conclusive as 
the HR and upper 95% CI are not less than the lower critical HR 
(Superior, not clinically meaningful); 
6. HR favours the new treatment and the upper bound of the CI is less 
than the lower critical HR therefore superiority is demonstrated 




Figure 1.6: Potential results of using an equivalence hypothesis comparing two drugs 
shown with HR and CI. HR = Hazard ratio; CI = Confidence interval. 
1.4.3 Non-inferiority hypothesis 
A phase III trial may assess another treatment that could be similar to the current 
standard treatment but less toxic or cost-effective hence a non-inferiority (NI) 
hypothesis may be implemented (Weiskopf et al. 2016, Saad 2018). The null 
hypothesis would be that the new treatment is inferior to the current treatment 
and the alternative hypothesis would be that the new treatment is not inferior to 
the current treatment (Table 1.1). Therefore, a p-value < 0.05 would suggests that 
NI has been demonstrated. A NI trial aims to show that a new treatment is no 
worse than the current standard by a certain amount also known as the NI margin. 
Therefore, NI can be demonstrated if the upper CI is within the pre-specified NI 
margin. Using a time-to-event outcome within a cancer setting, a new treatment 
demonstrates NI if the HR and the upper CI is below the critical HR.  
The use of NI hypothesis within phase III cancer trials has slowly increased over 
the years. The ClinicalTrials.gov website was used to search for all phase III cancer 
trials and from these trials how many implemented a NI hypothesis 
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(ClinicalTrials.gov 2020). The results found only 0.5% beyond 20 years ago (3/654), 
1.2% between 10 and 20 years ago (33/2840), 2.7% between 5 to 10 years ago 
(50/1839) and 2.7% in the past five years (67/2476) have implemented a NI 
hypothesis.  
The potential results obtained from a NI trial can be seen in Figure 1.7 and are as 
follows: 
1. HR favours the control treatment however the upper bound of the CI is 
greater than the critical HR hence suggesting that NI is not demonstrated 
(Not Inferior, not clinically meaningful); 
2. HR equals one indicating that there is an equal effect between the new and 
control treatment however the upper bound of the CI is greater than the 
critical HR suggesting that NI is not demonstrated (Equivalent, not 
clinically meaningful); 
3. HR favours the new treatment however the upper bound of the CI is 
greater than the critical HR suggesting that NI is not demonstrated 
(Superior, not clinically meaning);  
4. HR favours the control treatment and the upper bound of the CI is below 
the critical HR and the lower bound of the CI is greater one demonstrating 
NI but also suggesting that the new treatment is actual inferior to the 
control (Not Inferior and inferior, clinically meaningful);  
5. HR equals one indicating equal effect and the upper bound of the CI is 
below the critical HR therefore NI is demonstrated (Not inferior, clinically 
meaningful); 
6. HR favours the control treatment and the upper bound of the CI is below 
the critical HR but the lower bound of the CI is less than one suggesting 
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that the new treatment shows NI but is not conclusive (Not-inferior, 
clinically meaningful);  
7. HR favours the new treatment and the upper bound of the CI is above one 
but within the critical HR therefore NI is demonstrated but superiority is 
not demonstrated (Not inferior, clinically meaningful); 
8. HR favours the new treatment and the upper bound of the CI is less than 
one which indicates that both superiority and NI are demonstrated 
(Superior and not inferior, clinically meaningful);   
9. HR favours the control treatment but the upper bound of the CI above the 
critical HR and the lower bound of the CI is greater one suggesting that the 
new treatment is actual inferior to the control but cannot declare NI (Not 
inferior, not clinically meaningful).   
 
Figure 1.7: Potential results of a NI hypothesis comparing two drugs shown with HR and 
CI. HR = Hazard ratio; NI = Non-inferiority; CI = Confidence interval. 
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1.4.3.1 Why use a NI hypothesis? 
Due to the many toxicities of cancer therapy, testing treatments in phase III cancer 
trials with a NI design can result in improving the patient care with more 
convenient and acceptable regimens (Riechelmann et al. 2013). Applying a NI 
hypothesis offer trial stakeholders the opportunity to compare alternate 
treatments with potentially less toxicity or reduced durations of treatments 
against the current standardised treatments which can also appeal to patients. For 
example, a recent trial implemented a NI hypothesis to compare the use of 
intravenous (IV) treatment using Daratumumab in combination with standard 
regimens (control) against administering Daratumumab subcutaneously for 
patients diagnosed with multiple myeloma (Luo et al. 2019). Administering 
treatments subcutaneously instead of having IV treatment would benefit both 
patients and trialist as patients would be able to administer treatment within a 
significantly reduced time in the comfort of their own home hence reducing time 
spent in hospital. Thus, implementing these designs could offer benefits such as 
reduced toxicity, improved cost effectiveness and may be more appealing to 
patients. 
1.4.4 Selection of margin  
The selection of the margin is a critical step when designing trials (Cook et al. 
2018). The margin should be estimated based upon the performance of the 
control treatment in past trials, ideally within a placebo-controlled trial (US Food 
and Drug Administration 2016). It is then assumed that within the trial, the active 
control will have its expected effect; this is also known as assay sensitivity (US Food 
and Drug Administration 2016). Another way of interpreting assay sensitivity is 
that if the trial included a placebo then there would be a significant difference 
between the control treatment and placebo. Hence, a trial is said to be successful 
if there is an acceptable small difference between treatments however this may 
not have had assay sensitivity therefore not supporting the conclusion that the 
experimental treatment was effective.  
The selection of a margin based on a placebo-controlled trial may show statistical 
significance (robustness of study results) but may not be clinically significant 
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(impact on clinical practice). In the case of a superiority or NI hypothesis, another 
margin less than the original margins used in previous placebo-controlled trials 
may be defined as the largest difference between two treatments to be clinically 
acceptable and hence demonstrate superiority or NI respectively (US Food and 
Drug Administration 2016). Furthermore, the ICH E9 guidelines suggests that the 
NI margin should be smaller than the differences observed in superiority trials of 
the control group (European Medicines Agency 1998).  
In some studies, the obtained TTE outcome can differ to the original TTE event 
assumption made, therefore by using an absolute margin and adjusting the critical 
HR assumption at the time of analysis can preserve the power of the study.  
Patients play a pivotal role in determining what the NI margin should be by 
determining the amount of time or percentage chance of dying they would be 
willing to accept in return for having a less toxic treatment and the symptoms that 
go with it. Furthermore, trial teams should consult the DELTA2 guidance which 
provides recommendations in undertaking sample size calculations and choosing 
the target difference (Cook et al. 2018).  
1.4.5 Relationship between superiority and NI hypotheses 
For a one-sided trial with a superiority hypothesis comparing two treatment arms 
with a survival endpoint (Collett 2015), let 𝛿𝛿1 be defined as the critical HR where 





   
where 𝑆𝑆𝑛𝑛(𝑡𝑡) and 𝑆𝑆𝑐𝑐(𝑡𝑡) are the estimated survival functions at time 𝑡𝑡 on the new 




The null hypothesis, 𝐻𝐻0, and the alternative hypothesis, 𝐻𝐻1, can be defined by:  
𝐻𝐻0: 𝛿𝛿 ≥ 𝛿𝛿1 
𝐻𝐻1: 𝛿𝛿 < 𝛿𝛿1 
where 𝛿𝛿 is the obtained HR. Therefore, the probability to conclude superiority is:  
 𝑃𝑃(𝐶𝐶𝐶𝐶𝐸𝐸𝑜𝑜𝐸𝐸𝑠𝑠𝐻𝐻𝐸𝐸 𝑆𝑆𝑠𝑠𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐶𝐶𝐸𝐸𝐸𝐸𝑡𝑡𝑆𝑆; 𝛿𝛿𝑚𝑚𝑚𝑚𝑚𝑚 = 1) =  𝛼𝛼  
 𝑃𝑃(𝐶𝐶𝐶𝐶𝐸𝐸𝑜𝑜𝐸𝐸𝑠𝑠𝐻𝐻𝐸𝐸 𝑆𝑆𝑠𝑠𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐶𝐶𝐸𝐸𝐸𝐸𝑡𝑡𝑆𝑆;  𝛿𝛿𝑚𝑚𝑚𝑚𝑚𝑚 = 𝛿𝛿1) =  1 − 𝛽𝛽 = 𝑃𝑃𝐶𝐶𝑃𝑃𝐸𝐸𝐸𝐸  
where 𝛼𝛼 and 𝛽𝛽 are defined as the type I and type II error respectively (Collett 
2015). Assuming that patients are equally allocated to the two treatment arms, 
the number of events, 𝐸𝐸, required to determine whether the experimental arm is 













 and 𝐻𝐻𝛽𝛽 are the upper 𝛼𝛼 2�  and 𝛽𝛽 points respectively of the standard 
normal distribution (Collett 2015). Therefore, the number of patients required, 𝐸𝐸, 





where the probability of an event can be taken as:  
 𝑃𝑃(𝐸𝐸𝑠𝑠𝐸𝐸𝐸𝐸𝑡𝑡) = 1 − 1 6� �?̂?𝑆�𝑡𝑡𝑓𝑓� + 4?̂?𝑆 �
𝑡𝑡𝑟𝑟
2
+ 𝑡𝑡𝑓𝑓� + ?̂?𝑆�𝑡𝑡𝑟𝑟 + 𝑡𝑡𝑓𝑓��  
where 𝑡𝑡𝑟𝑟 and 𝑡𝑡𝑓𝑓 are defined as the recruitment time and follow-up time 






Hence, to implement this to a one-sided trial with a NI hypothesis comparing two 
treatment arms with a survival endpoint, let 𝛿𝛿2 be defined as the critical HR where 







The null hypothesis, 𝐻𝐻0, and the alternative hypothesis, 𝐻𝐻1, can be defined by:  
𝐻𝐻0: 𝛿𝛿 ≥ 𝛿𝛿2 
𝐻𝐻1: 𝛿𝛿 < 𝛿𝛿2 
Therefore, the probability to conclude NI is:  
 𝑃𝑃(𝐶𝐶𝐶𝐶𝐸𝐸𝑜𝑜𝐸𝐸𝑠𝑠𝐻𝐻𝐸𝐸 𝑁𝑁𝐼𝐼; 𝛿𝛿𝑚𝑚𝑚𝑚𝑚𝑚 = 𝛿𝛿2) =  𝛼𝛼  
 𝑃𝑃(𝐶𝐶𝐶𝐶𝐸𝐸𝑜𝑜𝐸𝐸𝑠𝑠𝐻𝐻𝐸𝐸 𝑁𝑁𝐼𝐼; 𝛿𝛿𝑚𝑚𝑚𝑚𝑚𝑚 = 1) =  1 − 𝛽𝛽 = 𝑃𝑃𝐶𝐶𝑃𝑃𝐸𝐸𝐸𝐸  
Therefore, assuming patients are equally allocated to the two treatment arms, the 
number of events can be calculated using the equation below, such that:  
 𝐸𝐸 =




Hence, the number of patients required can be calculated using the same equation 
above. This implies that using the same parameters in the NI design as used in the 
1-sided superiority design will result in the same number of events required and 
therefore the same sample size.  
1.4.5.1 Example – relationship between superiority and NI 
For a superiority hypothesis, a new treatment for patients diagnosed with breast 
cancer is expected to increase the overall survival rate at five years from 75% in 
the control arm (standard treatment) to 80%. In contrast for a non-inferiority 
hypothesis, the overall survival rate at five years is 80% in the control arm and the 
new treatment is expected to be no worse than 75%. Therefore, the corresponding 





= 0.776 𝛿𝛿2 =
𝐸𝐸𝐶𝐶𝑙𝑙 (0.75)
𝐸𝐸𝐶𝐶𝑙𝑙 (0.80)




Let 𝛼𝛼 = 0.05 and 1 − 𝛽𝛽 = 0.80, hence the number of deaths required to compare 
the two treatments such that there is an 80% chance of detecting a HR of 0.776 
(Superiority) or 1.289 (NI) to be statistically significant at the 5% significance level 




= 488 𝐸𝐸 =
4 × 7.85
(𝐸𝐸𝐶𝐶𝑙𝑙 1.289)2
= 488  
 
Therefore, it can be shown that 488 deaths are required to have 80% power to 
detect a HR of 0.776 or 1.289 for a one-sided superiority design or NI design 
respectively to conclude significance.  
It is anticipated that patients will be recruited over a three-year period with a 
follow-up period of two-years. Therefore, the number of patients required can be 
calculated such that the probability of an event is:  
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Using this information, the probability of death is: 
𝑃𝑃(𝐸𝐸𝑠𝑠𝐸𝐸𝐸𝐸𝑡𝑡) = 1 − 1 6� {0.9 + (4 × 0.84) + 0.78} = 0.16 
Therefore, the total number of patients required for the superiority design and NI 










Therefore 3050 patients (1525 in each arm) will be required over a period of three-
years when implementing a superiority or NI hypothesis.  
 Adaptive designs 
An alternative to the gold standard RCT parallel design, which has recently 
received much attention, are adaptive designs (Chow 2014, Bothwell et al. 2018). 
The definition of an adaptive design is any pre-planned modification made to the 
trial whilst preserving the validity and integrity of the trial (Gallo et al. 2006, US 
Food and Drug Administration 2018). These designs are attractive due to the 
efficiency and flexible nature in answering many questions within one trial (Berry 
2012). They often involve re-estimating the sample size at a certain time after the 
trial has begun, considering more than one intervention at the same time rather 
than conducting separate trials or adding in treatment arms. Additionally, the long 
duration of Oncology trials, the lack of efficacy of phase III drug trials and the cost 
involved with clinical trials has led to the encouragement and adoption from 
regulators for more novel trial designs (US Food and Drug Administration 2010, 
Berry 2012).  
Despite these advantages, adaptive designs in practice have lacked execution in 
comparison to the methodology that has been published. This may have been due 
to the Food and Drug Administration (FDA) classifying some of these designs as 
‘well-understood’ and others as ‘less well-understood’ in their 2010 draft guidance 
(US Food and Drug Administration 2010). The lack of implementation for these 
novel trial designs may be as a result of the fear that if these designs aren’t 
executed correctly, it could result in an unanswered trial (Chow 2014).  
The main concerns of adaptive designs are the control of the type I and type II 
error rates for the duration of the trial; failure to control these rates could lead to 
possible bias assessed by the amount the treatment effect deviates from its true 
value. For example, Figure 1.8 shows the time at which different interim analysis 
will take place when the required number of events are reached for three event 
rates for a clinical trial. If the event rate was linear (event rate B), then the 
appropriate time for an interim analysis would occur at time 2 as this is when the 
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required number of events is reached however if the interim analysis took place 
earlier i.e. at time 1 or later at time 3, then it could lead to a possible bias of the 
true value of the treatment effect. For event rate A or event rate C the appropriate 
time for an interim analysis would be at time point 1 and 3 respectively.   
 
Figure 1.8: Different event rates over time and how the timing of the interim analysis 
changes accordingly. If interim analysis took place too early, it could lead to possible 
bias.  1,2,3 – represent the interim analyses. A, B, C – Different event rates. RE – Required 
number of events to trigger interim analyses.  
 
  Research aim and rationale  
The research conducted in this thesis has been motivated by the rise in interest of 
adaptive design methods. Both the U.S FDA and the National Cancer Institute are 
investigating these novel designs due to the added pressures of speeding up both 
clinical trials and the evaluation of new drugs (Schmidt 2007).  
Only 34% of phase III cancer trials achieve statistical significance whilst the time 
and the number of patients required to perform these trials continues to increase 
(Reitsma et al. 2015). Hence, the incentive of creating novel trial designs in 
diseases such as cancer will support the ideologies of the trialist and patients to 
ensure that clinical trials will continue to become more efficient and effective in 
the future.  
The aim of this research is to examine the current types of adaptive designs within 
phase III cancer trials, within trials conducted at the Warwick Clinical Trials Unit 
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(CTU) and to explore innovative adaptive design methods that could be 
implemented.  
 Objectives 
The objectives of this PhD thesis were to:  
• Understand how adaptive designs are being applied and reported 
within phase III cancer clinical trials; 
• Perform a scoping exercise of all cancer trials executed at Warwick 
CTU to assess the adaptive methods involved; 
• Assess the application of multi-arm multi-stage (MAMS) designs to 
different cancer sites to examine what factors contribute to a 
‘successful’ MAMS design  
• Show through simulations how the MAMS designs can be used to 
implement a NI hypothesis; 
• Implement a MAMS design with a NI hypothesis when investigating 
treatment duration and make recommendations on the operational 
aspects when implementing these designs.  
 Thesis Structure 
This thesis begins by investigating some of the more common methods that are 
used and classed as ‘adaptive design’. Details of the literature review that was 
undertaken to evaluate the use of adaptive design methods in RCTs within the 
field of Oncology are presented in chapter three. Guidelines for improving the 
reporting of trials using adaptive designs are also described in chapter three. The 
conclusions drawn from chapter three that the reporting of adaptive design 
methods were inadequate in clinical trials led to the scoping exercise performed 
at Warwick CTU in chapter four to understand what adaptive methods were being 
implemented.  Hence, this chapter investigated the on-going/completed Oncology 
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trials within Warwick CTU and led to identifying any external RCT exemplars that 
had implemented adaptive design methods.  
Chapter five investigates the use of hypothetical MAMS designs using the ‘nstage’ 
command in Stata  (Blenkinsop et al. 2019) with a superiority hypothesis in three 
cancer sites: breast cancer, lung cancer and colon cancer. These specific cancer 
sites were selected due to their different survival rates and would provide a variety 
of results. 
In chapter six, simulations were conducted to show that a MAMS design with a NI 
hypothesis could be implemented using the ‘nstage’ command. Thereafter, 
hypothetical MAMS designs using a NI hypothesis in breast and colon cancer were 
investigated. 
Subsequently, in chapter seven, MAMS designs were applied to a proposed 
hypothetical trial investigating the optimum duration of Herceptin therapy in 
patients diagnosed with early breast cancer using a NI hypothesis. The idea behind 
creating this MAMS design was inspired by the Persephone trial (Earl et al. 2019) 
which was conducted at Warwick CTU and one of the numerous trials that 
followed the HERA trial in assessing various durations of Herceptin Therapy 
(Piccart-Gebhart et al. 2005). 
Finally, chapter eight discusses all the issues raised throughout this research and 
summarises the findings from the thesis, addresses the limitations and the future 




2 Overview of Adaptive Design methodology 
 Introduction 
The application of adaptive design methodology within a clinical trial allows for 
changes based on accrued information that was not available when the trial 
commenced. The FDA define an adaptive design as a study that includes 
prospectively planned adaptations (US Food and Drug Administration 2018). 
Various adaptive design methods have been developed and implemented such as: 
adaptive dose-finding, group sequential designs, sample size re-estimation, 
adaptive randomisation, seamless design etc.  
This chapter describes some of the commonly considered adaptive design 
methods found in the literature. The categorisations of adaptive design methods 
are based upon categories specified within the book titled Cancer Clinical Trials: 
Current and Controversial Issues in Design and Analysis (George et al. 2016).  
The focus of this PhD is on phase III cancer trials, thus adaptive dose-finding 
approaches/methods are only briefly discussed as these are more appropriate for 
early phase drug development.  
 Brief history of Adaptive designs 
Adaptive design methods can be first traced back to the USA in 1933 whereby the 
methodology to modify the randomisation process to favour a more promising 
drug was developed (Thompson 1933). This method was implemented on ethical 
grounds; to reduce the exposure of patients to inferior treatments. Sequential 
sampling was first introduced by Stein (1945), where an initial sample size was 
calculated and the results of that sample size was used to calculated an additional 
sample size required to achieve the appropriate precision (Stein 1945). Thereafter, 
Wald (1947) implemented pre-defined stopping rules in this setting where if 
results were significant then sampling would stop (Wald 1947). The application of 
adaptive designs in the UK can be traced back to 1954 whereby a sequential trial 
was implemented to assess the use of calcium chloride against adrenaline as a 
bronchodilator agent (Kilpatrick et al. 1954). The results for each patient were 
assessed as soon as patients completed the intervention. The trial was stopped 
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after only four patients were assessed on the calcium chloride arm due to futility. 
Thereafter, Snell and Armitage (1957) and Smith (1958) provide early examples of 
the use of sequential trials (Snell et al. 1957, Smith 1958) and Todd (2007) and 
Bothwell et al (2018) provide a review of the literature and the developments of 
adaptive design methodology (Todd 2007, Bothwell et al. 2018).  
In the past ten years, with the improvement in computer technology, adaptive 
design methodology and its application have increased, including the use of 
Bayesian techniques. The FDA initially released a draft guidance document for 
adaptive designs in 2010, where they categorised methods by ‘Well-understood 
methods’ and ‘Less well-understood methods’ (US Food and Drug Administration 
2010). The latest draft guidance document has removed these categories and 
provided exemplars of clinical trials that illustrate the advantages of implementing 
adaptive designs which clearly demonstrate the development of these designs (US 
Food and Drug Administration 2018). 
 Adaptive dose-finding designs for identifying optimal dose 
Phase I trials are conducted to identify a safe dose of a new drug to be given to 
humans. Adaptive dose-finding designs are usually applied within this phase 
whereby as the data is accumulated, the dose level is assessed against the toxicity 
level and decisions are made to either escalate, de-escalate or stay at the same 
dose (Zhang et al. 2006).  
One particular adaptive dose-finding design is known as the continual 
reassessment method (O'Quigley et al. 1990, Garrett-Mayer 2006). The aim of this 
design is to find the maximum tolerated dose of a new drug and has shown to be 
more precise in comparison to other dose-finding methods (Wheeler et al. 2019). 
To successfully execute an adaptive dose-finding design using the continual 
reassessment method, it is essential that the following parameters are discussed 
and decided by all trial stakeholders:  
• Which doses to study and how many doses are required; 
• The target toxicity level;  
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• Clarify the dose-toxicity model; this model helps identify the probability of 
a patient being subject to any dose limiting toxicities;  
• Clarity on how the trial data will be inferred for the dose-toxicity model; 
• What decision rules to put in place to ensure that the maximum tolerated 
dose is reached quickly without overdosing patients;  
• Planned sample size.  
Once these parameters for the trial are determined, simulations are performed to 
assess the operating characteristics (Wheeler et al. 2019).  
 Group Sequential designs 
The notion of sequential analyses has been defined as the repeated testing of 
hypothesis based on data that has accumulated over the course of a trial (Everitt 
et al. 2011). Initially, sequential analyses were performed after pairs of patients 
were allocated to each of the two treatment arms hence the number of analyses 
performed was subsequently high. Conversely O’Brien and Fleming, and Pocock 
developed designs whereby the number of analyses performed would be greatly 
reduced by performing analyses with groups of patients, hence these designs 
became popularly known as ‘group sequential designs’ (Pocock 1977, O'Brien et 
al. 1979, Jennison et al. 1999, Todd 2007). These group sequential designs have 
been developed to perform analyses at pre-specified time points also known as 
interims. At the interim, the accrued data can either indicate that there is no 
significant benefit of the new treatment (stopping for futility) or the new 
treatment is significantly beneficial (stopping for efficacy) (Pocock 1977, Todd 
2007).  
The application of group sequential methods are found in all four phases of clinical 
trials (Todd 2007, George et al. 2016). Initially within phase I trials, various doses 
are evaluated till the safe dose is found, this is subsequently evaluated within a 
phase II trial. Phase II trials are developed to assess whether a drug has an effect 
and to demonstrate thoroughly the efficacy of a drug. It is within phase II trials 
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that single-arm designs with multiple stages are implemented.  The most common 
multiple stage designs are the minimax design, Simon’s optimal two-stage design 
and flexible multi-stage designs (Simon 1989, Ensign et al. 1994, Chen 1997, 
Sargent et al. 2001). These single-arm phase II trials are followed by randomised 
phase II or phase III trials whereby the drugs are compared to the standard 
treatment or multiple treatments at multiple stages. It is within phase III trials that 
group sequential methods have been well developed and are well established 
(Todd 2007).  
Although the focus of this PhD is phase III trials within the field of oncology, the 
VIETNARMS phase II/III trial for patients with hepatitis C has been included within 
this thesis as it demonstrates a group sequential type design, further details can 
be found in appendix 1. The VIETNARMS trial implements a sequential process 
whereby a Bayesian monitoring procedure has been used to allow the stopping of 
inferior arms early and hence successive patients are randomised to the remaining 
arms if there is 95% posterior probability of less than a 90% cure in any of the 
treatment arms (McCabe et al. 2020).  
Group sequential methods can quicken the development of successful treatments 
and hence reduce the costs, resources and time taken to complete a trial. A 
retrospective analysis carried out for 72 cancer trials found that if group sequential 
methods were applied then approximately 80% of the trials would have stopped 
early (Rosner et al. 1989). Hence the FDA have stated that, “Early termination for 
efficacy should be generally reserved for circumstances where there is the 
combination of compelling ethical concern and robust statistical evidence” (US 
Food and Drug Administration 2018).  
2.4.1 Stopping rules 
In group sequential methods, the investigator can perform one or more interim 
analyses. Performing repeated interim analyses can inflate the false-positive-error 
rate or type I error rate, also known as the alpha value (α), due to simultaneously 
testing the same hypothesis multiple times, this is more commonly known as 
multiple hypothesis testing.  
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Therefore statistical stopping rules have been developed within group sequential 
designs to help control the type I error rate (Schulz et al. 2005). A graphical 
representation of a group sequential design can be seen in Figure 2.1, where over 
time, interim analyses are performed and if the test statistic is above or below a 
prespecified value then the trial can be stopped for either efficacy or futility. 
 
Figure 2.1: A graphical representation of a group sequential design.  
One of these stopping rules incorporates the Haybittle-Peto boundaries (Haybittle 
1971, Peto et al. 1977), whereby if at the interim analysis, the p-value is less than 
or equal to 0.001 then the trial is stopped early. This procedure continues at each 
interim stage up until the final stage, where the p-value is evaluated at the 5% 
significance level (Figure 2.2). Implementing a 5% significance level has made it 
easier for professionals from a non-statistical background to interpret the results, 
however it has been argued that this method is too stringent in deciding to stop a 
trial (Schulz et al. 2005).  
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Unlike the Haybittle and Peto stopping boundary, the O’Brien and Fleming 
stopping rule changes the significance level at each stage (O'Brien et al. 1979). 
Initially the stopping boundaries are conservative within the O’Brien and Fleming 
method, which is appealing to trial stakeholders, as at the initial stages of a trial 
the results are not stable but stabilise over time as more data is acquired (Figure 
2.2). At each subsequent interim analysis, the stopping boundaries become 
narrower as more data is accumulated.  
The Pocock approach (Figure 2.2) uses a fixed significance level and time for all 
interim and final stages calculated based on the number of stages altogether 
(Pocock 1992). This approach does not consider the potential instability of the data 
at the beginning of a trial by not having a conservative p-value in comparison to 
the aforementioned two methods. Furthermore, compared to a regular parallel 
trial with a final p-value of 0.05, the Pocock method would allow a less significant 
final p-value hence resulting in two different sets of results for two different trial 
designs.  
 
Figure 2.2: Graphical representation of different stopping rules that can be applied 
within group sequential designs.  
Unlike the Pocock approach, where the interim stages are equally spaced, the Lan 
and DeMets approach allows for some flexibility for the frequency and timing of 
these interim stages (Gordon Lan et al. 1983). This approach has given additional 
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flexibility to group sequential designs by using stopping boundaries defined by an 
alpha spending function. 
The triangular test proposed by Whitehead and Stratton (1983) not only applies a 
group sequential design but does not require pre-specification of when the interim 
analyses will be conducted and allows for continuous monitoring (Whitehead et 
al. 1983, Whitehead 1997). This approach has finite convergent boundaries giving 
an asymmetrical triangular continuation region (Figure 2.3). A trial is allowed to 
continue if it stays within the triangular region and the conclusion of the trial is 
dependent on which boundary is crossed, i.e. if the upper boundary is crossed 
then experimental arm is superior to control and if lower boundary crossed than 
the experimental arm is equal to or non-inferior to the control.  
 
Figure 2.3: Graphical representation of the different triangular test proposed by 
Whitehead et al (1983) 
The reverse triangular test (Figure 2.3) can be implemented if a NI hypothesis has 
been implemented. A double triangular test (Figure 2.3) is a combination of the 
triangular test and reverse triangular test which is used to detect either superiority 
or NI of an experimental arm. Unlike the triangular test, which stops the trial if 
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either the upper or lower boundary is crossed, the double triangular test continues 
the trial so definitive conclusion can be made of whether the experimental arm is 
equal, superior or non-inferior to the control arm.   
 Combination test and conditional error function approach 
The combination test and the conditional error function are used when combining 
data from different stages and when there are one or more looks at interim data. 
These designs have been commonly known as a more flexible version of the group 
sequential design (Bauer et al. 2016, Pallmann et al. 2018).    
If a trial has 𝑀𝑀 pre-planned interim stages, each stage has a null hypothesis to test 
the treatment effect. The combined test is a combination of the null hypothesis at 
all stages against the alternative hypothesis. Changes in the primary endpoint or 
patient eligibility criteria can lead to different null hypothesis being tested at the 
various stages. Thus, one way to test the final null hypothesis taking the results of 
the interim null hypotheses into consideration is to combine the p-value (or Z-
values) at stage m, denoted 𝑃𝑃𝑚𝑚 (𝑍𝑍𝑚𝑚), where 1 ≤ 𝐸𝐸 ≤ 𝑀𝑀 for which the two most 
popular methods are: 
1. Inverse χ2  (Fisher 1992), which rejects the null hypothesis if −2 log(𝑃𝑃1 ×
𝑃𝑃2 × … × 𝑃𝑃𝑀𝑀) > 𝜒𝜒2𝑀𝑀2  (𝛼𝛼), where 𝜒𝜒2𝑀𝑀2  (𝛼𝛼) is the upper tail point of the 𝜒𝜒2𝑀𝑀2  
distribution;   
2. Weighted inverse normal (Mosteller et al. 1954, Becker 1994, Goutis et al. 
1996) uses Z-values for which the null hypothesis is rejected if 
𝑃𝑃1𝑍𝑍1, …𝑃𝑃𝑀𝑀𝑍𝑍𝑀𝑀 > 𝐻𝐻(𝛼𝛼) where 𝑃𝑃1, …𝑃𝑃𝑀𝑀 are pre-specified weights such 
that ∑𝑃𝑃𝑖𝑖2 = 1 and  𝐻𝐻(𝛼𝛼) is the upper tail point of the standard normal 
distribution.  
The conditional error approach allows for modifications to the design of the trial 
at any time during the trial if the new conditional error given the data observed 
does not exceed the original conditional error. Various efforts have been made to 
find the best conditional error approach that for a given power, minimises the 
sample size (Liu et al. 2001, Brannath et al. 2002). 
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The conditional error approach and the combination test are similar as they both 
allow flexibility with regards to the number of interim looks and changes in 
primary endpoint (Bauer et al. 2006).  
 Multi-arm multi-stage (MAMS) designs 
In the clinical trial process, there can often be multiple promising treatments for a 
specific population; these treatments can be combinations of different drugs, 
different dosages of the same drug or different methods of administering a drug. 
Implementing MAMS designs can be an effective solution as these designs have 
the potential to evaluate several experimental arms against a single control arm 
and have the potential of accelerating treatment evaluation (Parmar et al. 2008, 
Royston et al. 2011, Wason 2015, Quartagno et al. 2018). Multiple stages can 
increase the efficiency in evaluating treatments as it allows for the elimination of 
ineffective treatments early (Barthel et al. 2009). The focus of this research is the 
MAMS design framework by Royston et al (2011). This type of MAMS design can 
utilise an intermediate outcome which can be a surrogate of the primary outcome 
and is used to assess the efficacy of the experimental arms at interim stages. At 
each stage, an interim analysis is performed whereby pairwise comparisons are 
made using an intermediate outcome for each of the experimental arms against 
the control arm. The results of these interim analyses will determine whether an 
experimental arm should be stopped for futility (the experimental arm has showed 
no benefit) or lack of benefit (showed benefit but not enough to progress to the 
next stage) or progress to the next stage. During an interim analysis, recruitment 
will continue to ensure that trials move seamlessly from one stage to the next. At 
the final stage, pairwise comparisons are made based on the primary outcome to 
decide upon the superiority of the remaining experimental arm(s) against the 
control.  
A fundamental element to consider when implementing a MAMS design for this 




• Familywise type I error rate (FWER) is defined as the probability of 
rejecting at least one null hypothesis when these hypotheses are true for 
a given family of hypotheses for the primary outcome if the null 
hypothesis is true. The FWER is more necessary in multi-arm settings when 
controlling the type I error rate as a whole rather than at each pairwise 
comparison. One approach to calculate the FWER, discussed in section 
2.6.7, is similar to the Dunnett’s approach to compare multiple treatments 
against a control using a multiple comparison procedure  (Dunnett 1955). 
Strong control of the FWER would apply when assessing the same drug for 
different durations.  
• Pairwise type I error rate (PWER) is defined as the probability of 
recommending an ineffective experimental arm against the control arm 
for the primary outcome irrespective of all other experimental arms. The 
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation 
of Drug Efficacy (STAMPEDE) trial is a MAMS platform trial (see chapter 
four for more information) which emphasised control of the PWER 
because distinct hypotheses are being tested in each of the experimental 
arms.  
MAMS designs have been applied in several phase III cancer trials (James et al. 
2008, Shiu et al. 2013, Mehanna 2015). The subsequent sections will further 
explain the methodology implemented for this framework.  
2.6.1 Nstage methodology 
The MAMS methodology specified by Royston et al (2011) is available within Stata 
using the command called ‘nstage’ (Barthel et al. 2009, StataCorp. 2017, 
Blenkinsop et al. 2019). In the following sections, the theory behind this MAMS 
design is described. 
2.6.2 Outcomes and hypothesis  
For a MAMS design, let 𝐼𝐼𝐼𝐼 and 𝑃𝑃𝐼𝐼 be defined as the time-to event intermediate 




Let 𝑗𝑗 ≥ 1 denote the number of experimental arms for which pairwise 
comparisons will be made against a common control arm, 𝐶𝐶. The true HR, Δ𝑖𝑖𝑖𝑖 is 
the effect of the experimental arm, 𝑗𝑗, on the control arm on the specified outcome 
at stage 𝐸𝐸, where 𝐸𝐸 is the 𝐸𝐸𝜆𝜆ℎ stage for 𝐸𝐸 = 1, … 𝑓𝑓 where 𝑓𝑓 is the final stage. The true 
HR is calculated using the 𝐼𝐼𝐼𝐼 from stage 1 to stage 𝑓𝑓 − 1 and 𝑃𝑃𝐼𝐼 at stage 𝑓𝑓. It is 
assumed that the proportional hazards assumption holds for all treatment 
comparisons. The null and alternative hypotheses can be defined as:  
 𝐻𝐻𝑖𝑖𝑖𝑖0 : Δ𝑖𝑖𝑖𝑖 = Δ𝑖𝑖𝑖𝑖0 ,  
𝐸𝐸 = 1, … ,𝑓𝑓, 𝑗𝑗 ≥ 1 
 𝐻𝐻𝑖𝑖𝑖𝑖1 : Δ𝑖𝑖𝑖𝑖 = Δ𝑖𝑖𝑖𝑖1 , 
A test of the accumulated data for each pairwise comparison is performed at stage 
𝐸𝐸 with nominal type I error rate 𝛼𝛼𝑖𝑖 and power 𝜌𝜌𝑖𝑖. If this is statistically significant 
then the experimental arm continues onto the next stage up until stage 𝑓𝑓 − 1, and 
at stage 𝑓𝑓 superiority is concluded. 
Under 𝐻𝐻0 and 𝐻𝐻1, the estimated log HR at stage 𝐸𝐸 defined as ln∆�𝑖𝑖  is distributed as:  
 𝐻𝐻0: ln∆�𝑖𝑖 ~ 𝑁𝑁(ln∆𝑖𝑖0 , 𝑠𝑠𝑖𝑖0)  
 𝐻𝐻1: ln∆�𝑖𝑖 ~ 𝑁𝑁(ln∆𝑖𝑖1 , 𝑠𝑠𝑖𝑖1)  
 
where the estimated variances under  𝐻𝐻0 and 𝐻𝐻1 are 𝑠𝑠𝑖𝑖0 and 𝑠𝑠𝑖𝑖1 respectively. 
Therefore, the probability under the null or alternative hypothesis of reaching 
stage 𝐸𝐸 + 1 or concluding superiority of either the control or experimental arm are 
based on normal approximations such that the appropriate critical HR and events 




The one-sided significance levels for each of the hypothesis tests can be thus 
related to the critical values for the test as follows:  
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where 𝜎𝜎𝑖𝑖0 is defined as square root of 𝑠𝑠𝑖𝑖0, the critical HR at stage 𝐸𝐸 is defined as 𝛿𝛿𝑖𝑖 
and Φ( ) is the standard normal distribution function.   
Likewise, the power for each of the hypothesis tests is such that:  









ln 𝛿𝛿𝑖𝑖 − ln∆𝑖𝑖1
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�  
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where 𝜎𝜎𝑖𝑖1 is defined as square root of 𝑠𝑠𝑖𝑖1. 
2.6.3 Critical HR 
The critical HRs are calculated for each stage to determine whether the 
experimental arm continues to the next stage 𝐸𝐸 + 1 or if superiority is concluded 
at the final stage when 𝐸𝐸 = 𝑓𝑓.  The critical HR is denoted by 𝛿𝛿𝑖𝑖 where 𝐸𝐸 is the 𝐸𝐸𝜆𝜆ℎ 
stage where 𝐸𝐸 = 1, … , 𝑓𝑓, is calculated by:  
 
 
ln 𝛿𝛿𝑖𝑖 = lnΔ𝑖𝑖0 + 𝜎𝜎𝑖𝑖0𝐻𝐻𝛼𝛼𝑖𝑖 = lnΔ𝑖𝑖
1 + 𝜎𝜎𝑖𝑖1𝐻𝐻𝜌𝜌𝑖𝑖   
where 𝐻𝐻𝛼𝛼𝑖𝑖  and 𝐻𝐻𝜌𝜌𝑖𝑖 are the pre-specified normal equivalent deviate for a one-sided 
significance and power respectively. The 𝜎𝜎𝑖𝑖0 and 𝜎𝜎𝑖𝑖1 are calculated using the 
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variance which are approximately the same under the null and alternative 
hypothesis (Tsiatis 1981) as follows:  







where 𝐸𝐸𝑖𝑖 and ?̂?𝐸𝑖𝑖 are the number of control arm events and experimental arm 
events respectively for each arm at stage 𝐸𝐸.  
2.6.4 Number of control arm events 
The event rate in the control arm governs the time at which the interim and final 
analyses takes place. The number of control arm events at each stage 𝐸𝐸 can be 




�ln  Δ𝑖𝑖1 − lnΔ𝑖𝑖0�
2  
Using the number of control arm events at each stage, a numerical search is 
performed to obtain the sample size that will give the required power at each 
stage (Royston et al. 2011), and hence the trial duration, assuming that the event 
times required for the 𝐼𝐼𝐼𝐼 and 𝑃𝑃𝐼𝐼 are exponentially distributed (see section 1.3).  
The rate at which patients are recruited into the control arm of the trial per unit 
time during stage 𝐸𝐸, is denoted by 𝐸𝐸𝑖𝑖 and it is assumed that recruitment occurs at 
a uniform rate in each given stage 𝐸𝐸.    
The period of stage 𝐸𝐸, can be defined by 𝐸𝐸 such that:  
 𝐸𝐸𝑖𝑖 = 𝑡𝑡𝑖𝑖 − 𝑡𝑡𝑖𝑖−1  
 
where 𝐸𝐸 = 1, … . ,𝑓𝑓 and 𝑡𝑡0 = 0. Therefore, the number of patients recruited during 
stage 𝐸𝐸 into the control arm is defined by: 
  𝐸𝐸𝑖𝑖 = 𝐸𝐸𝑖𝑖𝐸𝐸𝑖𝑖  
The number of patients recruited into one experimental arm during stage 𝐸𝐸 is also 
𝐸𝐸𝑖𝑖. Therefore, on the condition that all experimental arms, 𝑗𝑗, where 𝑗𝑗 ≥ 1, 
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continue past 𝑓𝑓 − 1 stages, the total number of patients required is calculated by 
the following:  





In practice, trial stakeholders may wish to set a period for recruitment, ?̂?𝑡 where 
?̂?𝑡 < 𝑡𝑡𝑓𝑓 and follow-up patients until the required number of events are observed. 
The only practical option is for ?̂?𝑡 to occur between stage 𝑓𝑓 − 1 and stage 𝑓𝑓 because 
ending recruitment prior to an intermediate stage would eliminate any possibility 
of ending recruitment to experimental arms early based on the assumption that 
at least one experimental arm reaches the final stage.  
However, there may be a situation where all experimental arms stop prior to stage 
𝑓𝑓 − 1, where 𝑓𝑓 ≥ 3,  due to futility or lack of benefit resulting in ending 
recruitment earlier than anticipated and reporting the outcome earlier than 
planned.   
If ?̂?𝑡 has been specified, then 𝐸𝐸 = ?̂?𝑡 − 𝑡𝑡𝑓𝑓−1. Hence, patients are followed up until the 
required number of control arm events are observed. Therefore, the number of 
patients required can be calculated by:  





2.6.5 Significance level and power at each stage 
Within the MAMS framework, the value of 𝛼𝛼𝑖𝑖 directly influences the number of 
control arm events required at each stage and hence the stage duration. The 
MAMS framework recommends using descending values of 𝛼𝛼𝑖𝑖 and larger than the 
usual significance values at the interim stages to allow for decisions to be made 
early on in the trial as to whether to drop experimental arms due to futility or lack 
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of benefit or continue to the next stage. The effect of using large significance 
values has been compensated by having a high power at each stage. For example 
in the STAMPEDE trial, at stages one to four the significance levels are 0.5, 0.25, 
0.1 and 0.025 respectively and the power value at each of these stages are 95% 
for stages one to three and 90% at stage four1 (Sydes et al. 2012).  
2.6.5.1 Stagewise significance level and power  
An experimental arm reaches stage 𝐸𝐸 with pairwise significance level, 𝛼𝛼𝑖𝑖 and 
power, 𝜌𝜌𝑖𝑖  on the condition that it has passed stage 𝐸𝐸 − 1 which implies that the 
experimental arm has passed previous stages 𝐸𝐸 − 2, … ,1. Therefore, 𝛼𝛼𝑖𝑖|𝑖𝑖−1 is 
denoted as the probability at stage 𝐸𝐸 under 𝐻𝐻0 of rejecting 𝐻𝐻0 given that the 
experimental arm has passed stage 𝐸𝐸 − 1. In the same way, the stagewise power 
is the probability at stage 𝐸𝐸 under 𝐻𝐻1 of rejecting 𝐻𝐻0 on the condition that it has 
passed stage 𝐸𝐸 − 1. 
Therefore, based on the rules of conditional probability,  
 𝛼𝛼𝑖𝑖|𝑖𝑖−1 =
Φ𝑖𝑖�𝐻𝐻𝛼𝛼1 , … 𝐻𝐻𝛼𝛼𝑖𝑖;𝐵𝐵
(𝑖𝑖)�
Φ𝑖𝑖−1�𝐻𝐻𝛼𝛼1 , … 𝐻𝐻𝛼𝛼𝑖𝑖−1;𝐵𝐵(𝑖𝑖−1)�
  
 (𝜌𝜌)𝑖𝑖|𝑖𝑖−1 =
Φ𝑖𝑖�𝐻𝐻(𝜌𝜌)1 , … 𝐻𝐻(𝜌𝜌)𝑖𝑖;𝐵𝐵
(𝑖𝑖)�
Φ𝑖𝑖−1�𝐻𝐻(𝜌𝜌)1 , … 𝐻𝐻(𝜌𝜌)𝑖𝑖−1;𝐵𝐵(𝑖𝑖−1)�
  
Where Φ𝑖𝑖 is the 𝐸𝐸-dimensional standard multivariate normal distribution function 
with mean 0 and variance matrix 𝐵𝐵(𝑖𝑖), where this is the matrix containing the first 
𝐸𝐸 rows and columns, for the standardised test statistics at the first 𝐸𝐸 interim 
analyses, with appropriate correlations. The overall PWER is given by the equation 
above when 𝐸𝐸 = 𝑓𝑓. 
Using the Royston et al (2011) framework when 𝐼𝐼𝐼𝐼 ≠ 𝑃𝑃𝐼𝐼, the maximum FWER 
occurs when all experimental arms are effective at each interim stage for the 𝐼𝐼𝐼𝐼 





design reducing to a one-stage trial as the interim stages become redundant and 
therefore 𝑃𝑃𝑃𝑃𝐸𝐸𝑃𝑃𝑚𝑚𝑚𝑚𝑚𝑚 =  𝛼𝛼𝑓𝑓. 
2.6.6 Overall significance level and power  
Once the stagewise significance level and power have been defined, the overall 
significance level, 𝛼𝛼, and power level, 𝜌𝜌 for when 𝐼𝐼𝐼𝐼 and 𝑃𝑃𝐼𝐼 are the same can be 
defined by:   
  𝛼𝛼 = 𝑃𝑃�Δ�1 < 𝛿𝛿1, … . ,Δ�𝑓𝑓 < 𝛿𝛿𝑓𝑓|𝐻𝐻0�  
 𝛼𝛼 = Φ𝑓𝑓 �𝐻𝐻𝛼𝛼1 , … , 𝐻𝐻𝛼𝛼𝑓𝑓;𝐵𝐵�  
 𝜌𝜌 = 𝑃𝑃�Δ�1 < 𝛿𝛿1, … . ,Δ�𝑓𝑓 < 𝛿𝛿𝑓𝑓|𝐻𝐻1�  
 𝜌𝜌 = Φ𝑓𝑓 �𝐻𝐻𝜌𝜌1 , … , 𝐻𝐻𝜌𝜌𝑓𝑓;𝐵𝐵�  
where it is assumed that �lnΔ�1 , … lnΔ�𝑓𝑓� is a multivariate normal distribution and 
Φ𝑓𝑓(;𝐵𝐵) is the standard f-dimensional multivariate normal distribution. 𝐵𝐵 is the 
correlation matrix where the 𝐸𝐸𝜆𝜆ℎ  and 𝑘𝑘𝜆𝜆ℎ element 𝐵𝐵𝑖𝑖𝑘𝑘 of 𝐵𝐵(𝐸𝐸,𝑘𝑘 = 1, … ,𝑓𝑓) is the 
correlation between the log hazard ratios, ln Δ�𝑖𝑖  and ln Δ�𝑘𝑘, for the outcome at the 
end of the 𝐸𝐸𝜆𝜆ℎ  and 𝑘𝑘𝜆𝜆ℎ stages respectively.  
However, if 𝐼𝐼𝐼𝐼 and 𝑃𝑃𝐼𝐼 differ, the overall significance level and power for the 
combined (𝑓𝑓 − 1) stages is defined as:   
 𝛼𝛼𝐼𝐼𝐼𝐼 = Φ𝑓𝑓−1 �𝐻𝐻𝛼𝛼1 , … , 𝐻𝐻𝛼𝛼𝑓𝑓−1;𝐵𝐵
𝑓𝑓−1�  
 𝜌𝜌𝐼𝐼𝐼𝐼 = Φ𝑓𝑓−1 �𝐻𝐻𝜌𝜌1 , … , 𝐻𝐻𝜌𝜌𝑓𝑓−1;𝐵𝐵
𝑓𝑓−1�  
Hence for the value of 𝐵𝐵𝑖𝑖𝑓𝑓, the lower limit, 𝐸𝐸, and upper limit, 𝑠𝑠 of the overall type 
I error and overall power can be calculated as follows:  
 𝛼𝛼𝑙𝑙 = 𝛼𝛼𝐼𝐼𝐼𝐼𝛼𝛼𝑓𝑓 ,𝛼𝛼𝑢𝑢 = min (𝛼𝛼𝐼𝐼𝐼𝐼𝛼𝛼𝑓𝑓)  
 𝜌𝜌𝑙𝑙 = 𝜌𝜌𝐼𝐼𝐼𝐼𝜌𝜌𝑓𝑓 ,𝜌𝜌𝑢𝑢 = min (𝜌𝜌𝐼𝐼𝐼𝐼𝜌𝜌𝑓𝑓)  
When there is 100% correlation between ln Δ�𝑙𝑙  and ln Δ�𝑓𝑓 the minima occurs, i.e. 
𝐵𝐵𝑖𝑖𝑓𝑓 = 1 ∀ 𝐸𝐸. When there is no correlation between ln 𝛿𝛿𝚤𝚤�  and ln 𝛿𝛿𝑓𝑓�  the maxima 
occurs, i.e. 𝐵𝐵𝑖𝑖𝑓𝑓 = 0 ∀ 𝐸𝐸. 
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It is important to note that within this MAMS design framework, the overall values 
of 𝛼𝛼 and 𝜌𝜌 are not required to make decisions at the interim stages or final stage 
to conclude superiority (Royston et al. 2011), however these overall values can 
lead one to change the selected values at 𝛼𝛼𝑖𝑖 and 𝜌𝜌𝑖𝑖. 
2.6.7 FWER  
The probability of passing all 𝐸𝐸 stages for one or more unsuccessful treatments is 
known as the familywise error rate (FWER). Within the multi-arm setting, it may 
be more necessary to assess the overall (FWER) type I error rate instead of the 
PWER . Furthermore, strong control of the FWER has been recommended more 
for confirmatory settings (phase III) in comparison to exploratory MAMS trials 
(phase II) (Wason et al. 2016).  
The Dunnett’s test is a procedure to compare many to one comparisons, hence 
using the Dunnett test (Dunnett 1955), 𝐹𝐹𝑃𝑃𝐸𝐸𝑃𝑃𝑚𝑚𝑚𝑚𝑚𝑚  can be calculated as follows: 
 𝐹𝐹𝑃𝑃𝐸𝐸𝑃𝑃𝑚𝑚𝑚𝑚𝑚𝑚 = 1 −Φ𝐽𝐽 �𝐻𝐻1−𝛼𝛼𝑓𝑓 , … 𝐻𝐻1−𝛼𝛼𝑓𝑓;𝑃𝑃�  
 
where 𝑃𝑃 is the 𝐽𝐽 × 𝐽𝐽 correlation matrix between arms with off-diagonal entries 
equal to 0.5.  
2.6.8 Example - applying the ‘nstage’ command  
To demonstrate the application of the ‘nstage’ command by Barthel et al (2009), 
a sample size calculation was performed for a hypothetical four arm three stage 
MAMS trial for patients diagnosed with colon cancer. OS was used for both the 𝐼𝐼𝐼𝐼 
and 𝑃𝑃𝐼𝐼 where patients had a five-year OS rate of 50.5% and the trial aimed to 
detect a 7% difference between the control arm and the experimental arm. It was 
hypothesized that one experimental arm would not significantly differ from the 
control arm at each interim stage resulting in an experimental arm being dropped 
at each stage. The stagewise significance values and stagewise power values were 
selected based on values suggested by Royston et al (2011) and initially 
implemented in the STAMPEDE trial (see Table 4.2). The parameters inputted into 
the ‘nstage’ command in Stata can be found in Table 2.1. 
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Nstage command Parameter Value 
nstage Total number of stages 3 
arms Number of arms in each stage 4, 3, 2 
accrue Rate per unit time that patients enter the 
trial during each stage 
625, 625, 625 
aratio Allocation ratio 1 
s Survival Probability for OS 0.505 
t Survival Time (years) 5 
hr0 HR under H0 specified for intermediate 
and final outcome 
1, 1 
hr1 HR under H1 specified for intermediate 
and final outcome 
0.81, 0.81 
alpha One-sided alpha for each stage 0.5, 0.25, 0.025 
omega Power for each stage 0.95, 0.95, 0.9 
tunit Time units 1 (= one year) 
tstop Time of recruitment stopping (years) 6 
Table 2.1: Parameters inputted for a hypothetical four arm three stage MAMS trial using 
the ‘nstage’ command in Stata, the intermediate and primary outcome was OS. OS – 
Overall survival, HR – Hazard ratio, H0 – Null hypothesis, H1 – Alternate hypothesis.   
 It can be seen from the sample size calculation in Figure 2.4 that 3750 patients 
would be required to be recruited over six years and followed up for 
approximately two years. The first interim analysis would take place when 134 
control arm events are obtained at approximately 3.8 years. The second interim 
analysis would take place when 258 control arm events are obtained at 
approximately 5.4 years and the final analysis would take place when 489 control 
arm events are obtained at 7.8 years. The critical HR at stages one and two are 1 
and 0.942 respectively; at these interim stages pairwise comparisons are made for 
each experimental arm against the control arm; if the obtained HR is less than the 
critical HR then that experimental arm would continue to the next stage. The 
critical HR at the final stage is 0.882, it was assumed that one experimental arm 
would reach this stage and if the obtained HR was less than the critical HR then 




Figure 2.4: Syntax and output obtained when implementing the ‘nstage’ command in 
Stata for a four arm three stage trial with a superiority hypothesis in patients diagnosed 




 Sample size re-estimation 
A suitable sample size calculation that has an appropriate power and significance 
level is essential to achieving the objectives of a trial. Adjusting the sample size as 
an adaptive design method allows for the re-calculation of the sample size based 
on observed data during an interim analysis. The European Medicines Agency 
(EMA) Committee for Medicinal Products for Human use states that “Blinded 
sample size reassessment that properly control the type I error should be used, 
especially if the sole aim of the interim analysis is the re-calculation of sample size” 
(CHMP 2012). However, depending on the reason, i.e. investigating a drug in a 
single arm trial in an unknown population, unblinded methods may need to be 
considered. For example, the HYPAZ trial aimed to explore the effect of a new 
cancer drug in an unknown population (Bond et al. 2011). Hence, an adaptive 
sample size re-estimation design was implemented due to this limited knowledge 
at the design stage.   
The EMA imply that sample size re-estimation should be prospectively planned, 
yet unplanned methods have been created whereby the sample size can be 
adjusted even though these were not planned at the start of the trial (Bauer et al. 
1994, Proschan et al. 1995, Fisher 1998). Unplanned sample size adjustments 
occur within clinical trials, with many of these adjustments due to changes to the 
on-going protocol. They could be based on characteristics of the accrued data at 
an interim stage (Chuang-Stein et al. 2006, Chow et al. 2011). For example, a 
randomised trial comparing adjuvant imatinib versus no further therapy for 
patients that have undergone surgery for localised, high or intermediate risk of 
gastrointestinal stromal tumour (Casali et al. 2015) involved an ad-hoc adaptation 
of the sample size. The sample size for the trial increased from 400 patients to 900 
patients due to a larger sample of patients being recruited with low and 
intermediate risk tumours than expected, which resulted in a higher than 
expected survival rate in the control group. Furthermore, the VICTOR trial (see 
section 4.2) which assessed the use of rofecoxib in colorectal cancer patients, 
required 7000 patients to detect an increase in survival to detect a relative 
difference of 20% with 85% power and using a 5% two-sided significance interval 
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(Midgley et al. 2010). The recruitment of patients to the trial was stopped early as 
the drug being used in the trial was withdrawn completely due to safety concerns. 
This resulted in the VICTOR trial team re-evaluating the statistical analysis plan to 
follow-up the 2434 patients to detect an increased relative difference of 25% in 
survival with 87% power using a two-sided 5% significance level rather than 
detecting the original 20% difference with a much lower power. These unforeseen 
changes required the trial team to act rapidly to ensure that this drug was recalled 
and no longer being consumed. This example demonstrates that unforeseen 
circumstances can arise which can force investigators to report using a much 
reduced sample size. Pragmatically speaking this adaptation is classed as an 
adaptive design method, however it would not be classed as an adaptive design in 
accordance to the guidelines provided by the FDA (US Food and Drug 
Administration 2018) as it was undertaken retrospectively and not pre-planned.  
Re-estimating the sample size during interim stages can assist a trial in various 
ways. For example, if there is limited information about the population in 
question, then an internal pilot study could be conducted whereby the sample size 
can be re-estimated based on the information accrued at the interim analysis. 
Birkett and Day (1994) have developed a method of using an internal pilot study 
to help calculate the final sample size. Usually sample size calculations are based 
on external data which may differ in terms of patient criteria or different 
treatment duration hence they may not truly represent the trial being designed. 
Birkett and Day‘s approach is useful as the final sample size is specified based on 
the results of the internal pilot study compared to other methods which calculate 
the pre-planned final sample size and only allow for an increase in sample size 
(Wittes et al. 1990, Birkett et al. 1994, Gould 1995).   
Sample size re-estimation can be extended to allow implementation within fully 
sequential, group sequential, and dose response designs (Bhatt et al. 2016). 
Sample size re-estimation methods are implemented to increase the sample size 
(Jennison et al. 2015). However, decreasing the sample size can be accomplished 
if it is within a group sequential design setting with thorough planning to ensure 
the type I error rates are controlled.  
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The following sections will discuss some of the different methods to re-estimate 
sample size. 
2.7.1 Internal Pilot studies 
Internal pilot studies can be executed prior to a main trial to help calculate sample 
size if there are any unknown parameters. These unknown parameters can be 
initially estimated to calculate the sample size and then after the accrual of data, 
the sample size can be re-estimated at an interim analysis.  
One simple approach is when there is a single analysis of a primary outcome 
measure. Given that the hypotheses, type I and type II error rates have all been 
specified then the sample size can be expressed as the function 𝑓𝑓(𝜃𝜃), where 𝜃𝜃 is 
an unknown parameter. The internal pilot study begins with an estimate for the 
unknown parameter, 𝜃𝜃1 and hence with an initial sample size of 𝑓𝑓(𝜃𝜃1). After the 
accrual of some data, a pre-planned interim analysis is performed whereby a new 
estimate, 𝜃𝜃2 is found. This value is utilised to re-estimate the sample size and 
hence the trial continues with the aim to reach a sample size of 𝑓𝑓(𝜃𝜃2) and it is with 
this final sample size that all data is analysed.     
2.7.2 Proschan and Hunsberger method 
The Proschan and Hunsberger method (Proschan et al. 1995, Posch et al. 1999) 
implements a two-stage design whereby decisions related to the sample size are 
made after the first stage based on conditional power. This method uses the 
significance of the treatment difference within the first stage to determine how 
many additional observations are required and the critical value to use at the end 
of the study.    
This method was implemented in a RCT assessing the effectiveness of phenytoin 
in preventing seizures in patients with brain tumours (De Santis et al. 2002). This 
trial aimed to detect a decrease in the incidence of seizures from 15% to 5%. To 
achieve this, a target sample size of 356 patients was required with 80% power 
and 5% significance level. The trial performed a pre-planned interim analysis after 
200 patients were recruited at which the incidence of seizures in the control arm 
was 11% and 13% in the treatment group. This resulted in a conditional power of 
approximately 27%, which meant that there would be less than a 27% probability 
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to detect the hypothesised difference between the two groups. Based on this 
interim result, recruitment was stopped.  
In contrast to the Proschan and Hunsberger method, the MAMS designs uses large 
pre-planned type I error values with fixed treatment difference(s) which is 
compensated by having a high power at each stage to help make decisions with 
regards to stopping or continuing experimental arms. 
2.7.3 Cui, Hung and Wang method 
The Cui, Hung and Wang method of sample size re-estimation investigates the use 
of observed data within group sequential clinical trials. This testing procedure 
preserves the type 1 error rate and may provide a considerable increase in power 
together with an increase in sample size (Cui et al. 1999).    
The VALOR trial was a phase III RCT that investigated vosaroxin plus cytarabine in 
patients diagnosed with leukaemia. This trial implemented the Cui, Hung and 
Wang sample size re-estimation method based on the number of events.  A total 
of 450 patients with 375 deaths were initially required to detect an improvement 
in median survival from 5 months (placebo) to 7 months (vosaroxin plus 
cytarabine) with 90% power and 5% two-sided significance level. Pre-specified 
statistical guidelines were set out for the Data and Safety Monitoring committee 
(DMC) to follow, based on the Cui, Hung and Wang sample size re-estimation 
method. The pre-planned decision criteria to be made at the interim analysis were 
to either stop the trial or increase to 562 deaths (approximately 675 patients).  The 
pre-planned interim analysis was performed when 173 deaths were reached. The 
DMC followed the pre-specified guidelines and made the decision to increase the 
sample size to 562 deaths. The independence of the recommendation from the 
DMC and the use of pre-specified criteria for the amendment to the sample size 
ensures the credibility of the study. 
2.7.4 Brutti, De Santis, and Gubbiotti method (Bayesian)  
The Bayesian predictive approach for sample size re-estimation by Brutti et al 
(2009) considers a mix of prior information for the quantity of interest (De Santis 
2006, Brutti et al. 2009). This method is an extension to the proposed methods by 
Gajewski and Mayo, and Wang (Gajewski et al. 2006, Wang 2007).  
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This method uses the predictive approach to choose the data probability 
distributions for the posterior calculations. For this method two distinct prior 
distributions are calculated, a design prior and an analysis prior. The design prior 
models the uncertainty on the parameter values at the planning stage and the 
analysis prior combines the data obtained with information collected prior to the 
study. At the interim stages, the weights of the prior distributions are updated 
which result in the sample size being re-estimated using the method by De Santis 
(2006).   
 Adaptive randomisation  
Randomisation is an essential procedure that is used within clinical trials to ensure 
that there is an equal balance of allocated treatments across patients. 
Furthermore, randomisation can ensure that the allocation of treatments can be 
balanced across specified baseline characteristics by employing stratification 
variables. There are two main types of adaptive randomisation methods; 
outcome-adaptive randomisation and covariate-adjusted randomisation, which 
can also be combined to form covariate-adjusted outcome-adaptive 
randomisation (George et al. 2016). Covariate-adjusted randomisation uses 
baseline demographics associated with prognostic features for each patient to 
assign them to relevant treatment groups. Many specific procedures have been 
developed to implement covariate adjustment of which two of the most popular 
methods are stratified block randomisation and minimisation (Kahan et al. 2012). 
Adaptive randomisation methods can be applied to outcomes that are binary, 
ordinal or continuous and can be applied to studies with multiple treatment arms.  
2.8.1 Outcome-adaptive randomisation 
The FDA define outcome-adaptive randomisation as “a form of treatment 
allocation in which the probability of patient assignment to any particular 
treatment group of the study is adjusted based on repeated comparative analyses 
of the accumulated outcome responses of patients previously enrolled” (US Food 
and Drug Administration 2010, US Food and Drug Administration 2018).  This 
method can be used to allocate patients to the treatment that suggests better 
outcomes, alternatively it can reduce the number of patients allocated to a 
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treatment that suggests that there may be a higher probability of patients having 
an adverse event. Implementing this method in trials can motivate patients to 
enrol in latter stages as it may increase their chances of being allocated to a ‘more 
successful treatment’. The practicality of implementing outcome-adaptive 
randomisation methods may not be suitable for trials that either have a long-term 
outcome or treatment duration, or trials with a large sample size (Chow et al. 
2008). The allocation could be dependent upon the outcome of the previous 
participant; thus, the need to wait until treatment is complete or the outcome 
obtained before implementing adaptive randomisation would significantly 
increase the completion time of the study.  
A frequentist approach to outcome-adaptive randomisation developed by Hu and 
Rosenberger demonstrate various procedures when comparing two or more 
treatment arms when the outcome is binary (Hu et al. 2003, Hu et al. 2006).   
Hu and Rosenberger consider the case of a trial with two treatment arms denoted 
𝐸𝐸 with a binary outcome. The response rates for treatment one and two are 
denoted by 𝐸𝐸𝑖𝑖 where 𝑞𝑞𝑖𝑖 = 1 − 𝐸𝐸𝑖𝑖 for 𝐸𝐸 = 1, 2. The optimal randomisation 
probability (𝜀𝜀1) is calculated to capitalise on the power to compare the response 





As the trial progresses, the optimal randomisation probability can be changed 
based on accrued data at interim analysis.  
An example of an outcome-adaptive randomisation trial that adjusts for covariates 
can be found in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial 
which aimed to give patients different amounts of insulin in hyperglycaemic acute 
ischemic stroke patients (Bruno et al. 2014). This two-arm trial aimed to ensure 
there was a balance in important prognostic factors and encourage patients to be 
randomised to the better performing treatment. Therefore, initially a 1:1 
allocation was employed but as the trial progressed the ratio changed to either 
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ensure baseline prognostic factors remained balanced or give more weight to the 
treatment group with the better outcome. The primary analysis for this trial 
assessed the proportion of patients in each treatment group with a favourable 
outcome after controlling for the key baseline prognostic factors.   
2.8.2 Bayesian adaptive randomisation 
There are various methods to perform adaptive randomisation using Bayesian 
methods (Hardwick et al. 1991, Thall et al. 2007, Lee et al. 2010). A common 
method applied is simple Bayesian adaptive randomisation (George et al. 2016), 
for example in a two arm study, patients are assigned to treatment one with 
probability 𝜀𝜀1  if the following equation is satisfied at time of randomisation: 
𝜀𝜀1 = 𝑃𝑃𝐸𝐸𝐶𝐶𝑃𝑃(𝜆𝜆1 > 𝜆𝜆2), 
where 𝜆𝜆𝑖𝑖 is the posterior probability for the treatment arms 𝐸𝐸 where 𝐸𝐸 = 1, 2. 
One example of where Bayesian adaptive randomisation has been used is in the 
Biomarker-integrated approaches of Targeted Therapy for Lung Cancer 
Elimination (BATTLE) trial. Patients with advanced nonsquamous non-small-cell 
lung carcinoma (NSCLC) that had been treated with chemotherapy and then 
experienced disease relapse were eligible for the trial (Liu et al. 2015). Patients 
were randomised to four different treatment arms based upon their biomarker 
profiles. A Bayesian adaptive design was incorporated to regularly monitor the 
data for futility. Furthermore, Bayesian adaptive randomisation was implemented 
whereby the performance of each treatment arm was evaluated and this updated 
information was used to guide the randomisation allocation. The trial allowed the 
assessment of four treatments in five biomarker groups within one trial rather 
than performing 20 separate phase II single arm studies. Having all these patients 
within one trial can make it easier to compare patients across the treatment arms 
(Liu et al. 2015).  
 Seamless designs 
The phases (phases I - III) of a clinical trial are usually conducted separately and in 
sequence to ensure robust conclusions about a new drug. However, it can be 
inefficient and costly to create separate trials for each phase, hence seamless 
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designs transition the new drug sequentially from one phase to another (George 
et al. 2016).  The overall aim of these designs is to reduce the time taken for a new 
drug to pass through the different phases of drug development as well as reduce 
patient exposure, which has been demonstrated by reductions in sample size by 
at least 30% (Inoue et al. 2002, Maca et al. 2006).  
Seamless designs are implemented within the field of Oncology by firstly assessing 
outcomes that can be measured sooner also known as surrogate outcomes such 
as DFS compared to longer-term outcomes such as OS (see section 1.3). These 
surrogate outcomes are measured to see the effect of a new treatment on the size 
of a tumour within a phase II setting and then a longer term outcome within a 
phase III setting (Stallard 2010). However, the surrogate outcome should correlate 
with the longer-term outcome. The success of a seamless phase II/III trial is 
dependent on the choice of outcome.   
Pick the winner designs can be used in seamless designs (Scher et al. 2002). A pick 
the winner design can have multiple arms with two stages; a selection stage (phase 
II) at which ‘the winner’ is chosen to be carried into the confirmation stage (phase 
III), where new patients are recruited and randomised to receive either the control 
or ‘the winner’. This design has been compared to a modified MAMS design as it 
can evaluate multiple treatments across at least two stages however the 
difference is that the MAMS design allows the continuation of a treatment based 
on critical values whereas the pick the winner approach evaluates improvement 
in outcomes regardless of statistical testing (Hills et al. 2011). 
An example of a phase II/III seamless study evaluated the safety and efficacy of 
pegteograstim on chemotherapy-induced neutropenia against pegfilgrastim in 
patients diagnosed with breast cancer (Lee et al. 2016). At phase II, patients were 
administered four to six cycles of chemotherapy and assigned to two different 
groups. It was at this phase where the optimal dose of pegteograstim was chosen 
to be seamlessly carried to a phase III trial.   
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  Master Protocols, Umbrella trials, Basket Trials, Platform-based trials 
The concept of precision medicine entails finding the biomarker of a patient’s 
cancer which then leads to personalised therapy (West 2017). Redman and Allegra 
et al (2015) have defined master protocols to be a top-level protocol within which 
multiple biomarker-based sub-trials can be contained each with their own 
protocols  (Redman et al. 2015, Hirakawa et al. 2018).  The different types of trial 
designs within a Master Protocol are Umbrella trials, Basket trials and Platform-
based trials. These trial designs all look at more than one treatment arm or 
population at a time, but they do not have their own exclusive adaptive 
methodology to undertake these trials. They implement methods that have been 
described in earlier sections to make decisions, for example the STAMPEDE trial is 
a platform trial but implements the MAMS methodology.   
A recent systematic review of Master protocol trials (Park et al. 2019) identified 
83 master protocols (49 basket trials, 18 umbrella trials and 16 platform trials) for 
which the majority of these were in oncology (76/83, 92%). These designs offer 
trialist improved efficiency by accelerating late stage development by assessing 
multiple drugs at once in comparison to two-arm trials resulting in the rapid rise 
of implementation of these designs (US Food and Drug Administration 2018, Park 
et al. 2019). Furthermore, these designs can be extremely useful in times of global 
health pandemics such as the coronavirus disease, to rapidly identify efficacious 
treatments and stop unnecessary research into non-effective treatments (Noor et 
al. 2020). 
An example of a master protocol is the Adjuvant Lung Cancer Enrichment Marker 
Identification and Sequencing (ALCHEMIST) trial as it integrates three trials 
(ALCHEMIST-Screening, ALCHEMIST-EGFR and ALCHEMIST-ALK) for patients with 
early stage lung cancer and allocates drugs that target specific genomic changes 
occurring within patients (Gerber et al. 2015). The ALCHEMIST-Screening trial aims 
to screen between 6000 and 8000 stage 1-3 NSCLC patients and assess the 
tumours for Epidermal Growth Factor Receptor (EGFR) mutations and Anaplastic 
Lymphoma Kinase (ALK) rearrangements. Patients that have the aforementioned 
tumour types will be referred to either the ALCHEMIST-EGFR (sample size = 410 
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patients) or ALCHEMIST-ALK (sample size = 360 patients) trials respectively. The 
remaining patients will be followed up for relapse and survival within the 
screening cohort. 
2.10.1 Umbrella trials 
Umbrella trials involve patients of the same cancer type being recruited and a test 
performed to detect which biomarkers are present in order to allocate patients to 
the relevant drug (West 2017) (Figure 2.5). Umbrella trials are usually phase II or 
phase II/III trials. An advantage of umbrella designs is that they allow multiple 
drugs to be tested simultaneously as different arms may open and close over time. 
Furthermore, patients are treated for the same tumour type and stage of disease, 
therefore any benefits observed in patients on the experimental arm can be linked 
to the biomarker hence assisting with prognostic homogeneity (Renfro et al. 2017, 
West 2017).  Implementing such a design could result in a potentially large trial 
with a long duration which comes about due to funnelling patients with one type 
of cancer into smaller sub-studies based on their biomarkers (Renfro et al. 2017). 
Trial stakeholders may not find the long duration of these designs appealing if in 
the situation where answers are swiftly required.  
An example of where the Umbrella design has been implemented is within the 
LUNG-MAP trial (Ferrarotto et al. 2015, LUNG-MAP 2017). The LUNG-MAP trial 
assesses patients diagnosed with lung cancer and endeavours to compare 
targeted treatment based on a patient’s genomic makeup versus current standard 
therapy. Hence there are many sub-studies within the LUNG-MAP trial based upon 
the treatment that is matches the patients’ tumour profile.  
Similarly, the FOCUS4 trial (FOCUS4 2019) implements an umbrella MAMS design 
with biomarker-stratified and non-stratified comparisons all with separate 
protocols within one master protocol. More details of this trial can be found in 




Figure 2.5: A graphical representation of an Umbrella trial design (Park et al. 2019). 
2.10.2 Basket trials  
A Basket trial enrols patients that have the same or similar biomarkers but could 
be diagnosed with different cancers and allocates them the same treatment (West 
2017) (Figure 2.6). Normally Basket trials are phase II, single-arm small (30-40 
patients) studies where within each cohort of patients there is a predefined target-
response hypothesis. However, they can also be implemented within phase III 
settings like the ADD-ASPIRIN trial (Coyle et al. 2016). The ADD-ASPIRIN trial 
investigates the use of aspirin in avoiding recurrence and improving survival in 
patients diagnosed with early stage cancer in four solid tumours (breast, 
colorectal, gastro-oesophageal and prostate).  Every patient has a run-in period 
whereby 100mg aspirin is taken daily for eight weeks, after which patients are 
randomised separately within each tumour-specific cohort to one of three arms: 
placebo, 100mg aspirin daily or 300mg daily. For the patients that are aged over 
75 years, they are only randomised to either placebo or 100mg aspirin daily.  
The advantages these trials offer are that a variety of treatments can be beneficial 
to a variety of disease types (Moore et al. 2016). However the disadvantages with 
these trials are the prognostic heterogeneity, whereby patients within the same 
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cohort may have completely different characteristics due to the different cancer 
types (Moore et al. 2016, Renfro et al. 2017).  
An example where a Basket trial design has been utilised is within the NCI 
Molecular Analysis for Therapeutic Choice (NCI-MATCH) trial. This trial assigns 
patients to receive treatments according to the genetic changes occurring within 
their tumours (National Cancer Institute 2017). Currently the trial has 18 different 
treatment arms available to patients, with most of the treatment arms enrolling 
up to 35 patients. The trial aimed to recruit 25% of patients that have a rare cancer 
type but currently have 60% of patients with rare cancer types thus exceeding 
their expectations.   
 
Figure 2.6: A graphical representation of a basket trial (Park et al. 2019). 
2.10.3 Platform trials  
A platform trial can be defined as a trial in which various sub-trials continue to 
enter and exit; sub-trials in a phase III setting may exit the platform due to futility 
or lack of benefit (Renfro et al. 2017) (Figure 2.7). Bayesian methods can be used 
within platform trials whereby Bayesian decision rules are utilised to determine 
whether treatments should continue or stop (Saville et al. 2016). The main 
advantage these types of designs offer are the flexibility of dropping ineffective 
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experimental arms at earlier stages and introducing new arms. Furthermore, trials 
can seamlessly progress from a phase II to a phase III trial. The potential size, 
duration and operational requirements of a platform trial can be a discouraging 
factor for stake-holders to implement this trial design. These designs can be useful 
in times of global health pandemics such as the coronavirus disease 2019 (COVID-
19) as there would be an urgent need to rapidly identify efficacious treatments 
and reject treatments that are futile, lack benefit or too toxic (Noor et al. 2020)   
An example of a platform trial is the STAMPEDE trial; which was initially classed as 
a MAMS design but evolved into a platform trial with the addition of treatments 
arms1. It is a phase II/III trial looking at patients with locally advanced prostate 
cancer who are commencing long-term Androgen Deprivation Therapy (ADT). The 
addition of experimental arms are treated like two-arm multi-stage trials (Sydes 
et al. 2011). More details of this trial can be found in chapter four.  
 
Figure 2.7: A graphical representation of a Platform trial design (Park et al. 2019). 
  Operational considerations  
The appropriate choice of adaptive design method to adopt is critical but it is also 





resource intensive demands required to execute adaptive trials. Underestimating 
this could result in the early closure of a trial due to lack of resource.   
At the planning stages of a trial, it is important to outline all trial processes, 
evaluate the hurdles that may occur and ensure strategic planning to either avoid 
these pitfalls or increase the efficiency of these processes. For example, remote 
online data entry at sites instead of using paper case report forms (CRFs) may be 
a more efficient way to collect the data and avoid data input errors by the trial 
team. If an adaptive trial has interim analyses, then the time between each interim 
stage must be sufficient to cater for the operational demands required prior to 
any analysis, like sufficient time required for data entry, validation and querying 
to ensure that all data is clean and up to date, the logistical preparation required 
such as organising meetings and being ready to action the outcome of these 
meetings, i.e. if the decision at an interim analysis meeting is to discontinue an 
experimental arm then ensure the trial team is prepared.  
Trials that employ adaptive designs should always have an independent Data 
Monitoring Committee (DMC) to ensure the credibility/integrity of the decisions 
made during the trial. Trial teams can face logistical difficulties in arranging DMC 
meetings which can lead to delays in making decisions. Therefore, to ensure 
quoracy is met, trial teams may want to employ a larger than normal DMC.  
Non-trial specific processes must be taken into consideration, for example, it is 
inevitable that there will be some sort of staff turnover during the life of the trial 
and hence trial teams must ensure that processes are in place to ensure efficient 
training of new staff members. 
The operational papers published by the STAMPEDE and FOCUS4 trial teams 
discuss at the data management challenges, operational aspects and personal 
experiences of the researchers involved on these teams and should be referred to 
prior implementing adaptive trials (Hague et al. 2019, Morrell et al. 2019, 
Schiavone et al. 2019).   
A few of the many aspects to consider when implementing any sort of adaptive 
trial have been outlined above. Trial teams can also refer to the Practical Adaptive 
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and Novel Designs and Analysis (PANDA) project1 which is currently under 
development, however will be a useful resource and aims to educate researchers 
with regards to the practical applications when applying adaptive designs in RCTs 
(ScHARR CTRU 2020). More considerations when designing an adaptive trial are 
discussed in chapter seven. 
  Software for Adaptive designs 
The design and analysis of adaptive designs can be complex in comparison to 
standard trials and hence the use of customised software is required (Gallo et al. 
2006). The development of computational software for adaptive design 
methodology is continually increasing and specialised software such as the FACTs 
(Fixed and Adaptive Clinical Trials Simulator), EAST and COMPASS software have 
been created to assist in designing adaptive trials (Corporation 2000, Berry et al. 
2010, Berry Consultants 2012, Bolognese 2017).  
The FACTs software created by Berry consultants2 allows users to design, simulate 
and compare adaptive design based clinical trials. This software can simulate dose 
escalation trials, dose finding trials and enrichment trials. Furthermore, this 
software allows various key components to be modified during the course of the 
trial such as treatment arms, allocation ratio and sample size and is extremely 
useful for designing phase I studies. The EAST software can also assist in the 
creation and simulation of adaptive based trial design. However, this software has 
different options compared to the FACTs software to assist in implementing 
adaptive designs such as ensuring strong error control of the FWER with multi-arm 
trials, providing an array of accurate early stopping boundaries to consider 
different options such as sample size, cost effectiveness and differences in time 
for implementing a MAMS design with options for sample size re-estimation, dose 
selection and early stopping. The COMPASS software focuses on designing 
adaptive dose-finding trials, giving both Bayesian and Frequentist methods and 






Programs have also been created to be used within commonly used software such 
as SAS, R or Stata (Chang 2014, Grayling 2017, Grayling 2019). For group sequential 
designs the ‘SEQDESIGN’ package within SAS can be used and is aimed at creating 
interim analyses for clinical trials, the ‘gsDesign’ package within R focuses mainly 
on designs to implement alpha and beta spending functions however only the 
Wang-Tsiatis method, O’Brien-Fleming and Pocock methods are available (Pocock 
1977, O'Brien et al. 1979, Wang et al. 1987).  
Michael Grayling and his colleagues have created a group of packages to design 
group sequential clinical trials with normally distributed outcome variables within 
Stata (Grayling 2017) such as the ‘HaybittlePeto’ package that implements a group 
sequential design with Haybittle-Peto boundaries (Haybittle 1971, Peto et al. 
1977) and the ‘WangTsiatis’ package that calculates the sample size and the 
boundaries required to implement a group sequential design with Wang-Tsiatis 
boundaries (Wang et al. 1987). The ‘LanDeMets’ package in Stata has been created 
by Ignacio Ulibarri and calculates the boundaries required for a group sequential 
design using the method of Lan and DeMets (Gordon Lan et al. 1983, Ullibarri 
2013).  This command further allows the user to select either the O’Brien-Fleming 
method or Pocock method to use as the alpha spending function. 
As mentioned previously, an extension to the group sequential design is the 
MAMS design, the ‘mams’ package within R has been created by Thomas Jaki and 
his colleagues to assist in designing these trials (Jaki et al. 2019). Prior to the 
release of this command, Patrick Royston and his colleagues developed the 
following packages within Stata to assist with the design and implementation of 
the MAMS designs: 
- The ‘artsurv’ command calculates both sample size and power for trials 
that have time-to-event outcomes  (Royston et al. 2010). 
- The ‘artpep’ command addresses the practical issue of staggered 
recruitment and accumulation of data in time-to-event outcome based 
trials (Royston et al. 2010). Sample size calculations are based on critical 
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assumptions and uses the number of events as an important indicator of 
trial progression. The ‘artpep’ command is used to project the power and 
events in trials.  
- The ‘nstage’ command offers calculations of sample size, number of events 
and trial duration for trials with two or more treatment arms with a time-
to-event outcome (Barthel et al. 2009, Blenkinsop et al. 2019). The 
command influences the decision to reject treatment arms that show lack 
of or no benefit against the control arm by comparing the HR obtained 
against a critical HR. Therefore, encouraging those treatment arms that 
indicate a difference to proceed based on the HR obtained. An 
intermediate outcome measure can be used instead of the primary 
outcome measure at the interim stages of testing. A pairwise comparison 
occurs between each experimental arm and control arm to determine 
which treatments continue to the next stage. Conclusively, treatments that 
have continued to the final stage are compared against the control arm on 
the primary outcome measure and superiority is concluded. This command 
can be used in conjunction with the ‘artsurv’ and ‘artpep’ to measure and 
calculate the timings of interim analyses based on real-time recruitment.   
Three MAMS based cancer trials (FOCUS4, STAMPEDE and CompARE trials) are 
described in chapter five, all three of these trials have been designed using the 
Stata commands, ‘artpep’ and ‘nstage’. 
 Conclusion 
There are numerous ways in which adaptive designs can be conducted within 
Oncology, as discussed within this chapter. Adaptive designs are implemented 
more in oncology than other disease areas due to the often long duration of these 
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trials. Therefore, it would be advisable to consider more than one treatment at a 
time and adapt a trial sooner rather than later for efficiency where possible in 
these disease settings. Adaptive trial designs have the capacity to modify sample 
sizes in comparison to standard trial design to ensure the most efficient number 
of patients are treated with the best possible treatment. However, the execution 
of these trials from an operational perspective must not be undermined and 
diligence is required to ensure a ‘successful’ trial.  
The next chapter will investigate whether these innovative adaptive trial design 





3 Literature review of Cancer RCTs 
 Introduction 
The previous chapter discussed some of the common adaptive design methods 
and provided examples of how these methods have been applied. This led onto 
investigating the current literature to understand the use of adaptive design 
methods in RCTs and how these trials are reported. 
Previous literature reviews have been conducted to investigate specific adaptive 
design methods or to identify all adaptive design RCTs using clinical trial registries 
and the National Institute for Health Research (NIHR) register (Bauer et al. 2006, 
Stevely et al. 2015, Hatfield et al. 2016).  
One such review by Hatfield et al. (2016) investigated the condition and 
characteristics of registered adaptive design trials. This review used the 
ClinicalTrials.gov website and the NIHR register to collate all phase II, II/III and III 
adaptive design trials registered between 29 February 2000 and 1 June 2014. 
Hatfield et al. (2016) found that the use of adaptive designs have increased over 
time and out of the 143 trials found, the highest were within the field of Oncology 
(35/143, 24%). The limitations of the interface of the ClinicalTrials.gov website and 
NIHR register restricted the capture of all trials with adaptive designs. This led to 
the authors proposing that clinical trial registers should promote the use of the 
term ’Adaptive design’ in either the title, summary or design sections of the 
register or allocate a section to adaptive design.  
Stevely et al. (2015) investigated the reporting of phase III group sequential RCTs 
against the Consolidated Standards of Reporting Trials (CONSORT) 2010 checklist. 
Full text papers in the English language published from the 1 January 2001 to 23 
September 2014 were reviewed. Papers were eligible for inclusion if they were 
parallel group RCTs with confirmatory objectives that applied group sequential 
methods using a Frequentist approach, papers that applied Bayesian methods 
were part of the exclusion criteria. Many eligible papers reviewed were from the 
field of Oncology (76%). The authors concluded that the reporting of group 
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sequential trials was not in line with the CONSORT 2010 guidelines and therefore 
these issues could be alleviated by creating an extension to the current CONSORT.    
Bauer and Einfalt (2006) performed a review to assess applications of applied 
adaptive design methods based on the combination test or conditional error 
function approach (see section 2.5). A list of 60 papers that were published 
between 1989 and 2004 were selected. Many other papers were eligible for 
assessment however these 60 papers were selected by the authors as they 
thought that these papers would be the most cited when practically implementing 
adaptive design methods. The review concluded that the standard of reporting 
statistical methods needs improving and suggested a list of points that should be 
addressed when providing a description of the statistical methods used.   
All the above-mentioned reviews have either investigated a specific adaptive 
design method or explored trial registries to find adaptive design trials prior to 
2014. However, it is unclear what the state of applications of adaptive design 
methods in RCTs within the field of Oncology is and whether reporting has 
improved over time. The aim of this literature review was to capture full-text 
papers that incorporated adaptive design methods within phase II, II/III (also 
known as seamless trials – see section 2.9) or III RCTs in the field of Oncology 
published in 2015 as previous reviews have shown that the majority of adaptive 
trials have been applied in this field and the context of this PhD is focused on phase 
III cancer trials. The objectives of this review were: 
• To understand the different applications of adaptive design methods; 
• Whether these methods were being explicitly stated or if it had to be 
inferred that adaptive design methods were applied; 
• Whether these methods were pre-determined or if circumstances 
influenced the need to implement any adaptive changes (ad-hoc).  
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3.1.1 Extension to the CONSORT guidelines 
In 1996, the first CONSORT guidelines were published with the aim of improving 
the reporting of RCTs (Begg et al. 1996, CONSORT 2010). Since then, the CONSORT 
guidelines have evolved with updates being made in 2001 and the latest version 
in 2010 (Moher et al. 2001, CONSORT 2010). The CONSORT guidelines are based 
on a two-arm parallel design however various extensions have been added to the 
CONSORT to accommodate different design aspects, interventions and types of 
data such as cluster trials, pragmatic trials, acupuncture interventions (Campbell 
et al. 2004, Zwarenstein et al. 2008, MacPherson et al. 2010).  
The contents within this chapter are based upon research that has been published 
during the course of this PhD (Mistry et al. 2017a) (appendix 2). At the time of this 
research, the CONSORT 2010 contained sections related to the use of interim 
analyses, however some authors had suggested for the CONSORT to be extended 
exclusively for trial designs implementing adaptive design methods (Stevely et al. 
2015, Hatfield et al. 2016). Therefore, an extension to the CONSORT guidelines to 
incorporate adaptive designs was proposed (Mistry et al. 2017a). Furthermore the 
outcome of this review and extension to the CONSORT guidelines were presented 
at the International Society for Clinical Biostatistics conference, Birmingham 2017 
and at the International Clinical Trials Methodology conference, Liverpool 2017 
(Mistry et al. 2017b).  
Since this publication, the Adaptive designs CONSORT Extension (ACE) group 
introduced an official extension to the guidelines and have published various 
papers (Dimairo et al. 2018, Dimairo et al. 2019, Dimairo et al. 2020). The ACE 
group was approached with the intention to collaborate with them; however, it 
was too late as most of the work by the ACE group was completed.  Therefore, 
another part of this chapter compares the similarities and differences between the 




3.2.1 Literature search 
The literature search was conducted using the Embase, Ovid and PubMed 
databases. The review was constrained to the following inclusion criteria:  
• Application of adaptive design methods; 
• Phase II, phase II/III, phase III RCTs;  
• Within the field of Oncology;  
• Disclosed results of the primary outcome; 
• Published in 2015; 
• Full obtainable text; 
• Written in the English language. 
Any duplicate records were removed based on the title, authors, abstract and year 
of publication. Any potential modifications made to the trial/statistical process 
that were either premeditated, implemented spontaneously or retrospective 
were used as the definition to recognise when adaptive design methods had been 
utilised (Chow et al. 2008, Bretz et al. 2009).   
A free text search was conducted using the key search terms to maximise the 
capture of phase II, II/III or III RCTs in the field of Oncology, the list of these search 
terms can be found in appendix 3. 
3.2.2 Data extraction 
An Excel spreadsheet was used to record the following data: 
• Standard demographics such as first author, title, name of the trial;  
• The journal that the paper was published in; 
• The sponsor or funder of the study; 
• Trial phase; 
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• Cancer type being reported; 
• Nature of the primary outcome; 
• Number of trial arms; 
• What sort of intervention was being implemented; 
• How many planned/unplanned interim analyses; 
• At what stage the trial is being reported, i.e. interim or final analysis; 
• If there was any planned/unplanned stopping criteria and reason;  
• If the trial was concluded early and the reason;  
• Initial planned sample size and the reported sample size; 
• Type of adaptive design method implemented; 
• Number of adaptive design methods that were applied; 
• Whether the adaptive design methods applied were pre-determined, ad-
hoc or both; 
• If the use of adaptive design methods were explicitly stated or if it had to 
be inferred; 
• The trial identifier if registered on clinical trial registries. 
The papers identified by the literature search were all reviewed, and the 
information was extracted and recorded in the Excel spreadsheet. Data that could 
not be found in the paper was researched by using the trial identifier or trial name 
to find out the relevant information. If no further information was available, then 
the data was classified as missing. The categorisation of the adaptive design 
methods were based upon those made by the FDA (US Food and Drug 
Administration 2018). 
The eligibility of all the papers and reasons for full text exclusions were checked 
by myself and supervisors (Andrea Marshall and Janet A. Dunn). A 10% sample was 
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checked for accuracy of all information by the supervisors. Any discrepancies were 
discussed and a consensus agreed.  
3.2.3 CONSORT extension  
The proposed CONSORT extension was developed through a series of discussions 
and an iterative process with the supervisors (Janet Dunn and Andrea Marshall). 
Each item of the CONSORT statement was evaluated to determine whether 
clarification for adaptive designs was necessary based on prior knowledge and 
evidence from the literature review. Suggestions for how adaptations should be 
incorporated into the extension were discussed until a consensus was agreed. 
Furthermore, proposed extensions were submitted as a manuscript and 
extensively reviewed prior to publication by Joseph Koopmeiners, Abigail Shoben 
and Kristen May Cunanan all of whom have experience with the adaptive designs, 
for the suitability and applicability of the proposed CONSORT extension.  
 Results 
Across the Ovid, Embase and PubMed databases, 8288 records were recognised 
as RCTs in the field of Oncology. There were 734 records which were related to 
adaptive design methods within phase II, phase II/III and phase III trial setting. The 
removal of duplicates reduced the number of papers to be screened to 464 
records. Of the 464 records, 364 were deemed ineligible due to the following 
reasons:  
• Only the abstract was published (n=263); 
• Did not meet all inclusion criteria (n=68); 
• Record was either a review or a methodology paper hence would not 
contain any results (n=33). 
This left 100 full text records which were assessed in more detail for eligibility, of 
which a further 46 records were removed for the following reasons:  
• Not a RCT (n=33); 
• The trial was not cancer related (n=3); 
96 
 
• No analysis on the primary outcome measure (n=9); 
• No relevant information provided (n=1). 
A total of 54 records were included in the final review which has been presented 
below using the PRISMA flow diagram in Figure 3.1 (Liberati et al. 2009). A detailed 
list of all 54 papers used can be found in appendix 4. 
 
Figure 3.1: PRISMA flow diagram showing the process to identify the papers for final 
review. 
The 54 papers reviewed were all RCTs and published in 21 different journals, of 
which the Journal of Clinical Oncology had the highest number of papers (12/54, 
22%), the Lancet Oncology journal followed with 11 papers (21%), followed by the 
New England Journal of Medicine (6/54, 11%), European Journal of Cancer (3/54, 




Figure 3.2: Pie chart of the journals in which the papers obtained from the literature 
review have been published. 
The number of arms within these trials ranged from a minimum of two arms to a 
maximum of five arms; 46 (85%) papers were two arm trials, 6 (11%) were three 
arm trials, 1 (2%) was a four arm trial and 1 (2%) was a five arm trial (Table 3.1). 
Of the 54 papers reviewed, 38 papers (70%) were phase III trials, of which 35 of 
these were two arm trials, 2 of these were three arm trials and one four arm trial. 
Of the phase II trials, 10 trials had implemented two arms, two trials implemented 
three arms. One two arm trial and one three arm trial were implemented in phase 
IIb. Additionally, there was one seamless phase II/III trial with five arms in which 
patients were assigned either placebo or one of four propranolol regimens. A pre-
planned interim analysis identified one of the four regimens and was carried 
forward into a phase III trial (Table 3.1). 
Trial phase 
reported 
Number of arms Total 
2 3 4 5 
Phase II 10 2 0 0 12 
Phase IIb 1 1 0 0 2 
Phase II/III 0 1 0 1 2 
Phase III 35 2 1 0 38 
Total 46 6 1 1 54 








The majority of papers (50/54, 93%) incorporated drugs as the intervention for the 
study, whilst the remaining four interventions were a surgery/chemotherapy/ 
radiotherapy intervention (3/54, 6%) or a vaccine intervention (1/54, 2%) (Table 
3.2). Additionally, the primary outcome measure for 45 out of 54 (83%) papers 
were time to event outcomes. The majority of primary outcomes were either PFS 






Table 3.2: List of categorised interventions of the papers. 
Primary outcome Frequency 
Bowel movement/Flushing episodes 1 
Disease Control Rate 1 
Optimal dose 1 
Overall pain response 1 
Response to treatment 1 
Cytogenic Response 2 
Success/Failure 2 
Time to event outcomes 
DFS 
EFS 
OS and RFS 
Time to neuropathy 
RFS 













Table 3.3: List of primary outcomes of the papers. PFS = Progression-free survival; OS = 
Overall Survival; RFS = Relapse-free survival; EFS = Event-free survival; DFS = Disease-free 
survival.  
There were 33 (61%) papers which published results obtained during an interim 
analysis, the remaining papers published results from either a subgroup analysis 
(1/54, 2%) or the final analysis (20/54, 37%). There were 26 (48%) papers that 
published results based on an interim analysis resulting in the trial reporting earlier 
than planned (Table 3.4), the reasons for reporting early were due to 
safety/efficacy/futility (21/26, 81%), met the primary endpoint (3/26, 12%) and 
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slow recruitment (2/26, 8%). All 26 papers had a pre-planned stopping criteria 
incorporated within the trial design for which an interim analysis would be 
performed that would check for safety/efficacy/futility i.e. group sequential 
methods (Table 3.4).  A pre-planned analysis was incorporated within the majority 
of the papers (48/54, 89%). During the course of the trial 34 out of 48 papers 
planned for one interim analysis, 9 planned for two interim analyses, 3 planned 
for three interim analyses and the 2 remaining trials planned to perform an interim 
analysis annually. 
Trial reported early Pre-planned stopping criteria  Total 
No Yes Unknown 
No 5 22 1 28 
Yes 0 26 0 26 
Total 5 48 1 54 
Table 3.4: Two-way table comparing early stoppage against pre-planned stopping 
criteria. 
A single adaptive design method was applied within 44 out of 54 papers (82%), 
two methods applied within 9 out of 54 papers (17%) and three methods applied 
within 1 paper (2%) (appendix 4). There were no papers published from the same 
protocol. A total of 65 applications of adaptive design methods were implemented 
with adaptations using group sequential methods being the highest with 50 out of 
65 applications (77%), followed by adaptations to treatment arm selection (8/65, 
(12%)), adaptations to sample size (4/65, 6%), adaptations to patient allocation 
(1/65, 2%), adaptations to endpoint selection (1/65, 2%) and adaptations to 
patient population (1/65, 2%).  
Adaptive design methods were pre-determined within 49 out of 54 papers (91%), 
four papers had incorporated pre-determined and ad-hoc methods and one paper 
had applied ad-hoc adaptive design methods. The explicit use of the phrase 
‘adaptive design’ to classify the use of adaptive design methods was stated in only 
two out of the 54 papers (4%); one paper incorporated multiple adaptive design 
methods including group sequential methods, sample size re-estimation and dose 
modification, the other paper stated the use of a ‘Bayesian adaptive response 
design’ which included dose modification and adaptive randomisation.  
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The different variables extracted from the papers have been categorised by 
adaptive design method applied (Table 3.5). Most studies using group sequential 
methods had two trial arms (42/50) and were in a phase III trial setting (35/50). All 
group sequential methods incorporated a planned stopping criteria as expected 
(see section 2.4) and 26 papers that reported an interim analysis resulted in early 
stopping of the trial. There were six trials that performed an interim analysis 
resulting in the trial continuing of which two were in the recruitment phase, two 
in the follow-up phase, one trial evaluated safety and one phase II trial concluded 
efficacy of a drug to be carried forward into a phase III trial.  
Papers that implemented dose modification methods all had pre-determined the 
application of adaptive design methods, although only one explicitly stated the 
use of this method. All four papers that implemented sample size re-estimation 
methods incorporated a planned stopping criteria and led to the trial stopping 
early. Additionally, three out of the four papers that applied sample size re-
estimation had both pre-determined and ad-hoc adaptive design methods.   
 Discussion  
Various reviews have given different taxonomies to adaptive design methods, 
therefore the question arose as to how to classify these methods. It was decided 
to utilise the categories specified by the FDA as these categories are standardised 
(US Food and Drug Administration 2007, Chow et al. 2008, Bhatt et al. 2016, 
Hatfield et al. 2016, US Food and Drug Administration 2018). As mentioned in 
chapter two, group sequential methods have been used widely for a number of 
years so the robustness and the familiarity of these methods qualified them to be 
classified as ‘well understood methods’ by the FDA  in the previous  adaptive 
design guidance produced in 2010 (Todd 2007, US Food and Drug Administration 
2010). Any papers from the literature search that incorporated interim analyses 
whereby treatment/trial related decisions were made were classed as group 
sequential methods.   
A sensitivity analysis was performed to check if there were any papers published 
in 2015 by the known exemplar adaptive trials (section 4.3) that satisfied our 
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inclusion criteria, which were missed by the search. Two possible papers were 
identified relating to the STAMPEDE trial (James et al. 2015, James et al. 2016), but 
the first reported the results for the control arm as a cohort study and not the 
primary comparative results of the randomised trial and therefore was not eligible. 
The second paper (James et al. 2016) had an issue date of 2016 and therefore just 
fell outside of the search strategy, as the date of issue was used in the search 
strategy and not the online published date, which may be a limitation of the search 
strategy.    
The review found that 53 out of 54 papers had pre-determined adaptive design 
methods which supported the definition specified by the FDA and many of these 
were phase III suggesting that adaptive design methods in RCTs are more 
frequently used in confirmatory trials. The extensive list of search terms (appendix 
3) assisted in the capture of papers relating to various adaptive design methods, 
however only two papers explicitly defined the trial design to be an ‘adaptive 
design’ whilst it was inferred from the remaining papers.  
One of the objectives of this literature review was to assess the reporting of the 
application of adaptive design methods within RCTs in the field of Oncology. This 
review reaffirmed the conclusions of the aforementioned reviews that there is a 
need to improve the reporting of adaptive design methods.  
Furthermore, this review reiterated the need for an extension to the current 
CONSORT statement to ensure successful capture of adaptive design methods in 
RCTs as concluded by Stevely et al. (2015) and Hatfield et al. (2016). Thus, I 
proposed an extension to the CONSORT 2010 guidelines which has been published 
in the BioMed Central Medical Research Methodology journal (Mistry et al. 
2017a). Thereafter, a consensus driven CONSORT extension for RCTs using 
adaptive design has been published (Dimairo et al. 2018) and a workshop was held 
by the ACE group in 2019 whereby the finalised guidelines were disseminated 
(appendix 5). Upon comparing the two extensions (Table 3.6), there were many 
similarities found, such as in section 2, where both CONSORT extensions 
emphasised the need for clearly defining the type of adaptive design used and 
reporting important changes in the design methods during the trial. In section 7 of 
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the proposed CONSORT extension guidelines, it was suggested that it is vital that 
any interim analyses that are performed are clearly shown and the decision 
making processes at this point are thoroughly explained.  
Conversely there are items proposed in my extension which have not been 
mentioned in the CONSORT Statement by the ACE group such as stating in the title 
that it is an adaptive randomised trial to make it transparent that adaptive design 
method was adopted although the title word limit may prohibit this. However, the 
ACE group stressed the use of the term ‘adaptive’ as a keyword, which will be 
useful as an identifier in future literature searches. Additionally, I proposed that 
the rationale for implementing an adaptive design must be explained which has 
not been added in the CONSORT Statement extension proposed by the ACE group. 
Providing a rationale as to why a particular adaptive design has been implemented 
can be useful in giving justification and promoting adaptive designs.    
The ACE group added sections to the original CONSORT 2010 checklist so it would 
cater more towards adaptive designs. In section 11, the ACE group emphasised 
that measures to ensure minimal interim information are reported to avoid any 
operational bias. An item in section 12 of the CONSORT 2010 has been added by 
the ACE group titled ‘Statistical Methods’ such that for any adaptive design 
feature, the statistical methods applied to make any key estimates or inferences 
were clearly shown. This was similarly proposed in my CONSORT extension 
whereby using simulation studies to show estimates or inferences has been 
suggested. A section reporting the results of any interim analyses has been added 
to section 17, ‘Outcomes and estimation’. This decision has been regarded as very 
important as the decisions made at an interim analysis can dictate the way a trial 
runs and hence to report these are regarded as fundamental for any trial 
implementing interim analyses. The ACE group had experts in adaptive designs 
that provided input into the CONSORT extension which was a limitation to the 
CONSORT Statement I proposed. The extension to the CONSORT Statement 
published by myself and the ACE group (Mistry et al. 2017a, Dimairo et al. 2018) 
share a similar goal in striving to raise awareness of better and more transparent 
reporting of adaptive designs.  
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Data extracted  
Adaptive method applied* 
Group sequential 












primary endpoint            
 (n=1) 
Change in patient 
eligibility      
  (n=1) 
Trial phase             
II 13 2 0 1 0 0 
II/III 2 1 1 0 0 0 
III 35 5 3 0 1 1 
Number of arms             
2 42 7 2 1 1 1 
3 6 1 0 0 0 0 
4 1 0 1 0 0 0 
5 1 0 1 0 0 0 
Stage of reporting             
Interim analysis 33 2 2 0 1 1 
Subgroup analysis 0 1 0 0 0 0 
Final analysis 17 5 2 1 0 0 
Planning of adaptive design method             
Pre-determined 45 8 1 1 0 1 
Ad-hoc 1 0 0 0 0 0 
Both 4 0 3 0 1 0 
Explicitly labelled as an adaptive design             
Yes 1 1 1 1 0 0 
No 49 7 3 0 1 1 
Planned stopping criteria              
Yes 50 5 4 0 1 1 
No 0 3 0 1 0 0 
Trial stopped early             
Yes 26 1 4 0 1 0 
No 18 6 0 1 0 1 
Not yet 6 1 0 0 0 0 
*Numbers based on the number of methods applied (65 adaptive methods) and not based on the number of papers.     
Table 3.5: Data extracted split by adaptive method applied. 
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Section/Topic Item No Standard Checklist item Proposed Extension for Adaptive Designs ACE Group Extension for Adaptive Designs 
Title and abstract 
  
1a Identification as a randomised trial in the title 
Identification as an adaptive 
randomised trial if it is an 
adaptive design    
1b 
Structured summary of trial design, 
methods, results, and conclusions (for 
specific guidance see CONSORT for 
abstracts) (Hopewell, Clarke et al. 2008, 
Hopewell, Clarke et al. 2008) 
Include the term ‘adaptive 
design’ or ‘adaptive methods’   
Trial design: Description of the trial design (for 
example, parallel, cluster, non-inferiority); include the 
word ‘adaptive’ in the content or at least as a 
keyword 
 
Outcome: Clearly defined primary outcome for this 
report 
 
Adaptation decisions made: Specify what trial 
adaptation decisions were made in light of the pre-
planned decision-making criteria and observed 
accrued data. 
Introduction  
Background and objectives 
2a Scientific background and explanation of rationale 
Rational for implementing an 
adaptive design    




Description of trial design (such as 
parallel, factorial) including allocation 
ratio 
Define what adaptive design/ 




Important changes to methods after trial 
commencement (such as eligibility 
criteria), with reasons 
Any changes during the trial 
should be reported as an 
adaptive method. 
Important changes to the design or methods after 
trial commencement (such as eligibility criteria) 
outside the scope of the pre-planned adaptive design 
features, with reasons 
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Section/Topic Item No Standard Checklist item Proposed Extension for Adaptive Designs ACE Group Extension for Adaptive Designs 
 3b  Pre-planned adaptive design features   
Type of adaptive design used, with details of the pre-
planned trial adaptations and the statistical 
information informing the adaptations 
Participants 
4a Eligibility criteria for participants 
Any changes in eligibility 
during the trial, should be 
classed as an adaptive design 
or adaptive method.  
  
4b Settings and locations where the data were collected 
    
Interventions 5 
The interventions for each group with 
sufficient details to allow replication, 
including how and when they were 
administered 
    
Outcomes 
6a 
Completely defined pre-specified primary 
and secondary outcome measures, 
including how and when they were 
assessed 
  Completely define pre-specified primary and 
secondary outcome measures, including how and 
when they were assessed. Any other outcome 
measures used to inform pre-planned adaptations 
should be described with the rationale 
6b Any changes to trial outcomes after the trial commenced, with reasons 
Any changes during the trial 
are classed as an adaptive 
method and should be 
mentioned.  
Any unplanned changes to trial outcomes after the 
trial commenced, with reasons 
Sample size 7a How sample size was determined 
Any changes to sample size or 
power during trial classed as 
an adaptive design or adaptive 
method and should be 
mentioned.   




Section/Topic Item No Standard Checklist item Proposed Extension for Adaptive Designs ACE Group Extension for Adaptive Designs 
7b When applicable, explanation of any interim analyses and stopping guidelines 
Explain why the interim 
analysis will be taking place, if 
potential pre-planned 
adaptations during interim 
analysis taking place then 
these should be mentioned in 
the methods as well (3b). 
Include details of any planned 
stopping boundaries for either 
the trial or dropping any of the 
intervention arms.    
Pre-planned interim decision-making criteria to guide 
the trial adaptation process; whether decision-making 
criteria were binding or nonbinding; pre-planned and 
actual timing and frequency of interim data looks to 
inform trial adaptations 
Randomisation: 
Sequence generation 
8a Method used to generate the random allocation sequence 
    
8b 
Type of randomisation; details of any 
restriction (such as blocking and block 
size) 
Details if adaptive 
randomisation has been 
implemented. 
Type of randomisation; details of any restriction (such 
as blocking and block size); any changes to the 
allocation rule after trial adaptation decisions; any 
pre-planned allocation rule or algorithm to update 
randomisation with timing and frequency of updates 
Allocation concealment 
mechanism 9 
Mechanism used to implement the 
random allocation sequence (such as 
sequentially numbered containers), 
describing any steps taken to conceal the 
sequence until interventions were 
assigned 
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Section/Topic Item No Standard Checklist item Proposed Extension for Adaptive Designs ACE Group Extension for Adaptive Designs 
 Implementation 10 
Who generated the random allocation 
sequence, who enrolled participants, and 
who assigned participants to interventions 
   
Blinding* 
11a 
If done, who was blinded after assignment 
to interventions (for example, 
participants, care providers, those 
assessing outcomes) and how 
    
11b If relevant, description of the similarity of interventions 
    
 11c  Confidentiality and minimisation of operational bias 
  Measures to safeguard the confidentiality of interim 
information and minimise potential operational bias 
during the trial 
Statistical methods* 
12a 
Statistical methods used to compare 
groups for primary and secondary 
outcomes 
Details of how the adaptive 
design or the adaptive 
methods were applied Details 
of how the statistical methods 
were evaluated before 
implementation i.e. through 
the use of simulations? 
  
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses     
12b  Estimation and inference methods 
  
For the implemented adaptive design features, 
statistical methods used to estimate treatment effects 
for key endpoints and to make inferences 
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Section/Topic Item No Standard Checklist item Proposed Extension for Adaptive Designs ACE Group Extension for Adaptive Designs 
Results 
Participant flow (a diagram 
is strongly recommended) 
13a 
For each group, the numbers of 
participants who were randomly assigned, 
received intended treatment, and were 
analysed for the primary outcome 
Ensure any adaptations are 
shown on this diagram, such 
as dropping of arms, 
treatment switching. 
For each group, the numbers of participants who 
were randomly assigned, received intended 
treatment, and were analysed for the primary 
outcome and any other outcomes used to inform pre-
planned adaptations, if applicable 
13b 
For each group, losses and exclusions 





14a Dates defining the periods of recruitment and follow-up 
    
14b Why the trial ended or was stopped 
Any changes to recruitment 
during trial classed as an 
adaptive method, should be 
mentioned.   
The reporting of reasons for stopping a trial early 
including circumstances leading to that decision could 
help readers to interpret results with relevant 
caveats.  
14c Adaptation decisions   
Specify what trial adaptation decisions were made in 
light of the pre-planned decision-making criteria and 
observed accrued data 
Baseline data* 15 A table showing baseline demographic and clinical characteristics for each group   
In the presence of marked differences in the numbers 
of randomised participants and those included in the 
interim or final analyses, authors are encouraged to 
report baseline summaries by treatment group for 
these two populations 
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Section/Topic Item No Standard Checklist item Proposed Extension for Adaptive Designs ACE Group Extension for Adaptive Designs 
15b Similarity between stages   
Summary of data to enable the assessment of 
similarity in the trial population between interim 
stages 
Numbers analysed 16 
For each group, number of participants 
(denominator) included in each analysis 
and whether the analysis was by original 
assigned groups 
  
In the number of participants by treatment group 
should be reported for each analysis at both the 
interim analyses and final analysis whenever a 
comparative assessment is performed (for example, 
for efficacy, effectiveness, or safety).  
Outcomes and estimation* 
17a 
For each primary and secondary outcome, 
results for each group, and the estimated 
effect size and its precision (such as 95% 
confidence interval) 
  
Reporting of results as detailed in the CONSORT 2010 
should mirror hypotheses of interest including 
subpopulations and full target populations. 
17b 
For binary outcomes, presentation of both 
absolute and relative effect sizes is 
recommended 
    
17c Interim results 
  Report interim results used to inform interim 
decision-making 
Ancillary analyses 18 
Results of any other analyses performed, 
including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from 
exploratory 
    
Harms 19 
All important harms or unintended effects 
in each group (for specific guidance see 
CONSORT for harms) (Ioannidis, Evans et 
al. 2004) 
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Section/Topic Item No Standard Checklist item Proposed Extension for Adaptive Designs ACE Group Extension for Adaptive Designs 
Discussion   
Limitations 20 
Trial limitations, addressing sources of 
potential bias, imprecision, and, if 
relevant, multiplicity of analyses 
  For AD randomised trials, further discussion should 
include any deviations from pre-planned adaptations, 
interim analyses, protocol amendments on trial 
adaptations and results, potential bias and 
imprecision of treatment effects, potential 
heterogeneity in patient characteristics and treatment 
effects between stages.  
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 
If ad-hoc adaptive methods 
were implemented, at what 
point was it decided to 
implement this and why.  
Authors should discuss the population to whom the 
results are applicable including any threats to internal 
and external validity which are trial dependent based 
on the implemented adaptations.  
Interpretation 22 
Interpretation consistent with results, 
balancing benefits and harms, and 
considering other relevant evidence 
    
Registration 23 Registration number and name of trial registry 
    
Protocol* 
24 Where the full trial protocol can be accessed, if available 
First and last protocol, with a 
list of amendments made.   
24b Statistical analysis plan and other relevant trial documents   
Where the full statistical analysis plan and other 
relevant trial documents can be accessed 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 
    
*Sections have additional checklist items by the ACE group which have been coloured in grey.  
Table 3.6: Proposed extension to the current CONSORT diagram (CONSORT 2010) compared to the ACE extension released in 2019 (Dimairo et al. 2019). ACE 
– Adaptive Design CONSORT Extension.   
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Clark (2013) reviewed unpublished research protocols submitted to research 
ethics committees in the UK in 2009 and found that out of a total of 446 protocols 
submitted, six reported an adaptive design using sample size re-estimation 
methods but an additional 88 protocols implemented a group sequential design 
(Clark et al. 2013). Therefore, trials that fit the definition of adaptive designs as 
specified within this literature review are encouraged to implement the proposed 
extension however trial stakeholders and methodologist incorporating stopping 
guidelines may wish to stick to the term ‘group sequential’ due to its familiarity 
and contribution to statistical methodology for many years (Todd 2007). The 
adaptive design extensions to the CONSORT 2010 will improve reporting and will 
ensure that more adaptive design based trials are captured in future literature 
searches and can help trial stakeholders to decide at what point a trial can be 
classed as adaptive.  Furthermore, the greater capture of these adaptive methods 
through the CONSORT Statement extensions will greatly assist all those involved 
within clinical trials to ensure thorough planning and reporting of all adaptive 
natured RCTs, allowing full transparency of all adaptive methods performed during 
the trial.  
 Conclusion 
In conclusion, from the literature review very few trials reporting in 2015 explicitly 
reported the use of adaptive design methods, which could imply that there may 
be many more trials using adaptive design methods without clearly stating so. The 
literature review also confirmed that the reporting of adaptive design methods 
within RCTs is poor and requires improvement. Following the adaptive design 
extension to the CONSORT 2010 guidelines may help to improve transparency of 




4 Review of Adaptive designs used in Oncology clinical trials  
 Introduction 
The literature review reported in chapter three suggested that adaptive methods 
were regularly implemented in oncology trials but not necessarily defined as 
‘adaptive trials’. This led to the decision to conduct a scoping exercise of the 
Warwick CTU trial portfolio, whereby on-going or completed cancer trials were 
assessed to see what trial design was implemented and if these trials used any 
adaptive methods. This exercise was expanded to examine exemplar oncology 
RCTs known to Warwick CTU that have implemented adaptive design methods.   
The number of phase III Oncology trials has continually increased over the years, 
with most trials adopting a superiority hypothesis when comparing new cancer 
therapies to the standard. However, there are some novel cancer therapies that 
have been developed which are just as effective as the standard of care but are 
more convenient and less toxic (non-inferior) (Saad 2018). Hence, the choice of 
the hypothesis within phase III trials is dependent on the goals of the study. The 
choice of hypothesis will also be explored within this chapter.  
 Warwick CTU Scoping Exercise 
Within Warwick CTU there were 13 on-going or completed phase II or phase III 
cancer trials in the portfolio in 2019 when the scoping exercise was undertaken. 
These 13 trials were assessed for the use of adaptive methods and choice of 
hypothesis with the results detailed below (Table 4.1). The Determination of 
Epidermal growth factor receptor-inhibitor versus Standard Chemotherapy early 
And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal 
squamous cell carcinoma (De-ESCALaTE) trial had no changes, and the Optimal 
Personalised Treatment of early breast cancer using Multi-parameter Analysis 
(Optima) trial (including Optima prelim– the feasibility phase) was developed with 
an adaptive design. The remaining 11 out of 13 trials showed some form of pre-
planned adaptation. The following adaptive methods were identified through this 
exercise; changes in the sample size including changes to the power of the study, 
changes in the eligibility criteria, and performing interim analyses to assess for 
113 
 
safety, efficacy or futility of drugs. Details of each trial and adaptations 
incorporated will be discussed in the following sections.   
4.2.1 ARTemis trial – Pre-planned interim analysis 
The Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with 
early breast cancer (ARTemis) trial was a randomised phase III trial in patients 
diagnosed with human epidermal growth factor receptor 2 (HER2)-negative early 
breast cancer (Earl et al. 2015). The trial aimed to determine whether the addition 
of an anti-angiogenic agent bevacizumab to neo-adjuvant chemotherapy is 
superior to the standard neo-adjuvant chemotherapy in terms of both short and 
long-term outcomes.  
The power calculations assumed a 70:30 split in the sample size between people 
with Oestrogen receptor (ER) positive and ER negative tumours and a pathological 
complete response on the standard arm of 10% and 25% respectively. A total of 
800 patients (400 patients in each arm) were recruited into the trial to allow an 
absolute difference of 10% to be detected between the treatment groups in the 
primary outcome of pathological complete response with 85% power at the 5% 
two-sided significance level. The assumptions used for the sample size calculations 
were checked by the DMC. A pre-planned interim safety analysis was performed 
on the first 200 patients completing treatment to check for any potential safety 
issues related to the bevacizumab drug. The results of this interim analysis were 
considered by the DMC, who reported no safety concerns. As an interim analysis 
due to safety had been incorporated within this trial, it could be classed as a group 
sequential adaptive design. 
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Trial Status*ⴕ Adaptive Method Hypothesis Summary 
ARTemis Long term follow-up Interim analysis Superiority 
Planned interim analysis for safety.  
Interim results showed no safety concerns, trial continued as planned. 
Superiority hypothesis implemented; absolute difference of 10%.  
AVAST-M Long term follow-up 
Interim analysis, 
change in eligibility Superiority 
Planned interim analysis for safety and efficacy. Interim results showed 
no concerns hence continued as planned. Final analysis when all 
patients had been on study for five years. 
Eligibility criteria broadened to help increase rate of recruitment.  
Superiority hypothesis implemented; absolute difference of 8%  
COUGAR-02 Completed Sample size change, change in eligibility Superiority 
Sample size decreased from 320 to 164 patients due to new external 
information obtained and change of assumptions in the control arm.  
Eligibility criteria broadened to help increase rate of recruitment.  
Superiority hypothesis implemented; increase in median survival of two 
months.  
LIHNCS Completed Sample size change, change in eligibility Superiority 
Sample size increased from 300 to 419 patients to allow for increased 
power in the pre-planned subgroup analysis.  
Eligibility criteria broadened to help increase rate of recruitment.  
Primary outcome looked at rate of dysplasia hence superiority 
hypothesis implemented to detect absolute difference of 13%.  
MAMMO-50 Follow-up phase Closing of cohort NI 
Closure of cohort study due to recruitment of patients being detracted 
from main RCT. 
NI hypothesis implemented; absolute NI margin of 3%. 
Neo-Escape Completed Interim analysis Superiority Phase II two arm trial implementing 'Pick the winner' approach.  Planned interim analysis resulting in closing of an arm due to futility.  
Optima Recruitment phase Addition of trial arm NI 
Adaptive design implemented - plan to add additional multi-parameter 
test arms.  
NI hypothesis implemented; absolute NI margin of 3%. 
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Trial Status*ⴕ Adaptive Method Hypothesis Summary 
Persephone Long term follow-up Interim analysis NI 
Unplanned interim analysis performed due to results released of 
another similar trial. Interim analysis results showed no concerns; trial 
continued as planned.  
NI hypothesis implemented; absolute NI margin of 3%.  
PET-NECK Completed 




A minimum of 140 deaths were required at the end of the planned two-
year follow-up period; this was not met resulting in extending the 
follow-up period to 5 years.   
Eligibility criteria was forced to be broadened due to a change in 
practice at many centres; this could have resulted in a significant 
reduction in recruitment if the change was not made.  
NI hypothesis implemented; absolute NI margin of 10%.  
Select-D Completed Sample size change Superiority 
The second randomisation was closed due to futility. Sample size 
reduction from 530 patients to 400 patients in first randomisation.  
Pilot study estimating VTE recurrence rate originally with a width of the 
95% CI of 8% but increased to a width of 9%.  
TEAMM Completed Sample size change Superiority 
Sample size increased from 800 patients to 1000 patients. 
Superiority hypothesis implemented; amended from 10% difference 
with 90% power to 7% difference with 80% power.  
VICTOR Completed Trial closure, sample size change Superiority 
Early closure of trial due to withdrawal of study drug. Sample size was 
8000 but forced to analyse the 2434 recruited.  
Superiority hypothesis implemented; amended from 20% difference 
with 85% power to 25% difference with 87% power.  
*Completed meaning that primary outcome has been reported and no longer following-up patients. ⴕStatus of the trials at December 2020. 




4.2.2 AVAST-M – Pre-planned interim analysis, change in eligibility 
Adjuvant Avastin trial in high risk melanoma (AVAST-M) was a randomised phase 
III trial with a superiority hypothesis that investigated whether bevacizumab after 
standard surgery would help patients diagnosed with melanoma who were at high 
risk of recurrence and to see if this population live longer. Patients were allocated 
to either bevacizumab or regular checks post-surgery. The trial required a 
minimum of 1320 patients (660 patients in each arm) to detect an absolute 
increase in five-year OS from 40% to 48% with 85% power at the 5% two-sided 
significance level. The trial recruited 1343 patients; 671 were allocated 
bevacizumab and 672 had regular check-ups (Corrie et al. 2014).  
A pre-planned interim analysis of safety and efficacy took place once all patients 
had finished treatment and had been in the study for at least a year which resulted 
in the continuation of the trial as planned. During the conduct of the trial, the 
eligibility criteria were broadened to extend the potential pool of patients suitable 
for the trial and improve recruitment. The inclusion criteria were extended to 
include patients greater than 16 years rather than 18 years, those with stage IIB 
disease and patients that may have received prior adjuvant therapy at an earlier 
stage of their disease. A final analysis of the AVAST-M trial was performed when 
all patients had been on the study for five years.  
4.2.3 COUGAR-02 – Sample size decrease, change in eligibility 
COUGAR-02 was a phase III open-label RCT with a superiority hypothesis that 
investigated the use of a chemotherapy drug, docetaxel, versus active symptom 
control for patients with advanced oesophago-gastric adenocarcinoma who 
relapsed within six months of previous chemotherapy (Ford et al. 2014).  
The initial sample size calculated that 320 patients were required to be recruited 
within two years with a follow-up period of approximately six months to detect a 
difference in median survival from four months to six months with 90% power and 
5% two-sided significance level. A minimum of 133 events in the control arm 
would be obtained by this time. However, the obtainment of new external 
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evidence from a similar trial showed that the actual OS was lower (2.4 months 
median OS) than initially assumed (Thuss-Patience et al. 2011). Hence after two 
years of recruitment and with 57 patients randomised, the sample size was 
amended using this new external data from 320 patients to 164 patients to be 
recruited within 3.5 years with six months for follow-up. The new sample size 
would require a minimum of 81 events to detect an increase in median survival 
from 3.5 to 5.5 months with 80% power and 5% two-sided significance level.  
Furthermore, the eligibility criteria were extended to include patients with 
oesophageal cancer and include patients that had more than one prior 
chemotherapy to increase the potential pool of eligible patients. Hence to adjust 
for the new type of cancers, stratification was adjusted from type of surgery 
(previous gastrectomy versus stomach in situ) to site of disease (oesophagus 
versus oesophago-gastric junction versus stomach).  
4.2.4 LIHNCS – Sample size increase, change in eligibility 
 The Lugol’s Iodine in Head and Neck Cancer Surgery (LIHNCS) phase III RCT with a 
superiority hypothesis investigated the use of Lugol’s iodine staining to improve 
clear resection margin rates in head and neck cancer surgery for oral and 
oropharyngeal carcinoma. Patients in this trial were allocated to either surgical 
treatment using Lugol’s iodine or the control group which was surgical treatment 
without the use of Lugol’s iodine (McCaul et al. 2013). 
The primary outcome for this trial was the rate of dysplasia at margins. Initially the 
planned total sample size was 300 patients to achieve 90% power with a 5% two-
sided significance level to detect a decrease of the rate of dysplasia from 20% in 
the control to 7% in the Lugol’s Iodine group. However, the samples size was 
increased to 419 patients to give more power to the pre-planned subgroup 
analysis of 300 patients with stage I/II: the good prognostic subgroup. 
4.2.5 MAMMO-50 – Closing of a cohort 
MAMMO-50 is an ongoing phase III RCT in women diagnosed with early breast 
cancer. It is investigating whether less frequent mammograms i.e. two yearly 
mammography for conservation surgery patients or three yearly for mastectomy 
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patients is not inferior to annual mammography (Mammo-50 2016). Furthermore, 
trial patients were over the age of 50 at initial diagnosis, previously treated for 
invasive or non-invasive breast cancer and were three years post diagnosis. 
Alongside this trial, eligible patients who did not want to be randomised had the 
option to be registered into a sister cohort.    
The total planned sample size of 5000 patients randomised were required to allow 
the detection of NI, where NI is defined as no worse than 3% below the control 
arm, assuming 5-year disease specific survival rate of 89%, with 90% power and a 
2.5% one-sided significance level. The cohort study was closed to recruitment after 
the feasibility phase as it detracted from recruitment into the main RCT. 
Recruitment of the target 5000 patients to the main RCT was completed in 
September 2018. As of December 2020, follow-up for these patients continues.  
4.2.6 Neo-escape – Pick the winner approach, pre-planned interim 
analysis 
The Neo-Escape trial was a two-arm randomised phase II trial to assess the 
feasibility of extended chemotherapy; comparing arm one: Neoadjuvant 
carboplatin, then surgery followed by adjuvant paclitaxel and gemcitabine versus 
arm two: Neoadjuvant gemcitabine and carboplatin, then surgery followed by 
adjuvant paclitaxel in patients with inoperable ovarian cancer (Poole et al. 2012).  
The primary feasibility outcome was the percentage of patients completing 12 
cycles of chemotherapy; >80% deemed an acceptable completion rate and <60% 
unacceptable. Fleming’s single stage procedure was used to calculate the required 
sample size of 44 patients for each trial arm to test feasibility with a type I error of 
5% and type II error of 10%. If both arms met the pre-specified feasibility criteria 
then the study would be extended to a comparative randomised trial using a ‘pick 
the winner’ approach (see section 2.9 for more information) for which an 
additional total of 36 patients would be recruited. Following an interim analysis, 
one of the trial arms was closed to recruitment on the grounds of futility, which 
suggested less than 5% probability of it reaching the pre-set criteria for feasibility. 
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The trial continued as a single arm phase II trial and closed to recruitment with 47 
patients recruited to the remaining trial arm.  
4.2.7 Optima trial – Add additional multi-parameter test arms  
The Optima trial is a partially blinded randomised phase III trial with a NI design 
comparing test directed therapy using a multi-parameter test with standard 
treatment of chemotherapy and endocrine therapy in early breast cancer patients 
(Stein et al. 2016). This trial has planned for the addition of other multi-parameter 
tests hence it has been classed as an adaptive design. It included a feasibility 
phase, Optima prelim, which evaluated various multi-parameter tests with a view 
to adapt the ‘gold-standard’ test after this preliminary stage if needed. One of the 
key conclusions from the Optima prelim trial was that although there is significant 
value to the National Health Service (NHS) to research into all multi-parameter 
tests, the Prosigna test was considered as the highest priority. This was a key 
reason for changing from the ‘gold standard’ Oncotype DX test in Optima prelim 
to the Prosigna test in the Optima main trial to determine which treatment 
patients would receive from the test results.  
The Oncotype DX test looks at tumour samples for a group of 21 genes (Paik et al. 
2004). The result of this test gives a recurrence score which calculates the risk of 
distant recurrence following endocrine therapy of ER positive node negative 
breast cancer and determines whether patients are low, intermediate or high risk. 
Various studies have supported the use of this test and have shown that it can 
predict chemotherapy sensitivity within an adjuvant setting (Gianni et al. 2005, 
Chang et al. 2008, Marchionni et al. 2008, Smartt 2010, Hornberger et al. 2012, 
Ward et al. 2013). However the restrictions that have been highlighted by this test 
include the limited amount of data supporting the use of this test as the data 
supporting these claims were based on small patient cohorts (Smartt 2010, 
Hornberger et al. 2012, Ward et al. 2013). Furthermore the effect of the Oncotype 
DX test on long term outcomes (e.g. overall survival) have not been shown (Stein 
et al. 2016). 
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The Prosigna test looks at a group of 58 genes to approximate the risk of 
recurrence which can be scored from 0 to 100 (Breast Cancer 2016) and 
categorised as low, intermediate or high risk (Sestak et al. 2013, Filipits et al. 2014, 
Breast Cancer 2016). Various studies have proven that through the use of Prosigna 
testing, the response to adjuvant chemotherapy can be predicted and can be 
differentiated between high risk and low risk patients that have ER positive disease 
(Parker et al. 2009, Esserman et al. 2012, Prat et al. 2016).  
The sample size required for the Optima prelim trial was 300 randomised patients 
to assess agreement between the various multi-parameter test. The Optima 
prelim trial registered 350 participants from 34 centres; of which 313 were 
randomised. 
The Optima main trial aims to recruit a sample size of 4500 patients to 
demonstrate NI of test-directed treatment (defined as no worse than 3% below 
the estimated 85% 5-year invasive DFS rate for the control arm) with 80% power 
and a 5% one-sided significance level. Furthermore, the adaptive designs of the 
Optima trial allows for the addition of other multi-parameter genomic tests in the 
future (Figure 4.1).  
The vital question that will be answered through this trial will be if the use of multi-
parameter genomic testing can accurately differentiate between high risk and low 





Figure 4.1: Proposed trial schema to add more multi parameter test to the Optima Trial (Stein et al. 2016). IDFS – Invasive disease-free survival. 
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4.2.8 Persephone – Pre-planned interim analysis  
The Persephone trial was a randomised phase III trial comparing two durations of 
Herceptin; six months versus 12 months to understand how well they work in 
treating women with HER2-positive early breast cancer with a NI design (Earl et al. 
2019, Earl et al. 2020). 4000 patients were required to evaluate an absolute NI 
margin of 3% for DFS for six months Herceptin verse 12 month Herceptin with 85% 
power and 5% 1-sided significance, assuming a 4-year disease-free survival rate of 
80% on the 12-month control arm. 
Initially the timing of randomisation was from the start of treatment however this 
was changed to any time between diagnosis and up to having received six months 
of Herceptin. At the beginning of the trial, only intravenous therapy administration 
was allowed, however this was subsequently changed to allow the use of 
subcutaneous administration as this form was introduced nationally. Patients may 
prefer subcutaneous administration as it takes significantly less time than 
intravenous therapy. Furthermore an unplanned interim analysis of the data was 
presented to the DMC following the results from the Herceptin Adjuvant (HERA) 
trial and Protocol of Herceptin Adjuvant with reduced exposure (PHARE) trials 
(Goldhirsch et al. 2013, Pivot et al. 2013). The DMC found no reason to change the 
conduct of the Persephone trial and encouraged the continuation of the trial 
without any change. The trial closed to recruitment with 4088 patients 
randomised. The trial published the primary outcome results and is now in long 
term follow-up (Earl et al. 2020). A meta-analysis is planned with other trials that 
have assessed the optimal duration of Herceptin in treating patients diagnosed 
with early breast cancer (Joensuu et al. 2009, Pivot et al. 2013, Mavroudis et al. 
2015, Joensuu et al. 2018). 
More information about this trial is provided in chapter seven. 
4.2.9 PET-NECK – Change in eligibility, follow-up extension  
Pet-Neck was a two-arm pragmatic phase III RCT assessing whether PET-CT 
(Position emission tomography - Computed tomography) guided need for surgery 
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was not inferior to immediate neck dissection in head and neck cancer patients in 
terms of OS (Mehanna et al. 2016).  
560 patients were required to evaluate an absolute NI margin of 10% assuming a 
survival rate of 75% at two years in the control arm (planned neck dissection) with 
90% power using a 5% one-sided significance level with 3 years recruitment and 2 
years follow-up. Only 111 of the 140 deaths required for the analysis had been 
observed towards the end of the original 2 year follow-up period and therefore 
the follow-up period was extended to 5 years to reach the target number of events 
and planned 90% power. If additional follow-up had not been sought, then the 
power would be 76% (Mehanna et al. 2017).    
During the conduct of the trial, the eligibility criteria were broadened to allow 
occult head and neck tumours as well as allowing neck dissection surgery to be 
performed either before or after chemoradiotherapy. Previously it was allowed 
only before chemotherapy. The reason for this amendment was that a change of 
practice was taking place at some centres during the trial and thus would have 
prohibited recruitment. Both the randomisation and primary analysis were 
stratified by the intended timing (before and after chemotherapy) to minimise bias 
and adjust for this choice in the comparison across trial arms.  
4.2.10 Select-D – Sample size decrease 
The Select-D trial was a randomised phase III pilot trial of Dalteparin and 
Rivaroxaban for the treatment of cancer patients. In addition, there was a second 
double-blind randomisation assessing the duration of anticoagulation treatment 
(Young et al. 2018). The trial had a pre-planned safety analysis which required 220 
patients (110 on the Dalteparin arm and 110 on the Rivaroxaban arm) to detect an 
excess of 10% assuming a rate of 5% on the control arm with 80% power and 5% 
one-sided significance level.  The trial was designed as a roll through into the full 
phase III trial if pre-defined criteria were met and sufficient funding was available.   
The sample size was initially calculated to recruit 530 patients to provide estimates 
of venous thromboembolism (VTE) recurrence rate (primary endpoint) to be 
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within a width of the 95% CI of 8% assuming the six months VTE recurrence rate is 
10%. 
The second randomisation was closed on the grounds of futility as an insufficient 
number of patients were being randomised and therefore it would never reach 
target. The closure of the second randomisation resulted in a reduction of the total 
sample size as initially larger numbers were required in the first randomisation to 
ensure sufficient numbers of patients went through to the second randomisation. 
The sample size was reduced to 400 patients, which would allow the primary 
endpoint to be estimated within a width of the 95% CI of 9% assuming the six 
months VTE recurrence rate is 10%. Furthermore, the eligibility criteria were 
changed to exclude patients with primary oesophageal or gastro-oesophageal 
cancer based on safety, which was recommended by the DMC.  
4.2.11 TEAMM – Sample size increase 
The Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial was a phase 
III, randomised double-blind, placebo controlled trial assessing the use of 
levofloxacin as prophylaxis to reduce febrile episodes or deaths.  
The primary endpoint of the trial was time to first febrile episode or death. An 
estimated proportion of 30% of patients experience a febrile episode or death 
within the first three months; the trial hypothesised that the use of prophylactic 
levofloxacin would reduce this to 20%. This required an initial sample size of 800 
patients to detect a 10% difference with 90% power using a 5% two-sided 
significance level. This sample size was re-estimated to 1000 patients to allow for 
the detection of smaller difference of 8% instead of 10% with 80% power and to 
make reasonable adjustment for drop-outs. Although a 10% difference was 
meaningful with the initial expected recruitment rate, an 8% difference was felt 
necessary to change clinical practice. This decision was made prior to the 
completion of the original recruitment target, due to the quicker than expected 
recruitment rate and availability of study drugs, and argued that it would provide 
more power for the assessment of the secondary outcomes (Drayson et al. 2019). 
Furthermore, there were changes to patient eligibility to only include patients that 
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were no more than 7 days into starting anti-myeloma treatment instead of 14 days 
starting prior treatment which made the trial available to considerably more 
patients.   
4.2.12 VICTOR – Early trial closure  
VICTOR was a phase III, randomised double-blind, placebo controlled trial 
assessing the use of rofecoxib (VIOXX) in preventing recurrence in colorectal 
cancer patients following potentially curative therapy. The trial required 7000 
patients to detect an increase in survival with a relative difference of 20% (HR = 
0.80) with 85% power using a 5% two-sided significance level. This was a 2x2 
factorial also assessing duration of two years versus five years rofecoxib. 
Rofecoxib was withdrawn worldwide by Merck & Co. Inc. due to the Adenomatous 
Polyp Prevention on Vioxx (APPROVe) trial (Bresalier et al. 2005)  finding an 
increased relative risk of cardiovascular incidents. This led to the early closure of 
the trial and all ongoing treatment stopped on the grounds of safety (albeit no 
safety concerns were raised by the VICTOR DMC). The statistical analysis plan was 
modified and the 2434 patients randomised were followed-up and the power 
calculations were modified with the trial now able to detect an increase in survival 
with a relative difference of 25% with 87% power using a 5% two-sided significance 
level (Midgley et al. 2010).   
4.2.13 Summary 
This scoping exercise of cancer trials within the Warwick CTU demonstrated that 
both superiority and NI hypotheses were implemented and that adaptive methods 
are regularly executed without classing them as adaptive designs. A summary from 
this exercise can be seen in Table 4.1. The key learnings are that broadening the 
eligibility in trials can help increase the rate of recruitment and allow subgroup 
analyses to be proposed if the criteria are being extended to specific populations. 
A time dependent indicator could be applied to indicate when these changes took 
place as a form of sensitivity to measure the impact of the change in eligibility and 
see if sufficient numbers were recruited. None of the trials have reported the 
impact the change in eligibility had on recruitment. Sample size re-estimation 
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methods were employed when new external evidence became available to ensure 
that the most appropriate assumptions for the control arm were used. When 
recruitment was doing well, sample sizes were increased to consider smaller 
differences and allow for subgroup analyses as well as accounting for drop-outs. 
Group sequential methods with pre-planned stopping rules for interim analyses 
allow the possibility of stopping the trial early on grounds of futility or efficacy, 
which can save time and money.  
The scoping exercise was an exhaustive investigation for all oncology trials 
conducted at Warwick CTU and was further extended to consider exemplar 
adaptive design trials. This exercise has further supported the proposed extension 
to the CONSORT 2010 guidelines as concluded from the literature review reported 
in the previous chapter as there were many trials that implemented some form of 
adaptation. It is important to note these adaptations in the reporting of the trial 
results. 
 Examples of current adaptive designs trials outside of the Warwick CTU 
The scoping exercise was extended to consider examples outside of Warwick CTU 
of adaptive trials within Oncology that were known to the CTU to explore how 
these trials were designed and are being conducted. The adaptive trials identified 
were STAMPEDE and FOCUS4 trials which are both being conducted by MRC CTU 
at University College London, CompARE (Comparing Alternative Regimens for 
escalating treatment of intermediate and high-risk oropharyngeal cancer) trial  
conducted by Cancer Research UK CTU in Birmingham, I-SPY 2 trial conducted by 
Quantum Leap Healthcare Collaborative in San Francisco and PARTNER (Platinum 
and PARP inhibitor for Neoadjuvant treatment of Triple Negative and/or BRCA 
positive breast cancer) trial conducted by the Cancer Research UK Cambridge 
Institute.  
4.3.1 STAMPEDE trial 
The STAMPEDE trial is a phase II/III RCT, which initially began as a MAMS trial and 





This trial is for patients with locally advanced prostate cancer who are 
commencing long-term Androgen Deprivation Therapy (ADT) (STAMPEDE trial 
2005, Sydes et al. 2009, Sydes et al. 2011, Sydes et al. 2012, Choodari-Oskooei et 
al. 2020). This trial is one of the largest exemplars of an innovative MAMS platform 
design (Carthon et al. 2016) as it allows for the evaluation of multiple arms at 
different interim stages and the addition and termination of experimental 
treatments during the trial (see section 2.10 on platform trials). This innovative 
design implemented by the STAMPEDE team has been used as an exemplar of 
adaptive design methodology by the FDA because it has efficiently evaluated 
several treatments simultaneously compared to several individual trials (US Food 
and Drug Administration 2018) for which there are also cost saving implications.      
Inclusion criteria for the trial involves patients being either high risk newly 
diagnosed non-metastatic patients or newly diagnosed metastatic patients or 
those treated with prior radical surgery and/or radiotherapy. The primary 
outcome of STAMPEDE is OS with the intermediate outcome being FFS. All sample 
sizes were based on a final stage power of 90% to detect a hazard ratio (HR) of 
0.75 with a one-sided 2.5% significance level.  
This trial began in 2005 with one control arm (Androgen deprivation therapy ± 
radiotherapy), which was continuously extended, versus five experimental arms 
(Arms B, C, D, E, and F) with subsequent additions of four extra arms at various 
points throughout the trial; Arm G – introduced in November 2011, arm H – 
introduced in March 2013, arm J – introduced in January 2014, arm K – introduced 
in January 2016 and arm L – introduced in June 2017. The control arm consists of 
contemporaneous patients, meaning that patients allocated to a new 
experimental arm are compared to control arm patients randomised after the new 
experimental arm was introduced. To date, the control arm has changed twice; 
first in 2017 to abiraterone then again in 2019 to radiotherapy for metastatic 
patients. 
 The trial was powered to detect a difference in relative improvement at each of 
the interim analysis stages by performing pairwise comparisons for each of the 
initial five experimental arms against the control arm when 113, 216 and 334 PFS 
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events were reported in the control arm. More emphasis was on controlling the 
PWER rather than the FWER because different hypotheses were being tested in 
each of the five experimental arms (Bratton et al. 2016). Stopping rule guidelines 
for discontinuing the specified experimental arms were produced (Table 4.2). At 
each increasing stage, the significance level becomes more stringent and requires 
a higher power. If the null hypothesis (i.e. effect of experimental arm treatment is 
the same or worse) is rejected then the treatment continues to the next stage 
where a greater amount of evidence is gathered (Sydes et al. 2009). At each stage 
the experimental treatments need to show evidence of a benefit over the control 
arm to continue to the next stage, i.e. the obtained HR should be below the critical 
HR to continue. It was approximated that for the first five experimental arms 
between 2800 and 3600 patients were required to be recruited within seven years. 
The primary outcome analysis for the first five experimental arms was planned 
when 403 deaths in the control arm have been observed.   
After the second interim analysis in April 2011, the evidence suggested that there 
was no evidence of benefit in arm D (HR = 0.94), which led to the DMC 
recommending discontinuing treatments in arms D and F (both arms used 
celecoxib) (James et al. 2011). Subsequently the additional research arm G was 
added in November 2011 and had equal allocation to control. The guidelines for 
stopping arm G were different to arms B-F (Table 4.2). The accrual of patients 
would be stopped when either 1500 patients were recruited or after three years. 
The primary outcome analysis would be performed when 267 deaths were 
observed in the control arm. The sample size for this arm increased from 1500 to 
1800 due to the proportion of non-metastatic patients expected to be recruited 
was higher.  
In March 2013 arm H was activated, which only recruited those patients with 
newly diagnosed metastatic cancer that will be on ADT for the first time. 
Experimental arm H had a similar approach to arm G; it would take the same 
number of events to trigger the interim analyses at the different stages (Table 4.2). 
The experimental arm H was applicable to around 60% of the STAMPEDE patient 
population. It was anticipated that around 1250 patients were required over 4 
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years of recruitment to observe 267 control arm deaths, which was expected to 
be reached 5.25 years after the activation of arm H.  
For the experimental arm J, which was activated in January 2014, two interim 
analyses were planned before reaching the final stage (Table 4.2). It was 
anticipated that it would require approximately 1800 patients within 3.5 years of 
recruitment to observe 267 deaths within six years after the activation of arm J. 
The experimental arm K was activated in January 2016. The key inclusion criteria 
for randomisation between the experimental arm K versus the control arm were 
patients who were non-diabetic. The timing of the interim and final analysis was 
determined by the number of deaths driven by patients with metastatic cancer 
(Table 4.2). OS was used as both the intermediate outcome measure and the final 
primary outcome measure. It was anticipated that it would require approximately 
1800 patients (1100 would be patients with metastatic cancer) recruited over 
three years to observe 473 deaths, which would trigger the primary outcome 
analysis at approximately eight years after the activation of arm K.  
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Guidelines for comparison of control arm to experimental arms B-F 
Stage Sig. level Power  Target HR Number of control arm events 
Consider discontinuation if 
HR1 (observed) is… 
Activity Stage I 0.500 95% 0.75 ~113 FFS >1.000 
Activity Stage II 0.250 95% 0.75 ~216 FFS >0.920 
Activity Stage III 0.100 95% 0.75 ~334 FFS >0.890 
Efficacy Stage IV*  0.025 90% 0.75 ~403 OS >0.850 
Guidelines for comparison of control arm to experimental arms G and H 
Activity Stage I 0.500 95% 0.75 ~75 FFS >1.000 
Activity Stage II 0.250 95% 0.75 ~142 FFS >0.920 
Activity Stage III 0.100 95% 0.75 ~221 FFS >0.890 
Efficacy Stage IV*  0.025 90% 0.75 ~267 OS >0.850 
Guidelines for comparison of control arm to experimental arms J 
Activity Stage I 0.400 95% 0.70 ~66 FFS >0.957 
Activity Stage II 0.120 95% 0.70 ~139 FFS >0.869 
Efficacy Stage III* 0.025 90% 0.75 ~267 OS  >0.85 
Guidelines for comparison of control arm to experimental arms K 
Activity Stage I 0.40 92% 0.80 ~121 M1 deaths >0.965 
Efficacy Stage II* 0.025 92% 0.80 ~473 M1 deaths >0.881 
Guidelines for comparison of control arm to experimental arms L 
Activity Stage I  Completed in the PATCH trial (2013) with 206 PFS events. 
Activity Stage II Planned formal interim upon reaching 410 PFS events in the control arm  
Efficacy Stage III* Performed upon reaching approximately 565 deaths and 815 PFS events  
*Outcome of treatment concluded at this stage 
Table 4.2: Guidelines for interim analysis at each of the activity stages (http://www.stampedetrial.org).HR = Hazard Ratio, M1 = Patients diagnosed with 
new metastatic cancer. FFS = Failure free survival; OS = Overall Survival.
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The experimental arm L was added around June 2017 (Gilbert et al. 2018). The 
inclusion criteria for this comparison included patients starting long-term 
hormone therapy for high-risk non-metastatic or metastatic prostate cancer that 
have had eight weeks of anti-androgens and no more than approximately a 
months’ worth of luteinizing hormone releasing hormone. This comparison 
allocates eligible participants to the control arm or arm L (combination of 
transdermal oestradiol ± radiotherapy ± docetaxel). The unique aspect of this 
comparison is that the evaluation of clinical efficacy will be based on a combined 
meta-analysis using data from the Prostate Adenocarcinoma: Transcutaneous 
Hormones (PATCH) trial. The STAMPEDE trial had originally planned for two 
activity stages, of which the first activity stage was incorporated in the PATCH trial 
in 2013 when 206 PFS events were reached, which led to the PATCH DMC 
recommending further recruitment into a phase III trial1. A formal interim analysis 
was planned for activity stage II when approximately 410 PFS events were 
observed in the control arm for both the PATCH and STAMPEDE trial, however, the 
number of events were accrued slower than originally anticipated and therefore 
this was removed from the analysis schedule (Langley 2020).  The final comparison 
requires approximately 2000 patients in total (500 patients from STAMPEDE) with 
co-primary endpoints of PFS and OS. A breakdown of the STAMPEDE trial can be 
seen in Figure 4.2. 
To date, for arms B to F, the primary results have been published and all active 
follow-up has been discontinued (James et al. 2016, Mason et al. 2017). For arm G 
and H, the primary results have been published and the trial remains on active 
follow-up to allow for long-term analysis (James et al. 2017, Parker et al. 2018). 
Arm J is in follow-up and arms K and L were both recruiting but were temporarily 











4.3.2 FOCUS4  
The FOCUS4 RCT utilises an umbrella MAMS design, including biomarker-stratified 
and non-stratified comparisons within one master protocol (see section 2.10) for 
patients with advanced or metastatic colorectal cancer (FOCUS4 2019). The primary 
outcome for this trial is PFS and an additional outcome of OS may be considered at 
the final stage. The intermediate outcome at each stage is also PFS.   
At the initial stage, all patients receive standard first-line chemotherapy treatment 
for approximately 16 weeks. During this period, biomarker testing is performed on 
the original tumour to identify which drug/s would be best suited and hence patients 
are stratified into one of five cohorts.  
The FOCUS4 trial utilises a MAMS design whereby there are four stages at which 
interim analyses will be performed on each of the first five cohorts. The reason for 
the analyses at each stage are as follows: stage I - safety, stage II – lack of sufficient 
activity, stage III – efficacy for PFS and a potential stage IV – efficacy for OS. The 
decision to continue the trial to assess stage IV is dependent on the resources 
required to achieve the necessary sample size and follow-up along with the adequate 
supply of the treatment. Stages I and II are regarded as a phase II study with stages 
III and IV classed as a phase III study. An example of the operating characteristics for 
a specific cohort can be seen in Table 4.3. 
Parameters 
Stage I Stage II Stage III Stage IV 
Safety LSA Efficacy PFS Efficacy OSꭞ  
Phase II Phase III 
One-sided Alpha 0.3 0.1 0.025 0.025 
Power  0.95 0.95 0.95 0.85 
Target HR  0.65 0.65 0.65 0.70 
Critical HR  0.91 0.83 0.79 0.80 
ꭞStage IV only undertaken if sufficient control arm events reached.  
Table 4.3: Possible generic operating characteristics for possible comparisons in all wildtype 
cohort. LSA = Lack of Sufficient Activity; PFS = Progression free survival; OS = Overall 
Survival; HR = Hazard ratio. 
The duration of recruitment is seven years with the aim to recruit over 1500 patients 
in total. Timing of interim analyses at each stage is determined by a maximum 
number of events required. Continuation on to the next stage is based on reaching a 
pre-specified critical HR, and corresponding maximum number of patients for each 
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stage required. The trial implements an allocation ratio of 2:1 in favour of the 
experimental arm as this allows for more information to be obtained on early safety 
and toxicity. A summary of this information can be found in Table 4.4. Specific details 
for each comparison have been detailed in separate protocols (FOCUS4 2019).  
 
Table 4.4: Summary of the operating characteristics and timelines for each of the cohorts, 
extracted from FOCUS4 protocol  (FOCUS4 2014). OS – Overall survival, PFS – Progression 
free survival; HR = Hazard ratio. 
To date, recruitment has been suspended to the trial in March 2020 due to the 
COVID-19 pandemic and follow-up closed to all patients in October.  
4.3.3 CompARE trial 
The CompARE trial is a MAMS phase III RCT trial investigating which treatment is the 
most effective for patients who have high-risk oropharyngeal cancer (Mehanna 
2015). The primary outcome is OS and the intermediate outcome measure is DFS. It 
was anticipated that approximately 650 patients would be recruited into the trial. 
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Patients were originally randomly allocated into either the control arm or one of 
three experimental arms: 
• Arm 1: Concomitant cisplatin chemotherapy plus radiotherapy (Control arm) 
• Arm 2: Induction chemotherapy followed by arm 1 
• Arm 3: Dose-escalated radiotherapy plus concomitant cisplatin 
• Arm 4: Resection of primary and selective neck dissection followed by arm 1  
The timing of the interim analyses is determined by the number of events in the 
control arm. Analysis for stage I is planned after 70 control DFS events have been 
reported, analysis at stage II will be after 114 control DFS events and analysis at stage 
III will be after 169 control DFS events.  The final analysis in the trial is scheduled to 
take place when 128 control patients have died in the trial; it is anticipated that the 
analysis of the primary outcome will be analysed 6.6 years after the start of 
recruitment. Table 4.5 below gives information about the power and significance 











HR1 (observed) is… 
Stage I 70 DFS 95% 0.5 >1.00 
Stage II 114 DFS 95% 0.3 >0.92 
Stage III 169 DFS 95% 0.15 >0.87 
Final analysis 128 deaths 85% 0.1   
Table 4.5: Summary of the operating characteristics at each of the stages and final analysis. 
DFS – Disease free survival, HR – Hazard ratio. 
A new arm has subsequently been added (durvalumab and chemoradiotherapy 
followed by durvalumab) and the original three experimental arms have been closed 
to recruitment (Cancer Research UK 2020) but no detail results have been published 
as to why these arms have closed. The Birmingham trials unit were contacted but no 
correspondence was received.  
4.3.4 I-SPY 2  
The I-SPY 2 is an adaptive phase II platform RCT that investigates the efficacy of drugs 
in combination with chemotherapy with the efficacy of standard therapy alone in the 
neo-adjuvant setting for women with large primary cancers of the breast (>3 cm)  
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(Barker et al. 2009). The primary outcome of the trial is the measure of pathologic 
complete response (pCR). The primary aim of the trial is to demonstrate the 
usefulness of specific treatment regimens for different patient subgroups based on 
their biomarker signatures.  
The adaptive method of the study implements the use of Bayesian adaptive 
randomisation whereby specific drugs that show higher efficacy will be favourably 
assigned to patients. Bayesian predictive probabilities will be implemented at interim 
points, if treatments reach a pre-specified level of efficacy then it will ‘graduate’, 
otherwise after reaching a maximum sample size, recruitment to the treatment arm 
may be stopped for futility. At this point the randomisation probability will be 
revised; Figure 4.3 shows the procedure of how the I-SPY 2 process will work.  
Implementing a Bayesian framework allows the trial to update the probabilities 
based on current data allowing more patients to be allocated to treatments that 
show promise and therefore accelerating the process of ‘graduating’ favourable 
treatment arms. This process continually allows new treatments to be added and 
evaluates favourable treatments efficiently. All treatment arms have a maximum 
sample size, where upon reaching this maximum, it would trigger the arm to be 
tested for futility. A limitation to this approach is that recruitment to poorly 
performing treatments will continue until a maximum sample size is reached. A 
solution would be to incorporate a futility boundary whereby at an interim stage if 
this boundary is crossed, recruitment to poorly performing treatments would be 
stopped.  
To date, the I-SPY 2 trial continues to recruit to seven treatment arms but 
recruitment to 15 treatment arms has finished, of which the trial results for two 
treatments are pending, phase III trials have been conducted to evaluate two of the 
treatments and are ongoing for a further three treatments and recruitment was 






Figure 4.3: Flow chart showing I-SPY 2 adaptive process (Berry 2015) 
4.3.5 Partner  
The Partner trial is a phase II/III three stage multi-centre RCT that “evaluates the 
safety and efficacy of the addition of Olaparib to platinum-based neoadjuvant 
chemotherapy in breast cancer patients” (Abraham 2017). The trial aimed to recruit 
at least 527 patients over the course of three stages with a minimum of 220 germline 
breast cancer gene (gBRCA) patients recruited. Patients are randomly allocated to 
one of three treatment arms (control arm and two experimental arms) in a 1:1:1 ratio 
at stages I and II and 1:1 at stage III. The trial implements a ‘pick the winner’ design 
(see section 2.7 for more information) whereby at stage II, one of the two 
experimental arms will be the ‘winner’ and hence taken forward into stage III. The 
concepts applied to this design are like that of a MAMS design because there are 
multiple arms and the decision to drop an arm is based on the results at an interim 
stage. The duration of the trial has not been given however patients will receive 21 
weeks of chemotherapy followed by breast surgery after which patients will be 
followed up for ten years.   
Stage I will determine the safety of the two research arms. The total sample size 
required at this stage is 75 patients (25 patients in each arm). Safety analysis will be 
performed when the first 25 patients in each of the research arms have received at 
least one dose of Olaparib, if the dose needs modifying then those initial patients will 
not be analysed in the final phase III primary analysis. 
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At the end of stage II, one research arm will be selected to continue onto stage III. 
The sample size for stage III will be 159 patients (53 patients in each arm). The 
outcome for stage II is the pCR rate and the analysis will be performed when this rate 
is available for 53 patients in each of the research arms. The research arm that will 
be selected to continue to stage III will be determined by the arm with the highest 
observed pCR rate.  
At the end of stage III, an efficacy analysis using the pCR rate will be performed. A 
total sample size of 444 patients is required with equal allocation for stage III 
between the control arm and the selected experimental arm to detect an 
improvement of 15% from approximately 45-55% in the control arm for all patients 
and a 20% improvement for gBRCA patients, with 80% power and an overall 5% two-
sided significance level. The trial has incorporated a futility analysis for the gBRCA 
patients and plans to create a set of stopping guidelines to terminate the trial on the 
grounds of efficacy. 
The DMC recommended that the trial continue without any change at stage one. In 
April 2018, recruitment to stage two was completed, the results for this were to be 
reviewed early in 2019 but no results have been published (Abraham et al. 2019). 
4.3.6 Summary 
This exercise examined some RCTs that have implemented adaptive design methods. 
A summary of the key points from these examples can be seen in Table 4.6. All trials 
shared a common theme to ensure correct decisions are made at the right time in an 
efficient manner. This was demonstrated by the multi-arm designs utilised in all trials 
by ensuring experimental arms that showed promise continued through the trial. The 
STAMPEDE, FOCUS4 and CompARE trials have implemented the MAMS design using 
the ‘nstage’ command in Stata (Barthel et al. 2009, Blenkinsop et al. 2019). For every 
stage, a high power has been used (≥ 85%) and all significance levels at intermediate 
activity stages are lenient but with a strict significance value used at the final stage 
to determine efficacy. A different outcome measure was used for the intermediate 
activity stages compared to OS, which was used at the final efficiency stage for the 
STAMPEDE and CompARE trial. All three of these MAMS trials have evolved to 
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‘platform’ trials by adding more treatment arms however only the STAMPEDE trial is 
labelled with this terminology. Additional comparisons are treated like a two-arm 
multi-stage trials to obtain the control arm events required to trigger the analysis at 
the end of each stage (Sydes et al. 2011). The repeated contributions of control arm 
patients demonstrate the efficiency and perhaps cost-savings involved from utilising 
these designs. Furthermore, allocating more patients to the experimental arm allows 
for more information to be obtained to take decisions with regards to safety and 
toxicity as seen in the FOCUS4 trial. 
This exercise demonstrates that implementing adaptive trials are ideal as they are 
efficient and effective, however the resource required to execute these large trials 
cannot be underestimated. As mentioned in chapter two, the work of Hague et al 
(2019) and Schiavone et al (2019) must be taken into consideration so Clinical Trial 
Units can fully understand the resource and forward planning required prior to any 
thought of implementing adaptive trials of this scale.  
Trial  Summary 
STAMPEDE 
Implemented a platform MAMS design. 
Selected values for stagewise significance 0.5, 0.25, 0.1, 0.025 
regularly used for the comparisons.  
Stagewise power value of 95% and final value power of 90% 
regularly used.  
Incorporated a new treatment arm with the aim to perform a meta-
analysis using another trial.  
Exemplar for adaptive design methodology as shown in latest FDA 
guidance. 
FOCUS4  
Incorporates an Umbrella MAMS design. Trial uses a master protocol 
as within this trial there are multiple trials with their own designs.  
Selected values for stagewise significance of 0.3, 0.1, 0.025, 0.025. 
Stagewise power value of 95% and final power of 85%. Allocation 
ratio 2:1 in favour of the experimental arm.  
Compare  
Implements a MAMS design with one arm as a surgical arm. Uses 
same stagewise power and final power values as the FOCUS4 trial. 
I-SPY 2  
Incorporates a Bayesian Adaptive randomisation whereby drugs that 
show promise will be allocated more patients. Interim analyses 
performed to make the decision of whether to continue or stop the 
drugs.  
Partner  
A three arm seamless (phase II/III) trial incorporating a pick-the-
winner approach - like a MAMS whereby one of the two 
experimental arms will not continue onto the phase III trial.  




This chapter captured adaptive methods applied within oncology trials at Warwick 
CTU but also considered exemplar adaptive trial designs external to Warwick CTU. 
The Warwick CTU scoping exercise found four trials (ARTemis, AVAST-M, Neo-Escape 
and Persephone) implemented interim analysis due to safety, efficacy or futility. Five 
trials (COUGAR-02, LIHNCS, Select-D, TEAM and VICTOR) changed the sample size 
which was not pre-planned. The VICTOR trial was unique as it made ad-hoc changes 
to the trial due to the withdrawal of the study drug. The Persephone trial ran 
simultaneously with other similar trials (more information in chapter seven) 
investigating the use of Herceptin duration hence the release of results for these 
other sister trials influenced the conduct of the Persephone trial. The Optima trial is 
the only trial at Warwick CTU that explicitly states that it is an ‘adaptive design’ as 
this trial plans to incorporate additional multi-parameter tests to compare against a 
contemporaneous control, it can be considered as a platform trial. Pre-planned 
adaptations should be strongly encouraged although the scoping exercise found that 
ad-hoc changes may be necessary to adapt to the current evidence and situation.   
All the exemplar trials considered in section 4.3 have multiple arms and have 
incorporated at least one interim analysis for safety, efficacy or futility. The 
STAMPEDE trial is the only trial labelled as a platform trial (section 2.10), whereas 
CompARE and I-SPY 2 trial have added new treatments into the trial like a platform 
design. I-SPY 2 is the only trial out of the examples in section 4.3 that is based in the 
pharmaceutical industry. There are other adaptive design based trials within the 
pharmaceutical industry, for example within Janssen Pharmaceuticals there are two 
actively running platform trials and a basket trial within oncology (Kyle 2021).Within 
Janssen Pharmaceuticals, there is an active support group that helps with the design 
and execution of adaptive designs and internal presentations are conducted related 
to adaptive designs to encourage and create an awareness of the advantages of 
implementing adaptive designs.  
It can be clearly seen from all these adaptive trial examples that detailed planning is 
required to implement the novel designs. For example, within the MAMS designs the 
number of stages, the significance level and power at each stage, the intermediate 
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and primary outcome, the alternate hypothesis needs to be pre-specified. These 
parameters will determine the number of control arm events required and the timing 
at each stage.  Furthermore, when deciding on the choice of outcome measures, it is 
assumed that the intermediate outcome measure occurs more frequently than the 
primary outcome measure, however there can be situations where the intermediate 
outcome is the same as the primary outcome (Sydes et al. 2009). The intermediate 
outcome measure provides a base for the amount of ‘activity’ emerging whereas the 
primary outcome is the base for definitive conclusions to be made. It is important to 
perform a variety of calculations for the sample size as within MAMS trial some 
parameters are fixed and some can be variable which can affect the power, 
significance level and sample size. For example, the number of arms that are available 
to trial stakeholders may be fixed however the rate at which patients are accrued or 
the relative difference between treatments can vary.  
It is evident that multi-arm methods, such as variations of the MAMS design (Wason 
2015), or seamless phase II/III design that assess multiple treatments or drop the 
loser/pick the winner design in the field of Oncology are increasingly popular. Parmar 
et al urges that more multi-arm randomised trials should be implemented in all areas 
of clinical trials as multiple treatments can be assessed simultaneously, which can 
result in a simpler, quicker and cheaper trials in comparison to several standard two-
arm trials (Parmar et al. 2014). The MAMS trials discussed in this chapter involved 
poor prognostic populations, for example the STAMPEDE trial assesses OS in a 
patient population with metastatic prostate cancer, where events can accrue quickly. 
However, within early breast cancer trials, time to event outcomes require much 
longer follow-up, typically greater than five years. Hence, if there were multiple 
treatments that needed to be evaluated within breast cancer, would a MAMS design 
still be more efficient than other trial designs to answer the same number of 
questions? How would a MAMS design change with a NI hypothesis rather than 
assessing superiority?   
In my next chapter I will investigate the use of MAMS designs in cancer sites with 




5 Comparison of hypothetical MAMS designs with long-term 
outcomes 
 Introduction 
A MAMS design, as mentioned in chapter two, consists of pairwise comparisons of 
multiple experimental arms against a single control arm. These designs are increasing 
in popularity due to their efficiency and effectiveness in testing several different 
treatments at once and are supported by patients and clinicians willingness to 
participate in these studies (Parmar et al. 2014). These MAMS designs have been 
employed in trials such as STAMPEDE, CompARE and FOCUS4 (James et al. 2008, Shiu 
et al. 2013, Mehanna 2015), all of which have been discussed in chapter four. The 
MAMS trials have up to now, as seen in the exemplar studies presented in previous 
chapter, been conducted in poor prognostic populations where the events accrue 
quickly, for example the STAMPEDE trial assesses OS in a patient population with 
metastatic prostate cancer that has a five-year OS rate of approximately 50% (Sydes 
et al. 2009). Hence, the application of a MAMS design in a good prognostic population 
e.g. breast cancer (five-year OS rate ≈ 85%), where there is a lower chance that a 
patient will experience an event(s) has not been explored.   
Various hypothetical MAMS designs were evaluated within this chapter in three 
cancer sites: breast, colon and lung cancer, primarily focusing on the longer-term 
outcome of OS. These three cancer sites have the highest incidence rates but varying 
survival rates (Cancer Research UK 2018) which helped to further understand if it was 
feasible to conduct MAMS designs in different scenarios. The trial designs were 
compared through three phases using a superiority hypothesis. 
The first phase investigated the use of MAMS designs using the survival rates 
obtained from the Office for National Statistics (ONS) for patients in England  
between 2013 to 2017 and followed up to 2018 (Office for National Statistics 2019). 
The stagewise significance levels and power values were estimated such that an 
overall significance level less than 5% and power of at least 80% was reached. The 
aim of the first phase was to gain insight into the different MAMS designs and 
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evaluate within which setting a MAMS design was more feasible using a superiority 
hypothesis. 
The second phase of the MAMS designs aimed to compare the designs obtained from 
the first phase with those implementing the method recommended by Royston et al 
(2011) for the stagewise significance levels and power for each cancer site to see 
which method proved to be more robust and hence most appropriate for use in the 
third phase.  
The third phase investigated four trials that had published primary outcome results 
for each of the three cancer sites. The aim of this phase was to understand the 
feasibility of applying a MAMS design as well as understanding its efficiency 
compared to standard two-arm trials.  
5.1.1 Choice of parameters 
The Cancer Research UK website (Cancer Research UK 2018) was used to screen all 
phase III clinical trials that had published results related to the primary endpoint to 
help with the choice of parameters to be used in all three phases of the calculations. 
The reason for selecting breast, colon and lung cancer were because they have the 
highest incidence rates and distinctively vary in their OS rates, thus the results will be 
more heterogenous (Cancer Research UK 2018, Office for National Statistics 2019).  
Trials that involved the testing of treatments and had results published in a medical 
journal were further explored for eligibility. The trials were eligible if the following 
results were provided: 
• An OS rate at any time point;  
• The number of deaths for the control arm;  
• The minimally clinical important difference (MCID) the trial aimed to detect; 
• Patient eligibility information; 
• The number of treatment arms; 
• The initial planned sample size, power value and level of significance; 
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• The actual sample size, time taken to recruit and the follow-up period. 
Twelve trials were selected (four from each cancer site) that fulfilled the eligibility 
criteria and gave diverse results. This would help in understanding the application of 
MAMS designs in different trial settings. Details of these 12 trials are provided in the 
following section and a summary of these trials can be found in Table 5.1.  
The Clinicaltrials.gov website identified 182 clinical trials that are actively recruiting 
within the UK for each of the selected cancer sites (ClinicalTrials.gov 2020). The 
number of trials and the mean sample size within each phase split by cancer site was 
used to calculate an estimate of the proportion of patients that entered phase III 
clinical trials every year. This calculation would be part of the criteria to determine 
the feasibility of implementing a MAMS design in sections 5.3 and 5.4. The title, 
phase and sample size for all 182 trials can be found in appendix 6.    
5.1.2 Description of the 12 CRC UK phase III trials used to inform the choice of 
parameters for the hypothetical MAMS designs 
5.1.2.1 Breast cancer trials 
Four breast cancer trials were found that fulfilled the eligibility criteria stated in 
section 5.1.1. Details of these trials that were used in the MAMS design calculations 
are provided below.  
5.1.2.1.1 DEVA trial  
The Docetaxel Epirubicin Adjuvant (DEVA) trial assessed the efficacy and toxicity of 
combining docetaxel after Epirubicin in postmenopausal node-positive early breast 
cancer patients which could be classified as either luminal B or HER2 enriched 
patients (Coombes et al. 2011). The DEVA trial was a phase III RCT with a partial 2 x 2 
factorial design. Patients were randomly assigned to either Epirubicin (control) or 
Epirubicin followed by docetaxel (experimental). A subset of centres gave patients 
the option of being randomised a second time to assess the timing of tamoxifen 
treatment. The TTE outcomes for this trial were DFS for the primary outcome and OS 
as a secondary outcome. The sample size was calculated based on the log-rank test 
which required 792 patients with 90% power and 5% significance level to detect an 
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absolute improvement from 70% (control arm) to 80% (experimental arm) for five-
year DFS. The DEVA trial recruited 803 patients in approximately eight years with a 
median follow-up of 64.7 months. The five-year DFS and OS rate for the control arm 
was 72.7% and 81.8% respectively with 75 deaths reported on the control arm. The 
five-year DFS and OS rate for the experimental arm was 79.5% and 88.9% 
respectively.  
5.1.2.1.2 SoFEA trial 
The SoFEA trial was a phase III RCT which aimed to assess the use of steroidal anti-
oestrogen fulvestrant by incorporating it with continued oestrogen deprivation in 
postmenopausal women with hormone-receptor-positive breast cancer, which could 
be classified as either luminal A or luminal B patients (Johnston et al. 2013). Patients 
were randomised to one of three arms: exemestane (control arm), fulvestrant plus 
anastrozole (FA) or fulvestrant plus placebo (FP). The TTE outcomes for this trial was 
PFS for the primary outcome and OS as a secondary outcome. A planned sample size 
of 750 patients would be able to detect an improvement in median PFS from 5.5 
months in the FA arm to 7.5 months in the FP arm and detect an improvement from 
four months in the control arm to 5.5 months in the FA arm with 90% power and 5% 
two-sided level of significance. The trial recruited 723 patients in six years with a 
median follow-up of 37.9 months. The median PFS rates were 3.4 months in the 
control arm, 4.4 months in the FA arm and 4.8 months in the FP arm. The median OS 
rates were 21.6 months in the control arm with 173 events, 20.2 months in the FA 
arm and 19.4 months in the FP arm. The trial performed interim analysis for which 
no further details could be obtained. The MAMS design applied to this trial utilised 
the treatment difference between the control arm and the FA arm. 
5.1.2.1.3 HERA trial  
The HERA trial was a three-arm phase III RCT comparing Herceptin for one year, 
Herceptin for two years or observation (control arm) for patients diagnosed with 
HER2 positive early stage breast cancer that had completed locoregional therapy, 
which could be classified as either luminal B or HER2 enriched patients (Piccart-
Gebhart et al. 2005, Goldhirsch et al. 2013, Cameron et al. 2017). Patients would 
begin the allocated treatment only after patients received either neoadjuvant 
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chemotherapy, adjuvant chemotherapy or both. The TTE outcomes for this trial was 
DFS for the primary outcome and OS as a secondary outcome. The sample size was 
calculated based on the log-rank test which required 4482 patients to reach 951 DFS 
events with 80% power and 2.5% two-sided significance level to detect an absolute 
improvement from 65% (control arm) to 71.8% (experimental arm) for five-year DFS. 
The HERA trial team performed three interim safety analyses to assess cardiac safety 
of Herceptin. The primary analysis of patients on Herceptin for one year against 
observation took place after patients had a median follow-up period of two years. 
The trial recruited 5102 patients in approximately 3.5 years. The three-year DFS and 
OS rates for the control arm were 74.3% and 89.7% respectively. The three-year DFS 
and OS rates for patients allocated to Herceptin for one year was 80.6% and 92.4% 
respectively. More details about the HERA trial are described in chapter seven.  
5.1.2.1.4 NEAT trial 
The National Epirubicin Adjuvant Trial (NEAT) and BR9601 trial were two joint phase 
III RCT that compares Epirubicin with cyclophosphamide, methotrexate and 
fluorouracil (CMF) against CMF alone (control arm) (Poole et al. 2006). These trials 
looked at the efficacy of anthracyclines in women with early breast cancer (all 
subtypes) that require adjuvant chemotherapy and could begin treatment within 10 
weeks after having surgery. The TTE primary outcomes for this trial were OS and RFS. 
A combined sample size of 2000 patients aimed to detect a difference of 7% in OS 
and relapse-free survival (RFS) between the control arm and experimental arm with 
85% power and 5% two-sided significance level. The NEAT and BR96001 trials 
recruited 2401 patients in approximately six years with a median follow-up of four 
years. The five-year OS rate was 75% with 171 deaths for the control arm and 82% 
for the Epirubicin plus CMF group. The five-year RFS rate was 69% and 76% for the 
control arm and the Epirubicin plus CMF group respectively.  
5.1.2.2 Colon cancer trials 
Four colon cancer trials were found that fulfilled the eligibility criteria stated in 




5.1.2.2.1 QUASAR 2 trial  
The QUASAR 2 trial was a phase III RCT that investigated the use of bevacizumab in 
improving DFS for patients with colorectal cancer who were histologically proven to 
be high-risk stage II or stage III, had a primary resection four to ten weeks before 
randomisation and with a life expectancy of a minimum of five years (Kerr et al. 
2016). The patients were assigned to receive either oral capecitabine alone (control 
arm) or oral capecitabine with bevacizumab. The TTE outcomes for this trial were 
three-year DFS for the primary outcome and three-year OS for the secondary 
outcome. A planned sample size of 2240 patients was required to find a 6% 
improvement in three-year DFS from the control arm group to the oral capecitabine 
with bevacizumab group with 90% power and 5% two-sided significance level. The 
QUASAR 2 trial recruited 1952 patients in approximately 5.5 years with a median 
follow-up of 4.92 years. The three-year DFS rate for control arm group was 78.4% 
and 75.4% for the oral capecitabine with bevacizumab group. The three-year OS rate 
for the control arm group was 89.4% with 169 deaths and 87.5% for the oral 
capecitabine with bevacizumab group.  
5.1.2.2.2 COIN trial  
The COIN trial aimed to assess the use of the EGFR targeted antibody cetuximab in 
combination with chemotherapy in patients with good organ function and with 
advanced colorectal cancer (stage IV) who had not received any prior chemotherapy 
(Maughan et al. 2011). The sample size and results used within this section for the 
calculations were based on patients with KRAS wild-type tumours as the primary 
outcome was OS in this group of patients. Patients were assigned to either oxaliplatin 
and fluoropyrimidine chemotherapy (control arm) or the control arm plus cetuximab. 
The other TTE outcome for this trial was PFS. This subgroup aimed to detect an 
improvement in two-year OS from 20% to 29.4% with 87% power and a 5% two-sided 
significance level. The COIN trial recruited 729 patients with KRAS wild-type tumours 
in approximately three years with a median follow-up of 21 months in the control 
arm and 23 months in the experimental arm. The median OS rates were 17.9 months 
with 257 deaths in the control arm and 17 months in the experimental arm and the 
median PFS rates were 8.6 months in both arms. During this trial, multiple interim 
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analyses were performed and reviewed by an independent DMC to advise on the 
safety of the trial treatment or recommend either continuation or closure of the trial. 
5.1.2.2.3 FOCUS trial  
The FOCUS trial investigated the use of different chemotherapy strategies to 
understand which regimens worked well to maximise the period of disease control 
with minimum adverse effects in patients with advanced or inoperable metastatic 
colorectal cancer (stage IV) (Seymour et al. 2007). In this phase III three-arm RCT, 
patients were allocated to either single-agent fluorouracil until failure then if patients 
were fit enough, they were given single-agent irinotecan (control group), fluorouracil 
until failure then either Irinotecan or oxaliplatin (arm B) or combination 
chemotherapy of either Irinotecan and fluorouracil or oxaliplatin and fluorouracil 
(arm C).  The TTE primary outcome was OS and the secondary TTE outcome was PFS. 
A planned sample size of 2100 patients (700 in each arm) was required to detect a 
7.5% improvement in two-year OS, from 15% in the control group to 22.5% in any 
pairwise comparisons of the control group versus either experimental arm. Hence, 
1050 patients were required for any pairwise comparison with 80% power and 1% 
one-sided significance level. There were 2135 patients recruited into the trial over a 
period of 2.5 years with a median follow up of 26.5 months. The two-year OS rate 
was 22% for the control group with 617 deaths, 25% for arm B and 28% for arm C. 
The median PFS values for those given first-line treatment were 6.3 months for the 
control arm and arm B, 8.5 months for patients allocated to arm C that had Irinotecan 
and fluorouracil and 8.7 months for patients allocated to arm C that had oxaliplatin 
and fluorouracil.  
5.1.2.2.4 PICCOLO trial  
The PICCOLO trial aimed to combine panitumumab with irinotecan in patients that 
had advanced inoperable colorectal cancer (stage IV) which had progressed either 
during or after having chemotherapy containing fluoropyrimidine (Seymour et al. 
2013). The TTE primary outcome was OS and the secondary TTE outcome was PFS. In 
this three-arm trial, patients were assigned to irinotecan (control arm), irinotecan 
plus ciclosporin or irinotecan plus panitumumab (IRPAN) however the sample size 
and results reported here are based on the comparison between the control arm and 
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the IRPAN arm for patients with KRAS wild-type tumours. A planned sample size of 
466 patients was required to detect an anticipated improvement in median survival 
from 9 months in the control arm to 12.9 months in the IRPAN arm with 80% power 
and 5% two-sided significance level. The trial recruited 460 patients in two years with 
a median follow-up of 25.4 months. The median OS for the control arm was 10.9 
months with 208 deaths and 10.4 months in the IRPAN arm. The median PFS for the 
control arm was 4.7 months and 5.5 months in the IRPAN arm. At the time of the 
interim analysis to test the superiority or inferiority of IRPAN against control using a 
p-value = 0.001, the IRPAN arm did not demonstrate superiority or inferiority hence 
continued to the final stage (Seymour et al. 2013).    
5.1.2.3 Lung cancer trials 
Four lung cancer trials were found that fulfilled the eligibility criteria stated in section 
5.1.1. Details of these trials that were used in the calculations are provided below.  
5.1.2.3.1 FRAGMATIC trial  
The FRAGMATIC trial evaluated whether the use of LMWH improved survival for 
patients diagnosed with lung cancer (Macbeth et al. 2015).  This two-arm phase III 
RCT assigned patients to receive LMWH or no LMWH (control arm). The TTE primary 
outcome was OS and the secondary TTE outcome was MFS.  A planned sample size 
of 2200 patients was required to detect an improvement in one-year survival from 
25% in the control arm to 30% in the experimental arm with 89% power and 5% two-
sided significance level. The trial recruited 2202 patients in approximately four years 
with a median follow-up of 23.1 months. The one-year OS rates were 41.3% and 
42.5% in the LMWH and control arms respectively, with 1020 deaths reported in the 
control arm. The one-year MFS rates were 16.2% and 14.9% in the LMWH and no 
LWMH arms respectively. During this trial, multiple interim analyses were performed 
and reviewed by an independent DMC to advise on safety of the trial treatment or 
recommend either continuation or closure of the trial. 
5.1.2.3.2 FORTIS-M trial  
The FORTIS-M trial investigated the use of talactoferrin which is an oral dendritic cell-
mediated immunotherapy in patients with advanced (stage IIIb/IV) NSCLC 
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(Ramalingam et al. 2013). In this double-blind phase III RCT, patients were assigned 
to either receive talactoferrin or placebo (control arm). The TTE primary outcome 
was OS and secondary TTE outcome was PFS. A planned sample size of 720 patients 
was required to detect a 30% improvement in median OS from 4.6 months in the 
placebo arm (control arm) to six months in the talactoferrin arm with 85% power and 
5% two-sided significance level. There were 742 patients recruited into the trial over 
a period of 2.5 years with a median follow-up of 18.1 months in the placebo arm and 
19.6 in the talactoferrin arm.  The median OS rate was 7.66 months in the placebo 
arm with 401 deaths and 7.49 in the talactoferrin arm. The median PFS rate was 1.64 
months in the placebo arm and 1.68 months in the talactoferrin arm.  
5.1.2.3.3 Big Lung trial  
The Big Lung trial aimed to assess the benefits of adjuvant chemotherapy following 
a complete resection for patients with stage I-III NSCLC (Waller et al. 2004). For this 
phase III RCT, patients were assigned to either surgery alone (control) or surgery plus 
cisplatin-based chemotherapy. The TTE primary outcome was OS and the secondary 
TTE outcome was PFS. A planned sample size of 4000 patients was required to detect 
a 5% difference of OS at five years from 50% with surgery alone to 55% for surgery 
plus cisplatin-based chemotherapy. The trial team felt it was not possible to recruit 
such a large number of patients and hence accrued a sample of 500 patients, which 
could be added as an update to a meta-analysis. A total of 381 patients were 
recruited over a period of six years with a median follow-up of 34.6 months for the 
183 patients that were alive, however the original sample size of 4000 patients was 
used as a comparator to deem whether or not the MAMS design was feasible. The 
two-year OS rate was 60% and 74% for the surgery and the surgery plus cisplatin 
group respectively. The two-year PFS rate was 51% and 53% for the surgery and 
surgery plus cisplatin group respectively.  The event rate for this trial was not 
assessed as this trial would become part of a meta-analysis. During this trial, multiple 
interim analyses were performed and reviewed by an independent DMC to advise on 
safety of the trial treatment or recommend either continuation or closure of the trial.  
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5.1.2.3.4 TOPICAL trial  
The TOPICAL trial evaluated the use of erlotinib in improving the clinical outcome for 
patients diagnosed with advanced (stage IIIb/IV) NSCLC (Lee et al. 2012). This double 
blind, superiority phase III RCT allocated patients to receive either erlotinib or a 
matching placebo (control).  The TTE primary outcome was OS and the secondary TTE 
outcome was PFS.  The main aim of this study was to detect an increase in one-year 
OS from 10% in the placebo arm to 17.5% in the control arm. To achieve this, a target 
sample size of 664 patients was required with 90% power and 5% two-sided 
significance level. The trial recruited 670 patients over a period of four years with an 
additional two years for follow-up. The median OS rate was 3.6 months in the placebo 
arm with 314 deaths and 3.7 months in the erlotinib arm. The median PFS rate was 
2.6 months in the placebo arm and 2.8 months in the erlotinib arm.  
5.1.2.4 Summary 
The 12 trials used for the different cancer sites have been summarised in terms of 
the number of arms, sample size, recruitment time, follow-up time and event rates 
in Table 5.1. Based on these results, three arm two stage, four arm three stage and 









Rec. time  
(Years) 









deaths IA performed† 
Breast cancer 
Deva 2 Luminal B/  HER2 enriched OS, DFS 8 5.5 
5-year DFS  
70% to 80% (0.63) 792 803 75 No 
SoFEA 3 Luminal A/ Luminal B OS, PFS 6 3 
Median PFS 
4 to 5.5 months (0.73) 750 723 173 Yes 
HERA 3 Luminal B/ HER2 enriched OS, DFS 3.5 2 
5-year DFS  
65% to 72% (0.77) 4482 5102 90 Yes 
NEAT 2 All four subtypes OS, RFS 6 4 5-year RFS  45% to 52% (0.82) 2000 2401 171 No 
Colon cancer 
QUASAR 2   2 Stage II/III OS, DFS 5.5 5 3-year DFS  66% to 72% (0.79) 2240 1952 169 No 
COIN 2 Stage IV OS, PFS 3 1.75 2-year OS 20% to 29% (0.76) 784 729 257 Yes 
FOCUS 3 Stage IV OS, PFS 2.5 2.2 2-year OS 15% to 22.5% (0.79) 2100 2135 617 No 
PICCOLO 3 Stage IV OS, PFS 2 2 Median OS 9 to 12 months (0.75) 466 460 208 Yes 
Lung cancer 
FRAGMATIC  2 Stage I/II/III/IV OS, MFS 4 2 1-year OS 25% to 30% (0.87) 2200 2202 1020 Yes 
FORTIS  2 Stage III/IV OS, PFS 2.5 1.5 Median OS 4.6 to 6 months (0.77) 720 742 401 No 
Big Lung  2 Stage I/II/III OS, PFS 6 3 5- year OS 50% to 55% (0.86) 500 381 99 Yes 
TOPICAL  2 Stage III/IV OS, PFS 4 2 1-year OS  10% to 17.5% (0.76) 664 670 314 No 
†Further details of the interim analyse have been presented in section 5.5. 
Table 5.1: Details obtained from the different phase III cancer trials for breast cancer, colon cancer and lung cancer. TTE – Time to event; FU- Follow-up; SS – 
Sample size; IA – Interim analysis; OS – Overall Survival, DFS – Disease free survival, PFS – Progression free survival, RFS – Relapse free survival, MFS – 




 Methods for the first and second phase calculations 
The hypothetical performance of a three arm two stage, four arm three stage trial 
using a superiority hypothesis were assessed for each of the three cancer sites. The 
first and second phase calculations based the recruitment, follow-up time and 
treatment difference on the results obtained from the selected 12 trials (Table 5.1). 
The total trial length (recruitment time plus follow-up time) would vary between 5.5 
to 13.5 years for breast cancer, four to 10.5 years for colon cancer and four to nine 
years for lung cancer. Additional time for recruitment was given as the number of 
trial arms increased, i.e. a recruitment period of seven years for a three arm breast 
cancer trial and a recruitment period of eight years for a four arm breast cancer trial. 
The survival rates used for the first and second phase calculations were based on the 
rates obtained from the ONS in which one-year and five-year estimated survival rates 
for various types of cancers between the years 2013 to 2017 in England were stated 
(Office for National Statistics 2019). These figures represent the estimates for the 
general population. Although, it is unlikely that a clinical trial would be performed for 
the general population, this was implemented as a baseline for future trials 
implementing MAMS designs. The one-year and five-year estimated survival rates for 
breast, colon and lung cancer are displayed in Table 5.2. 
Type of cancer Survival rate 
1-year 5-year 
Breast (only Women) 95.8% 85.0% 
Colon 76.0% 57.5% 
Lung 40.8% 16.4% 
Table 5.2: One-year and five-year survival rates for breast, colon and lung cancer from 
England between 2013-17 (Office for National Statistics 2019).  
5.2.1 Scenarios 
To better understand and appreciate the MAMS designs, each cancer site had up to 
three different scenarios that were considered based on the number of arms at the 
beginning of the trial (Table 5.3): 
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1) At every interim stage, the pairwise comparisons would show that all 
experimental arms were statistically significant from the control arm hence 
all experimental arms would continue to the final stage; 
2) At every interim stage, pairwise comparisons would show all but one 
experimental arm to be statistically significant from the control arm using a 
superiority hypothesis hence progressively removing one experimental arm 
at each interim stage; 
3) For the four arm three stage MAMS design, at the first interim stage the 
pairwise comparisons would show that one experimental arm would be 
statistically significant at the pre-specified level when compared to the 
control arm, i.e. the trial would begin with three experimental arms, and 
would be reduced to only one experimental arm after the first interim 
analysis. 
Scenario Number of arms at each stage (inc. control arm) 
3 arm 2 stage 
1 3, 3 
2 3, 2 
4 arm 3 stage 
1 4, 4, 4 
2 4, 3 2 
3 4, 2, 2 
Table 5.3: Number of arms at each stage (including control arm) for the different scenarios 
for a three arm two stage and four arm three stage MAMS design.  
5.2.2 Assumptions 
The following assumptions were used for the hypothetical calculations:  
• The allocation ratio would be equal for all arms;   
• Patients would be accrued at a uniform rate over the recruitment period; 
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• The sample size for each MAMS design would be fixed hence allowing for the 
total length of the trial to vary based on the different scenarios. This would 
be to ensure maximum information was obtained and not to minimise the 
sample size as in the VIETNARM trial (see appendix 1); 
• The hypotheses would be all distinct therefore focus was on controlling the 
PWER as in the STAMPEDE trial;  
• The first stage significance value would be 50% and all stagewise significance 
values thereafter descend in value. 
5.2.3 Guidelines to determine a feasible MAMS design 
The proportion of patients in the phase III trials for each cancer site were used to 
calculate an estimate for the maximum number of patients to enter phase III trials 
based on the estimated number of patients entering clinical trials each year. This 
estimation was based upon approximately 367,000 patients annual diagnosed with 
cancer in the UK between 2015-2017, of which approximately 55,000, 42,000 and 
48,000 patients were diagnosed with breast, colon and lung cancer respectively 
(Cancer Research UK 2018). It is estimated that one in six patients diagnosed with 
cancer in the UK joins a clinical trial, which is approximately 61,000 patients 
(Ajithkumar et al. 2017). Therefore, by taking one in six patients for each of the 
selected cancer sites approximately 9170 patients enter a breast cancer trial, 7000 
patients enter a colon cancer trial and 8000 patients enter a lung cancer trial. 
Furthermore, searching the ClinicalTrials.gov website (ClinicalTrials.gov 2020) 
identified a total of 182 clinical trials that are recruiting within the UK. The title, phase 
and the planned number of patients to be enrolled onto the study for all 182 clinical 
trials can be found in appendix 6. The number of trials and the mean planned sample 





Breast Colon Lung 
 No. of trials 
Target  
Mean SS No. of trials 
Target 
Mean SS No. of trials 
Target  
Mean SS 
Phase I 17 (23.6%) 203 (6.8%) 10 (33.3%) 204 (4.8%) 16 (20%) 267 (11.7%) 
Phase I/II 16 (22.2%) 402 (13.5%) 8 (26.7%) 501 (11.9%) 22 (27.5%) 337 (14.7%) 
Phase II 17 (23.6%) 287 (9.6%) 8 (26.7%) 305 (7.2%) 20 (25%) 275 (12%) 
Phase II/III 4 (5.6%) 578 (19.4%) 0 (0%) 0 (0%) 2 (2.5%) 105 (4.6%) 
Phase III 18 (25%) 1511 (50.7%) 4 (13.3%) 3199 (76%) 19 (23.8%) 705 (30.8%) 
Phase IV 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.3%) 600 (26.2%) 
Total 72 2981 30 4209 80 2289 
Table 5.4: Number of on-going clinical trials and the target mean sample size for each 
phase for breast, colon and lung cancer. SS – Sample size.  
The maximum number of patients entering phase III trials for each cancer site is 
obtained using the proportion of patients entering phase III trials given in Table 5.4 
and the estimated target number of patients that enter trials for the given cancer site 
which can be seen in Table 5.5. For example, from Table 5.4, the proportion of 
patients entering phase III breast cancer trials is 50.7%. Hence, using this information 
it is estimated that a maximum of 4649 patients (387 patients per month) are 
available to enter phase III breast cancer trials per year (calculated by taking 50.7% 





Patients entering clinical 
trials per year 
Estimated max. number of Patients 
entering phase III trials per month 
Breast 55000 9170 387 
Colon 42000 7000 443 
Lung 48000 8000 205 
Table 5.5: The maximum number of patients that could be recruited into a trial per month 
for breast, colon and lung cancer. 
For a MAMS design within the first and second phase calculations to be classed as 
feasible, the following must hold true: 
• The number of patients recruited per month would be no more than the 
values stated in Table 5.5 for each of the cancer sites;   
• A minimum duration of six months would be required between each stage as 
the time for operational tasks with this time period such as data entry, 
validating the data etc. needs to be accounted for;  
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• An achievable time given to recruit and follow-up patients which was based 
upon the 12 clinical trials mentioned in section 5.1.1 . 
 First phase of calculations 
5.3.1 Methods 
The first phase of the MAMS designs evaluated three cancer sites using an 
intermediate and primary outcome of five-year survival rate for breast and colon 
cancer and one-year survival rate for lung cancer (Table 5.2). The high mortality rate 
of patients diagnosed with lung cancer resulted in applying a one-year survival rate. 
The HR within a superiority setting (calculation of these values are shown in chapter 
one), the number of years for recruitment for each hypothetical MAMS design and 
the follow-up period after recruitment for each of the cancer sites are displayed in 
Table 5.6. These parameters were selected based upon the trials shown in  Table 5.1 
and used for the first phase of calculations.  
The time to perform the analysis for each stage is dependent upon the number of 
events reached in the control arm, hence the number of control arm events at each 
interim and final stage, the duration of each stage and the total sample size were 
recorded. Furthermore, the aim of this phase was to select an appropriate 
significance level and power at each stage such that the overall PWER was 5% and a 















Breast 85.0% (7.5%) 0.48 
3 7 4 
4 8 4 
Colon 57.5% (7.5%) 0.78 
3 4 3 
4 5 3 
Lung 40.8 (5.0%) 0.87 
3 4 2 
4 5 2 
Table 5.6: HR calculated using five-year survival rates for breast and colon cancer with 7.5% 
absolute treatment difference. HR calculated using one-year survival rate for lung cancer 
with 5% absolute treatment difference. Parameters selected based upon trials shown in 
Table 5.1 and used for the first phase of calculations. HR – Hazard Ratio; MCID – Minimally 
clinical important difference.  
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5.3.2 Example – First phase calculations 
Below is an example of a hypothetical four arm three stage MAMS design with a 
superiority hypothesis for patients diagnosed with breast cancer. Five-year OS 
survival rate of 85% will be used for the intermediate and primary outcome.  A HR of 
0.48 would be interpreted as an absolute improvement of 7.5% in survival from 85% 
to 92.5% at five years for any experimental arm compared to the control. For a four 
arm three stages MAMS design to have a pairwise power of approximately 80%, the 
MAMS design would require 95% power at stage one, 88% power at stage two and 
86% power at the final stage for each pairwise comparison. To have a PWER of 5%, 
the MAMS design would require a 50% alpha value at stage one, 20% at stage two 
and 5% at the final stage. Approximately 640 patients would be recruited in eight 
years (accrued at a uniform rate of 7 patients per month) and allocated equally to all 
treatment arms, so that patients would be followed-up for approximately three 
years. This MAMS design was applied to the three different scenarios stated earlier. 
The parameters inputted into the ‘nstage’ command in Stata can be found in Table 
5.7 and the syntax and results for scenario one is shown in Figure 5.1. 
 
Parameter Value  
Total number of stages 3 
Number of arms in each stage 4, 4, 4 
Total accrual  640 
Allocation ratio 1 
Survival Probability for OS 0.85 
Survival Time (years) 5 
HR under H0 1 
HR under H1  0.48 
One-sided alpha for each stage 0.5, 0.2, 0.05 
Power for each stage 
0.95, 0.88, 
0.86 
Time units 1 (= one year) 
Time of recruitment stopping (years) 8 
Table 5.7: Parameters inputted for a hypothetical four arm three stage MAMS trial using 
the ‘nstage’ command in Stata, the intermediate and primary outcome was OS. OS – Overall 




Applying the different scenarios resulted in variations in the lengths of follow-up and 
the number of cumulative experimental arm events across stages (Table 5.8) because 
the sample size and accrual period remained fixed, but the number of experimental 
arms varied for each scenario. For scenario one, the rate for which patients would be 
accrued in the control arm would be lower and therefore would take longer to reach 
the required number of control arm events to trigger the final analysis in comparison 
to the rate in scenarios two and three and therefore required more follow-up time.    
Scenario FU time 
Experimental events 
at each stage 
Total Trial length 
(years) 
1 3.2 24, 30, 51 11.2 
2 3 24, 20, 17 11 
3 2.75 24, 10, 17 10.75 
Table 5.8: The difference in FU time and cumulative experimental events required at each 
stage for the different scenarios. FU – Follow-up  
From the results, the three scenarios for the MAMS design applied in breast cancer, 
7 patients would be recruited per month satisfying the first criteria whereby a 
maximum of 387 patients could be recruited per month. The duration of each stage 
for all scenarios would be more than six months (Table 5.9) and recruitment and 
follow-up for patients would be achieved within a reasonable time when compared 
to the breast cancer trials (between 5.5 to 13.5 years for breast cancer stated in 





Figure 5.1: Syntax and output obtained for the first phase 4A3S MAMS design with a 
superiority hypothesis in a breast cancer setting for scenario one. 
END OF NSTAGE
 ** Events are for the same outcome at all 3 stages
    for those arms to which patients are still being recruited
 ** Events are cumulative across stages, but are only displayed
 *  Patients are cumulative across stages
                                    
Events**        84       33       51
Patients*      640      160      480
Acc. rate       80       20       60
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 3         
Events**        49       19       30
Patients*      639      160      479
Acc. rate       80       20       60
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 2         
Events**        39       15       24
Patients*      564      141      423
Acc. rate       80       20       60
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 1         
Sample size and number of events
     expressed in cumulative periods.
     assumes survival times are exponentially distributed. Time is
 **  Length (duration of each stage) is expressed in  periods and
 *   All alphas are one-sided
Note: patient accrual stopped at time  8.000
                                                                             
Familywise Error Rate (SE)   0.1008 (0.0006)
Pairwise Error Rate          0.0421              Pairwise Power   0.8117
                                                                             
3           0.0500    0.865    1.000    0.480    0.667    3.217   11.193
2           0.2000    0.881    1.000    0.480    0.761    0.923    7.976
1           0.5000    0.953    1.000    0.480    1.000    7.053    7.053
                                                                             
Stage  Alpha(LOB)*    Power    HR H0    HR H1  Crit.HR Length**   Time**
                                                                             
Operating characteristics
Median survival time: 21.3 time units
Note: I outcome and D outcome are identical
                                                                 
(2019) Clinical Trials 16(2)
based on Royston et al. (2011) Trials 12:81 and Blenkinsop et al.
Sample size for a 4-arm 3-stage trial with time-to-event outcome
                                                                 
n-stage trial design                    version 4.0.1, 2 Nov 2018
>  omega(0.95 0.88 0.86) t(5 5) s(0.85 0.85) nstage(3) tstop(8)
. nstage, accrue(80 80 80) arms (4 4 4) alpha(0.5 0.2 0.05) hr0(1 1) hr1(0.48 0.48)
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5.3.3 Results  
A summary of the results from the first phase of the calculations is provided in Table 
5.9. For the MAMS designs, it was evident that trials in lung cancer would require the 
most patients, followed by colon cancer then breast cancer. In comparison to the 
other cancer sites, the MAMS designs for lung cancer had the smallest treatment 
difference and had the smallest overall trial length which would result in requiring 
the most patients. Therefore, more events would be required and hence more 
patients to determine this difference. Thus, an improved survival rate indicated that 
fewer events would occur which meant that fewer events would be required to test 
the null hypothesis for futility or lack of benefit at each interim stage and to conclude 
superiority at the final stage.  
There would be no difference to the overall length of the trial when comparing 
scenarios one and two for the three arm two stage breast cancer trial as the first 
interim stage would occur at seven years for both scenarios at which point all 
patients would be randomised. The only difference would be in the number of 
experimental arm events at the final stage as for scenario one both experimental 
arms would remain, whereas in scenario two, one experimental arm would be 
dropped and not analysed at the final stage.  Follow-up would cease for those 
patients on the experimental arm which would be discontinued. The initial aim of the 
three arm two stage breast cancer trial was to have seven years for recruitment and 
four years for follow-up however these hypothetical trials would only need a 
maximum of 3.5 years follow-up to reach the required number of events with the 
estimated number of patients.  A decrease in the number of patients to extend the 
follow-up period to four years would have resulted in the recruitment period 
completing before stage one. This design would have then been considered 
‘infeasible’ as per the key principle of the MAMS design framework that the 
recruitment completes in between the interim stage before the final stage and the 
final stage (Blenkinsop et al. 2019). The results of these two scenarios satisfied all the 
criteria mentioned earlier whereby 5 patients would be recruited each month, the 
duration of each stage would be all greater than six months and recruitment and 
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follow-up would be completed between nine to 13.5 years - an achievable time, 
hence deeming all three arm two stage breast cancer trials as feasible.  
For the four arm three stage breast cancer trial (used as an example in section 5.3.2), 
the second scenario would have a reduced follow-up period compared to the first 
scenario as an experimental arm would be discontinued whilst recruitment was on-
going as the first interim stage occurred at seven years (recruitment period up until 
eight years). This would lead to an increase in the rate at which newly recruited 
patients would be allocated in the remaining arms which meant events occurred 
quicker and therefore reduced the duration of the follow-up period. For the third 
case, where it was hypothesised that an experimental arm was discontinued at each 
stage, the overall trial length would be further reduced. Hence, for this four arm 
three stage breast cancer trial, the overall trial varied from 10.75 years to 11.2 years 
based on the outcome of the pairwise comparisons at each stage. As mentioned in 
the previous section, the four arm three stage MAMS designs would be all deemed 
feasible.  
The two scenarios of dropping arms for three arm two stage colon cancer trial would 
be like the three arm two stage breast cancer trial such that there would be no 
difference in the overall length of the trial as the first interim stage would occur at 
approximately before four years for both scenarios (four years for recruitment). The 
duration of each interim stage would be greater than six months and the recruitment 
period and follow-up period would be achievable (total trial length between four to 
10.5 years for colon years to be deemed achievable) and the number of patients 
required would be less than the estimated maximum number of patients recruited 
per month (32 patients per month vs 443 estimated maximum patients per month). 
The four arm three stage colon cancer trial like the four arm three stage breast cancer 
trial, would reduce the total length for each progressive case. The overall trial would 
vary from 7.5 years to 6.9 years based on the outcome of the pairwise comparisons 
at each stage. It was initially aimed to have a total trial length of eight years (five 
years recruitment and three years follow-up) however this would not be permitted 
by the ‘nstage’ command as any increase in patients would result in recruitment 
ceasing during an interim stage prior to the final stage. The four arm three stage trial 
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would require 40 patients per month to be recruited compared to the estimated 
maximum number of patients that could be recruited per month (443 patients) 
deeming this trial feasible.  
The results of the two scenarios for the three arm two stage lung cancer trial would 
be like that of the breast cancer and colon cancer trials in terms of fewer 
experimental arm events required for the second case. However, the follow-up 
period would be reduced from two years in the first case to 1.6 years in the second 
case which would be because the interim analysis occurred at 2.6 years (whilst 
recruitment would be ongoing) unlike breast cancer and colon cancer where the first 
interim stage would take place at the end of the recruitment period. The three arm 
two stage lung cancer trial would require 45 patients per month which is less than 
the 205 estimated maximum patients that could be recruited per month deeming 
this trial as feasible.  
The results of the three scenarios for the four arm three stage lung cancer trial would 
be also like that of breast cancer and colon cancer in that for each progressive case 
the follow-up time and the number of experimental arms required would decrease. 
However, compared to the other cancer sites, the durations of the interim stages 
would be less than a year (ranging from 0.7 years to 0.9 years). The total trial length 
ranged from five years for the third scenario to seven years for the first scenario, 
hence the third scenario would perform the final stage analysis at the end of 
recruitment which would mean there would be several patients that would have 
reduced or no follow-up. The four arm three stage MAMS designs for lung cancer 
would require 55 patients per month compared to 205 patients that could be 






Significance value Power value Total 
Patients (pts 
per month) 






















3 arm 2 stage - Breast 
1 0.5, 0.05 0.05 0.95, 0.82 0.81 427 (5) 15 28 16, 30 7 7, 3.5 10.5 
2 0.5, 0.05 0.05 0.95, 0.82 0.81 427 (5) 15 28 16, 15 7 7, 3.5 10.5 
4 arm 3 stage - Breast 
1 0.5, 0.2, 0.05 0.04 0.95, 0.88, 0.86 0.81 640 (7) 15, 19 33 24, 30, 51 8 7, 1, 3.2 11.2 
2 0.5, 0.2, 0.05 0.04 0.95, 0.88, 0.86 0.81 640 (7) 15, 19 33 24, 20, 17 8 7, 1, 3 11 
3 0.5, 0.2, 0.05 0.04 0.95, 0.88, 0.86 0.81 640 (7) 15, 19 33 24, 10, 17 8 7, 1, 2.75 10.75 
3 arm 2 stage - Colon 
1 0.5, 0.05 0.05 0.95, 0.82 0.81 1540 (32) 97 216 156, 358 4 4, 3 7 
2 0.5, 0.05 0.05 0.95, 0.82 0.81 1540 (32) 97 216 156, 179 4 4, 3 7 
4 arm 3 stage - Colon 
1 0.5, 0.2, 0.05 0.041 0.95, 0.88, 0.86 0.8 2380 (40) 96, 138 246 234, 336, 609 5 4, 1, 2.5 7.5 
2 0.5, 0.2, 0.05 0.041 0.95, 0.88, 0.86 0.8 2380 (40) 96, 138 246 234, 224, 203 5 4,1, 2.2 7.2 
3 0.5, 0.2, 0.05 0.041 0.95, 0.88, 0.86 0.8 2380 (40) 96, 138 246 234, 112, 202 5 4, 1, 1.9 6.9 
3 arm 2 stage - Lung 
1 0.5, 0.05 0.05 0.95, 0.82 0.81 2164 (45) 294 690 550, 1354 4 2.6, 3.4 6 
2 0.5, 0.05 0.05 0.95, 0.82 0.81 2164 (45) 294 690 550, 664 4 2.6, 2 4.6 
4 arm 3 stage - Lung 
1 0.5, 0.2, 0.05 0.041 0.95, 0.88, 0.86 0.8 3245 (54) 293, 433 782 825, 1236, 2310 5 2.8, 0.9, 3.3 7 
2 0.5, 0.2, 0.05 0.041 0.95, 0.88, 0.86 0.8 3245 (54) 293, 433 782 825, 822, 751 5 2.8, 0.8, 1.5 5.1 
3 0.5, 0.2, 0.05 0.041 0.95, 0.88, 0.86 0.8 3245 (54) 293, 433 782 825, 410, 750 5 2.8, 0.7, 1.5 5 
Table 5.9: First phase of calculations. Sample size outcomes for a four arm three stage and three arm two stage hypothetical MAMS designs for  
Breast, Colon and Lung cancer with a superiority hypothesis.
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 Second phase calculations 
5.4.1 Methods 
The second phase calculations for the hypothetical MAMS trials evaluated the 
outcomes when the stagewise significance and stagewise power values as suggested 
by Royston et al (2011) were implemented. The authors within this paper suggest 
using for the significance level at interim stage 𝐸𝐸 the formula 𝛼𝛼𝑖𝑖 = 0.5𝑖𝑖  (𝐸𝐸 < 𝑓𝑓) and 
𝛼𝛼𝑓𝑓 = 0.025 where 𝑓𝑓 is the final stage. Furthermore, the power for each interim stage 
should be at least 95% and a power of at least 90% for the final stage. This method 
reduces the overall alpha value and increases the power, which in turn increases the 
robustness of these trials, additionally these values were implemented in the earlier 
comparisons of the STAMPEDE trial (see Table 4.2).  
Based on the results of the first phase calculations, the recruitment period for the 
three arm two stage trials for the colon and lung cancer trials were extended from 
four years to six years and from five years to seven years in the four arm three stage 
trials to decrease the recruitment rate per month.  
The results from this phase were compared to the results from the first phase 
calculations in terms of the differences between the overall significance values, the 
overall power values, the sample size, the number of events required for the control 
and experimental arms and the duration of the stages.  
5.4.2 Example – Second phase calculations 
The example shown in section 5.3.2 is continued here except the difference is that 
this MAMS design would provide 95% power at stages one and two and 90% power 
at the final stage for each pairwise comparison. A type I error rate of 50% at stage 
one, 25% at stage two and 2.5% at stage would be used as the significance level for 
each pairwise comparison. Assuming 872 patients are recruited in eight years 
(accrued at a uniform rate of 9 patients per month) and equally allocated, it is 
anticipated that patients will be followed-up for approximately 3.4 years. This 
hypothetical MAMS design was applied to the three different scenarios stated 
earlier. The parameters inputted into the ‘nstage’ command in Stata can be found in 




Parameter Value  
Total number of stages 3 
Number of arms in each stage 4, 4, 4 
Total accrual  872 
Allocation ratio 1 
Survival Probability for OS 0.85 
Survival Time (years) 5 
HR under H0 1 
HR under H1  0.48 
One-sided alpha for each stage 0.5, 0.25, 0.025 
Power for each stage 0.95, 0.95, 0.9 
Time units 1 (= one year) 
Time of recruitment stopping (years) 8 
Table 5.10: Parameters inputted for a hypothetical four arm three stage MAMS trial using 
the ‘nstage’ command in Stata, the intermediate and primary outcome was OS. OS – Overall 
survival, HR – Hazard ratio, H0 – Null hypothesis, H1 – Alternate hypothesis. 
Applying the different scenarios for the second phase resulted in different lengths of 
follow-up and cumulative experimental arm events across stages compared to those 
seen in the first phase (Table 5.11). 
Scenario FU time Experimental events at each stage 
1 3.4 24, 42, 72 
2 3 24, 28, 24 
3 2.4 24, 14, 24 
Table 5.11: The difference in FU time and cumulative experimental events require at each 
stage for the different scenarios for the second phase of calculations. FU – Follow-up. 
From the second phase calculations, the three scenarios for the MAMS design 
applied in breast cancer, 9 patients would be recruited per month satisfying the first 
criteria whereby a maximum of 387 patients could be recruited per month. The 
duration of each stage for all scenarios were more than six months (Table 5.13) and 
recruitment and follow-up for patients would be achieved within a reasonable time 
when compared to the breast cancer trials in Table 5.1 hence deeming these MAMS 





Figure 5.2: Syntax and output obtained for the second phase four arm three stage MAMS 




A summary of the results from the second phase calculations are provided in Table 
5.13. For the MAMS designs, like the first phase calculations, lung cancer would 
require the most patients, followed by colon cancer then breast cancer and for each 
hypothesized MAMS trial, the follow-up time would decrease for each progressive 
case. Furthermore, based on guidelines stated in section 5.2.3, the breast cancer and 
the colon cancer trials would be deemed as feasible MAMS designs that could be 
implemented using survival as the intermediate and primary outcome.  
The number of control arm events and patients that would be required in the first 
phase and second of calculations can be seen in Table 5.12. A change in the stagewise 
significance values and stagewise power values would increase the events and 
patients required. Extending the recruitment period would reduce the number of 
patients required to be recruited into the trials per month for the colon cancer trials 
and the four arm three stage lung cancer trial but at the same time the change in the 
stagewise significance and power values would inflate the sample size.   
  









Breast 3A2S 28 46 427 539 
Breast 4A3S 33 46 640 872 
Colon 3A2S 216 347 1540 2172 
Colon 4A3S 246 347 2380 3115 
Lung 3A2S 690 1111 2164 3420 
Lung 4A3S 782 1111 3245 4536 
Table 5.12: Number of control events and patients required in the first phase and second 
phase of calculations. 3A2S – Three arm two stage; 4A3S – Four arm three stage.  
The use of the stagewise significance and power values as stated by Royston et al 
(2011) would give an overall lower alpha value and higher power value for each trial 
demonstrating the robustness within this phase compared to the first phase. 
Additionally, a high power at each interim stage would ensure that an experimental 
arm is not incorrectly discontinued from the trial as the futility boundary at the 




Significance value Power value 
Total Patients  
(pts per month) 






















3 arm 2 stage - Breast 
1 0.5, 0.025 0.02 0.95, 0.9 0.88 539 (6) 15 46 16, 48 7 6.2, 6.5 12.7 
2 0.5, 0.025 0.02 0.95, 0.9 0.88 539 (6) 15 46 16, 24 7 6.2, 6 12 
4 arm 3 stage - Breast 
1 0.5, 0.25, 0.025 0.02 0.95, 0.95, 0.9 0.87 872 (9) 15, 26 46 24, 42, 72 8 6, 2, 3.4 11.4 
2 0.5, 0.25, 0.025 0.02 0.95, 0.95, 0.9 0.87 872 (9) 15, 26 46 24, 28, 24 8 6, 2, 3 11 
3 0.5, 0.25, 0.025 0.02 0.95, 0.95, 0.9 0.87 872 (9) 15, 26 46 24, 14, 24 8 6, 1.9, 2.5 10.4 
3 arm 2 stage - Colon 
1 0.5, 0.025 0.02 0.95, 0.9 0.87 2172 (30) 96 347 156, 580 6 4, 5 9 
2 0.5, 0.025 0.02 0.95, 0.9 0.87 2172 (30) 96 347 156, 288 6 4.1, 4.2 8.3 
4 arm 3 stage - Colon 
1 0.5, 0.25, 0.025 0.02 0.95, 0.95, 0.9 0.86 3115 (37) 96, 185 347 234, 453, 867 7 4.2, 1.8, 3 9 
2 0.5, 0.25, 0.025 0.02 0.95, 0.95, 0.9 0.86 3115 (37) 96, 185 347 234, 302, 287 7 4.2, 1.7, 2.3 8.3 
3 0.5, 0.25, 0.025 0.02 0.95, 0.95, 0.9 0.86 3115 (37) 96, 185 347 234, 150, 286 7 4.2, 1.6, 2 7.8 
3 arm 2 stage - Lung 
1 0.5, 0.025 0.02 0.95, 0.9 0.87 3420 (48) 294 1105 550, 2180 6 2.5, 5.5 8 
2 0.5, 0.025 0.02 0.95, 0.9 0.87 3420 (48) 294 1111 550, 1070 5.8 2.5, 3.3 5.8 
4 arm 3 stage - Lung 
1 0.5, 0.25, 0.025 0.02 0.95, 0.95, 0.9 0.86 4536 (54) 293, 573 1105 825, 1647, 3276 7 2.8, 1.8, 4.4 9 
2 0.5, 0.25, 0.025 0.02 0.95, 0.95, 0.9 0.86 4536 (54) 293, 573 1111 825, 1096, 1069 6.4 2.8, 1.6, 2 6.4 
3 0.5, 0.25, 0.025 0.02 0.95, 0.95, 0.9 0.86 4536 (54) 293, 573 1111 825, 1647, 3276 5.8 2.8, 1.2, 1.8 5.8 
Table 5.13: Second phase of calculations. Sample size outcomes for a four arm three stage and three arm two stage hypothetical MAMS designs for  
Breast, Colon and Lung cancer with a superiority hypothesis.
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 Methods for third phase calculations  
The third phase of MAMS design calculations used the parameters obtained from the 
12 phase III RCTs as summarised in Table 5.1 to:  
1. Re-calculate sample size for a standard two-arm trial using OS as a primary 
outcome;  
2. Create fictional scenarios to calculate sample sizes for MAMS designs where 
multiple treatments were available to compare against a common control 
using the ‘nstage’ command; 
3. Use the guidelines (see section 5.5.1.1) to compare the efficiency of standard 
two-arm trials compared to MAMS designs. 
Three arm two stage, four arm three stage and five arm four stage hypothetical 
MAMS designs were calculated.  
5.5.1 Methods 
The focus of the third phase was to assess the application of MAMS designs with 
longer term outcomes such as OS. These will be applied in a fictitious setting whereby 
multiple treatments would be available to evaluate against a common control by 
comparing the effectiveness of MAMS designs against the running of standard two-
arm trials using the aforementioned phase III trials (Table 5.1). To ensure consistency 
and comparability against the MAMS designs, all trials had sample size re-calculated 
as a standard two-arm trial with the same assumptions as used in the MAMS design 
and were renamed with the suffix “_OS” to emphasise that OS had been used as the 
primary outcome. To recalculate these trials, the OS result obtained for the control 
arm, the planned treatment difference for the primary outcome in the original trial, 
power of 90% and one-sided significance of 2.5% were all used. The new sample size 
and number of events can be seen in Table 5.14. 
Trial Name OS (Target HR) SS (Control SS) Control events 
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Breast cancer trials 
Deva_OS 5 year 81.8% (0.43) 278 (139) 33 
SoFEA_OS Median 0S 21.6 mo. (0.73) 482 (241) 218 
HERA_OS 3 year 89.7% (0.31) 448 (224) 19 
NEAT_OS 5 year 75% (0.69) 1094 (547) 156 
Colon cancer trials  
QUASAR 2_OS 3 year 89.4% (0.42) 344 (172) 32 
COIN_OS Median 17.9 mo. (0.76) 766 (383) 285 
FOCUS_OS 2 year 22% (0.81) 950 (475) 368 
PICCOLO_OS Median 10.9 mo. (0.75) 718 (359) 259 
Lung cancer trials  
FRAGMATIC_OS 1 year 42.5% (0.87) 2320 (1160) 1090 
FORTIS-M_OS Median 7.6 mo. (0.77) 908 (454) 313 
Big Lung_OS 2 years 60% (0.84) 1980 (990) 728 
TOPICAL_OS Median 3.6 mo. (0.80) 842 (421) 420 
Table 5.14: Re-calculated sample sizes using OS results. SS = Sample size.  
 
The stagewise significance level and power values as suggested by Royston et al 
(2011) were used for all MAMS design in this phase of calculations. The primary and 
intermediate outcome for all trials were OS. It was assumed that for these MAMS 
designs all experimental arms would continue to the final stage hence maximising 
the number of patients and time required, therefore capitalising on any funding given 
to support the trial. This is the worst case scenario from a funding and time 
perspective however it is the best case scenario for hope for future patients as it 
means that there is a higher possibility that more treatments are worthwhile. 
The survival probability and survival time used for each of the MAMS trials can be 
seen in Figure 5.3. The recruitment time, estimated follow-up time and the absolute 
treatment difference for each trial that was used in the calculations for the MAMS 




Figure 5.3: Scatter plot showing the survival probability and the time for each of the trials 
which was used to calculate sample sizes for the MAMS trials.  
Trial Name Rec. Time (Years) 
Med. FU 
(Years) Absolute Trt. Difference 
Breast Cancer Trials 
Deva_OS 8 5.5 10% 
SoFEA_OS 6 3 29.6 months 
HERA_OS 3.5 2 7% 
NEAT_OS 6 4 7% 
Colon Cancer Trials 
QUASAR 2_OS 5.5 5 6% 
COIN_OS 3 1.75 23.5 months 
FOCUS_OS 2.5 2.2 7.5% 
PICCOLO_OS 2 2 14.5 months 
Lung Cancer Trials 
FRAGMATIC_OS 4 2 5% 
FORTIS-M_OS 2.5 1.5 10 months 
Big Lung_OS 6 3 5% 
TOPICAL_OS 4 2 7.5% 
Table 5.15: Summary of the parameters that were used to apply MAMS designs for each 





5.5.1.1 Guidelines to determine a feasible MAMS design for the third phase 
Incidence rates of the subgroups for each cancer site were used to estimate the 
potential maximum number of patients that could be recruited per month for each 
of the 12 trials. Breast cancer subtypes are defined by three tumour markers; ER, PR 
which are both classed as hormone receptors (HoR) and HER2. The subtypes of breast 
cancer (formed by the joining of these markers) and the incidence rates for each of 
these subtypes have been classified in Figure 5.4  (Howlader et al. 2014, Komen 
2017). The incidence rates of the different stages of colon and lung cancer in the UK 
between 2010-2014 (Cancer Research UK 2018) have been classified in Figure 5.5. 
The incidence values for the different sub-types/stages for each cancer site and the 
maximum number of patients entering phase III cancer trials from Table 5.5 were 
used to calculate the maximum number of patients that could be recruited per 
month (Table 5.16). These values were used as one of the comparators to deem 
whether the results for the re-analysed trials from the third phase of calculations 
produced a feasible MAMS design. 
 
Figure 5.4: The estimated maximum number of patients to enter phase III trials per month 
spit by sub-type for Breast Cancer. HoR = Hormone Receptors; HER2 – Human Epidermal 





Figure 5.5: The estimated maximum number of patients to enter phase III trials per month 
spit by stage for Colon and Lung cancer. U/K – Unknown. 
 
The hypothetical MAMS design for the trials were classed as feasible if all three of 
the following proved to be successful:  
1. The MAMS design would require fewer patients per month when compared 
to the estimated maximum number of patients entering phase III trials per 
month (Table 5.16); 
2. The number of control arm patients required in the MAMS designs would be 
no more than 10% greater than the two-arm trial;  
3. If the number of control arm deaths from the MAMS design would be no more 
than 10% greater compared to those from the two-arm trial.  
If all three criteria were met then the trials were assessed taking the work of 
Schiavone et al (2019) and Hague et al (2019), which has been mentioned in chapter 
two, into consideration to ensure the practicality aspect of employing a MAMS design 
(Hague et al. 2019, Schiavone et al. 2019). For example, a five arm four stage MAMS 
with a trial length of four years may show success with the criteria above but to have 
three stages within four years may not be practical.  
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Lastly, a further analysis was conducted comparing the sample size required for six 
separate standard two arm trials versus two separate four arm three stage trials 
versus three separate three arm two stage trials. All these trials had one control arm 
and six experimental arms. The aim of this comparison was to further understand if 
applying MAMS designs showed to be advantageous by requiring fewer patients to 
achieve the same number of answers.  
Trial name Max. number of potential patients per month (per year) 
Recruitment time 
(years) Total patients 
Breast cancer trials 
DEVA_OS 58 (696) 8 5568 
SoFEA_OS 322 (3864) 6 23184 
HERA_OS 58 (696) 3.5 2436 
NEAT_OS 387 (4644) 6 27864 
Colon cancer trials 
QUASAR 2_OS 226 (2712)  5.5 14916 
COIN_OS 97 (1164) 3 3492 
FOCUS_OS 97 (1164) 2.5 2910 
PICCOLO_OS 97 (1164) 2 2328 
Lung cancer trials 
FRAGMATIC_OS 184 (2208) 4 8832 
FORTIS-M_OS 137 (1644) 2.5 4110 
Big Lung_OS 90 (1080) 6 6480 
TOPICAL_OS 137 (1644) 4 6576 
Table 5.16: The maximum number of potential patients that could be recruited into each of 
the trials per month and altogether based on the subtype of patients recruited in the 
original trial. 
5.5.2 Example – Third phase calculations 
To understand the process for the third phase calculations, the three arm two stage 
DEVA_OS trial will be used as an example. The DEVA_OS standard parallel trial would 
require 278 patients (139 patients for each arm) with 33 control arm events at 90% 
power with one-sided significance of 2.5% to detect an increase in survival at five-
years from 81.8% to 91.8%.  
The three arm two stage DEVA_OS MAMS trial would provide 95% power at stage 
one and 90% power at the final stage for each pairwise comparison. A type I error 
rate of 50% at stage one, 2.5% at the final stage would be used as the significance 
level for each pairwise comparison. A total of 336 patients (112 patients on each arm) 
would be required to be recruited in eight years with an anticipated follow-up for 5.5 
years. The parameters inputted into the ‘nstage’ command in Stata can be found in 




Parameter Value  
Total number of stages 2 
Number of arms in each stage 3, 3 
Total accrual  336 
Allocation ratio 1 
Survival Probability for OS 0.818 
Survival Time (years) 5 
HR under H0 1 
HR under H1  0.426 
One-sided alpha for each stage 0.5, 0.025 
Power for each stage 0.95, 0.9 
Time units 1 (= one year) 
Time of recruitment stopping (years) 8 
Table 5.17: Parameters inputted for a hypothetical three arm two stage DEVA_OS MAMS 
trial using the ‘nstage’ command in Stata, the intermediate and primary outcome was OS. 
OS – Overall survival, HR – Hazard ratio, H0 – Null hypothesis, H1 – Alternate hypothesis 
Using the guidelines specified in 5.5.1.1, to deem this MAMS design as feasible a 
maximum of 58 patients per month for eight years could be recruited (Table 5.16); 
the three arm two stage MAMS trial would require only three patients per month. 
For the control arm, the DEVA_OS trial would require 139 patients with 33 events 
compared to the MAMS trials which would require 109 patients with 35 events. 
Therefore, all three procedures were successful so the three arm two stage MAMS 
design was classed as feasible.  
Furthermore, if in the situation where six experimental treatments were available to 
be compared against a common control for the DEVA_OS trial then three separate 
three arm two stage DEVA_OS trials would require a significantly fewer number of 
patients in comparison to performing six separate trials; 984 patients vs. 1668 




Figure 5.6: Syntax and output obtained for the third phase three arm two stage MAMS 




5.5.3.1 Breast Cancer Trials 
Figure 5.7 shows the number of patients that would be required per month for each 
of the different MAMS designs for the breast cancer trials to achieve the required 
sample size. The five arm four stage MAMS DEVA_OS trial would require 11 patients 
per month to be recruited to reach the sample size. As per Table 5.16, an estimated 
maximum of 58 patients per month could be recruited for this trial hence deeming 
the first criteria successful. Similarly, it was found that the other MAMS breast cancer 
trials would require fewer than the estimated maximum number of patients that 
could be recruited per month (Figure 5.7). Thus, concluding that all these trials had 
the potential to carry out these MAMS designs.  
 
Figure 5.7: Total number of patients required assuming that all experimental arms reach 
the final stage for a three arm two stage, four arm three stage and five arm four stage 
MAMS design when applying the parameters obtained from the different breast cancer 
trials. 3A2S = Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm four 
stage. 
 
For the second criteria to be successful, the number of control arm patients required 
for the MAMS design would be similar to the standard two-arm trial. It can be seen 
in Figure 5.8 that more than 10% of control arm patients would be required for only 
the NEAT_OS five arm four stage trial in comparison to the two-arm trial. An increase 
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in control arm patients for these MAMS designs were observed because with each 
increase MAMS design, the follow-up length decreased, which indicated that more 
patients would require required to achieve the appropriate number of events. A 
simple solution to this would be to decrease the rate at which patients were recruited 
into the trial however this would lead to ceasing of the recruitment period in a stage 
prior to the final stage, which is a restriction in the ‘nstage’ program.  
 
Figure 5.8: The number of control arm patients for the standard design compared to the 
number of control arm patients required for the different MAMS designs for the breast 
cancer trials. 3A2S = Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm 
four stage. 
 
The third criteria assessed the number of control arm events that would be required 
in the final stage of the MAMS design to conclude superiority compared to the total 
number of control arm events required in the standard two-arm trial. The change in 
the number of control arm events compared to the standard two-arm trial can be 
seen in Figure 5.9. The maximum decrease in the number of control arm events 
compared to the standard two-arm trial would be for the five arm four stage 
DEVA_OS trial which required approximately 12% fewer control arm events at the 
final stage. The NEAT_OS MAMS designs would require approximately 5% more 
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control arm events compared to the standard two-arm trial. Although, most of the 
MAMS designs would require more control arm events, the difference was not 
considered to be that large (i.e. fewer than nine events), resulting in deeming all 
MAMS designs as feasible.   
 
Figure 5.9: The change in the number of control arm events required for the different MAMS 
designs compared to the standard trial for breast cancer. 3A2S = Three arm two stage; 4A3S 
= Four arm three stage; 5A4S = Five arm four stage. 
A cross-check of the five arm four stage trials with the total trial length found that to 
perform the HERA_OS trial would not be viable. The total trial length for the five arm 
four stage HERA_OS trial would be five years and to plan and execute three interim 
analyses within this time would not be practical due to the operational tasks to 
consider prior to each interim analysis i.e. set-up of sites, allowing for sufficient 
follow-up bearing in mind that the treatment arms looked at different duration of 
one-year of Herceptin, collecting data, cleaning the data, validating data, arranging 
meetings with the DMC etc.   
A summary of the results for all the breast cancer trials can be seen in Table 5.18. It 
is clear according to criteria one that all MAMS designs are feasible. The five arm four 
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stage MAMS designs for the DEVA_OS trial failed the second criteria as more control 
arm patients would be required compared to the standard design however when 
further investigated, it was found that the intended total trial length was reduced. 
To extend the trial length, fewer patients would be required however this would lead 





1 2 3 5A4S Cross-check 
DEVA_OS 
3A2S     
4A3S    
5A4S     
SoFEA_OS 
3A2S     
4A3S    
5A4S     
HERA_OS 
3A2S     
4A3S    
5A4S     
NEAT_OS 
3A2S     
4A3S    
5A4S     
Table 5.18: Summary of the outcomes for the MAMS designs for all breast cancer trials. 
3A2S = Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm four stage.  
The sample size calculations for breast cancer found that if in the situation where six 
drugs are available for testing against a common control, then to achieve the same 
number of answers performing either three separate three arm two stage or two 
separate four arm three stage MAMS trials resulted in requiring fewer patients then 
conducting six separate standard two-arm trials (Figure 5.10). For example, for the 
NEAT_OS trial performing three separate three arm two stage trials (4464 patients 
altogether) or two separate four arm three stage trials (4620 patients) would require 





Figure 5.10: Comparing sample sizes to achieve the same number of answers for three 
separate three arm two stage versus two separate four arm two stage versus six standard 
parallel designs for breast cancer trials. 3A2S = Three arm two stage; 4A3S = Four arm three 
stage. 
5.5.3.2 Colon Cancer Trials 
The number of patients that would be required per month for each of the MAMS 
designs for the different colon cancer trials are displayed in Figure 5.11. To reach the 
calculated sample size for the five arm four stage COIN trial, 67 patients per month 
would need to be recruited for three years. An estimated maximum of 97 patients 
per month could be recruited for this trial hence deeming the first criteria successful. 
Similarly, all other MAMS colon cancer trials except the five arm four stage 
FOCUS_OS trial (total of 106 patients required per month compared to estimated 
maximum of 97 patients per month) required fewer patients than the estimated 




Figure 5.11: Total number of patients required assuming that all experimental arms reach 
the final stage for a three arm two stage, four arm three stage and five arm four stage 
MAMS design when applying the parameters obtained from the different colon cancer 
trials. 3A2S = Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm four 
stage. 
 
Figure 5.12 shows more than 10% of control arm patients would be required 
compared to the standard two-arm trials for all QUASAR_OS, five arm four stage 
COIN_OS, FOCUS_OS and PICCOLO_OS trials. The five arm four stage MAMS design 
for the COIN_OS, FOCUS_OS and PICCOLO_OS had an increase in the number of 
patients as the length of follow-up decreased for these trials indicating that more 
patients would be required to obtain the number of events. The three arm two stage 
and four arm three stage MAMS designs for the COIN_OS and PICCOLO_OS trial 






Figure 5.12: The number of control arm patients for the standard design compared to the 
number of control arm patients required for the different MAMS designs for the colon 
cancer trials. 3A2S = Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm 
four stage. 
 
All MAMS designs would require similar control arm events in comparison to the 
standard two-arm trial (Figure 5.13). The greatest increase in the number of control 
arm events for the MAMS designs compared to their respective standard two-arm 
trial would be for the five arm four stage FOCUS_OS trial which would require an 
additional five control arm events. The five arm four stage MAMS trials for the 
COIN_OS, FOCUS_OS and PICCOLO_OS all had an increase in the number of control 
arm events that would be required resulting from a decrease in the total trial length 
leading to reduced times between each interim stage.   
Although, most of the MAMS designs would require more control arm events, the 
difference would not be that large (i.e. fewer than five events and less than 10%). 







Figure 5.13: The change in the number of control arm events required for the different MAMS 
designs compared to the standard trial for colon cancer. 3A2S = Three arm two stage; 4A3S 
= Four arm three stage; 5A4S = Five arm four stage. 
A cross-check of the five arm four stage trials with the total trial length found that to 
perform the COIN_OS, FOCUS_OS and PICCOLO_OS trials would not be practical as 
the total trial length for these trials were 3.7, 3.16 and 2.5 years respectively. Hence, 
to accommodate three interim analyses within this short space of time would be 
impractical.   
A summary of the results for all colon cancer trials can be seen in Table 5.19. 
According to first criteria from the guidelines, all MAMS designs would be feasible 
except the five arm four stage FOCUS_OS trial. There is an increase in the number of 





1 2 3 5A4S Cross-check 
QUASAR 2_OS 
3A2S     
4A3S    
5A4S     
COIN 
3A2S     
4A3S    
5A4S     
FOCUS 
3A2S     
4A3S    
5A4S     
PICCOLO 
3A2S     
4A3S    
5A4S     
Table 5.19: Summary of the outcomes for the MAMS designs for all colon cancer trials. 3A2S 
= Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm four stage. 
If in the situation where six drugs are available for testing against a common control, 
then to achieve the same number of answers, performing either three separate three 
arm two stage or two separate four arm three stage MAMS trials for colon cancer 
resulted in requiring fewer patients then conducting six separate standard two-arm trials 
(Figure 5.14). 
 
Figure 5.14: Comparing sample sizes to achieve the same number of answers for three 
separate three arm two stage versus two four arm two stage versus six standard parallel 
designs for colon cancer trials. 3A2S = Three arm two stage; 4A3S = Four arm three stage. 
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5.5.3.3 Lung cancer Trials  
The number of patients that would be required per month for each of the MAMS 
designs for the different lung cancer trials are displayed in Figure 5.15. To reach the 
calculated sample size for the five arm four stage TOPICAL trial, 50 patients per 
month would need to be recruited for three years. An estimated maximum of 137 
patients per month could be recruited for this trial hence deeming the first criteria 
successful. Similarly, the other MAMS lung cancer trials required fewer patients 
compared to the estimated maximum number that could be recruited per month 
concluding that these trials had the potential to carry out these MAMS designs.  
 
Figure 5.15: Total number of patients required assuming that all experimental arms reach 
the final stage for a three arm two stage, four arm three stage and five arm four stage 
MAMS design when applying the parameters obtained from the different lung cancer trials. 
3A2S = Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm four stage. 
 
More than 10% of control arm patients would be required compared to the standard 
designs for the five arm four stage Big Lung_OS (Figure 5.16). All FORTIS_OS MAMS 
trials, the three arm two stage and four arm three stage Big Lung_OS MAMS designs 
showed that fewer control arm patients would be required compared to the standard 
trial. The five arm four stage Big Lung_OS trial would have the length of follow-up 
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resulting in an increase in the number of patients that would be required to reach 
the correct number of events.  
 
Figure 5.16: The number of control arm patients for the standard design compared to the 
number of control arm patients required for the different MAMS designs for the lung cancer 
trials. 3A2S = Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm four 
stage. 
 
The number of control arm events that would be required for the FRAGMATIC_OS, 
FORTIS-M_OS and TOPICAL_OS trials did not greatly differ from the events required 
for their standard two-arm trial (maximum increase/decrease of 2%) (Figure 5.17). 
The largest change of 11 events could be seen in the Big Lung_OS trial where the 
standard design required 728 deaths compared to 739 control arm deaths which is 
an increase of 1.5% required in the five arm four stage MAMS design. The difference 
in the number of control arm events between the standard two-arm trials and the 
MAMS trials was not considered to be that large. This resulted in deeming all MAMS 






Figure 5.17: The change in the number of control arm events required for the different MAMS 
designs compared to the standard trial for lung cancer. 3A2S = Three arm two stage; 4A3S = 
Four arm three stage; 5A4S = Five arm four stage. 
Taking into consideration the administrative tasks required to execute MAMS 
designs, a cross-check of the five arm four stage trials with the total length concluded 
that these designs could be executed as the minimum length for these trials were six 
years.  
The results for all the lung cancer trials can be seen in Table 5.20. According to first 
criteria from the guidelines, all MAMS designs are feasible. There is an increase in the 
number of control arm patients for the Big Lung_OS MAMS trial compared to their 
respective two-arm trials for the second criteria and the control arm events were all 






1 2 3 5A4S Cross-check 
FRAGMATIC 
3A2S     
4A3S    
5A4S     
FORTIS-M 
3A2S     
4A3S    
5A4S     
Big Lung 
3A2S     
4A3S    
5A4S     
TOPICAL 
3A2S     
4A3S    
5A4S     
Table 5.20: Summary of the outcomes for the MAMS designs for all lung cancer trials. 3A2S 
= Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm four stage. 
If in the situation where six drugs are available for testing against a common control, 
then to achieve the same number of answers, performing either three separate three 
arm two stage or two separate four arm three stage MAMS trials for lung cancer would 
result in requiring fewer patients then conducting six separate standard two-arm trials 
(Figure 5.18). 
 
Figure 5.18: Comparing sample sizes to achieve the same number of answers for three 
separate three arm two stage versus two four arm two stage versus six standard parallel 
designs for lung cancer trials. 3A2S = Three arm two stage; 4A3S = Four arm three stage. 
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 Discussion  
The sample of phase III trials that were taken from the Cancer Research Centre UK 
were used to implement MAMS designs for all phases of the calculations. The 
findings from the calculations indicated that the application of MAMS designs within 
breast, colon and lung cancer trials would be feasible. It is difficult to establish the 
ideal situation where applying a MAMS design would be appropriate as there are 
many variables that can influence the outcome of these designs. The OS rate gives 
an indication of the number of events that would be accumulated over the course of 
the trial; hence an improved OS rate would indicate fewer events would occur so a 
MAMS design would need to recruit more patients. The longer the overall trial length 
(recruitment and follow-up period), the more time is given for the accrual of events 
hence reducing the number of patients required within a MAMS design. In the first 
phase of calculations, the first interim stage for a three arm two stage breast cancer 
trial took place at seven years, this may not be practical for trialists hence a solution 
could be to increase the number of patients recruited into the trial to reach the 
required number of events earlier or to use a surrogate endpoint as an intermediate 
outcome. Furthermore, fewer patients are required to detect a greater absolute 
treatment difference. Moreover, it was decided to use the alpha stagewise values as 
specified by Royston et al (2011) as these resulted in being more robust compared to 
the values used in the first phase calculations and had been implemented in the 
STAMPEDE trial. However, the choice of alpha and power at each stage can be 
decided collectively by the trial team based on the requirements of the trial. The 
choice of the alpha can be smaller, for example the FOCUS4 utilises a one-sided alpha 
value of 0.3 in the first stage. Using a smaller alpha value would mean a more rigorous 
futility boundary and therefore more events would be required to trigger the interim 
analysis. Trial stakeholders may be more familiar with an overall power of 80% and 
overall alpha of 5% in comparison to 88% power and 2% alpha, for which more 
stringent stagewise alpha and power values would be used. 
The third phase of calculations considered the extreme case of MAMS designs where 
all experimental arms continue to the final stage because from a funding perspective, 
it would be wise to ensure that trial stakeholders apply for the maximum amount 
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possible to ensure the trial does not close due to lack of funds. It is evident from 
these calculations that the use of MAMS designs can be implemented within cancer 
sites with longer term outcomes. However, it is recommended that due diligence is 
taken for higher survival rates which result in fewer events. Trialist and patients may 
not be convinced that conclusions can be drawn with so little events. For example, 
the HERA_OS trial required approximately 20 deaths to deem superiority of trial 
drugs. In this situation, it would be better to use a surrogate outcome and use OS as 
a secondary endpoint. The third criteria to deem these MAMS designs as feasible was 
if the number of control arm deaths would be no more than 10% greater compared 
to those from the two-arm trial. The number of control arm deaths for all the MAMS 
trials did not vary much and the difference could be due to rounding error. Some of 
the five arm four stage trials considered in this chapter struggled to adhere to the 
intended trial length set out by the ‘nstage’ command resulting in an increase in the 
number of patients and therefore events required. For example, the five arm four 
stage COIN_OS, FOCUS_OS and PICCOLO_OS trials resulted in a total trial length of 
3.7, 3.2 and 2.5 years respectively. Therefore, it is recommended to ensure various 
endpoints are considered with a range of trial lengths which will lead to the decisions 
being made in the most efficient, effective and ethical manner.  
To add to the integrity and practicality of applying MAMS designs, the calculations 
could be further enhanced by implementing changes to the allocation ratio or 
additional eligibility criteria to ensure accuracy when gauging the maximum number 
of patients that could be recruited within a MAMS phase III trial. For example, the 
incidence rate of cancer by age group or ethnicity etc. Also, the MAMS designs within 
this chapter assumed that patients were accrued at a uniform rate, however in 
practice this may not be the case. For example, in the STAMPEDE trial, the initial 
recruitment began slowly which was due to the time taken in the opening of sites 
(Schiavone et al. 2019), as the momentum of the trial picked up, the rate at which 
patients were recruited increased. Therefore, changing the rate at which patients are 
accrued can add to the integrity when applying MAMS designs.  
However, further research could be undertaken to investigate the practicality of 
performing these MAMS design as there are other factors that have not been 
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considered, such as further defining the incidence rates of cancer by taking baseline 
characteristics such as age, gender ethnicity etc. into consideration to estimate 
realistic sample size targets. Furthermore, only the incidence rates of the subgroups 
have been calculated and used for each of the trials in the third phase of calculations 
to estimate the maximum number of patients that can be recruited. For example, the 
DEVA trial assessed only women that were postmenopausal, which has not been 
taken into consideration. Additionally, there are many challenges when recruiting 
patients which needs to be taken into consideration, for example the poor health 
status for lung cancer patients may deem it difficult to recruit patients into studies 
(Schofield et al. 2008). However, the estimates calculated for the maximum number 
of patients recruited are limited to the UK hence extending recruitment to 
international sites could greatly benefit the recruitment into trials.  It was essential 
that these estimates were calculated based upon recent data to ensure the validity 
of the comparisons made within this chapter as the incidence of cancer has 
significantly increased over the past 30 years with improvements in cancer detection 
but also the survival rates have improved with improvements in treatments (Cancer 
Research UK 2018). 
The results from the third phase of calculations show that based on the estimated 
maximum number of patients, MAMS designs using up to four experimental arms are 
feasible in these common disease settings. It was evident that in certain situations 
more control arm patients are required but the number of events required for the 
control arm did not vary significantly compared to the standard two-arm trials. 
Additionally, when comparing the total sample size of various MAMS trials against 
repeating two-arm trials, it was evident that MAMS designs require fewer patients 
because all experimental arms for the MAMS design share a common control. Hence, 
MAMS designs answer many questions within one trial which can considerably 
reduce the cost associated with trials compared to conducting separate two-arm 
trials as fewer patients and fewer regulatory applications are required.   
The outcome from this chapter support the results produced from a previous paper, 
whereby four trials in three cancer sites (renal, ovarian and colorectal cancer) with a 
standard parallel design were reanalysed implementing the MAMS methodology 
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(Barthel et al. 2009). The authors concluded that implementing MAMS designs can 
be both effective and efficient in evaluating if possible, many different treatments 
against a control, which supports the outcome of this chapter.  
Phase III clinical trials within the field of Oncology are continually increasing in terms 
of size and expense, however there is a concern with regards to the rate of success 
and the cost associated with running these trials. Hence there is a need for novel 
adaptive designs that can answer multiple questions within one trial (Berry 2012, 
Reitsma et al. 2015, Wilson et al. 2015, Hind et al. 2017, Parmar et al. 2017). The use 
of MAMS designs within phase III trials can be implemented to aid the advancement 
and testing of new therapies (Parmar et al. 2017). Furthermore, research could be 
carried out to investigate the relationship between MAMS designs and Umbrella 
trials, Basket trials and Platform-based designs; all of which answer many questions 
within one trial.   
 Conclusion 
The aim of this chapter was to develop a firm understanding of whether MAMS 
designs could work with longer term outcomes and to understand the development 
of these designs with varying survival rates. This chapter has shown that MAMS 
designs using a superiority hypothesis can be implemented in a variety of settings 
and not just in areas with poor survival. The next chapter will focus on implementing 




6 MAMS designs extended to a NI hypothesis  
 Introduction 
The many toxicities endured by patients from cancer therapies has encouraged 
trialists to find solutions that are just as effective but result in a reduced number of 
side effects (Riechelmann et al. 2013). Furthermore, the COVID-19 pandemic which 
began in 2019, has encouraged trial stakeholders to urgently seek-out treatments 
that are more convenient and require reduced time for patients to spend in hospital. 
Therefore, implementing trial designs with a NI hypothesis allows trial stakeholders 
to compare potential treatments that are less toxic, cost effective but just as efficient 
as the standard treatment.  
This chapter extends the previous use of MAMS designs with a superiority hypothesis 
to a NI hypothesis and explains how the ‘nstage’ command can still be used to 
undertake these designs. Firstly, the underlying methodology applied to the MAMS 
design is extended for use with a NI hypothesis, thereafter simulations were 
performed to evaluate the statistical properties of this design using the parameters 
from the selected trials identified in the previous chapter. Lastly, like the third phase 
of calculations in the previous chapter, hypothetical MAMS designs were obtained 
using the selected trials and compared to running standard two-arm designs with OS 
as the primary endpoint.  
 Methodology to use a NI hypothesis within the MAMS framework  
The MAMS framework specified by Royston et al (2011) and details provided in 
section 2.6 is intended to be implemented for a trial with a one-sided superiority 
hypothesis. However, it was shown in chapter one that the properties used in one-
sided superiority designs will result in the same number of events required using the 
same parameters for a NI design. NI trials tend to be larger in size as they allow for a 
small loss of effectiveness and more events are required to detect these smaller 
treatment differences compared to superiority trials that seek to gain efficacy with 
larger treatment differences. The below sections demonstrate how the methodology 
for a MAMS design can be adapted for use with a NI hypothesis and how it can be 
applied using the ‘nstage’ command.  
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Let 𝐼𝐼𝐼𝐼 and 𝑃𝑃𝐼𝐼 be defined as the time-to event intermediate outcome and primary 
outcome respectively, where 𝐼𝐼𝐼𝐼 = 𝑃𝑃𝐼𝐼 can also be a possibility for a MAMS designs 
using a NI hypothesis.  
Let 𝑗𝑗 ≥ 1 denote the number of experimental arms for which pairwise comparisons 
will be made against a common control arm, 𝐶𝐶. The true HR, Δ𝑖𝑖𝑖𝑖 is the effect of the 
experimental arm, 𝑗𝑗 on the control arm on the specified outcome at stage 𝐸𝐸, for 𝐸𝐸 =
1, …𝑓𝑓 where 𝑓𝑓 is the final stage. The true HR is calculated using the 𝐼𝐼𝐼𝐼 from stage 1 
to stage 𝑓𝑓 − 1 and using the 𝑃𝑃𝐼𝐼 at stage 𝑓𝑓. It is assumed that the proportional 
hazards assumption holds for all treatment comparisons. The null and alternative 
hypotheses can be defined as:  
 𝐻𝐻𝑖𝑖𝑖𝑖0 : Δ𝑖𝑖𝑖𝑖 = Δ𝑖𝑖𝑖𝑖0 ,  
𝐸𝐸 = 1, … ,𝑓𝑓, 𝑗𝑗 ≥ 1 
 𝐻𝐻𝑖𝑖𝑖𝑖1 : Δ𝑖𝑖𝑖𝑖 = Δ𝑖𝑖𝑖𝑖1 , 
where Δ𝑖𝑖𝑖𝑖0  is the value at the edge of the inferiority region for which the HR > 1 and 
Δ𝑖𝑖𝑖𝑖1  is the no-difference value where the HR = 1. This differs from the superiority 
hypothesis which assumes at the null hypothesis there is no difference. Therefore, 
the probability to claim NI under the null and alternative hypothesis is desired to be 
as:  
 𝑃𝑃𝐸𝐸(𝐶𝐶𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝐸𝐸𝐶𝐶𝐸𝐸 − 𝐸𝐸𝐸𝐸𝑓𝑓𝐸𝐸𝐸𝐸𝐸𝐸𝐶𝐶𝐸𝐸| 𝐸𝐸𝐸𝐸𝑓𝑓𝐸𝐸𝐸𝐸𝐸𝐸𝐶𝐶𝐸𝐸) = 𝛼𝛼 
 
 Pr(𝐶𝐶𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝐸𝐸𝐶𝐶𝐸𝐸 − 𝐸𝐸𝐸𝐸𝑓𝑓𝐸𝐸𝐸𝐸𝐸𝐸𝐶𝐶𝐸𝐸| 𝐸𝐸𝐶𝐶𝐸𝐸 − 𝐸𝐸𝐸𝐸𝑓𝑓𝐸𝐸𝐸𝐸𝐸𝐸𝐶𝐶𝐸𝐸) = 1 − 𝛽𝛽 = 𝜌𝜌 
where α and β represent the type I and type II error rates respectively (see Figure 
6.2). 
A non-inferiority test of the cumulated data for each pairwise comparison is 
performed at stage 𝐸𝐸 with nominal type I error rate 𝛼𝛼𝑖𝑖 and power 𝜌𝜌𝑖𝑖 = 1 − 𝛽𝛽𝑖𝑖 where 
𝛽𝛽𝑖𝑖 is the type II error rate at each stage 𝐸𝐸. If this is significant at level 𝛼𝛼𝑖𝑖 (indicating NI) 
then just like the MAMS design using the superiority hypothesis the experimental 




Under 𝐻𝐻0 and 𝐻𝐻1, the estimated log HR at stage 𝐸𝐸, ln∆�𝑖𝑖 is distributed as:  
 𝐻𝐻0: ln∆�𝑖𝑖 ~ 𝑁𝑁(ln∆𝑖𝑖0 , 𝑠𝑠𝑖𝑖0)  
 𝐻𝐻1: ln∆�𝑖𝑖 ~ 𝑁𝑁(ln∆𝑖𝑖1 , 𝑠𝑠𝑖𝑖1)  
where the estimated variances under 𝐻𝐻0 and 𝐻𝐻1 are 𝑠𝑠𝑖𝑖0 and 𝑠𝑠𝑖𝑖1 respectively. The one-
sided significance level for each of these hypotheses can be specified such that:  
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where 𝜎𝜎𝑖𝑖0 is defined as square root of 𝑠𝑠𝑖𝑖0, the critical HR at stage 𝐸𝐸 is defined as 𝛿𝛿𝑖𝑖 and 
Φ( ) is the standard normal distribution function.   
The power for each of these hypotheses can be defined as follows:  
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Therefore, the probability under the null or alternative hypothesis of reaching stage 
𝐸𝐸 + 1 or concluding NI of either the control or experimental arm are based on normal 
approximations such that the appropriate critical HR and events are given by the 
multivariate tail areas, which is the same when using a superiority hypothesis.  
 NI hypothesis application using ‘nstage’ 
In practice, for the methodology discussed above to work using the ‘nstage’ 
command in Stata, the values Δ𝑖𝑖𝑖𝑖0  and Δ𝑖𝑖𝑖𝑖1  are entered as ‘hr0’ and ‘hr1’ (Figure 6.1). 
Using the example given in chapter two (section 2.6.8) where a four arm three stage 
MAMS trial was designed with an assumed five-year OS rate for the control arm of 
50.5% to find an increase in OS of 7% in the experimental arm which resulted in a 
relative HR of 0.81. This example was amended to reflect the use of a NI hypothesis 
instead of a superiority hypothesis to demonstrate the interchangeability of this 
command (Figure 6.2). Therefore, the five-year OS rate for these patients were 57.5% 
with an absolute NI margin of 7% which resulted in a relative HR of 1.23. Using these 
assumptions resulted in 4368 patients required to obtain the appropriate number of 
events in the same amount of time using a NI hypothesis compared to 3750 patients 
required using a superiority hypothesis as shown in the example in section 2.6.8. The 
reason why there is a difference in the number of patients is because there is an 
improved survival rate in the control arm when applying a NI hypothesis which 
requires more patients to reach the required number of events when the duration of 




Figure 6.1: Syntax and output obtained from implementing the ‘nstage’ command in Stata 






Figure 6.2: Demonstrating the interchangeability between a superiority hypothesis and NI 
hypothesis from section 2.6.8.  α - Type I error rate; β - Type II error rate; HR – Hazard Ratio; 
OS – Overall Survival,  
This design would require 4368 patients recruited for six years and followed up for 
approximately two years for this fictional sample size calculation (Figure 6.1). It was 
assumed that one experimental arm was inferior (obtained HR greater than the 
critical HR) at each stage. The first interim analysis would take place when 127 control 
arm events are obtained at approximately 3.8 years. The second interim analysis 
would take place when 252 control arm events are obtained at approximately 5.4 
years and the final analysis would take place when 491 control arm events are 
obtained at 7.8 years. The critical HR at stages one and two are 1.23 and 1.16 
respectively. At these interim stages, pairwise comparisons are made for each 
experimental arm against the control arm; if the obtained HR is less than the critical 
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HR than that experimental arm would continue to the next stage (Figure 6.3). The 
critical HR at the final stage is 1.09, it was assumed that one experimental arm would 
reach this stage and if the obtained HR was less than the critical HR then NI would be 
declared.  
 
Figure 6.3: Region for which 𝐻𝐻0 is rejected for the pairwise comparisons at each stage for 
the example four arm three stage MAMS design using a NI hypothesis and comparing it 
against the example used in chapter two with a superiority hypothesis. NI = Non-inferiority; 
HR = Hazard Ratio.   
The switching from a one-sided superiority hypothesis used in chapter two to a NI 
hypothesis resulted in similar number of control arm events as anticipated from the 
theory provided in section 1.4.5 and previous section within this chapter. The 
similarity of the number of events when changing between both the one-sided 
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superiority and NI hypotheses supports the use of the MAMS framework by Royston 
et al (2011) for MAMS designs with a NI hypothesis. However, to confirm this 
empirical finding, simulations were performed to validate the statistical properties 
of the MAMS design with a NI hypothesis.  
 Simulations to validate MAMS design with NI hypothesis   
Simulations studies can be implemented to evaluate the performance of innovative 
statistical methods in pre-defined situations (Burton et al. 2006). Simulations were 
performed to evaluate the statistical properties of the NI designs obtained using the 
‘nstage’ command. The number of events for each treatment arm, the type I error 
rate and the power obtained from the simulations were compared with the 
corresponding parameters from using the ‘nstage’ command.  
The first and second phase calculations in the previous chapter were exploratory to 
help further understand the MAMS designs hence the calculations applied within this 
chapter use the methods applied for the third phase of calculations. Due to the poor 
survival rates of patients diagnosed with lung cancer, it would not be appropriate to 
apply a NI hypothesis. The results from the third phase of calculations in the previous 
chapter for the four different trials within each cancer site gave similar conclusions 
therefore, hypothetical MAMS designs with a NI hypothesis were applied only to the 
DEVA trial (breast cancer) and the QUASAR 2 trial (colon cancer). 
6.4.1 Aims 
The aims of the simulations were (1) to evaluate the stagewise and pairwise type I 
error and power and (2) to compare operational characteristics to the output from 
‘nstage’ command for a three arm two stage MAMS design when using a NI 
hypothesis. Three scenarios using different alpha and power values for the DEVA and 
QUASAR2 trials were used to validate the statistical properties of these designs 
(Table 6.1).  These two trials will be referred to as DEVA_NI and QUASAR 2_NI 
respectively to emphasise that a NI hypothesis has been implemented.  
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Scenario Alpha Power 
Stage One Final Stage Stage One Final Stage 
Scenario 1  0.5 0.025 0.95 0.9 
Scenario 2  0.5 0.05 0.9 0.9 
Scenario 3  0.25 0.05 0.9 0.85 
Table 6.1: The different stage one and final stage alpha and power values used to evaluate 
the simulations.  
6.4.2 Method 
The sample size for the three arm two stage DEVA_NI trial and QUASAR 2_NI trial 
was calculated using a 3% absolute NI margin and the parameters outlined in Table 





Accrual rate per year 845 
Survival rate 5-year OS - 81.8% 




Accrual rate per year 579 
Survival rate 3-year OS - 89.4% 
Recruitment period (years)  5.5 
Table 6.2: Parameters used to calculate the sample size using the ‘nstage’ command. 
The results of the sample size calculations which were used in the simulations can be 
seen in Table 6.3 with full details of the results in appendix 7. From these results the 
critical HR, the time (when no arms dropped and when 1 arm dropped) and the total 
sample size were used in the simulations. The type I error and power at stage one 
(Table 6.1), the PWER, pairwise power and the number of control arm events at each 





Scenario 1 Scenario 2 Scenario 3 
Stage Stage Stage 









Pairwise Power 0.87 0.83 0.81 
Critical HR 1.188 1.070 1.188 1.078 1.119 1.069 
Time (no arms dropped) 5.9 13.5 4.6 11.5 7.1 10.2 
Time (1 arm dropped) 5.9 12.6 4.6 10.4 7.1 10.0 
Sample Size 4995 6760 3857 6760 5988 6760 










Pairwise Power 0.87 0.83 0.81 
Critical HR 1.305 1.111 1.305 1.124 1.191 1.109 
Time (no arms dropped) 4.8 11.6 4.4 11.9 5.7 8.2 
Time (1 arm dropped) 4.8 11.1 4.4 10.8 5.7 8.2 
Sample Size 2755 3185 1808 2665 3297 3474 
CA Events 77 298 47 243 109 204 
Table 6.3: Results from the sample size calculation using the ‘nstage’ command and used in 
the simulations. PWER = Pairwise Error Rate; HR = Hazard Ratio; CA = Control arm  
Data were simulated based on the total sample size for each of the trials, i.e. for the 
three arm two stage DEVA_NI trial, the number of observations, 𝐸𝐸𝑜𝑜𝑜𝑜𝑜𝑜 = 6760. Data 
were generated under the null hypothesis and the alternative hypothesis for each 
scenario as detailed in Table 6.1.  
Initially, data for the first stage were generated and then based on the decision at 
the first stage, data for the second stage were generated. The time-to-event data for 
the first stage were simulated for the number of patients denoted, n𝑖𝑖1obs, where 𝐸𝐸 ∈
(1, 2, 3) denotes the treatment arm.  Patients were equally allocated to one of the 
three treatment arms. It was assumed that the patients’ survival followed an 
exponential distribution (see section 1.3) with hazard rate λ𝑖𝑖 = −
log  S𝑖𝑖(t)
t𝑖𝑖
. For 𝐸𝐸 =
1, 2, the hazard rate was generated based on the control arm survival rate and for  
𝐸𝐸 = 3, the hazard rate was based on the alternative hypothesis. It was assumed that 
patients were recruited at a uniform rate during the whole recruitment period. 
Therefore the time at which patients were recruited was generated using a uniform 
distribution from the start of the trial to the first interim stage as this occurred prior 
to the end of the recruitment period, i.e. start of trial < first interim stage < 
recruitment period < final stage. If the recruitment time plus the survival time was 
greater than the time of the first stage, patients were censored at the first interim 
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analysis stage. Pairwise comparisons between the control arm (𝐸𝐸 = 1) and the two 
experimental arms (𝐸𝐸 = 2, 3) were made using a Cox proportional hazards model.  If 
the resulting HR for each pairwise comparison was less than the critical HR obtained 
from the output of the ‘nstage’ command, then the experimental arm continued to 
the next stage. If both experimental arms resulted in hazard ratios greater than the 
critical HR, then the trial was stopped, and inferiority of both experimental arms was 
declared.  
If at least one experimental arm continued to the second stage, time-to-event data 
was again simulated using an exponential distribution for the number of patients 
required in the second stage denoted, n𝑖𝑖2obs, where 𝐸𝐸 ∈ (1,2,3), (1,2) or (1,3) 
depending on the results of the first stage. Recruitment time was generated using a 
uniform distribution from the end of the first stage to the end of the recruitment 
period. The data simulated for the second stage were appended to the data 
generated in the first stage (𝐸𝐸𝑜𝑜𝑜𝑜𝑜𝑜 = n𝑖𝑖1obs + n𝑖𝑖2obs) with those experimental arms that 
continued to the next stage. If the recruitment time plus the survival time was greater 
than the time of the final stage, then patients were censored. Pairwise comparisons 
were performed between the control and the experimental arm(s) that continued to 
the second stage. If the hazard ratio(s) were less than the critical HR at the final stage, 
then NI was declared. 
The type I error and power at stage one was calculated by the proportion of 
simulations that had a HR less than the critical HR at stage one when comparing 
treatment one against treatment two and treatment one against treatment three 
respectively. Similarly, the PWER and pairwise power were calculated by the 
proportion of simulations that had a HR less than the critical HR at the final stage 
when the comparing treatment one against treatment two and treatment one 
against treatment three respectively. It was hypothesized that with 10,000 
simulations, the 95% CI of the estimated rates should be within the true type I error, 
power, PWER and pairwise power (true values were obtained from ‘nstage’ output).  
The number of events in the control arm at stage one and the final stage were stored 
and the average number of events were compared to the ‘nstage’ output. Histograms 
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were plotted for the hazard ratios for each pairwise comparison to assess normality. 
Data were simulated 10,000 times using Stata 16 with input seed ‘130933’ and the 
code used to implement these simulations can be found in appendix 8. 
6.4.2.1 Worked example 
The steps performed to execute scenario one of the simulations using the DEVA_NI 
three arm two stage trial is shown below using the results from Table 6.3: 
1. Data were simulated for 4995 patients; patients were equally allocated to one 
of three treatment arms using a uniform distribution. 
2. Time-to-event data were simulated using an exponential distribution for each 
treatment arm with the following lambda values, 𝜆𝜆1 = 𝜆𝜆2 = 0.0402 and 𝜆𝜆3 =
0.0476 so that the properties under the null and alternative hypothesis could 
be assessed. 
3. Part of the recruitment period was generated using a uniform distribution 
beginning at zero to 5.9 years (time of first stage). 
4. If recruitment time plus the survival time was greater than 5.9 years then 
patients were censored using an indicator variable (0 = censored, 1 = event).  
5. Pairwise comparisons were performed using Cox proportional hazards model 
between the control arm (𝐸𝐸 = 1) and each experimental arm (𝐸𝐸 = 2, 3). If the 
resulting hazard ratios was less than 1.188 then the respective experimental 
arm continued onto the next stage, this resulted in one of four possibilities:  
i. Both experimental arms continued 
ii. Only experimental arm two continued  
iii. Only experimental arm three continued  




6.  Data were simulated for the remaining 1765 patients (Total sample size 
minus patients recruited in first stage), patients were allocated equally to the 
remaining treatment arms using a uniform distribution. 
7. The remaining recruitment period was generated using uniform distribution 
beginning at 5.9 to eight years (end of recruitment period) 
8. Data were appended to the data generated in the first stage, for which there 
were two possible outcomes:  
i. Both experimental arms continued to the next stage and if the 
recruitment time plus survival time was greater than 13.527, patients 
were censored using an indicator variable.  
ii. If only one experimental arm continued to the next stage and if the 
recruitment time plus survival time was greater than 12.586, patients 
were censored using an indicator variable. 
9. Pairwise comparisons were performed between the control and experimental 
arm(s) that continued to the second stage. If the resulting hazard ratio(s) 
were less than 1.07 then NI was declared. 
10. The events in each arm at the interim and final stage were stored for each 
simulation alongside the hazard ratios at each stage for each pairwise 
comparison.   
The simulations were used to calculate the type I error and power at stage one and 
the PWER and pairwise power at the final stage. The proportion of simulations at 
stage one for the pairwise comparison between treatment arm 1 vs 2 and treatment 
arm 1 vs 3 that had a HR less than 1.188 provided the type I error and power 
respectively at this stage. The proportion of simulations at the final stage for the 
pairwise comparison between treatment arm 1 vs 2 and treatment arm 1 vs 3 that 
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had a HR less than 1.07 provided the PWER and pairwise power respectively at this 
stage. 
6.4.3 Results  
Table 6.4 shows the results obtained from the simulations of the type I error, power, 
PWER, pairwise power and the average number of control arm events. It can be 
clearly seen for the three arm two stage DEVA_NI trial, that the type I error rate, 
PWER, power and pairwise power of the true rates were contained within the 95% 
CI of the simulated values.  When comparing the mean number of control arm events 
for the 10,000 simulations at each stage for the DEVA_NI at each scenario, majority 
have the same control arm events as obtained from the ‘nstage’ output. The average 
final stage control arm events obtained through the simulations for scenario one 
required an additional five events and scenario two showed an additional four more 
events required compared to the ‘nstage’ output which most probably is due to 
rounding error.  
Figure 6.4 shows a plot of the hazard ratios obtained from the pairwise comparisons 
between the control arm (treatment one) and treatment two or treatment three for 
the DEVA_NI trial. As expected, the hazard ratios for the pairwise comparison 
between treatment one and treatment two are normally distributed around the null 
hypothesis (HR = 1). Similarly, the hazard ratios for the pairwise comparison between 
treatment one and treatment three were normally distributed around the alternative 
hypothesis (HR = 1.188). 
Similarly, the QUASAR 2_NI trial showed that the type I error rate, PWER, power and 
pairwise power of the true rates were contained within the 95% CI of the simulated 
values for majority of the scenarios (Table 6.4). However, the true PWER and pairwise 
power for scenario two were somewhat greater than the upper boundary of the 95% 
CI of the simulated values. 
A plot of the hazard ratios obtained from the pairwise comparisons between the 
control arm (treatment one) and treatment two or treatment three for the QUASAR 
2_NI trial can be seen in Figure 6.5. The hazard ratios for the pairwise comparison 
between treatment one and treatment two were normally distributed just below the 
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null hypothesis (HR = 1) for scenario one and two which is also reflected by the PWER 
estimates obtained in Table 6.4. The hazard ratios for the pairwise comparison 
between treatment one and treatment three were normally distributed around the 
alternative hypothesis (HR = 1.305). 
To ensure the correctness of these simulations, similar simulations were performed 
using a superiority hypothesis (as intended by the ‘nstage’ command) for the 
DEVA_SUP trial using the parameters from chapter five (Appendix 9). 
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Trial Scenario Stage 
Nstage 
Type I 
error   
Simulated 












1 0.500  0.499 (0.489 – 0.509) 95.0%  94.6% (94.2% - 95.0%) 183 183 
Final (PWER/Pairwise power)* 0.023  0.021 (0.018 – 0.024) 87.0% 86.6% (85.9% - 87.3%) 710 715 
2 
1 0.050  0.507 (0.497 – 0.517) 90.0% 89.6% (89.0% - 90.2%) 111 111 
Final (PWER/Pairwise power)* 0.042 0.038 (0.034 – 0.042) 83.0% 82.3% (81.6% - 83.0%) 579 583 
3 
1 0.250 0.247 (0.239 – 0.255) 90.0% 90.0% (89.4% - 90.6%) 259 259 





1 0.500 0.501 (0.491 – 0.511) 95.0% 94.9% (94.5% - 95.3%) 77 77 
Final (PWER/Pairwise power)* 0.023 0.021 (0.018 – 0.024) 87.1% 86.7% (86.0% - 87.4%) 298 297 
2 
1 0.500 0.499 (0.489 – 0.509) 90.0% 89.6% (89.0% - 90.2%) 47 47 
Final (PWER/Pairwise power)* 0.042 0.036 (0.032 – 0.040) 83.2% 82.0% (81.2% - 82.8%) 243 240 
3 
1 0.250 0.240 (0.232 – 0.248) 90.0% 90.1% (89.5% - 90.7%) 109 109 
Final (PWER/Pairwise power)* 0.044 0.040 (0.036 – 0.044) 81.5% 81.7% (80.9% - 82.5%) 204 202 
*Showing final pairwise error rate and pairwise power for the nstage and simulated outputs. 
Table 6.4: Results of the simulations performed for the DEVA_NI and QUASAR 2_NI three arm two stage compared to the true values and the 95% CI given by 




Figure 6.4: Plot of the hazard ratios from the simulations for the pairwise comparisons1 for 
each scenario for the DEVA_NI three arm two stage trial.  
  
 
1 Data generated for treatment arm two using same survival rate as the control arm, data generated 





Figure 6.5: Plot of the hazard ratios from the simulations for the pairwise comparisons1 for 
each scenario for the QUASAR_NI three arm two stage trial. 
 Third phase calculations extended to implement NI hypothesis  
In chapter five, the feasibility of applying a MAMS design with long-term outcomes 
using a superiority hypothesis were evaluated. The third phase of calculations that 
were applied in chapter five were extended within this chapter to evaluate the 
feasibility of applying MAMS designs using a NI hypothesis.  
6.5.1 Methods  
For the DEVA_NI and the QUASAR 2_NI trials, sample sizes for a two arm trial were 
re-calculated with an absolute NI margin of 3%, the obtained OS results for the 
control arm, power of 90% and one-sided alpha of 2.5%. The two trials were re-
 
1 Data generated for treatment arm two using same survival rate as the control arm, data generated 
for treatment arm three using the alternative hypothesis.   
213 
 
named with the suffix “_NI” respectively to emphasise that a NI hypothesis has been 
implemented and the new sample size and number of control arm events can be seen 
in Table 6.5. 
Trial Name OS (Target HR) SS (Control SS) Control events 
Deva_NI 5 year 81.8% (1.188) 4264 (2132) 713 
QUASAR 2_NI 3 year 89.4% (1.305) 2136 (1068) 301 
Table 6.5: Re-calculated sample sizes using OS results with a NI hypothesis for a two arm 
trial. OS = Overall Survival; HR = Hazard ratio; SS = Sample size. 
Thereafter, fictional scenarios where multiple treatments were available that could 
be no worse than the standard treatment (NI hypothesis) were created and sample 
sizes calculated for MAMS designs using the ‘nstage’ command. The stagewise 
significance and power level as defined by Royston et al (2011) and implemented in 
the STAMPEDE trial (Table 4.2) were used and it was assumed that all experimental 
arms would reach the final stage.  
Like chapter five, the hypothetical MAMS design for the trials were classed as feasible 
if the number of control arm patients and events required in the MAMS designs were 
broadly similar to the two-arm trial. The sample size required for six separate 
standard two arm trials versus two separate four arm three stage trials versus three 
separate three arm two stage trials was compared to see if fewer patients were 
required using the MAMS design if fixing for time.  
It was anticipated that more patients would be required using a NI hypothesis 
compared to the number of patients using a superiority hypothesis (section 5.5) as a 
smaller treatment difference was used (3% absolute NI margin). Therefore, the 
number of patients required per month was compared to the estimated maximum 
number of patients (Table 5.5) but for exploratory purposes. This estimation was 
calculated based on patients within the UK, however international recruitment could 
be considered to accommodate extra patients.  
Lastly, the trials were assessed taking the work of Schiavone et al (2019) and Hague 
et al (2019) as mentioned in chapter two into consideration to ensure the practicality 
aspect of employing a MAMS design (Hague et al. 2019, Schiavone et al. 2019). Based 
on the total trial length (recruitment and follow-up) of both the DEVA and QUASAR 2 
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trials, it was anticipated that executing a five arm four stage trial would be infeasible. 
This was still explored in case the total trial length reduced as seen in chapter five.  
6.5.2 Results 
The results of the sample size calculations which were used for the third phase can 
be seen in Table 6.6. Figure 6.6 shows the number of control arm patients and control 
arm events required for the standard two-arm trial and the MAMS designs for the 
DEVA_NI and QUASAR 2_NI trials. The number of control arm patients for both these 
trials were similar for the standard two-arm trial and the three arm two stage MAMS 
designs. The number of control arm patients increased for both trials for the four arm 
three stage and five arm four stage because the length of the trial was reduced 
resulting in more patients being required to obtain the required number of events. 
The total number of control arm events required for the DEVA_NI and QUASAR 2_NI 
trial were the same for all trial designs.  
Trial Results 
3A2S 4A3S 5A4S 
Stage Stage Stage 





    
0.021 
      
0.021 
Pairwise Power 0.87 0.86 0.85 
Critical HR 1.188 1.070 1.188 1.13 1.07 1.188 1.13 1.107 1.07 
Time  5.9 7.6 5.6 8.0 12.3 4.6 6.6 8.0 9.5 
Sample Size 4995 6760 7043 10087 10120 10505 15005 18236 18240 
CA Patients 1665 2253 1761 2522 2530 2101 3001 3647 3648 






    
0.021 
      
0.021 
Pairwise Power 0.87 0.86 0.85 
Critical HR 1.305 1.111 1.305 1.208 1.111 1.305 1.208 1.169 1.111 
Time  4.8 11.6 4.6 6.5 9.9 4.3 6.1 7.3 8.7 
Sample Size 2755 3185 3828 5459 5460 5105 7276 8811 9000 
CA Patients 918 1062 957 1365 1365 1021 1455 1762 1800 
CA Events 77 298 77 153 298 77 153 221 298 
Table 6.6: Results from the sample size calculation for the three arm two stage (3A2S), four 
arm three stage (4A3S) and five arm four stage (5A4S) for the DEVA_NI and QUASAR 2_NI 





Figure 6.6: Number of control arm patients (dark green) and events (light green) required 
for DEVA_NI and QUASAR 2_NI 2-arm trial and MAMS trials.  
From the sample size calculations it can be seen that if in the situation where six drugs 
were available for testing for NI against a common control, then performing either three 
separate three arm two stage or two separate four arm three stage MAMS trials resulted 
in requiring fewer patients then conducting six separate standard two-arm trials (Figure 
6.7). Furthermore, if there was more than one experimental arm to consider, MAMS 
designs required fewer patients than standard two-arm trials therefore proving that 
MAMS designs can be more efficient.  For example, for the DEVA_NI trial, performing a 
three arm two stage trial would require 6760 patients compared to 8528 patients 
required for two separate two-arm trials.  
 
Figure 6.7: Comparing sample sizes for three separate three arm two stage versus two 
separate four arm two stage versus six standard parallel designs for the DEVA_NI and 
QUASAR 2_NI trials.  




Figure 6.8 shows the number of patients that would be required per month for each 
of the DEVA_NI and QUASAR 2_NI trial compared to the estimated maximum number 
of patients that could be recruited. For all the DEVA_NI trials, more patients would 
be required than the estimated maximum number of patients. The five arm four stage 
MAMS DEVA_NI trial required 190 patients per month to be recruited to reach the 
sample size compared to a maximum of 58 patients that could be recruited per 
month. The three arm two stage and four arm three stage QUASAR 2_NI trials 
required fewer patients compared to the estimated maximum number of patients.   
 
Figure 6.8: Total number of patients required assuming that all experimental arms reach the 
final stage for a three arm two stage, four arm three stage and five arm four stage MAMS 
design when applying the parameters obtained from the different breast cancer trials. 
Absolute line showing the estimated maximum number of patients that could be recruited. 
3A2S = Three arm two stage; 4A3S = Four arm three stage; 5A4S = Five arm four stage. 
 Discussion 
The outcome of the simulation studies showed that the ‘nstage’ command can be 
used with a NI hypothesis. The statistical properties were validated using simulations 
and were similar to the values inputted and produced by the ‘nstage’ command. The 
true values for the PWER and pairwise power for scenario two for the QUASAR 2_NI 
trial were greater than the upper boundary of the 95% CI of the simulated values. 
This may be due to the slight lack of normality, which was seen in the histogram plots 
(Figure 6.5), however as the number of simulations tend to infinity, the estimated 
PWER and pairwise power will tend to the true value. A limitation to these 
simulations was that only the properties for a three arm two stage MAMS design with 
the same intermediate and primary outcome were assessed. Hence, further work 
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could be to perform simulations to validate the statistical properties for when the 
intermediate and primary outcome differ.  
The results from the hypothetical MAMS designs using a NI hypothesis showed that 
based on the estimated maximum number of patients, MAMS design using up to 
three experimental arms were feasible. Anything beyond this would require more 
patients per month compared to the estimated maximum number of patients, which 
can always be overcome by increasing the recruitment period to allow for a lower 
rate of patients recruited per month. Additionally, international recruitment could be 
considered as the estimated maximum number of patients recruited per month was 
based on figures in the UK only. The results showed that if in the situation where 
there are six drugs available for testing for NI against a common control then a MAMS 
design would result in requiring fewer patients compared to conducting six separate 
two arm trials. For example, if there were six different statin drugs, a MAMS design 
using a NI hypothesis could be implemented to evaluate these and focus placed on 
controlling the PWER. However, if the drugs were the same and perhaps assessed 
different dosing requirements, then emphasis would be placed on controlling the 
FWER. More investigation into the use of different durations and the need to control 
the FWER is considered in the next chapter.  
One of the rules of the ‘nstage’ command is that all interim stages must take place 
prior to the end of the recruitment period (more information provided in chapter two 
and chapter five), therefore as the number of stages increased and potentially the 
number of experimental also arms increased, more patients were required to ensure 
that all interim stages met the required number of control arm events within the pre-
specified recruitment period, which led to a decrease in the amount of follow-up 
required.  
When comparing the total sample size of various MAMS trials against repeating two-
arm trials, it was clear that MAMS designs required fewer patients because all 
experimental arms share a common control.   
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 Conclusion  
With the rise of trials implementing a NI hypothesis (section 1.4.3), being able to 
assess multiple arms across multiple stages instead of executing multiple two-arm 
trials in this setting can be advantageous and cost effective. In comparison to a 
superiority setting, NI trials generally require more patients due to smaller margins 
that are often used. However, the long term benefits such as improving the standard 
of care by reducing the toxicities, potential administration work as well cost 
effectiveness can put NI trials in a better limelight with trial stakeholders and 
patients. 
This chapter showed that MAMS designs can be implemented using the ‘nstage’ 
command with a NI hypothesis. The understanding developed within this chapter will 
be used to apply a MAMS design to assess different durations of treatment. 
Furthermore, MAMS designs may statistically show promise however the operational 
aspects of running a MAMS design should not be underestimated as seen for the 
STAMPEDE and FOCUS4 trials. The HERA, FinHer, PHARE, HORG, SOLD and 
Persephone trials (Piccart-Gebhart et al. 2005, Joensuu et al. 2009, Pivot et al. 2013, 
Mavroudis et al. 2015, Earl et al. 2019) all assessed the duration of Herceptin in breast 
cancer patients. The next chapter will assess whether a MAMS design would have 
been suitable rather than performing these trials separately and what operational 
aspects would have had to be taken into consideration to successfully execute this 




7 The application of a MAMS design to test different durations 
of Herceptin treatment. 
 Introduction 
In the previous chapters MAMS designs were applied to different cancer sites and it 
was concluded that these designs are more applicable when there is a high event rate 
but were still useful for lower event rates such as breast cancer studies. MAMS 
designs work well due to their efficacy and effectiveness in looking at multiple 
treatments simultaneously but must have adequate event rates to give power to the 
comparisons.  
The focus of this chapter is on applying a MAMS design with a NI design to assess the 
optimal duration of Herceptin therapy for patients diagnosed with early breast 
cancer. The motivation behind this research was due to the Persephone trial which 
was conducted at Warwick CTU and published primary analysis results in 2019 (Earl 
et al. 2019). The Persephone trial compared six months of Herceptin therapy against 
12 months of Herceptin therapy in patients diagnosed with early breast cancer (Earl 
et al. 2019). Alongside this trial, there were other international trials being conducted 
(FinHer trial, SOLD trial, HORG trial and PHARE trial) assessing different durations of 
Herceptin therapy in the same patient populations. Thus, the aim of this research was 
to investigate whether a MAMS design would have been more effective instead of 
many separate trials to assess the optimal Herceptin duration and explore some of 




 Existing trials testing the duration of Herceptin therapy 
Descriptions of the HERA, FinHer, SOLD, HORG, PHARE and Persephone trials, all of 
which assessed different durations of Herceptin therapy in patients diagnosed with 
breast cancer are provided in the following sections. The patients recruited to each 
of the arms and the duration of Herceptin can be seen in Figure 7.1. A summary of 
the primary outcome results showing the obtained HR, the 95% CI and the relative 
margin for each trial can be seen in Figure 7.2. A summary of recruitment and the 
outcome of the trial can be seen in Table 7.1. These figures and table will be 
frequently referenced throughout section 7.2. 
 
Figure 7.1 Patients recruited for each treatment arm for the HERA, FinHer, SOLD, HORG, 




Figure 7.2: Primary outcome results showing the HR and 95% CI obtained and the planned 
relative margin (shown in green) for the HERA, FinHer, SOLD, HORG, PHARE and Persephone 






Trial information HERA FinHer* SOLD  HORG PHARE Persephone 
Treatment arms 
No trt (control) vs  
12 mths vs 24 mths 
No trt (control) 
vs 9 wks 
9 wks vs  
12 mths (control) 
6 mths vs  
12 mths (control) 
6 mths vs  
12 mths (control) 
6 mths vs  
12 mths (control) 
Total number of patients 5099 232 2176 481 3384 4088 
Recruitment time (years) 3 3 7 8 4 8 
Median follow-up 11 years 36 months 5.2 years 51 months & 47 months 42.5 months 5.4 years 
TTE PO  DFS RFS DFS DFS DFS DFS 
Primary outcome results   
No treatment  63% - 10 yr DFS 77.6% - 3 yr RFS - - - - 
9 weeks - 89.3% - 3 yr RFS 88% - 5 yr DFS - - - 
6 months - - - 93.3% - 3 yr DFS 91.2% - 2 yr DFS 89.4% - 4 year DFS 
12 months 69% - 10 yr DFS - 90.5% - 5 yr DFS 95.7% - 3 yr DFS 93.8% - 2 yr DFS 89.8% - 4 year DFS  
24 months 69% - 10 yr DFS - - - - - 




0.76 (0.68 to 0.86)  
No trt vs 12 mths 
0.42 (0.21 – 0.83) 
 No trt vs 9 wks 
1.39 (90% CI: 1.12-1.72) 
9 wks vs 12 mths 
1.58 (0.86-2.10) 
12 mths vs 6 mths 
1.28 (1.05-1.56) 
 6 mths vs 12 mths 
1.07 (90% CI: 0.93-1.24)  
6 mths vs 12 mths 
0.77 (0.69-0.87)  
No trt vs 24 mths - - - - - 
1.02(0.89-1.17) 
 12 mths vs 24 mths - - - - - 
*Only subgroup treated with Herceptin   
Table 7.1: Patients recruited, time taken to recruit, median follow-up time, and primary outcome results for the HERA, FinHer, SOLD, HORG, PHARE and 




7.2.1 HERA trial 
 The HERA trial, as mentioned in chapter five, was a three-arm phase III RCT 
comparing Herceptin for one year, Herceptin for two years or observation (control 
group) for patients with HER2 positive early stage breast cancer (Piccart-Gebhart et 
al. 2005).  
At the time of designing the HERA study, the impact of Herceptin therapy in patients 
with early breast cancer had not yet been established. Hence, a superiority primary 
endpoint was used to compare DFS for patients randomised to one year of Herceptin 
versus no Herceptin and two years of Herceptin versus no Herceptin. A superiority 
difference of 6.8% was used to calculate the sample size. Pairwise comparisons were 
made using the unstratified log-rank test with the addition of the Holm-Bonferroni 
method which ensured that the FWER was 0.05 (Holm 1979). A target sample size of 
4482 patients was required to reach a target number of 951 DFS events for all 
treatment arms to achieve 80% power to detect at least a 6.8% absolute difference 
in DFS from the observation arm (estimated to be 65% for 5-year DFS) (Figure 7.3).  
An additional exploratory analysis plan was implemented to compare the use of one 
year of Herceptin versus two years of Herceptin and to examine various TTE 
outcomes such as OS and RFS.   
An interim analysis was implemented to compare DFS for patients randomised to one 
year Herceptin versus observation and two years of Herceptin versus observation, 
which took place after half of the estimated total number of DFS events were 
observed. At this interim analysis, the DMC suggested to release the results of the 
one-year of Herceptin as these results were highly statistically significant and showed 





Figure 7.3: Outline of the HERA design parameters. DFS = Disease-free survival 
To date, there have been various papers published at different follow-up time points 
(Piccart-Gebhart et al. 2005, Smith et al. 2007, Goldhirsch et al. 2013, Cameron et al. 
2017). The first paper compared patients on the observation arm versus one year 
Herceptin and was published with at least one-year median follow-up. The results 
from this paper showed that there was a clinical and statistical significant difference 
in DFS (HR: 0.54, 95% CI: 0.43 to 0.67, p-value<0.001) for those patients that received 
Herceptin for one year versus those patients that received no Herceptin (Piccart-
Gebhart et al. 2005). This led to a protocol amendment whereby patients in the 
observation group were invited to receive Herceptin. The latest paper, published in 
2017 after patients had reached a median follow-up of 11 years, (Cameron et al. 
2017) reported that the 10 year DFS was 69% for both the one year and two year 
arms suggesting that the study was powered adequately to show that these trial arms 
were the same or NI, however this was only exploratory analysis (Table 7.1).   
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The HERA trial proved to be a revolutionary trial, changing practice for women with 
HER2 positive breast cancer by showing that Herceptin therapy can significantly 
reduce the risk of breast cancer recurring (Gianni et al. 2011). This trial became the 
basis of future trials such as the FinHer trial, PHARE trial, Persephone trial and the 
SOLD trial, all of which assessed shorter durations of Herceptin therapy in women 
with HER2 positive early stage breast cancer (Persephone 2007, Joensuu et al. 2009, 
Pivot et al. 2013, Joensuu et al. 2018). 
7.2.2 FinHer trial 
The FinHer trial compared the use of Docetaxel plus a regimen consisting of 
fluorouracil, epirubicin and cyclophosphamide (FEC) against Vinorelbine plus FEC but 
involved a second randomisation for the HER2 positive patients to no Herceptin or 
nine weeks of Herceptin (Joensuu et al. 2009). This phase III RCT recruited women 
with axillary-node positive or high-risk node-negative cancer to each of these arms, 
of which it was estimated that 30% of patients would be HER2 positive. A sample of 
300 HER2 positive patients were needed to be randomised to receive either no 
Herceptin or Herceptin for nine weeks to detect a difference in five year RFS from 
50% with no Herceptin to 67% with a power of 80% and 5% two-sided level of 
significance, which required approximately 1000 patient to be recruited to full trial 
(Joensuu et al. 2018) (Figure 7.4).   
The FinHer trial recruited 232 HER2 positive patients within three years. At the time 
of analysis, with a median follow-up of three years, there was a statistically significant 
difference in RFS between the no treatment and nine weeks of Herceptin treatment 
arms; with a three year RFS of 77.6% and 89.3% respectively (p-value = 0.01) (Table 
7.1).  
The trial recruited 232 HER2 positive patients out of a required 300 patients, which 
was a limitation to the study. The trial team concluded that their results indicate that 
a nine-week period is effective but the optimal duration of Herceptin therapy 
requires a further RCT (Joensuu et al. 2009). This trial resulted in the creation of the 





Figure 7.4: Outline of the FinHer design parameters. RFS = Recurrence-free survival 
 
7.2.3 SOLD trial  
The SOLD trial was a phase III RCT that compared the use of Herceptin with docetaxel 
over a nine week period against Herceptin with docetaxel over a 12 month period 
(current standard) in women with HER2 positive early stage breast cancer (Joensuu 
et al. 2018).  
The initial sample size calculated assumed superiority between the treatment arms. 
A sample size of approximately 3000 patients with a power of 80% and two-sided 
significance level of 5% would be required to be recruited over four years to detect 
an improvement in OS after five years of follow-up from 80% to 84% in the better 
arm but they did not state which the better arm is.  
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The sample size calculations for this trial were revised due to two reasons: 1) External 
data suggesting higher values for five-year DFS and 2) Changing from a superiority 
assumption to a NI assumption as reducing treatment duration was not likely to 
reduce the number of breast cancer recurrences. Changing the hypothesis from a 
superiority to a NI hypothesis is a major change to the design. However, a NI 
hypothesis would have been more appropriate in the first place and all other 
worldwide studies looking at the duration of Herceptin were using a NI design, which 
may have been why the change was agreed. Hence the new sample size calculation 
required 2168 patients to be recruited in 7.5 years to reach a total of 366 events with 
a HR set at 1.3 (4% absolute NI margin) and the five-year DFS assumed to be 85% for 
the 12 month treatment arm as per the updated research with 80% power and a one-
sided significance level of 5% (Figure 7.5). The SOLD trial did not consider anything 
less than a 4% absolute NI margin as it was not considered clinically significant and 
believed that the estimated 5-year DFS could be higher than 85%. For this reason, 
sample size calculations were estimated for 5-year DFS rates ranging from 84% to 
88%. In re-designing the trial using a NI hypothesis, the trial team also updated the 
initial assumptions made when designing using a superiority hypothesis as the DFS 
rates were also updated and the time for recruitment was increased from four years 
to 7.5 years, as the enrolment rate of patients was slower than expected.  
The SOLD trial team recruited 2174 patients and after a median of five years of follow-
up, the five-year DFS was found to be 88% for the nine week arm and 90.5% for the 
12 month treatment arm with a hazard ratio of 1.39 (90% CI: 1.12-1.72). The trial 
failed to show that nine weeks of Herceptin was non inferior to one year of Herceptin 




Figure 7.5: Outline of the SOLD design parameters. NI = Non-inferiority; DFS = Disease-free 
survival 
7.2.4 HORG trial  
The Hellenic Oncology Research Group (HORG) RCT, based in Greece, compared the 
use of Herceptin for six months against 12 months for women with HER2 positive 
early breast cancer (Mavroudis et al. 2015). The sample size calculated for this trial 
required a total of 478 patients to be accrued within three years to demonstrate NI 
using an 8% absolute NI margin for three-year DFS assuming an expected DFS in the 
12 month group of 85% with 80% power and one-sided significance level of 5% 
(Figure 7.6). The HORG team reported that “the noninferiority hazard ratio margin of 
1.53 was derived from an estimated absolute difference in 3-year DFS of 8%. To reject 
the null hypothesis and therefore to conclude noninferiority, the upper bound of the 
95% confidence interval should be less than this margin” (Mavroudis et al. 2015).. 
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The trial struggled to recruit the estimated number of patients within three years and 
hence extended its recruitment to eight years. The median follow-up time of the 481 
patients recruited was 51 months for the six month arm and 47 months for the 12 
month arm. The three year DFS were 93.3% for six months and 95.7% for 12 months 
of Herceptin treatment (Table 7.1) with a HR=1.57 (95% CI: 0.86 to 2.10; p-
value=0.137) (Mavroudis et al. 2015). The p-value showed that there was no 
statistically significant difference between the two groups however the HR and 
therefore the upper bound of the 95% CI for this trial were greater than the HR 
margin (1.53) and therefore could not conclude the NI of six months of Herceptin 
treatment. The reporting of the upper 95% CI was a limitation to this study as the 
team implemented a 5% significance level, they should have used the upper bound 
of a 90% CI. The study implemented a large NI margin, which reflected the relatively 
small number of patients required for this study. A larger NI margin may discourage 
patients to enrol as the NI margin reflects ‘how much worse of a treatment’ patients 
are willing to accept for a shorter duration of treatment.  Another limitation to the 
study was that the original assumption for three-year DFS improved from 85% to 
95%, therefore there were fewer events than originally predicted. The original critical 
HR was used to assess NI and therefore there was less power to detect this level as 
the obtained DFS meant a smaller NI margin was used. Therefore, by using an 
absolute margin and readjusting the critical HR accordingly, there would be more 





Figure 7.6: Outline of the HORG, PHARE and Persephone design parameters. NI = Non-inferiority; DFS = Disease-free survival 
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7.2.5 PHARE trial  
The PHARE trial was the French phase III RCT similar to Persephone which compared 
the use of Herceptin for six months against 12 months in women with HER2 positive 
early breast cancer (Pivot et al. 2013, Pivot et al. 2019).   
The initial sample size calculated required a total of 7000 patients to observe 1040 
events to demonstrate a 2% absolute NI margin for DFS based on an expected two-
year DFS of 85% for 12 months of Herceptin together with a one-sided 5% 
significance level and 80% power assuming two years recruitment followed by two 
years follow-up (Figure 7.6). The trial team reported that “a two-sided 95% CI with 
the upper bound with a HR less than 1.15 would conclude NI as the primary objective 
of the trial was to assess if six months of Herceptin was no worse than 12 months”. 
As mentioned in chapter one, assessing the upper bound of a 95% CI would 
correspond to using a 2.5% one-sided significance level whereas the initial sample 
size was based on a 5% one-sided significance level. Thus instead, the PHARE trial 
should have concluded NI if the upper bound of the 90% CI was less than 1.15.  
The PHARE trial team struggled to obtain the required accrual rate and hence the 
sample size was changed to a four year recruitment period with an analysis planned 
at eight years, which would require 3400 patients instead to achieve the same 
number of events. Annual interim efficacy analyses were performed using the 
Haybittle-Peto method whereby the treatment would be stopped if there was a 
statistically significant difference of p<0.001 for efficacy (Pocock 2005, Pivot et al. 
2013).  A stop-go criteria was enforced whereby the trial would be stopped if the 
HERA study results showed that two years of Herceptin was superior to one year of 
Herceptin.  
The PHARE trial recruited 3384 patients in four years and had a median of 42.5 
months of follow-up instead four years follow-up. The original sample size calculated 
that 1040 DFS events would be required however the actual trial accumulated 384 
DFS events as the DFS rate was considerably higher than originally expected, which 
could impact the overall power of the study as considered in the previous section. 
The 2-year DFS rate was 93.8% and 91.1% in the six month and 12 month arm 
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respectively (Table 7.1) giving a HR of 1.28 (95% CI: 1.05 to 1.56; p-value=0.29). After 
a median of 3.5 years of follow-up, the PHARE trial team reported that they could not 
show that six months of Herceptin was non-inferior to 12 months of Herceptin as the 
upper confidence interval of the HR exceeded 1.15 (Pivot et al. 2019). 
7.2.6 Persephone trial  
The Persephone trial, similar to the PHARE trial, was a RCT comparing the use of 
Herceptin for six months versus 12 months in a phase III NI trial in HER2 positive 
patients diagnosed with early breast cancer (Earl et al. 2019). 4000 patients were 
required to evaluate an absolute NI margin of 3% for DFS for six months Herceptin 
versus 12 month Herceptin with 85% power and 5% one-sided significance level 
(Figure 7.6).  
The Persephone trial ran parallel to the PHARE trial, which therefore influenced the 
oversight of the trial as new evidence from PHARE emerged. Three interim analyses 
were performed in Persephone; two pre-planned and the third was an emergency 
unplanned analysis triggered by the PHARE trial group publishing their own third 
interim analysis and concluding that 12 months duration was superior. The 
Persephone DMC concluded that there was no reason to stop Persephone and 
encouraged the trial to continue. 
The Persephone trial demonstrated that six months of Herceptin treatment is not 
inferior to 12 months in this cohort of patients (Earl et al. 2019). The Persephone 
team set the NI margin to be no more than 3% absolute reduction of 4-year DFS. 
Furthermore, the upper bound of a 90% confidence interval was used to determine 
whether six months of Herceptin was non-inferior to 12 months of Herceptin 
treatment. After recruiting 4089 patients with 512 events, the four-year DFS rate was 
89.8% in the 12 month arm and 89.4% in the six month arm (Table 7.1). This gave a 
HR of 1.07 (upper bound of the 90% CI: 1.24) with one-sided p-value of 0.01 for NI, 
hence demonstrating that six months of Herceptin treatment was not inferior to 12 
months (Earl et al. 2019).  
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7.2.7 Summary of the results for the HERA, FinHer, SOLD, HORG PHARE and 
Persephone trials   
The results of all these trials were used to determine the parameters that would be 
implemented to explore whether the use of a MAMS design would have been more 
efficient to test the optimal duration of Herceptin compared to performing separate 
trials using the 12 months of Herceptin treatment as the control arm and treatment 
durations less than 12 months as the experimental arm using a NI hypothesis (Table 
7.1).   
The results of the HERA, FinHer and SOLD trials showed that 12 months of Herceptin 
was better than no treatment and nine weeks. The HORG, PHARE and Persephone 
trials all compared six months of Herceptin treatment against 12 months but all had 
different countries involved.  The Persephone trial showed six months to be non-
inferior to 12 months. PHARE and HORG trials both failed to demonstrate NI of six 
months of Herceptin treatment compared to 12 months but it could be argued that 
the statistical considerations were flawed.  
In 2020, three meta-analyses were published comparing the effects of different 
durations of Herceptin therapy (Deng et al. 2020, Gulia et al. 2020, Yu et al. 2020). 
Deng et al (2020) performed a meta-analysis across the PHARE, Persephone and 
HORG trials; all three of these trials compared 12 months of Herceptin against six 
months. The meta-analysis found no statistically significant difference for DFS (HR: 
1.10, 95% CI: 0.99-1.23, p-value = 0.09) and OS (HR = 1.14, 95% CI: 0.99-1.32, p-value 
= 0.07) between the two treatment durations suggesting that there was no evidence 
of a difference between six and 12 months of Herceptin. Furthermore, Deng et al 
(2020) reported more AEs for patients treated with 12 months Herceptin versus six 
months (Risk ratio = 0.66, 95% CI: 0.56-0.77, p-value < 0.001). Gulia et al (2020) used 
published data from six trials assessing Herceptin therapy; four of the trials were 
Persephone, SOLD, PHARE and HORG (Gulia et al. 2020). The meta-analysis compared 
shorter duration of Herceptin versus 12 months of Herceptin using a relative NI 
margin of 1.3, calculated by taking the median NI margin across the six trials. The 
meta-analysis found that shorter use of Herceptin was no worse than using 12 
months of Herceptin therapy (HR = 1.14, 95% CI: 1.03-1.25, p-value = 0.004) and less 
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risk of cardiac events using shorter durations (Relative risk = 0.53, 95%: 0.38-0.74). 
Yu et al (2020) combined 12 Herceptin based trials including PHARE, HORG, SOLD, 
Persephone and HERA trials, consisting of approximately 20,000 patients and used 
12 months of Herceptin as the standard therapy (Yu et al. 2020). The team found that 
there was a statistically significant association (p-value = 0.002) between treatment 
time and recurrence risk. Each month Herceptin treatment was shortened from the 
12 month standard would result in an increase in recurrence risk by 5.1%.  
The three meta-analyses described here all obtained the data through public 
platforms, as of December 2020, the Persephone team at Warwick CTU are in the 
process of obtaining individual patient data for the PHARE, SOLD and HORG trials 
with the aim of performing a combined meta-analysis.  
 MAMS design with NI hypothesis 
The trials described in section 7.2 were used to design a hypothetical MAMS trial 
using a NI hypothesis. The control arm was 12 months of Herceptin treatment and 
was compared to nine weeks, three months and six months of Herceptin treatment, 
therefore a four arm three stage MAMS design was implemented. The previous 
chapter showed the statistical properties of using a NI hypothesis with the ‘nstage’ 
command. The example used in the previous chapter was a three arm two stage trial 
but extending to a four arm three stage trial with a NI hypothesis would also work 
using the ‘nstage’ command. 
7.3.1 Selection of parameter values for the MAMS design 
The intermediate and primary outcome used for the MAMS design was DFS as this is 
what was used in the majority of the trials. It was assumed that the DFS rate at three 
years for 12 months of Herceptin was 90%, which was based on the latest DFS rates 
obtained from the Persephone and PHARE trials (Pivot et al. 2019, Earl et al. 2020) 
and randomisation would take place prior to any treatment. The total length of the 
trial was approximately 11 years; seven years for recruitment and four years follow-
up. The MAMS designs used the same stagewise power values used in section 5.5, 
i.e. 95% at stages one and two and 90% at stage three and a one-sided FWER no more 
than 5%; strong emphasis was placed on controlling the FWER as all the arms of the 
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trial were implementing the same drug at different durations. Therefore, the 
stagewise alpha values were set at 0.50 for stage one, 0.25 for stage two and 0.02 for 
final stage to ensure a FWER no more than 5%. The focus of these MAMS designs was 
strong control of the FWER however in order to assess the impact of this approach, 
the MAMS designs were also calculated to have strong control of the PWER with the 
assumption that all treatments were independent of each other. For the MAMS 
designs with strong control for the PWER, the stagewise alpha values were set at 0.50 
for stage one, 0.25 for stage two and 0.05 for the final stage to ensure a PWER no 
more than 5%. The MAMS designs with strong control of FWER and the MAMS 
designs with strong control of PWER were compared in terms of trial duration, 
number of control arm events and the critical HR. Like in chapters five and six, it was 
assumed that all experimental arms continued to the final stage and therefore 
maximise on the number of patients and time required as it is important that trial 
teams consider the extreme case scenario to present to funders to ensure they 
capitalise on funding given to support the trial. If trial teams do not consider the 
extreme case scenario, it may result in an under-budgeted study, which could result 
in either re-applying for additional funding or the closure of the trial. An outline of 
the hypothetical four arm three stage with strong control for the FWER and PWER 
can be seen in Figure 7.7. 
A NI hypothesis was implemented as all experimental arms were reduced durations 
of the Herceptin drug. To consider the impact on the trial design, various NI margins 
were considered that reflected the superiority differences and NI margins that were 
implemented in the aforementioned trials (section 7.2). Additionally, the ICH E9 
guidelines suggest that the NI margin should be smaller than the difference observed 
in the superiority trials of the control group (see section 1.4) (European Medicines 
Agency 1998). The superiority difference used in the HERA trial to compare 12 
months of Herceptin against observation only was an absolute difference of 6.8%, 
therefore the NI absolute margin needed to be less than 6.8%. Hence, NI absolute 




Figure 7.7: Flow diagram of the hypothetical four arm three stage MAMS trial with strong 
control for FWER and PWER. *Final Significance level of 0.02 used for FWER and 0.05 for 
PWER. MAMS = Multi-arm multi-stage; NI = Non-inferiority; DFS = Disease-free survival; IA = 
Interim analysis; IO = Intermediate outcome; PO = Primary outcome.  
The total number of patients, the number of control arm events, the critical HR and 
timing of the interim analysis required for each of the different NI margins were 
recorded and compared. The sample size for each of the MAMS designs with 
different NI margins were compared against SOLD, HORG, PHARE and Persephone 
trials if these trials were repeated three times to accommodate three different 
durations. These trials were used as comparators as they all implemented a NI 
hypothesis.   
7.3.2 Results 
Applying a four arm three stage MAMS design with strong control for the FWER with 
the different NI margins resulted in, as expected, the 2% absolute NI margin requiring 
the most patients; approximately 2600 control arm patients followed by the design 
with a 3% margin, which required 1243 control arm patients, 4% margin required 752 
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control arm patients and then 5% margin that required 516 control arm patients 
(Figure 7.8). When using a 5% absolute NI margin, approximately 120 control arm 
events were required at the final stage compared to approximately 174 control arm 
events required when implementing a 4% NI margin. A 3% absolute NI margin 
required approximately 289 control arm events at the final stage analysis and more 
than double the number of control arm events were required at the final stage 
analysis for a 2% absolute NI margin (approximately 613 control arm events). The 
output for these calculations using the ‘nstage’ command can be found in appendix 
10.  
 
Figure 7.8: Number of control arm patients (dark green) and events (light green) for the 
MAMS designs with strong control of the FWER using different absolute NI margins. NI = 
Non-inferiority.  
 
Table 7.2 shows the number of control arm events, the cumulative time of the 
analysis and the critical HR at each stage for the different NI margin values. If the 
pairwise comparison between the control arm and experimental arm has a HR 
greater than the critical HR, then this would result in discontinuing the experimental 
arm as it would deduce the inferiority of an experimental arm. It can be seen, as 
expected, that as the NI margin increases, the number of control arm events required 
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decreases and the critical HR values gets further away from the target HR. 
Furthermore, the timing of the analysis is consistent for all NI margins.  
Stage Target HR 



















HR (observed) is… 
Stage I 1 ≈149 4.9 > 1.210 ≈71 4.9 > 1.320 
Stage II 1 ≈297 7.0 > 1.145 ≈140 7.0 > 1.218 
Final Stage III 1 ≈613 11.1 > 1.076 ≈289 11.1 > 1.113 
  4% 5% 
Stage I 1 ≈43 4.9 > 1.430 ≈30 5.0 > 1.540 
Stage II 1 ≈85 7.0 > 1.289 ≈58 7.0 > 1.359 
Final Stage III 1 ≈174 11.1 > 1.147 ≈120 11.1 > 1.181 
*Time is cumulative     
Table 7.2: The number of control arm events and critical HR at each stage for the different 
absolute NI margins. NI = Non-inferiority; HR = Hazard ratio. 
The sample sizes for each of these different MAMS designs were compared against 
the number of patients recruited in the SOLD, HORG, PHARE and Persephone trials 
repeated three times (Figure 7.9). The HORG trial would require the lowest number 
of patients however this trial did implement an absolute NI margin (8%), larger than 
the difference used in the HERA trial (HORG took place after the HERA trial results 
were released). Using a 3% (Persephone absolute NI margin), 4% (SOLD absolute NI 
margin) or 5% absolute NI margin would require fewer patients for a MAMS design 
compared to repeatedly performing the SOLD, PHARE or Persephone trial. 
Implementing a MAMS design with a 2% absolute NI margin would require fewer 
patients compared to repeatedly performing the Persephone trial however required 
more patients compared to repeatedly performing the PHARE trial (10500 patients 
for 2% absolute NI margin vs. 10152 patients for PHARE). The reason for the 
difference in the number of patients between the two trials could be due to the 
PHARE trial implementing a power of 80% compared to a higher power used at each 




Figure 7.9: Comparing the sample size of the MAMS designs with different absolute NI 
margins against the number of patients recruited in the SOLD, HORG, PHARE and 
Persephone trials if these were repeated three times. NI = Non-inferiority. 
The MAMS calculations for strong control of the PWER for the different absolute NI 
margins produced the same results for the interim control arm events, interim critical 
HRs and timing of the interim stages compared to the MAMS calculations for strong 
control of the FWER. The differences between the two occurred at the final stage. It 
can be seen in Table 7.3 that a larger final critical HR was used when controlling for 
the PWER in comparison to controlling for the FWER and as a result fewer control 
arm events were required. Therefore, it would take less time to reach these events 
and hence strong control for the PWER instead of the FWER would result in a trial 
duration of approximately 9 years in comparison to 11 years required. These results 
are as expected as a larger final stage alpha value of 0.05 is being used for the PWER 
MAMS calculations compared to a value of 0.02 when control for FWER.  
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MAMS designs  PWER FWER 
2% Abs. NI Margin 
Control arm events  ≈472 ≈613 
Consider NI if HR (observed) is…    < 1.087 < 1.076 
Time of Analysis (Years) 9.2 11.1 
3% Abs. NI Margin 
Control arm events  ≈223 ≈289 
Consider NI if HR (observed) is… < 1.130 < 1.113 
Time of Analysis (Years) 9.2 11.1 
4% Abs. NI Margin 
Control arm events  ≈134 ≈174 
Consider NI if HR (observed) is… < 1.170 < 1.147 
Time of Analysis (Years) 9.2 11.1 
5% Abs. NI Margin 
Control arm events  ≈92 ≈120 
Consider NI if HR (observed) is… < 1.208 < 1.181 
Time of Analysis (Years) 9.2 11.1 
Table 7.3: Comparison of the final number of control arm events, final critical HR, time of 
the analysis at the final stage for when calculating MAMS designs for the different absolute 
NI margins with strong control of PWER and strong control of the FWER. MAMS = Multi-arm 
Multi-stage; PWER = Pairwise type I error rate; FWER = Familywise type I error rate; NI = 
Non-inferiority; HR = Hazard ratio. 
 
7.3.3 Summary  
Hypothetical four arm three stage MAMS designs using different NI margins were 
calculated and compared between each other and to existing trials that have tested 
different durations of Herceptin treatment to see if a MAMS design could have been 
implemented with less patients. The extreme case, where all experimental arms 
continue to the end of the trial was considered, however if the ‘best case’ scenario 
where all but one experimental arm showed inferiority at the first interim stage was 
considered then using the same number of patients for each NI margin would further 
reduce the trial length from 11 years to approximately 9.75 years. Especially when 
assessing different durations, the timing of the interim analysis is essential as there 
needs to be sufficient time for the treatment arms to differ. This is because there will 
be points in the trial where patients in different arms may have had the same 
duration, for example a patient randomised to 12 months of Herceptin may have only 
had three months of Herceptin when then interim analysis takes place. Therefore, if 
the interim analysis takes place too early, then there may be some patients that may 
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not have completed treatment and therefore do not have sufficient follow-up which 
may lead to incorrectly dropping an experimental arm or taking forward inadequate 
treatments as all patients are having the same treatment for a period of time and 
therefore unlikely to see any early differences. The MAMS designs considered in this 
chapter had the first interim analysis taking place at approximately five years, 
allowing patients on the control arm that had the longest duration of Herceptin 
therapy (12 months) to complete treatment and have sufficient follow-up.  
Our calculations showed that these trials could have been executed using fewer 
patients with a MAMS design however it would be dependent on the choice of the 
NI margin which would require clinical input. Additionally, a snapshot of these 
designs were calculated however these could vary further by using different DFS 
rates, varying the allocation ratio, varying the number of interim stages etc.  
The next section will look at some of the operational aspects that must be considered 
to execute these designs.  
 Operational considerations for MAMS trials 
From a statistical standpoint, executing a MAMS trial may seem feasible however this 
is conditional upon the competence of where the trial will be hosted. Trial teams 
must take this into account whilst planning the trial and must take into consideration 
that other trials running simultaneously at the host site may impact operational 
efficiency.  
Prior to conducting a MAMS trial, it is important that there is sufficient funding as 
MAMS trials may require extra funds especially when implementing a NI hypothesis 
where smaller margins are used compared to trials with a superiority hypothesis and 
therefore more patients are required. It is recommended that trial teams should 
consider the maximum number of patients and time required to ensure maximum 
funding is obtained and thus plan for all experimental arms continuing to the final 
phase. Additionally, trial teams could outline in the funding application that 
experimental arms may be added and by combining these additional arms into one 
trial can be considerably less in terms of cost then creating another standard two-
arm RCT (Schiavone et al. 2019).  
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Upon writing the protocol, it is important to write it according to the SPIRIT guidelines 
(Chan et al. 2013). Include in the protocol the option to expand the trial to new 
experimental arms if new treatments warrant investigation during the course of the 
trial. Ensure the protocol is version controlled and any changes are clearly outlined 
to ensure transparency to all parties involved.  
Data collection is a crucial component of any clinical trial. CRFs are used to record 
data for a trial and can be recorded in different ways. The method of obtaining data 
can directly impact the trial in terms of efficiency and cost. Implementing paper CRFs 
can be time consuming as site staff are required to fill these out and then trial team 
members would have to input this data onto a database. Time would be further 
consumed if there are difficulties in understanding what has been written on the 
CRFs. Trial teams can consider remote data entry performed by site staff, this ensures 
that data is legible, and processes can be put into place to try and ensure data is 
correctly entered. For example, if site staff input a patients’ height as five meters, 
then the system would highlight this incorrect value. Innovative patient-centric 
methods to collect data where possible can be put into place. A mobile phone 
application linked to hospital records could be used to capture data. Implementing a 
smart application can reduce the number of patient and carer visits to sites and the 
smart application could be used to remind patients to enter data as well as direct 
reminders for appointments. However, creating an application may be costly, out of 
budget and may not be popular with patients who are not familiar with the 
technology.  
Every clinical trial has its own designed database to reflect the CRFs requirements 
and to store all the data. The development of these systems can be timely and if the 
system is created in-house where there are a few specialists to create these systems 
then thorough planning is required to ensure this database is ready on-time. Using 
online cloud-based platforms to develop an appropriate database and capture 
patient data could be an alternative as these platforms allow for sufficient and safe 
data storage however these online platforms can be costly.   
As discussed in chapter two, it is important to outline all trial processes before, during 
and after a trial to encourage efficiency. For example, at an interim analysis where 
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experimental arms may not continue, trial teams can plan for different situations to 
ensure that they are ready to go based upon the outcome of the interim analysis. 
Independent committees such as DMCs and trial management committees guide the 
decisions made during the trial. Trial teams can consider employing larger 
committees to ensure that sufficient quorate is met. 
The COVID19 pandemic has encouraged trialists to think of innovative methods to 
run clinical trials. One way could be to decentralise trials by utilising technology so 
trials can be conducted virtually which is beneficial as it allows home video 
consultations and minimises hospital visits and these can continue amidst a global 
pandemic. The FDA have also encouraged trial stakeholders to look at decentralised 
trials and utilise mobile technology to assist in conducting clinical trials (Shapiro et al. 
2019, US Food and Drug Administration 2019).  
Promoting efficient working practices is essential for all trials but especially for larger 
and more complicated MAMS design to ensure that costs are kept to a minimum. 
 Discussion 
A MAMS design was considered to assess the duration of Herceptin therapy in 
women with early breast cancer to understand whether implementing a MAMS 
design would have been more efficient and effective compared to conducting 
multiple two arm trials to compare different durations.   
Twelve months of Herceptin therapy became standard of care for women with early 
breast cancer after the execution of the HERA trial. The HERA trial became the basis 
on which many Herceptin trials were moulded with the aim of assessing the optimal 
duration of Herceptin. Six trials relating to the duration of Herceptin therapy in 
women with early breast cancer were assessed to help to form a MAMS based trial. 
It was vital that a NI hypothesis was used as the MAMS trial aimed to show a shorter 
duration could be no worse than the current standard of 12 months.  
The PHARE trial specified a one-sided test with a 5% significance level and therefore 
should have used a 90% CI. The Persephone trial also specified a 5% one-sided 
significance level and hence it correctly uses the 90% CI limit for the HR to assess NI. 
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Additionally, a 90% CI was used within the SOLD trial (Joensuu et al. 2018). Therefore, 
if the PHARE trial implemented a 90% CI and a 2% absolute margin, i.e. recalculated 
the critical HR given their obtained control arm rate, as in the Persephone trial, then 
the results of PHARE would have demonstrated NI. Sample sizes for MAMS trials with 
different NI margins were calculated and compared. The bigger the NI margin, the 
fewer number of patients would be required. If the margin was too big then this 
would reflect on the robustness of the conclusions deemed from the trial, the clinical 
impact and patients may not favour a large NI margin. Implementing a 2% absolute 
NI margin would provide strong evidence to the conclusions obtained from the 
MAMS trial however the sample size required for this was over double the sample 
size required compared to using a 3% NI margin. It is important to note that different 
assumptions were made for all the original trials, for example the Persephone trial 
used 85% power and the PHARE trial used 80% power. These differences have not 
been fully taken into consideration when comparing these trials to the MAMS designs 
in Figure 7.9. However, it is envisaged that these discrepancies do not make a 
significant difference to the overall message that is being portrayed i.e. MAMS 
designs can be more efficient.  
Emphasis was placed on controlling the FWER as this controls the probability of 
erroneously concluding that any duration is more effective than the control 
treatment as all the trial arms implemented the same drug at different durations 
(European Medicines Agency 2002). The trial team can make a priori assumption that 
longer durations will not be dropped earlier than shorter durations and therefore 
provide an ordering preference of dropping experimental arms, in this case a step-
down procedure can be used to control the FWER (Bauer 1997). If an experimental 
arm were to stop during an interim analysis, the ‘nstage’ command calculates the 
FWER using the Dunnett probability which assumes that all experimental arms will 
continue to the final stage therefore the spend of alpha is conservative in that the 
FWER is smaller than the nominal level. Posch et al (2005) provided guidance on how  
to reduce this conservatism by allowing only for the arms which were actually 
included at each stage (Posch et al. 2005). There still remains some debate over 
whether control of the FWER is required when the arms are different drugs rather 
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than different durations of the same drug as evaluated in this chapter (Wason et al. 
2014, Bretz et al. 2020, Parker et al. 2020). 
The decision to drop or continue a trial arm at the interim stage of a MAMS clinical 
trial is often the role of the DMC, based on the pre-planned interim stopping rules 
provided by the trial team. Quartagno et al (2018) propose ‘duration designs’ 
whereby the duration-response curve is modelled to identify appropriate treatment 
durations, this method can be incorporated into a MAMS design to aid the DMC in 
decision making. For example, information could be gathered from the duration-
response curve to estimate an acceptable duration which would have a specified loss 
of efficiency. This information could also be combined with toxicity or cost-
effectiveness to ensure that the DMC have an adequate amount of information to 
assist in making key decisions. The choice of design cannot be solely decided by a 
statistician hence various scenarios must be reviewed when designing adaptive trials 
to paint a clear picture for all those involved with the decision of which scenario to 
implement.  
Some of the operational aspects to execute an adaptive trial have been discussed in 
this chapter and in chapter two. The lessons learnt from the STAMPEDE and FOCUS4 
trials demonstrate that to encourage the smooth running of a trial, proper processes 
and thorough planning is a necessity. Trial teams that wish to execute large trials are 
encouraged to refer to the operational papers published by the STAMPEDE and 
FOCUS4 team (Hague et al. 2019, Schiavone et al. 2019). 
 Conclusion 
The application of a MAMS designs with a NI hypothesis from a statistical viewpoint 
seems feasible however the input of other trial stakeholders including clinicians, 
patients and trial team members is crucial to understand the clinical and operational 
feasibility of implementing large adaptive trials.  
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8 Discussion, future work and conclusions 
 Discussion and Key thesis findings 
Phase III RCTs are the gold standard way to test a new intervention or procedure in 
people with the aim to find out if these treatments are safe, have any side effects, 
are better than the currently used treatment or have any effect on the quality of life 
of patients (Cancer Research UK 2018). The use of adaptive designs has greatly aided 
and improved the way trials are executed and conducted in all phases by making 
them more efficient. These innovative approaches in conducting trials are becoming 
more appreciated and known by people within the medical profession and fit very 
well in the oncology setting where there are often many drugs to consider at the 
same time (Kairalla et al. 2012).  
The first chapter laid the foundations of the research by providing an introduction 
into RCTs, survival analysis, adaptive designs and briefly highlighting the differences 
between Bayesian and frequentist philosophies. Hypothesis testing options were 
also addressed and it was shown how a superiority hypothesis and a NI hypothesis 
can be interchanged, which was necessary in order to support the research reported 
in subsequent chapters throughout the thesis.  
Chapter two explored the commonly considered adaptive design methods, e.g. 
sample size re-estimation, adaptive randomisation, group sequential designs, and 
their application within phase III cancer trials. This thesis has primarily focused on 
the MAMS framework by Royston et al (2011), hence chapter two details the 
methodology of this adaptive method and provides an example of how to apply the 
‘nstage’ command in Stata that can be used to apply this framework. The draft 
guidance on adaptive designs given by the FDA in 2010 was originally followed (US 
Food and Drug Administration 2010) but modified to reflect the amended FDA 
guidelines for adaptive designs (US Food and Drug Administration 2018) that were 
released during the PhD. The latest set of guidelines are more compact and efficient, 
but the use of certain key words is different, i.e. the 2010 guidelines used ‘Type I 
error rate’ whereas the updated guidelines use ‘Type I error probability’. These 
updated guidelines emphasise the vital role simulations play in planning adaptive 
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designs compared to the previous guidelines which referred to the use of simulations 
as ‘not fully understood’. As mentioned in chapter two, the FDA originally categorised 
the different adaptive designs into well understood and less well understood 
methods; these have now been removed from the updated version which reflects 
the FDAs familiarity with these designs. Therefore, it is evident from the different 
adaptive methods researched that there will be continuous evolution of adaptive 
design methodology with more novel methods being developed and considered to 
assist the clinical trial community at all phases of clinical trials.  
It was clear from the literature review different adaptive design methods are 
available however it wasn’t clear how much these adaptive designs had been applied 
in phase III RCTs in Oncology. Hence, this led to performing a review of the current 
literature to recognise the application of adaptive design methodology in RCTs in 
cancer and how these RCTs were being reported. A literature search was conducted 
reviewing the use of adaptive design methods within cancer trials in 2015. Within 
one year, 54 papers that used some form of adaptive design method within cancer 
trials were found. Previous literature reviews (Bauer et al. 2006, Stevely et al. 2015, 
Hatfield et al. 2016) investigated the methods and reporting of adaptive design, 
however the review in chapter three was unique and relevant to this PhD as the aim 
was to only concentrate on the application of adaptive designs methods within phase 
II, phase II/III and phase III RCTs in cancer. The conclusions drawn from this literature 
review suggested that adaptive design methods are regularly implemented but 
reporting of these methods were poor. This reaffirmed the conclusions made by 
previous literature reviews who also investigated the reporting of adaptive designs 
(Bauer et al. 2006, Stevely et al. 2015, Hatfield et al. 2016).  
Due to the poor reporting of adaptive designs highlighted from the literature review, 
an extension to the current CONSORT Statement guidelines was proposed to improve 
the reporting of adaptive designs in the future. The literature review reported within 
chapter three was published during the course of this PhD (Mistry et al. 2017a). A 
consensus driven CONSORT Statement extension for RCTs using adaptive design was 
later published (Dimairo et al. 2018) and a workshop was held by the ACE group in 
2019 whereby the finalised guidelines were disseminated (appendix 5). The 
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differences and similarities between the two guidelines have been compared in 
chapter three.   
The conclusions drawn from chapter three led to the scoping exercise of the cancer 
trials run within Warwick CTU to assess their use of adaptive methods as it was 
evident from chapter three that adaptive design methods were being implemented 
but not being reported as adaptive. The scoping exercise in chapter four showed that 
the cancer trials within Warwick CTU regularly made adaptations without classing 
them as adaptive designs, thus supporting the need for better guidelines to report 
adaptive designs. This led to the assessment of exemplar trials in chapter four where 
trials that had successfully implemented adaptive designs, one of which was the 
STAMPEDE trial which used a MAMS design to compare different treatments for 
patients diagnosed with prostate cancer which has a poor prognosis and therefore 
the events occur quickly. Additionally, the MAMS framework by Royston et al (2011) 
was used in the FOCUS4 and CompARE trials.  
MAMS designs are becoming increasingly popular due to the ability and efficiency of 
assessing multiple experimental arms within one trial to answer many questions 
rather than conducting separating trials and the subsequent cost saving implications. 
MAMS designs have received great support from patients and clinicians (Parmar et 
al. 2014). It was felt important to further delve into the application of these MAMS 
designs within the field of Oncology and its use in trials with differing prognosis. 
Therefore, the trials that implemented a MAMS design in chapter four aided in the 
selection of key parameters in subsequent chapters.   
Chapter five found that applying a MAMS designs with a superiority hypothesis to 
three cancer sites (breast, colon and lung cancer) would be feasible and fewer 
patients are required compared to conducting several two-arm trials. The reason for 
selecting these specific cancer sites was because the five-year OS rate could range 
from 16% in lung cancer to 85% in breast cancer and hence would give a good 
overview of the application of these designs. For poor, moderate and good survival 
outcomes it was concluded that the outcome of a MAMS design can be influenced 
by various factors and how the factors influence the sample size and duration of a 
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MAMS design are listed below and these learnings were taken forward in subsequent 
chapters:  
• Primary and intermediate outcome: Using a time-to-event outcome that 
provides with sufficient events that clinicians are comfortable with, for 
example in chapter five, implementing OS in the HERA_OS trial resulted in 
only 20 events required to conclude superiority. Therefore, clinicians and 
patients may not be convinced that conclusions can be made with few events;  
• Number of arms at each stage: It is recommended that trial teams consider a 
range of scenarios. When applying for funding, show the most extreme case 
to make sure that there are enough resources available when applying for 
money from funders. The definition of ‘extreme’ can be subjective as per the 
trial teams objectives however in this thesis ‘extreme’ is defined as all 
experimental arms continuing to the final stage as this would require the 
most patients and therefore the most cost to funding; 
• Significance level (α): Suitable choice for alpha as the value at each stage can 
influence the overall alpha value and the timing of the interim analyses. 
Implementing the values specified by Royston et al (2011) and the STAMPEDE 
are a suitable benchmark however these can vary depending on the 
requirements of the trial. 
A key novel aspect of this PhD was presented in chapter six where it was shown how 
to implement a NI hypothesis using the ‘nstage’ command. Simulations were 
performed that validated the statistical properties of using the ‘nstage’ command 
with a NI hypothesis. Furthermore, the calculations applied in chapter five were 
extended to implement MAMS designs with two of these trials using a NI hypothesis. 
The calculations showed that MAMS designs with a NI hypothesis can be 
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implemented and required fewer patients in comparison to performing separate 
two-arm trials. However, it is recommended that the MAMS designs with a NI 
hypothesis are not applied where there is a low survival rate with small NI margins 
e.g. in lung cancer as it is felt that within this patient population that only large 
clinically relevant differences would be appropriate.   
The assessment of the Persephone trial in chapter four, the application of a MAMS 
design to early breast cancer in chapter five and implementing a NI hypothesis in 
chapter six led to the development of a trial looking at Herceptin treatment duration 
in chapter seven. The use of Herceptin therapy in women with early breast cancer 
was first assessed in the HERA trial. Thereafter, the Persephone trial and many other 
trials were created to assess the optimal duration of Herceptin therapy.  
Various trials that have evaluated the different durations of Herceptin treatment in 
patients diagnosed in early breast cancer were assessed to see if applying a MAMS 
design with a NI hypothesis would have been more efficient than conducting the 
trials separately and explore the operational aspects required to execute these 
designs.  The results of these investigations have shown that MAMS designs can be 
considered for cancers with good survival rates, whereas they have been only 
previously implemented for cancer with poor survival rates. Thus, extending the use 
of these MAMS designs to more situations.  
There was a difference in the assumed rate of DFS used for the Persephone trial. The 
sample size calculation used 80% four-year DFS rate compared to the observed rate 
in the final analysis of 89.8% four-year DFS rate. The substantial change in the DFS 
rate reflects the progress made in the management of the cancer disease from 
screening procedures or early diagnosis to treatment and care provided to patients 
diagnosed with the disease (Quaresma et al. 2015). The UK took active precautions 
to reduce the number of deaths due to Cancer by creating ‘The NHS Cancer plan’ 
(Department of Health 2000). Over time this plan has developed and continues to 
pledge to reduce the number of cancer deaths (Burki 2019). The plan published in 
January 2019 (Burki 2019)  aims to ensure that any patient that may be at the risk of 
cancer will receive a diagnosis within 28 days of being referred. Hence, there has 
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been active and prioritised research in the field of Oncology which explains the 
improvement in the DFS rates over time.  
In chapters five and six, the treatment arms in the MAMS designs were different 
drugs and therefore considered independent whereas in chapter seven the 
investigations involved different durations of the same drug. This added an additional 
complexity to the decision making process. Thus emphasis was placed on controlling 
the FWER as this controls the probability of erroneously concluding that any duration 
is more effective than the control treatment. However, MAMS designs with strong 
control of the PWER were also calculated and contrasted to the MAMS designs with 
strong control of the FWER. Strong control of the PWER would result in requiring a 
larger final critical HR and hence fewer control arm events in comparison to 
controlling for the FWER due to a larger final stage alpha value of 0.05 for the PWER 
MAMS calculation compared to a value of 0.02 when controlling for the FWER. 
In 2018, a methodology paper investigating the use of NI for optimising treatment 
duration was published (Quartagno et al. 2018). The authors of this paper proposed 
a multi-arm randomised trial of different treatment durations and modelled the 
duration-response curve to identify appropriate treatment durations. The aim of this 
paper was similar to the aims of this PhD, exploring the use of a NI hypothesis in a 
trial of multiple arms to assess treatment duration.  However, this PhD investigates 
the optimal treatment duration within Oncology trials using multiple arms as well as 
multiple stages allowing the dropping of experimental arms at each stage due to lack 
of benefit or futility. The modelling of the duration-response curve could be 
implemented within this MAMS framework to aid decision making by estimating the 
duration that allows for a specified loss of efficiency.  The approach by Quartagno et 
al (2018) considered models looking at treatment duration, these models could be 
extended further to incorporate key prognostic factors. Therefore, allow clinicians to 
prescribe different durations for specified subgroups and hence a more personalised 
medicine approach.  
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 Limitations of this thesis and future work   
The aim of this thesis has been primarily focused on the statistical elements of 
applying adaptive designs, in particular MAMS designs with a superiority and NI 
hypothesis within the field of Oncology. Future work could entail implementing a 
MAMS design with the vital input from other trial stakeholders. This would prove 
valuable in raising the robustness that these MAMS design can provide. Obtaining 
valuable guidance from experienced trial stakeholders and patients could support 
the inclusion for a set of guidelines for various stages of a MAMS design and address 
the following:  
• Setting the key parameters for the MAMS design such as the hazard ratio, 
the treatment difference or the number of years required to recruit patients;  
• Seeking guidance from anyone that may internally/externally specialise in 
adaptive designs to assist with the write up of the protocol or statistical 
analysis plan;  
• Speaking to teams that have employed adaptive designs to ensure efficiency 
in all operational aspects. For example, what process could be put into place 
to allow sufficient turn-around time for data management, how to engage 
site staff and keep them motivated, how to conduct training to get new staff 
members up to speed etc. 
• Allowing sufficient time between any interim analyses for other tasks such as 
up to date data entry, data validation, data queries etc.; 
• Consider whether a pilot study is required to assess the feasibility of 
performing a MAMS design;  
• Is there sufficient funding to support the MAMS design? What is the potential 
for obtaining extra funding to support the inclusion of additional 
experimental arms?  
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It may be difficult to apply a MAMS design to rare cancers such as renal cancer, where 
the diagnosis of patients is low or where there is a very good prognosis cancer with 
high survival rates hence very low event rates. Furthermore, MAMS designs are only 
valuable if there are multiple treatments to assess. Also trial teams that do not have 
the operational capacity should not employ MAMS designs.  
The ‘nstage’ command offers a wide range of different options that could be applied 
to MAMS designs. The latest update has been released for the ‘nstage’ command 
whereby a selection of efficacy stopping boundaries can be implemented (Blenkinsop 
et al. 2019). The scope of this work could be further extended in various ways, few 
of which have been mentioned in previous chapters and some suggested below:  
• Continuing with a NI design and assess adding different treatment durations 
whilst a trial is on-going; 
• Implementing an adaptive randomisation procedure within a MAMS design 
whereby more patients are allocated to treatments that are performing 
better; 
• Sample size re-estimation based on observed data at an interim analysis; 
• Extend the ‘nstage’ command to consider non-proportional hazards; 
• Implement the MAMS design to other cancer sites or non-cancer areas to 
assess treatment duration. For example, these designs could be applied to 
the treatment of bacterial infections to understand the optimal duration for 
anti-biotics treatment.  
 Conclusions 
It is evident that since the start of this PhD in January 2016, adaptive designs have 
come a long way with more streamlined guidelines released by the FDA, a consensus 
driven CONSORT Statement extension for reporting of adaptive designs and more 
literature related to adaptive design published. It is apparent from these 
achievements that the use and demand for adaptive designs is continually increasing. 
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Additionally, adaptive designs have proved to be extremely valuable in the 
investigation of new treatments and vaccines for COVID-19 (Noor et al. 2020, Stallard 
et al. 2020). 
This thesis demonstrated with time to event outcomes in the field of oncology that 
the use of MAMS designs can be more efficient than the gold standard parallel two-
arm RCT and be applied in disease areas with good survival outcomes, i.e. in early 
breast cancer where the five-year disease free survival rates can be around 90%. 
Furthermore, these MAMS designs can be extended to implement a NI hypothesis, 
and not just comparing treatments in the superiority setting. These MAMS designs 
can be applied to other therapeutic areas like cardiovascular disease where TTE 
outcomes such as time to first occurrence of myocardial infarction are implemented. 
A similar version of the ‘nstage’ command is called ‘nstagebin’, which applies MAMS 
designs with binary intermediate and primary outcomes and are analysed using the 
absolute difference in proportions (Bratton et al. 2013). These designs can be applied 
to various disease areas with endpoints such as whether a patient is cured or not, if 
a patient had a major cardiac event etc. This research has shown the value of applying 
adaptive designs but urges trial stakeholders and funders to consider implementing 
adaptive designs where possible. These designs will greatly aid all those involved in 
clinical trials by ensuring that trials are ethical (fewer patients required and quicker 
set-up times), efficient (one control arm for several treatment comparisons and 
quicker set-up times) and effective (variety of treatments considered so trial is never 
outdated by new treatments). It has been emphasised in this thesis that trial teams 
must be fully aware of the operationally aspects required for these designs and not 
to underestimate the resources required to run them. It is anticipated that with more 
support and trust given to these types of designs, adaptive designs may eventually 
become the new ‘gold standard’ for phase III clinical trials or at least be considered 





Appendix 1: The VIETNARMS trial 
There are very limited trials that have focused on decreasing the length of treatment 
of hepatitis C (currently treatment last between 8-12 weeks) especially in cohorts of 
patients with genotype six. The VIETNARMS trial team have proposed a large trial 
using two NI hypotheses followed by a superiority hypothesis in which patients are 
factorially randomised to 14 treatment arms and stratified by genotype six vs. non-
genotype six (McCabe et al. 2020). The trial implements a binary primary endpoint 
where patients have either a sustained virologic response or treatment failure. The 
term ‘factorially randomised’ has been used as patients are randomised to either one 
of two drug regiments given for 12 weeks (regimen comparison), control or three 
treatment decreasing strategies (strategy comparison) and of those randomised to 
treatment decreasing strategies, they will also be randomised to adjunctive ribavirin 
or no adjunctive ribavirin (RBV comparison) (Figure 9.1).  
The sample size calculations assumed that the true cure rate was 90% in each group 
(null hypothesis) compared to an unacceptably low cure rate of 70% (alternative). A 
sample size of 39 patients would be required within each treatment arm to exclude 
the cure rate being lower than 70% with 90% power and a one-sided significance 
level of 5%. A total of 1092 patients will be required as there are two strata multiplied 
by the 14 treatment arms multiple by 39 patients in each stratified treatment arm. If 
any one of the groups are stopped at an interim analysis, then future patients will be 
assigned to any of the remaining groups to ensure that maximum information is gain 






Figure 9.1: Patients are factorially randomly assigned to two drug regimens, three treatment reducing strategies or control and either adjunctive ribavirin or 
no ribavirin. SOF = Sofosbuvir; VEL = Velpatasvir; DCV = Daclatasvir; RGT = Response guided therapy; D7 VL = Day 7 Viral load; PEGIFN = Pegylated 
interferon; RBV = Ribavirin. 
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Based on the initial sample size calculations for all treatment arms and assuming an 
overall cure rate of 95%, 1092 patients are sufficient to demonstrate 5% NI between 
drug regimens with 97% power and 10% NI between the strategy comparison with 
96% power both with a one-sided significance value of 5%. Superiority comparisons 
will take place between ribavirin and the regimen comparisons and the strategy 
comparison conditional that the above two comparisons meet the NI margin. The 
sample size will allow for an absolute difference of 5% to be detected with 90% power 
for the drug regimens or ribavirin comparison and an absolute difference of 7% to be 
detected with 80% power for the strategy comparison both with two-sided 
significance of 5%. The trial team selected a 5% absolute NI margin for the regimens 
comparison based on clinical judgement and its previous use in other trials. A larger 
NI margin was used for the strategy comparison because for the same cost 
significantly more patients can be treated.  
The hypothesis, treatment, allocation ratio and sample size used for each comparison 
can be seen in Table 9.1. 




comparison 5% NI 
1. SOF/VEL  
1:1 
546 
2. SOF/DCV 546 
Strategy 
comparison 10% NI 
1. No strategy (control) 
1:2:2:2 
156 
2. RGT guided by D7 VL  312 
3.Induction Maintenance 312 
4. PEGIFN 4W 312 
RBV 
comparison*  
5% Superiority difference - 
Regimen/RBV comparison 
> 7% superiority difference - 
Strategy/RBV comparison 
1. No RBV 
1:1 
468 
2. RBV 468 
*Excludes patients that have been allocated no strategy control group    
Table 9.1: Hypothesis, treatment, allocation ratio and sample size used for each comparison 
for the VIETNARM trial. SOF = Sofosbuvir; VEL = Velpatasvir; DCV = Daclatasvir; RGT = 
Response guided therapy; D7 VL = Day 7 Viral load; PEGIFN = Pegylated interferon; RBV = 
Ribavirin 
  
This trial has implemented a Bayesian monitoring procedure to allow the stopping of 
inferior arms early and hence successive patients to be randomised to the remaining 
arms if there is 95% posterior probability of less than a 90% cure in any of the 
treatment arms. This approach has been implemented because there is limited 
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knowledge about what effect the interventions will have as it will allow for flexibility 
in deciding when to implement an interim analyses compared to frequentist methods 
such as the MAMS design in which the timing and number of interim analyses are 
pre-specified (Royston et al. 2011).  The trial implemented four interim analyses, the 
timing of these were determined by assessing projected recruitment schedules to 
ensure sufficient patients were accrued and applying the probability of stopping the 
groups over different cure rates using a monitoring beta (α, β) prior, where α and β 
are shape parameters and α = 4.5 and β = 0.5. This prior beta (4.5, 0.5) was selected 
with a mean of 0.9, variance of 0.015 and a 34% probability that a cure rate of less 
than 90%; a low precision prior was selected as it would allow the data to be more 
influential in the posterior distribution. 
The trial will be assessed by an independent DMC and they will make the final 
decision as to whether a group should be stopped using the pre-specified stopping 
guidelines as well as different sensitivity analyses such as different prior values to 































Appendix 3: List of search terms used for literature review 
A free text search was conducted using the following key search terms to maximise 
the capture of phase II, II/III or III RCTs in the field of Oncology:   
• “phase II” 
•  “phase 2”  
• “phase III” 
• “phase 3” 
• “phase II/III” 





• “randomised controlled trial” 
• “randomised controlled trials” 
• “randomized controlled trial” 
• “randomized controlled trials” 
•  “randomised clinical trial” 
• “randomised clinical trials” 
• “randomized clinical trial” 
• “randomized clinical trials”  
• “trial” 
• “controlled clinical trial” 
• “controlled clinical trials”  
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The following key search terms were used together with the Boolean operator “OR” 
to maximise the capture of results related to adaptive design methods:  
• “adaptive design” 
• “adaptive designs” 
• “flexible design” 
• “flexible designs”  
• “group sequential” 
• “adaptive randomisation” 
• “adaptive randomization” 
• “sample size re-estimation” 
• “sample size adjustment” 
• “sample size modification” 
• “MAMS” 
• “multi arm multi stage” 
• “multi-arm multi-stage 
• “multi arm” 
• “multiple arm” 
• “multi stage” 
• “multi-stage”  
• “interim analysis” 
• “interim analyses” 
•  “adaptive seamless” 
• “biomarker adaptive” 
• “adaptive clinical trial” 
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• “adaptive clinical trials” 
• “two-stage adaptive” 
• “multiple adaptive” 
• “adaptive enrichment” 
• “dose escalation” 
• “dose selection” 
• “drop the loser” 
• “pick the winner”  
• “treatment switch” 
• “treatment switching” 
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Appendix 4: List of 54 published papers used in the literature review 
















Reason for early 
stopping 
1 
5-fluorouracil, leucovorin, and 
oxaliplatin (mFOLFOX6) plus sunitinib 
or bevacizumab as first-line treatment 
for metastatic colorectal cancer: A 
randomized Phase IIb study 




PFS Drug Interim analyses Yes Yes Lack of efficacy 
2 
A Multicenter, Phase II, Randomized, 
Noncomparative Clinical Trial of 
Radiation and Temozolomide with or 
without Vandetanib in Newly 
Diagnosed Glioblastoma Patients 




OS Drug Interim analyses Yes Yes Futility 
3 
A phase IIb multicentre study 
comparing the efficacy of trabectedin 
to doxorubicin in patients with 
advanced or metastatic untreated soft 
tissue sarcoma: the TRUSTS trial 




PFS Drug Interim analyses Yes Yes Lack of superiority 
4 
A phase III randomized trial of adding 
topical nitroglycerin to first-line 
chemotherapy for advanced nonsmall-
cell lung cancer: the Australasian lung 
cancer trials group NITRO trial 









A phase III study of radiation therapy 
(RT) and O6-benzylguanine, (O6-BG) 
plus BCNU versus RT and BCNU alone 
and methylation status in newly-
diagnosed glioblastoma (GBM) and 
gliosarcoma: Southwest Oncology 
Group (SWOG) Study S0001 




OS Drug Interim analyses Yes Yes Futility 
6 
A randomized phase II study of the 
MEK1/MEK2 inhibitor trametinib 
(GSK1120212) compared with 
docetaxel in KRAS-mutant advanced 
non-small-cell lung cancer (NSCLC) 
Blumenschein 




PFS Drug Interim analyses Yes Yes Futility 
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Reason for early 
stopping 
7 
A randomized trial comparing 
concurrent chemoradiotherapy with 
single-agent cisplatin versus cisplatin 
plus gemcitabine in patients with 
advanced cervical cancer: An Asian 
Gynecologic Oncology Group study 




OS/PFS Drug Interim analyses Yes Yes Slow recruitment 









s to Sample 
Size 
Success/Failure Drug Final analyses Yes No N/A 
9 
A randomized, open-label phase II trial 
of volasertib as monotherapy and in 
combination with standard-dose 
pemetrexed compared with 
pemetrexed monotherapy in second-
line treatment for non-small-cell lung 
cancer 




PFS Drug Final analyses Yes No N/A 
10 
Abiraterone acetate plus prednisone 
versus placebo plus prednisone in 
chemotherapy-naive men with 
metastatic castration-resistant prostate 
cancer (COU-AA-302): final overall 
survival analysis of a randomised, 
double-blind, placebo-controlled phase 
3 study 




OS/PFS Drug Final analyses Yes No N/A 
11 
Adjuvant sorafenib for hepatocellular 
carcinoma after resection or ablation 
(STORM): A phase 3, randomised, 
double-blind, placebo-controlled trial 









RFS Drug Final analyses Yes No N/A 
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Reason for early 
stopping 
12 
BCR-ABL1 mutation development 
during first-line treatment with 
dasatinib or imatinib for chronic 
myeloid leukemia in chronic phase 









analyses No No N/A 
13 
Bendamustine, thalidomide and 
dexamethasone combination therapy 
for relapsed/refractory myeloma 
patients: results of the MUKone 
randomized dose selection trial 




Optimal dose Drug Interim analyses Yes Yes Futility 
14 
Biological 18[F]-FDG-PET image-guided 
dose painting by numbers for painful 
uncomplicated bone metastases: A 3-
arm randomized phase II trial 














analyses Yes No N/A 
15 
Bosutinib versus imatinib in newly 
diagnosed chronic-phase chronic 
myeloid leukaemia: Results from the 
24-month follow-up of the BELA trial 
Brummendorf, 









analyses Yes No N/A 




PFS Drug Final analyses Yes No N/A 
17 
Capecitabine combined with docetaxel 
versus vinorelbine followed by 
capecitabine maintenance medication 
for first-line treatment of patients with 
advanced breast cancer: Phase 3 
randomized trial 






























Reason for early 
stopping 
18 
Carfilzomib and dexamethasone versus 
bortezomib and dexamethasone for 
patients with relapsed or refractory 
multiple myeloma (ENDEAVOR): a 
randomised, phase 3, open-label, 
multicentre study 
Dimopoulos, M. 




PFS Drug Final analyses Yes No N/A 
19 
Efficacy and Safety of Abiraterone 
Acetate in Elderly (>=75 years) 
Chemotherapy-Naive patients with 
Metastatic Castration-Resistant 
Prostate Cancer 




OS Drug Final analyses Yes No N/A 
20 
Efficacy and Safety of Trabectedin or 
Dacarbazine for Metastatic 
Liposarcoma or Leiomyosarcoma After 
Failure of Conventional Chemotherapy: 
Results of a Phase III Randomized 
Multicenter Clinical Trial 




OS/PFS Elotuzumab Therapy 
Final 
analyses Yes No N/A 




PFS Drug Final analyses Yes No N/A 
22 
Everolimus for the treatment of 
advanced, non-functional 
neuroendocrine tumours of the lung or 
gastrointestinal tract (RADIANT-4): a 
randomised, placebo-controlled, phase 
3 study 




OS Surgery/RT Interim analyses Yes No N/A 
23 
First interim analysis of a randomised 
trial of whole brain radiotherapy in 
melanoma brain metastases confirms 
high data quality 







analyses Yes Yes Safety/Efficacy 
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Reason for early 
stopping 
24 
Fulvestrant with or without 
selumetinib, a MEK 1/2 inhibitor, in 
breast cancer progressing after 
aromatase inhibitor therapy: a 
multicentre randomised placebo-
controlled double-blind phase II trial, 
SAKK 21/08 




Success/Failure Drug Interim analyses Yes Yes Futility 
25 
High-Dose FOLFIRI plus Bevacizumab in 
the Treatment of Metastatic Colorectal 
Cancer Patients with Two Different 












Ibrutinib combined with bendamustine 
and rituximab compared with placebo, 
bendamustine, and rituximab for 
previously treated chronic lymphocytic 
leukaemia or small lymphocytic 
lymphoma (HELIOS): a randomised, 
double-blind, phase 3 study 





s to  Patient 
Population 
PFS Drug Interim analyses Yes No N/A 
27 
Impact of bone-targeted therapies in 
chemotherapy-naive metastatic 
castration-resistant prostate cancer 
patients treated with abiraterone 
acetate: post hoc analysis of study 
COU-AA-302 




OS Drug Interim analyses Yes Yes Efficacy 
28 
Improved overall survival in melanoma 
with combined dabrafenib and 
trametinib 




OS Drug Interim analyses Yes No N/A 
29 
Italian multicenter phase III 
randomized study of cisplatin-
etoposide with or without 
bevacizumab as first-line treatment in 
extensive stage small cell lung cancer: 
treatment rationale and protocol 
design of the GOIRC-AIFA 
FARM6PMFJM trial 




OS Drug Interim analysis Yes Yes Efficacy 
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Reason for early 
stopping 
30 
Maintenance pazopanib versus placebo 
in Non-Small Cell Lung Cancer patients 
non-progressive after first line 
chemotherapy: A double blind 
randomised phase III study of the lung 
cancer group, EORTC 08092 (EudraCT: 
2010-018566-23, NCT01208064) 








Maintenance Therapy With Tumor-
Treating Fields Plus Temozolomide vs 
Temozolomide Alone for Glioblastoma: 
A Randomized Clinical Trial 




OS Drug Final analysis Yes No N/A 
32 
Metformin in patients with advanced 
pancreatic cancer: A double-blind, 
randomised, placebo-controlled phase 
2 trial 









EFS Drug Final analysis Yes No N/A 
33 
Methotrexate, doxorubicin, and 
cisplatin (MAP) plus maintenance 
pegylated interferon alfa-2b versus 
MAP alone in patients with resectable 
high-grade osteosarcoma and good 
histologic response to preoperative 
MAP: First results of the EURAMOS-1 
good response randomized controlled 
trial 





s to Sample 
Size 
PFS Drug Interim analysis Yes Yes Futility 
34 
Nilotinib versus imatinib as first-line 
therapy for patients with unresectable 
or metastatic gastrointestinal stromal 
tumours (ENESTg1): a randomised 
phase 3 trial 




OS Drug Final analysis Yes No N/A 
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Reason for early 
stopping 
35 
Nivolumab versus chemotherapy in 
patients with advanced melanoma who 
progressed after anti-CTLA-4 treatment 
(CheckMate 037): a randomised, 
controlled, open-label, phase 3 trial 




PFS Drug Interim analysis Yes No N/A 
36 
Ofatumumab maintenance versus 
observation in relapsed chronic 
lymphocytic leukaemia (PROLONG): an 
open-label, multicentre, randomised 
phase 3 study 




PFS Drug Final analysis Yes No N/A 




PFS Drug Interim analysis Yes No N/A 
38 
Pembrolizumab versus investigator-
choice chemotherapy for ipilimumab-
refractory melanoma (KEYNOTE-002): a 
randomised, controlled, phase 2 trial 




PFS Drug Final analysis Yes No N/A 
39 
Pertuzumab, trastuzumab, and 
docetaxel in HER2-positive metastatic 
breast cancer 




OS Drug Interim analysis Yes Yes Futility 
40 
Phase III randomized trial of second-
line ixabepilone versus paclitaxel or 
doxorubicin in women with advanced 
endometrial cancer 











Phase III study of pasireotide long-
acting release in patients with 
metastatic neuroendocrine tumors and 
carcinoid symptoms refractory to 
available somatostatin analogues 




OS Surgery/CT Interim analysis Yes Yes Slow recruitment 
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Reason for early 
stopping 
42 
Phase III Study of Surgery Versus 
Definitive Concurrent 
Chemoradiotherapy Boost in Patients 
With Resectable Stage IIIA(N2) and 
Selected IIIB Non-Small-Cell Lung 
Cancer After Induction Chemotherapy 
and Concurrent Chemoradiotherapy 
(ESPATUE) 




PFS  Interim analysis Yes Yes Safety/Futility 
43 
Phase III study on efficacy of taxanes 
plus bevacizumab with or without 
capecitabine as first-line chemotherapy 
in metastatic breast cancer 







analysis Yes Yes Safety 
44 
Preventive effect of Goshajinkigan on 
peripheral neurotoxicity of FOLFOX 
therapy (GENIUS trial): a placebo-
controlled, double-blind, randomized 
phase III study 




PFS Drug Final analysis Yes No N/A 
45 
Randomized Phase II Trial of 
Ridaforolimus in Advanced Endometrial 
Carcinoma 




RFS Drug Interim analysis Yes Yes Futility 
46 
Randomized phase III study of 2 
cisplatin-based chemoradiation 
regimens in locally advanced head and 
neck squamous cell carcinoma: impact 
of changing disease epidemiology on 
contemporary trial design 








Randomized phase III trial comparing 
weekly docetaxel plus cisplatin versus 
docetaxel monotherapy every 3 weeks 
in elderly patients with advanced non-
small-cell lung cancer: the intergroup 
trial JCOG0803/WJOG4307L 




PFS Drug Interim analysis Yes Yes Futility 
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Reason for early 
stopping 
48 
Randomized Phase III Trial of Paclitaxel 
Once Per Week Compared With 
Nanoparticle Albumin-Bound Nab-
Paclitaxel Once Per Week or 
Ixabepilone With Bevacizumab As First-
Line Chemotherapy for Locally 
Recurrent or Metastatic Breast Cancer: 
CALGB 40502/NCCTG N063H (Alliance) 




PFS Drug Subgroup analysis No No N/A 
49 
Regorafenib for advanced 
gastrointestinal stromal tumors 
following imatinib and sunitinib 
treatment: a subgroup analysis 
evaluating Japanese patients in the 
phase III GRID trial 







treatment Adding acid 
Final 
analysis No No N/A 
50 
Results of phase 2 randomized study of 
low-dose decitabine with or without 
valproic acid in patients with 
myelodysplastic syndrome and acute 
myelogenous leukemia 









OS Vaccine Final analysis Yes No N/A 
51 
Safety and survival with GVAX pancreas 
prime and Listeria Monocytogenes-
expressing mesothelin (CRS-207) boost 
vaccines for metastatic pancreatic 
cancer 




DFS Drug Third Interim Yes No N/A 
52 
SWOG S0221: a phase III trial 
comparing chemotherapy schedules in 
high-risk early-stage breast cancer 





s to Sample 
Size 
PFS Drug Final analysis Yes No N/A 
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Reason for early 
stopping 
53 
The cyclin-dependent kinase 4/6 
inhibitor palbociclib in combination 
with letrozole versus letrozole alone as 
first-line treatment of oestrogen 
receptor-positive, HER2-negative, 
advanced breast cancer (PALOMA-
1/TRIO-18): a randomised phase 2 
study 




OS/RFS Drug Interim Analysis Yes No N/A 
54 
Time to Definitive Failure to the First 
Tyrosine Kinase Inhibitor in Localized GI 
Stromal Tumors Treated With Imatinib 
As an Adjuvant: A European 
Organisation for Research and 
Treatment of Cancer Soft Tissue and 
Bone Sarcoma Group Intergroup 
Randomized Trial i 











OS/PFS Drug Interim analyses Yes No N/A 
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Appendix 6: List of all trials obtained from ClinicalTrials.gov (Extraction date: 28 March 2020)  
No. Title Phase(s) Enrolment URL 
Breast cancer trials 
1 
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation 
(PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative 
Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast 
Cancer 
Phase 2|Phase 3 527 https://ClinicalTrials.gov/show/NCT03150576 
2 Pre-operative Immunotherapy Combination Strategies in Breast Cancer Phase 2 160 https://ClinicalTrials.gov/show/NCT03395899 
3 
A Pre-operative Window Study of Letrozole Plus PR Agonist 
(Megestrol Acetate) Versus Letrozole Alone in Post-menopausal 
Patients With ER-positive Breast Cancer 
Phase 2 189 https://ClinicalTrials.gov/show/NCT03306472 
4 ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER 
Positive Lobular Breast Cancer or Diffuse Gastric Cancer Study 
Phase 2 58 https://ClinicalTrials.gov/show/NCT03620643 
5 
A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib 
+ Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With 
PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally 
Advanced or Metastatic Breast Cancer 
Phase 2|Phase 3 400 https://ClinicalTrials.gov/show/NCT04191499 
6 
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment 
for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced 
or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-
Positive, HER2-Negative Breast Cancer 
Phase 2|Phase 3 450 https://ClinicalTrials.gov/show/NCT03337724 
7 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be 
Surgically Removed or Has Spread [DESTINY-Breast02] 
Phase 3 600 https://ClinicalTrials.gov/show/NCT03523585 
8 
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor 
Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast 
Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-
Breast03] 
Phase 3 500 https://ClinicalTrials.gov/show/NCT03529110 
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No. Title Phase(s) Enrolment URL 
9 Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer Phase 2 160 https://ClinicalTrials.gov/show/NCT03048942 
10 The UK Plasma Based Molecular Profiling of Advanced Breast Cancer 
to Inform Therapeutic CHoices (plasmaMATCH) Trial 
Phase 2 1150 https://ClinicalTrials.gov/show/NCT03182634 
11 
Phase 1 / 2 Study of SAR439859 Single Agent and in Combination 
With Palbociclib in Postmenopausal Women With Estrogen Receptor 
Positive Advanced Breast Cancer (AMEERA-1) 
Phase 1|Phase 2 259 https://ClinicalTrials.gov/show/NCT03284957 
12 
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for 
Locally Advanced (Inoperable) or Metastatic HR+/HER2âˆ’ Breast 
Cancer 
Phase 3 834 https://ClinicalTrials.gov/show/NCT04305496 
13 Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer Phase 3 1200 https://ClinicalTrials.gov/show/NCT04109066 
14 Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of 
Patients With ER+/HER2- Advanced Breast Cancer 
Phase 3 466 https://ClinicalTrials.gov/show/NCT03778931 
15 
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine 
Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early 
Breast Cancer 
Phase 3 4000 https://ClinicalTrials.gov/show/NCT03701334 
16 
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for 
HER2-low Breast Cancer That Has Spread or Cannot be Surgically 
Removed [DESTINY-Breast04] 
Phase 3 540 https://ClinicalTrials.gov/show/NCT03734029 
17 
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant 
or Letrozole, Based on Prior Endocrine Therapy, in Patients With 
PIK3CA Mutation With Advanced Breast Cancer Who Have 
Progressed on or After Prior Treatments 
Phase 2 340 https://ClinicalTrials.gov/show/NCT03056755 
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18 
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination 
With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in 
the Treatment of Early-Stage Estrogen Receptor-Positive, Human 
Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast 
Cancer (MK-3475-756/KEYNOTE-756) 
Phase 3 1140 https://ClinicalTrials.gov/show/NCT03725059 
19 
A Study Of Ipatasertib in Combination With Atezolizumab and 
Paclitaxel as a Treatment for Participants With Locally Advanced or 
Metastatic Triple-Negative Breast Cancer. 
Phase 3 1155 https://ClinicalTrials.gov/show/NCT04177108 
20 MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer Phase 1 48 https://ClinicalTrials.gov/show/NCT03767335 
21 
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of 
Opportunity and Post-surgical Adjuvant Biomarker Study of DNA 
Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in 
Patients With Neoadjuvant Chemotherapy Resistant Residual Triple 
Negative Breast Cancer 
Phase 2 81 https://ClinicalTrials.gov/show/NCT03740893 
22 SYD985 vs. Physician's Choice in Participants With HER2-positive 
Locally Advanced or Metastatic Breast Cancer 
Phase 3 345 https://ClinicalTrials.gov/show/NCT03262935 
23 Study of AZD9833 Alone or in Combination With Palbociclib in 
Women With Advanced Breast Cancer 
Phase 1 182 https://ClinicalTrials.gov/show/NCT03616587 
24 A Study of Novel Anti-cancer Agents in Patients With Metastatic 
Triple Negative Breast Cancer 
Phase 1|Phase 2 110 https://ClinicalTrials.gov/show/NCT03742102 
25 
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In 
Combination With Adjuvant Anthracycline/Taxane-Based 
Chemotherapy Versus Chemotherapy Alone In Patients With 
Operable Triple-Negative Breast Cancer 
Phase 3 2300 https://ClinicalTrials.gov/show/NCT03498716 
26 HR+/HER2- Advanced Breast Cancer and Endocrine Resistance Phase 2 196 https://ClinicalTrials.gov/show/NCT03322215 
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27 
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel 
in Participants With Previously Untreated Locally Advanced or 
Metastatic Triple Negative Breast Cancer (TNBC) 
Phase 3 600 https://ClinicalTrials.gov/show/NCT03125902 
28 A Study of GDC-9545 in Postmenopausal Women With Stage I-III 
Operable, Estrogen Receptor-Positive Breast Cancer 
Phase 1 75 https://ClinicalTrials.gov/show/NCT03916744 
29 
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus 
Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor 
Positive and HER2 Negative Locally Advanced Unresectable or 
Metastatic Breast Cancer 
Phase 3 370 https://ClinicalTrials.gov/show/NCT04060862 
30 
A Study to Evaluate the Safety and Efficacy of Ipatasertib in 
Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in 
Participants With Locally Advanced or Metastatic Triple-Negative 
Breast Cancer 
Phase 1 202 https://ClinicalTrials.gov/show/NCT03800836 
31 
A Study of GDC-9545 Alone or in Combination With Palbociclib 
and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in 
Locally Advanced or Metastatic Estrogen Receptor-Positive Breast 
Cancer 
Phase 1 220 https://ClinicalTrials.gov/show/NCT03332797 
32 
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in 
Hormone Receptor-Positive, HER2-Negative Locally Advanced or 
Metastatic Breast Cancer 
Phase 1|Phase 2 102 https://ClinicalTrials.gov/show/NCT02983071 
33 
A Study Evaluating the Efficacy and Safety of Multiple 
Immunotherapy-Based Treatment Combinations in Patients With 
Metastatic or Inoperable Locally Advanced Triple-Negative Breast 
Cancer 
Phase 1|Phase 2 280 https://ClinicalTrials.gov/show/NCT03424005 
34 
A Study of the Efficacy and Safety of Atezolizumab Plus 
Chemotherapy for Patients With Early Relapsing Recurrent Triple-
Negative Breast Cancer 
Phase 3 572 https://ClinicalTrials.gov/show/NCT03371017 
35 Adjuvant Palbociclib in Elderly Patients With Breast Cancer Phase 2 366 https://ClinicalTrials.gov/show/NCT03609047 
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36 
To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-
0077 Single Agent in Participants With Solid Tumors and in 
Combination With Endocrine and Targeted Therapies in Participants 
With Breast Cancer 
Phase 1 104 https://ClinicalTrials.gov/show/NCT03006172 
37 Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02) Phase 3 400 https://ClinicalTrials.gov/show/NCT03901339 
38 Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor 
Resistant Breast Cancer 
Phase 2 160 https://ClinicalTrials.gov/show/NCT02530411 
39 Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Phase 3 384 https://ClinicalTrials.gov/show/NCT03786094 
40 To Assess Safety and Efficacy of Agents Targeting DNA Damage 
Repair With Olaparib Versus Olaparib Monotherapy. 
Phase 2 350 https://ClinicalTrials.gov/show/NCT03330847 
41 
The XENERAâ„¢ 1 Study Tests Xentuzumab in Combination With 
Everolimus and Exemestane in Women With Hormone Receptor 
Positive and HER2-negative Breast Cancer That Has Spread 
Phase 2 100 https://ClinicalTrials.gov/show/NCT03659136 
42 PALbociclib Rechallenge in horMone Receptor-posItive/HER2- 
Negative Advanced Breast Cancer (PALMIRA) 
Phase 2 198 https://ClinicalTrials.gov/show/NCT03809988 
43 Capivasertib+Paclitaxel as First Line Treatment for Patients With 
Locally Advanced or Metastatic TNBC 
Phase 3 800 https://ClinicalTrials.gov/show/NCT03997123 
44 
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus 
Pembrolizumab After Induction With First-Line Chemotherapy Plus 
Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-
009/KEYLYNK-009) 
Phase 2|Phase 3 932 https://ClinicalTrials.gov/show/NCT04191135 
45 Ascending Doses of Ceralasertib in Combination With Chemotherapy 
and/or Novel Anti Cancer Agents 
Phase 1|Phase 2 322 https://ClinicalTrials.gov/show/NCT02264678 
46 A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Phase 1 315 https://ClinicalTrials.gov/show/NCT02890069 
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47 
A Study Of PF-05212384 In Combination With Other Anti-Tumor 
Agents and in Combination With Cisplatin in Patients With Triple 
Negative Breast Cancer in an Expansion Arm (TNBC) 
Phase 1 124 https://ClinicalTrials.gov/show/NCT01920061 
48 Cambridge Brain Mets Trial 1 Phase 1|Phase 2 70 https://ClinicalTrials.gov/show/NCT02768337 
49 GEN1029 (HexaBodyÂ®-DR5/DR5) Safety Trial in Patients With 
Malignant Solid Tumors 
Phase 1|Phase 2 520 https://ClinicalTrials.gov/show/NCT03576131 
50 Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and 
Urothelial Cancer 
Phase 1 99 https://ClinicalTrials.gov/show/NCT03523572 
51 Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 
When Given Alongside Tamoxifen 
Phase 1|Phase 2 290 https://ClinicalTrials.gov/show/NCT02285179 
52 MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour Phase 1 120 https://ClinicalTrials.gov/show/NCT03934827 
53 
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic 
Activity of RO6874281 as a Single Agent (Part A) or in Combination 
With Trastuzumab or Cetuximab (Part B or C) 
Phase 1 205 https://ClinicalTrials.gov/show/NCT02627274 
54 
A Study of RO7198457 as a Single Agent and in Combination With 
Atezolizumab in Participants With Locally Advanced or Metastatic 
Tumors 
Phase 1 770 https://ClinicalTrials.gov/show/NCT03289962 
55 
GB1275 Monotherapy and in Combination With an Anti-PD1 
Antibody in Patients With Specified Advanced Solid Tumors or in 
Combination With Standard of Care in Patients With Metastatic 
Pancreatic Adenocarcinoma 
Phase 1|Phase 2 202 https://ClinicalTrials.gov/show/NCT04060342 
56 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Phase 1|Phase 2 412 https://ClinicalTrials.gov/show/NCT03829501 
57 A CR-UK Phase I Trial of LY3143921 Phase 1 68 https://ClinicalTrials.gov/show/NCT03096054 
58 
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease 
Recurrence and Survival After Primary Therapy in Common Non 
Metastatic Solid Tumours 
Phase 3 11000 https://ClinicalTrials.gov/show/NCT02804815 
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59 Study of Cabozantinib in Combination With Atezolizumab to 
Subjects With Locally Advanced or Metastatic Solid Tumors 
Phase 1|Phase 2 1732 https://ClinicalTrials.gov/show/NCT03170960 
60 A Phase I/Ib Study of NZV930 Alone and in Combination With 
PDR001 and /or NIR178 in Patients With Advanced Malignancies. 
Phase 1 344 https://ClinicalTrials.gov/show/NCT03549000 
61 
A Dose Escalation and Cohort Expansion Study of NKTR-214 in 
Combination With Nivolumab and Other Anti-Cancer Therapies in 
Patients With Select Advanced Solid Tumors ( PIVOT-02 ) 
Phase 1|Phase 2 780 https://ClinicalTrials.gov/show/NCT02983045 
62 Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced 
Or Metastatic Solid Tumors 
Phase 2 242 https://ClinicalTrials.gov/show/NCT03330405 
63 
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients 
With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK 
Gene Rearrangements (Fusions) 
Phase 2 300 https://ClinicalTrials.gov/show/NCT02568267 
64 
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an 
Investigational Drug CX-2009 for Patients With Selected Solid 
Tumors 
Phase 1|Phase 2 150 https://ClinicalTrials.gov/show/NCT03149549 
65 Phase 1b Multi-indication Study of Anetumab Ravtansine in 
Mesothelin Expressing Advanced Solid Tumors 
Phase 1 348 https://ClinicalTrials.gov/show/NCT03102320 
66 
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid 
Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid 
Cancer 
Phase 1|Phase 2 970 https://ClinicalTrials.gov/show/NCT03157128 
67 
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in 
Combination With Temozolomide (TMZ) in Participants With Locally 
Advanced or Metastatic Solid Tumors 
Phase 1|Phase 2 150 https://ClinicalTrials.gov/show/NCT03150810 
68 A Study to Test the Effect of the Drug Larotrectinib in Adults and 
Children With NTRK-fusion Positive Solid Tumors 
Phase 2 203 https://ClinicalTrials.gov/show/NCT02576431 
69 A Study Of Avelumab In Combination With Other Cancer 
Immunotherapies In Advanced Malignancies (JAVELIN Medley) 
Phase 2 620 https://ClinicalTrials.gov/show/NCT02554812 
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70 
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With 
Locally Advanced Or Metastatic Solid Or Primary CNS Tumors 
And/Or Who Have No Satisfactory Treatment Options 
Phase 1|Phase 2 68 https://ClinicalTrials.gov/show/NCT02650401 
71 
Study of Intratumorally Administered Stimulator of Interferon Genes 
(STING) Agonist E7766 in Participants With Advanced Solid Tumors 
or Lymphomas - INSTAL-101 
Phase 1 120 https://ClinicalTrials.gov/show/NCT04144140 
72 A Study of the CD73 Inhibitor LY3475070 Alone or in Combination 
With Pembrolizumab in Participants With Advanced Cancer 
Phase 1 120 https://ClinicalTrials.gov/show/NCT04148937 
Colon cancer trials 
1 Study of Intrahepatic Arterial Infusion of TG6002 in Combination 
With 5-FC in Patients With Metastatic Colorectal Cancer 
Phase 1|Phase 2 75 https://ClinicalTrials.gov/show/NCT04194034 
2 iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer Phase 2 25 https://ClinicalTrials.gov/show/NCT03867799 
3 Acoustic Cluster Therapy (ACT) With Chemotherapy in Metastatic 
Liver Metastases of Gastrointestinal Origin 
Phase 1 37 https://ClinicalTrials.gov/show/NCT04021277 
4 A Safety Study of NUC-3373 in Combination With Standard Agents 
Used in Colorectal Cancer Treatment 
Phase 1 62 https://ClinicalTrials.gov/show/NCT03428958 
5 
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy 
With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor 
T-cells 
Phase 1 36 https://ClinicalTrials.gov/show/NCT03692429 
6 A Safety and Effectiveness Study of Pre-operative Artesunate in 
Stage II/III Colorectal Cancer 
Phase 2 200 https://ClinicalTrials.gov/show/NCT02633098 
7 A Phase II Trial Assessing Nivolumab in Strong Class II Expressing 
Microsatellite Stable Colorectal Cancer 
Phase 2 36 https://ClinicalTrials.gov/show/NCT03981146 
8 
A Study Evaluating the Efficacy and Safety of Multiple 
Immunotherapy-Based Treatment Combinations in Patients With 
Metastatic Colorectal Cancer (Morpheus-CRC) 
Phase 1|Phase 2 326 https://ClinicalTrials.gov/show/NCT03555149 
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9 Phase III Study in First-line Treatment of Patients With Metastatic 
Colorectal Cancer Who Are Not Candidate for Intensive Therapy. 
Phase 3 854 https://ClinicalTrials.gov/show/NCT03869892 
10 
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's 
Choice Chemotherapy for the Treatment of Patients With Deficient 
Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) 
Metastatic Colorectal Cancer (mCRC) 
Phase 3 494 https://ClinicalTrials.gov/show/NCT04008030 
11 GEN1042 Safety Trial in Subjects With Malignant Solid Tumors Phase 1|Phase 2 126 https://ClinicalTrials.gov/show/NCT04083599 
12 A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Phase 1 315 https://ClinicalTrials.gov/show/NCT02890069 
13 Gevokizumab With Standard of Care Anti-cancer Therapies for 
Metastatic Colorectal, Gastroesophageal, and Renal Cancers 
Phase 1 172 https://ClinicalTrials.gov/show/NCT03798626 
14 EPA for Metastasis Trial 2 Phase 3 448 https://ClinicalTrials.gov/show/NCT03428477 
15 PIPAC for the Treatment of Colorectal Peritoneal Metastases Phase 2 30 https://ClinicalTrials.gov/show/NCT03868228 
16 A CR-UK Phase I Trial of LY3143921 Phase 1 68 https://ClinicalTrials.gov/show/NCT03096054 
17 
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease 
Recurrence and Survival After Primary Therapy in Common Non 
Metastatic Solid Tumours 
Phase 3 11000 https://ClinicalTrials.gov/show/NCT02804815 
18 
A Dose Escalation and Cohort Expansion Study of NKTR-214 in 
Combination With Nivolumab and Other Anti-Cancer Therapies in 
Patients With Select Advanced Solid Tumors ( PIVOT-02 ) 
Phase 1|Phase 2 780 https://ClinicalTrials.gov/show/NCT02983045 
19 GEN1029 (HexaBodyÂ®-DR5/DR5) Safety Trial in Patients With 
Malignant Solid Tumors 
Phase 1|Phase 2 520 https://ClinicalTrials.gov/show/NCT03576131 
20 A Phase 1/2 Study of INCB001158 in Combination With 
Chemotherapy in Subjects With Solid Tumors 
Phase 1|Phase 2 249 https://ClinicalTrials.gov/show/NCT03314935 
21 
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients 
With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK 
Gene Rearrangements (Fusions) 
Phase 2 300 https://ClinicalTrials.gov/show/NCT02568267 
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22 
A Study of RO7198457 as a Single Agent and in Combination With 
Atezolizumab in Participants With Locally Advanced or Metastatic 
Tumors 
Phase 1 770 https://ClinicalTrials.gov/show/NCT03289962 
23 
GB1275 Monotherapy and in Combination With an Anti-PD1 
Antibody in Patients With Specified Advanced Solid Tumors or in 
Combination With Standard of Care in Patients With Metastatic 
Pancreatic Adenocarcinoma 
Phase 1|Phase 2 202 https://ClinicalTrials.gov/show/NCT04060342 
24 Study of Cabozantinib in Combination With Atezolizumab to 
Subjects With Locally Advanced or Metastatic Solid Tumors 
Phase 1|Phase 2 1732 https://ClinicalTrials.gov/show/NCT03170960 
25 A Phase I/Ib Study of NZV930 Alone and in Combination With 
PDR001 and /or NIR178 in Patients With Advanced Malignancies. 
Phase 1 344 https://ClinicalTrials.gov/show/NCT03549000 
26 A Study to Test the Effect of the Drug Larotrectinib in Adults and 
Children With NTRK-fusion Positive Solid Tumors 
Phase 2 203 https://ClinicalTrials.gov/show/NCT02576431 
27 Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Phase 2 250 https://ClinicalTrials.gov/show/NCT03485209 
28 A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon 
Receptor Inhibitor (AhRi) in Patients With Advanced Cancer 
Phase 1 114 https://ClinicalTrials.gov/show/NCT04069026 
29 
Study of Intratumorally Administered Stimulator of Interferon Genes 
(STING) Agonist E7766 in Participants With Advanced Solid Tumors 
or Lymphomas - INSTAL-101 
Phase 1 120 https://ClinicalTrials.gov/show/NCT04144140 
30 Study of Pembrolizumab (MK-3475) in Participants With Advanced 
Solid Tumors (MK-3475-158/KEYNOTE-158) 
Phase 2 1395 https://ClinicalTrials.gov/show/NCT02628067 
Lung cancer trials 
1 SBRT With Immunotherapy in Early Stage Non-small Cell Lung 
Cancer: Tolerability and Lung Effects 
Phase 1|Phase 2 31 https://ClinicalTrials.gov/show/NCT03383302 
2 AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer Phase 1 48 https://ClinicalTrials.gov/show/NCT03371485 
3 Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy Phase 2 50 https://ClinicalTrials.gov/show/NCT02151604 
292 
 
No. Title Phase(s) Enrolment URL 
4 Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer Phase 1|Phase 2 46 https://ClinicalTrials.gov/show/NCT03298763 
5 Deciphering Antitumour Response and Resistance With INtratumour 
Heterogeneity 
Phase 2 119 https://ClinicalTrials.gov/show/NCT02314481 
6 
STUDY 15 - Comparing Gemcitabine/Carboplatin and 
Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in 
Small Cell Lung Cancer (SCLC) 
Phase 2 112 https://ClinicalTrials.gov/show/NCT02722369 
7 ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC Phase 1|Phase 2 50 https://ClinicalTrials.gov/show/NCT04032847 
8 
A Study of Atezolizumab Plus Carboplatin and Etoposide With or 
Without Tiragolumab in Patients With Untreated Extensive-Stage 
Small Cell Lung Cancer 
Phase 3 400 https://ClinicalTrials.gov/show/NCT04256421 
9 
A Study of Osimertinib With or Without Chemotherapy as 1st Line 
Treatment in Patients With Mutated Epidermal Growth Factor 
Receptor Non-Small Cell Lung Cancer (FLAURA2) 
Phase 3 586 https://ClinicalTrials.gov/show/NCT04035486 
10 
A Study to Determine Safety of Durvalumab After Sequential Chemo 
Radiation in Patients With Unresectable Stage III Non-Small Cell Lung 
Cancer 
Phase 2 150 https://ClinicalTrials.gov/show/NCT03693300 
11 
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) 
With or Without Pembrolizumab (MK-3475) in Adults With Medically 
Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-
3475-867/KEYNOTE-867) 
Phase 3 530 https://ClinicalTrials.gov/show/NCT03924869 
12 
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant 
Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB 
(T>5cm N2) Completely Resected Non-small Cell Lung Cancer 
Acronym: CANOPY-A 
Phase 3 1500 https://ClinicalTrials.gov/show/NCT03447769 
293 
 
No. Title Phase(s) Enrolment URL 
13 
Study of Pemetrexed + Platinum Chemotherapy With or Without 
Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- 
(TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated 
Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-
3475-789/KEYNOTE-789) 
Phase 3 480 https://ClinicalTrials.gov/show/NCT03515837 
14 
An Investigational Immuno-therapy Trial of Nivolumab, or 
Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet 
Chemotherapy, Compared to Platinum Doublet Chemotherapy in 
Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) 
Phase 3 2220 https://ClinicalTrials.gov/show/NCT02477826 
15 
A Study of Nivolumab and Ipilimumab in Untreated Patients With 
Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not 
Planned to be Removed by Surgery 
Phase 3 1400 https://ClinicalTrials.gov/show/NCT04026412 
16 
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + 
Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-
7902/E7080) as First-line Intervention in Adults With Metastatic 
Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-
G000-315/LEAP-006) 
Phase 3 726 https://ClinicalTrials.gov/show/NCT03829319 
17 
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum 
Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for 
Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-
4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) 
Phase 3 786 https://ClinicalTrials.gov/show/NCT03425643 
18 A Study of LY3295668 Erbumine in Participants With Extensive-stage 
Small-Cell Lung Cancer 
Phase 1|Phase 2 64 https://ClinicalTrials.gov/show/NCT03898791 
19 
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib 
(E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-
Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After 
Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-
008/E7080-G000-316/LEAP-008) 
Phase 3 405 https://ClinicalTrials.gov/show/NCT03976375 
294 
 
No. Title Phase(s) Enrolment URL 
20 Study of JNJ-61186372, a Human Bispecific EGFR and cMet 
Antibody, in Participants With Advanced Non-Small Cell Lung Cancer 
Phase 1 460 https://ClinicalTrials.gov/show/NCT02609776 
21 
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based 
Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-
3475-495/KEYNOTE-495) 
Phase 2 318 https://ClinicalTrials.gov/show/NCT03516981 
22 
A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of 
Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell 
Lung Cancer (IMscin001) 
Phase 1|Phase 2 260 https://ClinicalTrials.gov/show/NCT03735121 
23 National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer Phase 2 569 https://ClinicalTrials.gov/show/NCT02664935 
24 Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With 
Previously Treated c-Met+ Non-Small Cell Lung Cancer 
Phase 2 310 https://ClinicalTrials.gov/show/NCT03539536 
25 
Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in 
HLA-A2 Positive Patients With Advanced NSCLC After Failure of 
Immune Checkpoint Inhibitor 
Phase 3 363 https://ClinicalTrials.gov/show/NCT02654587 
26 A Study of Selpercatinib (LY3527723) in Participants With Advanced 
or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer 
Phase 3 400 https://ClinicalTrials.gov/show/NCT04194944 
27 A Trial of Pembrolizumab in Combination With Chemotherapy and 
Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799). 
Phase 2 216 https://ClinicalTrials.gov/show/NCT03631784 
28 
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib 
(BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung 
Cancer, and Other Advanced Solid Tumors 
Phase 1|Phase 2 527 https://ClinicalTrials.gov/show/NCT03037385 
29 
Study of Pembrolizumab With Maintenance Olaparib or 
Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous 
Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) 
Phase 3 792 https://ClinicalTrials.gov/show/NCT03976323 
30 BT1718 in Patients With Advanced Solid Tumours. Phase 1|Phase 2 130 https://ClinicalTrials.gov/show/NCT03486730 
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31 
Durvalumab vs Placebo Following Stereotactic Body Radiation 
Therapy in Early Stage Unresected Non-small Cell Lung Cancer 
Patients 
Phase 3 706 https://ClinicalTrials.gov/show/NCT03833154 
32 First-in-human Study of S-588210 (S-488210+S-488211) Phase 1 10 https://ClinicalTrials.gov/show/NCT04316689 
33 Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With 
EGFR Wild-type Advanced Non-small Cell Lung Cancer 
Phase 2 373 https://ClinicalTrials.gov/show/NCT02414139 
34 Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity Phase 2 48 https://ClinicalTrials.gov/show/NCT02183883 
35 
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or 
Without Other Anti-Cancer Immunotherapy Agents In Patients With 
Advanced Malignancies 
Phase 2 80 https://ClinicalTrials.gov/show/NCT03317496 
36 
Study to Test the Safety and How Radium-223 Dichloride an Alpha 
Particle-emitting Radioactive Agent Works in Combination With 
Pembrolizumab an Immune Checkpoint Inhibitor in Patients With 
Stage IV Non-small Cell Lung Cancer With Bone Metastases 
Phase 1|Phase 2 164 https://ClinicalTrials.gov/show/NCT03996473 
37 Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults 
With Small Cell Lung Cancer 
Phase 1 162 https://ClinicalTrials.gov/show/NCT03319940 
38 
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-
Based Chemotherapy in Patients With ALK Positive Non-Small Cell 
Lung Cancer 
Phase 3 255 https://ClinicalTrials.gov/show/NCT03456076 
39 
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus 
Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, 
or Select IIIB Non-Small Cell Lung Cancer (IMpower030) 
Phase 3 374 https://ClinicalTrials.gov/show/NCT03456063 
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No. Title Phase(s) Enrolment URL 
40 
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus 
Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical 
Removal and Adjuvant Treatment With Nivolumab or Placebo for 
Participants With Surgically Removable Early Stage Non-small Cell 
Lung Cancer 
Phase 3 452 https://ClinicalTrials.gov/show/NCT04025879 
41 
A Study of Pembrolizumab (MK-3475) With or Without Maintenance 
Olaparib in First-line Metastatic Squamous Non-small Cell Lung 
Cancer (NSCLC, MK-7339-008/KEYLYNK-008) 
Phase 3 735 https://ClinicalTrials.gov/show/NCT03976362 
42 
A Study Of Multiple Immunotherapy-Based Treatment Combinations 
In Participants With Metastatic Non-Small Cell Lung Cancer 
(Morpheus- Non-Small Cell Lung Cancer) 
Phase 1|Phase 2 305 https://ClinicalTrials.gov/show/NCT03337698 
43 GEN1042 Safety Trial in Subjects With Malignant Solid Tumors Phase 1|Phase 2 126 https://ClinicalTrials.gov/show/NCT04083599 
44 Cambridge Brain Mets Trial 1 Phase 1|Phase 2 70 https://ClinicalTrials.gov/show/NCT02768337 
45 A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of 
Patients With ALK-Positive NSCLC 
Phase 3 280 https://ClinicalTrials.gov/show/NCT03052608 
46 MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour Phase 1 120 https://ClinicalTrials.gov/show/NCT03934827 
47 A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Phase 1 315 https://ClinicalTrials.gov/show/NCT02890069 
48 
A Study to Determine Safety, Tolerability, Pharmacokinetics, and 
Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in 
Adult Participants With Previously Treated Cancers 
Phase 1 112 https://ClinicalTrials.gov/show/NCT04272203 
49 Bemcentinib (BGB324) in Combination With Pembrolizumab in 
Patients With Advanced NSCLC 
Phase 2 77 https://ClinicalTrials.gov/show/NCT03184571 
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No. Title Phase(s) Enrolment URL 
50 
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod 
Alpha (IMP321) and Pembrolizumab in Patients With Previously 
Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X 
Refractory NSCLC or With Recurrent or Metastatic HNSCC 
Phase 2 109 https://ClinicalTrials.gov/show/NCT03625323 
51 Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma Phase 2 116 https://ClinicalTrials.gov/show/NCT02863055 
52 Stereotactic Body Radiotherapy for the Treatment of OPD Phase 2|Phase 3 110 https://ClinicalTrials.gov/show/NCT03256981 
53 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Phase 2 75 https://ClinicalTrials.gov/show/NCT03645928 
54 
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid 
Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid 
Cancer 
Phase 1|Phase 2 970 https://ClinicalTrials.gov/show/NCT03157128 
55 
A Dose Escalation and Cohort Expansion Study of NKTR-214 in 
Combination With Nivolumab and Other Anti-Cancer Therapies in 
Patients With Select Advanced Solid Tumors ( PIVOT-02 ) 
Phase 1|Phase 2 780 https://ClinicalTrials.gov/show/NCT02983045 
56 
This Study Tests the New Medicine BI 754111 Alone or in 
Combination With Another New Substance BI 754091 in Patients 
With Advanced Cancer. The Study Tests Different Doses to Find the 
Best Dose for Continuous Treatment. 
Phase 1 215 https://ClinicalTrials.gov/show/NCT03156114 
57 A CR-UK Phase I Trial of LY3143921 Phase 1 68 https://ClinicalTrials.gov/show/NCT03096054 
58 
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients 
With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK 
Gene Rearrangements (Fusions) 
Phase 2 300 https://ClinicalTrials.gov/show/NCT02568267 
59 GEN1029 (HexaBodyÂ®-DR5/DR5) Safety Trial in Patients With 
Malignant Solid Tumors 
Phase 1|Phase 2 520 https://ClinicalTrials.gov/show/NCT03576131 
60 A Trial of BXCL701 and Pembrolizumab in Patients With Small Cell 
Neuroendocrine Prostate Cancer 
Phase 1|Phase 2 40 https://ClinicalTrials.gov/show/NCT03910660 
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No. Title Phase(s) Enrolment URL 
61 Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients 
With Solid Tumors 
Phase 1|Phase 2 374 https://ClinicalTrials.gov/show/NCT02988817 
62 
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an 
Investigational Drug CX-2009 for Patients With Selected Solid 
Tumors 
Phase 1|Phase 2 150 https://ClinicalTrials.gov/show/NCT03149549 
63 
A Study of RO7198457 as a Single Agent and in Combination With 
Atezolizumab in Participants With Locally Advanced or Metastatic 
Tumors 
Phase 1 770 https://ClinicalTrials.gov/show/NCT03289962 
64 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Phase 1|Phase 2 412 https://ClinicalTrials.gov/show/NCT03829501 
65 Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in 
Advanced Solid Malignancies (FAK-PD1) 
Phase 1|Phase 2 59 https://ClinicalTrials.gov/show/NCT02758587 
66 Study of Cabozantinib in Combination With Atezolizumab to 
Subjects With Locally Advanced or Metastatic Solid Tumors 
Phase 1|Phase 2 1732 https://ClinicalTrials.gov/show/NCT03170960 
67 A Phase I/Ib Study of NZV930 Alone and in Combination With 
PDR001 and /or NIR178 in Patients With Advanced Malignancies. 
Phase 1 344 https://ClinicalTrials.gov/show/NCT03549000 
68 Preoperative Paravertebral Block in Cancer Surgery of the Lung Phase 2|Phase 3 100 https://ClinicalTrials.gov/show/NCT04209868 
69 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid 
Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements 
Phase 1|Phase 2 450 https://ClinicalTrials.gov/show/NCT03093116 
70 A Study Of Avelumab In Combination With Other Cancer 
Immunotherapies In Advanced Malignancies (JAVELIN Medley) 
Phase 2 620 https://ClinicalTrials.gov/show/NCT02554812 
71 Phase 1b Multi-indication Study of Anetumab Ravtansine in 
Mesothelin Expressing Advanced Solid Tumors 
Phase 1 348 https://ClinicalTrials.gov/show/NCT03102320 
72 
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in 
Combination With Temozolomide (TMZ) in Participants With Locally 
Advanced or Metastatic Solid Tumors 
Phase 1|Phase 2 150 https://ClinicalTrials.gov/show/NCT03150810 
73 A Study to Test the Effect of the Drug Larotrectinib in Adults and 
Children With NTRK-fusion Positive Solid Tumors 
Phase 2 203 https://ClinicalTrials.gov/show/NCT02576431 
299 
 
No. Title Phase(s) Enrolment URL 
74 Durvalumab Long-Term Safety and Efficacy Study Phase 4 600 https://ClinicalTrials.gov/show/NCT04078152 
75 Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) 
Monoclonal Antibody, in Participants With Advanced Solid Tumors 
Phase 1 740 https://ClinicalTrials.gov/show/NCT02715284 
76 Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Phase 2 250 https://ClinicalTrials.gov/show/NCT03485209 
77 Study of Pembrolizumab (MK-3475) in Participants With Advanced 
Solid Tumors (MK-3475-158/KEYNOTE-158) 
Phase 2 1395 https://ClinicalTrials.gov/show/NCT02628067 
78 A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon 
Receptor Inhibitor (AhRi) in Patients With Advanced Cancer 
Phase 1 114 https://ClinicalTrials.gov/show/NCT04069026 
79 A Study of the CD73 Inhibitor LY3475070 Alone or in Combination 
With Pembrolizumab in Participants With Advanced Cancer 
Phase 1 120 https://ClinicalTrials.gov/show/NCT04148937 
80 A Safety, Tolerability and PK Study of DCC-2618 in Patients With 
Advanced Malignancies 




Appendix 7: Output of all calculations using ‘nstage’ command with NI 
hypothesis 
DEVA_NI Scenario 1 
nstage, nstage(2) alpha(0.5 0.025) omega(0.95 0.9) hr0(1.1878 1.1878) hr1(1 







nstage, nstage(2) alpha(0.5 0.025) omega(0.95 0.9) hr0(1.1878 1.1878) hr1(1 




DEVA_NI Scenario 2 
nstage, nstage(2) alpha(0.5 0.05) omega(0.9 0.9) hr0(1.1878 1.1878) hr1(1 







nstage, nstage(2) alpha(0.5 0.05) omega(0.9 0.9) hr0(1.1878 1.1878) hr1(1 





DEVA_NI Scenario 3 
nstage, nstage(2) alpha(0.25 0.05) omega(0.9 0.85) hr0(1.1878 1.1878) hr1(1 







nstage, nstage(2) alpha(0.25 0.05) omega(0.9 0.85) hr0(1.1878 1.1878) hr1(1 





QUASAR 2_NI Scenario 1 
nstage, nstage(2) alpha(0.5 0.025) omega(0.95 0.9) hr0(1.3046243 1.3046243)  






nstage, nstage(2) alpha(0.5 0.025) omega(0.95 0.9) hr0(1.3046243 1.3046243)  




QUASAR 2_NI Scenario 2  
nstage, nstage(2) alpha(0.5 0.05) omega(0.9 0.9) hr0(1.3046243 1.3046243)  






nstage, nstage(2) alpha(0.5 0.05) omega(0.9 0.9) hr0(1.3046243 1.3046243)  





QUASAR 2_NI Scenario 3 
nstage, nstage(2) alpha(0.25 0.05) omega(0.9 0.85) hr0(1.3046243 1.3046243) 






nstage, nstage(2) alpha(0.25 0.05) omega(0.9 0.85) hr0(1.3046243 1.3046243) 





Appendix 8: Annotated Stata code used to implement the simulations 
DEVA_NI Scenario 1 
* What: Generating sample sizes for DEVA NI trial with different alpha and 
power values 
 
* Set working directory 
 
cd "C:\Users\pmistry2\OneDrive - JNJ\PhD\3. Post PhD\Thesis\Chapter 
6\Analysis\DEVA" 
 
* Generate survival and event data, exponential distribution, 
* Control arm = 5 year OS 81.8%, lambda = log(0.818)/-5 
* Experimental 1 = 5 year OS 81.8 to test under H0 lambda = log(0.818)/-5 = 
0.04017859 





* Scenario 1 
* Alpha = 0.5, 0.025 
* Power = 0.95, 0.9 
 
nstage, nstage(2) alpha(0.5 0.025) omega(0.95 0.9) hr0(1.1878 1.1878) hr1(1 
1) accrue(845 845) 
arms(3 3) t(5 5) s(0.818 0.818) tstop(8) 
 
nstage, nstage(2) alpha(0.5 0.025) omega(0.95 0.9) hr0(1.1878 1.1878) hr1(1 
1) accrue(845 845) 
arms(3 2) t(5 5) s(0.818 0.818) tstop(8) x 
 
/* 
Alpha = 0.5, 0.025 
Power = 0.95, 0.9 
Sample size in first stage = 4995 
Duration of the first stage including recruitment = 5.912 
 
Sample size in second stage = 1765 
Total trial length (no arms dropped) = 13.527 
Total trial length 2 (1 arm dropped) = 12.586 
 
Critical HR at stage 1 = 1.188 
Critical HR at final stage = 1.070 
*/ 
 
program drop DEVA_3A2S_NI 
 
prog define DEVA_3A2S_NI, rclass 
 
* Simulate First stage of the trial 
clear 
 
local ss_s1 4995 // Set sample size in first stage 
local time_s1 5.912 // Set duration of first stage 
local lambda_trt1 0.04017859 // Lambda for the control arm 




local lambda_trt3 0.04765144 // Lambda forthe second exp. arm (Alternative 
hypothesis) 
local trial_length 13.527 // Total trial length if no arms are dropped 
local c_hr_s1 1.188 // Critical HR at stage 1 
 
local ss_s2 1765 // Remaining number of patients to be randomised 
local trial_length2 12.586 // Total trial length if 1 arm dropped 
 
 
set obs `ss_s1' 
 
gen trt = runiformint(1,3) // Generate 3 treatment arms 
gen rectime = runiform(0, `time_s1') // Generate recruitment (uniform rate) 
from 0 to 5.912 
 
* Generate survival time for these patients till end of study, 13.527 years 
if arms continue to 
very end and if one arm is dropped then trial length will reduce to 12.586 
 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt == 3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
* Generate NEW survival variable for which events and patients are censored 
till time 5.912 - end 
of first stage 
 
* Censoring survival time 
gen stime_s1 = stime 
replace stime_s1 = `time_s1' - rectime if stime_s1+rectime > `time_s1' 
 
* Censoring survival events at stage 1 
gen event_s1 = event 
replace event_s1 = 0 if rectime+stime > `time_s1' 
 
* Storing number of patients on each arm at stage 1 
 
quietly: tab trt, matcell(trt_s) 
quietly: gen trt_s1_1 = trt_s[1,1] in 1 
quietly: gen trt_s1_2 = trt_s[2,1] in 1 
quietly: gen trt_s1_3 = trt_s[3,1] in 1 
 
* Storing number of events on each arm at stage 1 
quietly: tab event_s1 trt if event_s1==1, matcell(event_s1_) 




* Set survival data to perform analysis between arms 1 and 2 
stset stime_s1 if trt==1 | trt==2, failure(event_s1 = 1) 
 
* Perform cox regression (PH Assumption) pairwise comparison and store HR 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s1_12 (exp(_b[2.trt])) 
gen hr_s1_12 = `hr_s1_12' in 1 // store the HR 
 
drop _* 
stset stime_s1 if trt==1 | trt==3, failure(event_s1 = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s1_13 (exp(_b[3.trt])) 




* Generating a flag to indicate the outcome of the pairwise comparisons 
gen s1_flag = 1 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Both arms continue 
replace s1_flag = 2 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Arm 2 continue, Arm 3 
stop 
replace s1_flag = 3 if hr_s1_12 > `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Arm 2 stop, Arm 3 
continue 
replace s1_flag = 4 if hr_s1_12 > `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Both arm stop 
 
* Below shows the relevant calculations for each option 
if s1_flag == 1 in 1 { // Both arms continue 
 




set obs `ss_s2' // Remaining patients to be randomised 
gen trt = runiformint(1,3) // Both arms continue hence equally distributed 
between 3 arms 
140 gen rectime = runiform(`time_s1', 8) // recruitment time between 6.832 
and 8 years 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt ==1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt==3 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
315 
 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 




append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
 
drop _* 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 





if s1_flag == 2 in 1 { // Arm 2 continue, Arm 3 stop 
 
* Censoring survival time & events as arm dropped, trial length reduced and 
update to 
incorporate recruitment 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring all events on arm 3 
replace event = 0 if rectime+stime > `time_s1' & trt==3 
 
 




set obs `ss_s2' 
 
gen trt = runiformint(1,2) 
gen rectime = runiform(`time_s1', 8) 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 




* Cenosoring the survival time 





append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
 




if s1_flag == 3 in 1 { // Arm 2 stops, Arm 3 continues 
 
* Censoring survival time as arm dropped and update to incorporate 
recruitment & 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
* Censoring all events on arm 2 






set obs `ss_s2' 
gen trt = runiformint(1,2) 
replace trt = 3 if trt==2 
gen rectime = runiform(`time_s1', 8) 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt==1 
replace lambda = `lambda_trt3' if trt==3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring the survival time 










stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
 





if s1_flag == 4 in 1 { // Both arm stops 
 
gen hr_s2_12 = . 





* Storing number of patients and events on each arm at stage 1 
* Patients 
quietly: tab trt, matcell(trt_s2_) 
quietly: gen trt_s2_1 = trt_s2_[1,1] in 1 
quietly: gen trt_s2_2 = trt_s2_[2,1] in 1 
quietly: gen trt_s2_3 = trt_s2_[3,1] in 1 
 
* Events 
quietly: tab event trt if event==1, matcell(event_s2_) 





* Simulate the data 100 times, show number of patients, treatment, hr and 
p-values 
set seed 130933 
simulate trt_s1_1 = trt_s1_1 trt_s1_2 = trt_s1_2 trt_s1_3 = trt_s1_3 /// 
event_s1_1 = event_s1_1 event event_s1_2 = event_s1_2 event_s1_3 = 
event_s1_3 /// 
hr_s1_12 = hr_s1_12 hr_s1_13 = hr_s1_13 /// 
hr_s2_12 = hr_s2_12 hr_s2_13 = hr_s2_13 /// 
s1_flag = s1_flag /// 
trt_s2_1 = trt_s2_1 trt_s2_2 = trt_s2_2 trt_s2_3 = trt_s2_3 /// 
event_s2_1 = event_s2_1 event event_s2_2 = event_s2_2 event_s2_3 = 





* * * * * * * 
use DEVA_NI_Scenario1.dta,clear 
 
* Look at the means 
ci means trt_s1_1 trt_s1_2 trt_s1_3 event_s1_1 event_s1_2 event_s1_3 
event_s2_1 event_s2_2 




* Assessing the simulations out of total simulations 
 
* Type 1 error under H0 and Type II error under H1 at stage 1 
 
count if hr_s1_12 <= 1.188 
 
count if hr_s1_13 <= 1.188 
 
* Type 1 error under H0 and Type II error under H1 at final stage 
 
count if hr_s2_12 <= 1.070 
 
count if hr_s2_13 <= 1.070 
 
 
* Looking at both arms continues (s1_flag =1 ) 
ci means trt_s2_1 trt_s2_2 trt_s2_3 event_s2_1 event_s2_2 event_s2_3 
hr_s2_12 hr_s2_13 p_s2_12 
p_s2_13 if s1_flag==1 
 
* Looking at only arm 2 continues (s1_flag = 2) 
ci means trt_s2_1 trt_s2_2 event_s2_1 event_s2_2 hr_s2_12 p_s2_12 if 
s1_flag==2 
 
* Looking at only arm 3 continue (s1_flag = 3) 





DEVA_NI Scenario 2  
* What: Generating sample sizes for DEVA NI trial with different alpha and 
power values 
 
* Set working directory 
 
cd "C:\Users\pmistry2\OneDrive - JNJ\PhD\3. Post PhD\Thesis\Chapter 
6\Analysis\DEVA" 
 
* Generate survival and event data, exponential distribution, 
* Control arm = 5 year OS 81.8%, lambda = log(0.818)/-5 
* Experimental 1 = 5 year OS 81.8 to test under H0 lambda = log(0.818)/-5 = 
0.04017859 





* Scenario 2 
* Alpha = 0.5, 0.05 
* Power = 0.9, 0.9 
 
nstage, nstage(2) alpha(0.5 0.05) omega(0.9 0.9) hr0(1.1878 1.1878) hr1(1 
1) accrue(845 845) arms(3 3) t(5 5) s(0.818 0.818) tstop(8) 
 
nstage, nstage(2) alpha(0.5 0.05) omega(0.9 0.9) hr0(1.1878 1.1878) hr1(1 
1) accrue(845 845) arms(3 2) t(5 5) s(0.818 0.818) tstop(8) 
 
/* 
Alpha = 0.5, 0.05 
Power = 0.9, 0.9 
Sample size in first stage = 3857 
Duration of the first stage including recruitment = 4.564 
 
Sample size in second stage = 2903 
Total trial length (no arms dropped) = 11.499 
Total trial length 2 (1 arm dropped) = 10.425 
 
Critical HR at stage 1 = 1.188 
Critical HR at final stage = 1.078 
*/ 
 
prog define DEVA_3A2S_NI, rclass 
 
* Simulate First stage of the trial 
clear 
 
local ss_s1 3857 // Set sample size in first stage 
local time_s1 4.564 // Set duration of first stage 
local lambda_trt1 0.04017859 // Lambda for the control arm 
local lambda_trt2 0.04017859 // Lambda for the first exp. arm (Same as 
control) 
local lambda_trt3 0.04765144 // Lambda forthe second exp. arm (Alternative 
hypothesis) 
local trial_length 11.499 // Total trial length if no arms are dropped 
local c_hr_s1 1.188 // Critical HR at stage 1 
 
local ss_s2 2903 // Remaining number of patients to be randomised 
320 
 
local trial_length2 10.425 // Total trial length if 1 arm dropped 
 
 
set obs `ss_s1' 
 
gen trt = runiformint(1,3) // Generate 3 treatment arms 
gen rectime = runiform(0, `time_s1') // Generate recruitment (uniform rate) 
from 0 to 5.912 
 
* Generate survival time for these patients till end of study, 13.527 years 
if arms continue to 
very end and if one arm is dropped then trial length will reduce to 12.586 
 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt == 3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
* Generate NEW survival variable for which events and patients are censored 
till time 5.912 - end 
of first stage 
 
* Censoring survival time 
gen stime_s1 = stime 
replace stime_s1 = `time_s1' - rectime if stime_s1+rectime > `time_s1' 
 
* Censoring survival events at stage 1 
gen event_s1 = event 
replace event_s1 = 0 if rectime+stime > `time_s1' 
 
* Storing number of patients on each arm at stage 1 
 
quietly: tab trt, matcell(trt_s) 
quietly: gen trt_s1_1 = trt_s[1,1] in 1 
quietly: gen trt_s1_2 = trt_s[2,1] in 1 
quietly: gen trt_s1_3 = trt_s[3,1] in 1 
 
* Storing number of events on each arm at stage 1 
quietly: tab event_s1 trt if event_s1==1, matcell(event_s1_) 
quietly: svmat event_s1_ 
 
* Set survival data to perform analysis between arms 1 and 2 
stset stime_s1 if trt==1 | trt==2, failure(event_s1 = 1) 
 
* Perform cox regression (PH Assumption) pairwise comparison and store HR, 
p-value which obtained 
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from LR test however it is equivalent to the log-rank test 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s1_12 (exp(_b[2.trt])) 
gen hr_s1_12 = `hr_s1_12' in 1 // store the HR 
sts test trt, logrank 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
gen p_s1_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_12 > 1 in 1 
replace p_s1_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
drop _* 
stset stime_s1 if trt==1 | trt==3, failure(event_s1 = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s1_13 (exp(_b[3.trt])) 
gen hr_s1_13 = `hr_s1_13' in 1 // store the HR 
sts test trt, logrank 
 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
 
gen p_s1_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_13 > 1 in 1 
replace p_s1_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_13 < 1 in 1 // 




* Generating a flag to indicate the outcome of the pairwise comparisons 
gen s1_flag = 1 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Both arms continue 
replace s1_flag = 2 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Arm 2 continue, Arm 3 
stop 
replace s1_flag = 3 if hr_s1_12 > `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Arm 2 stop, Arm 3 
continue 
replace s1_flag = 4 if hr_s1_12 > `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Both arm stop 
 
* Below shows the relevant calculations for each option 
 
if s1_flag == 1 in 1 { // Both arms continue 
 




set obs `ss_s2' // Remaining patients to be randomised 
gen trt = runiformint(1,3) // Both arms continue hence equally distributed 
between 3 arms 
gen rectime = runiform(`time_s1', 8) // recruitment time between 6.832 and 
8 years 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
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gen lambda = `lambda_trt1' if trt ==1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt==3 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Censoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 




append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-value 
according to the value of HR 
 
drop _* 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 






if s1_flag == 2 in 1 { // Arm 2 continue, Arm 3 stop 
 
* Censoring survival time & events as arm dropped, trial length reduced and 
update to 
incorporate recruitment 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring all events on arm 3 









set obs `ss_s2' 
gen trt = runiformint(1,2) 
gen rectime = runiform(`time_s1', 8) 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring the survival time 





append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
gen p_s2_13 = . 




if s1_flag == 3 in 1 { // Arm 2 stops, Arm 3 continues 
 
* Censoring survival time as arm dropped and update to incorporate 
recruitment & 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
* Censoring all events on arm 2 








set obs `ss_s2' 
gen trt = runiformint(1,2) 
replace trt = 3 if trt==2 
gen rectime = runiform(`time_s1', 8) 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt==1 
replace lambda = `lambda_trt3' if trt==3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring the survival time 





append using `file2' 
 
 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 
Store p-value according to the value of HR 
 
 
gen p_s2_12 = . 





if s1_flag == 4 in 1 { // Both arm stops 
 
gen hr_s2_12 = . 
gen p_s2_12 = . 
gen hr_s2_13 = . 




* Storing number of patients and events on each arm at stage 1 
* Patients 
quietly: tab trt, matcell(trt_s2_) 
quietly: gen trt_s2_1 = trt_s2_[1,1] in 1 
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quietly: gen trt_s2_2 = trt_s2_[2,1] in 1 
quietly: gen trt_s2_3 = trt_s2_[3,1] in 1 
 
* Events 
quietly: tab event trt if event==1, matcell(event_s2_) 





* Simulate the data 100 times, show number of patients, treatment, hr and 
p-values 
set seed 130933 
simulate trt_s1_1 = trt_s1_1 trt_s1_2 = trt_s1_2 trt_s1_3 = trt_s1_3 /// 
event_s1_1 = event_s1_1 event event_s1_2 = event_s1_2 event_s1_3 = 
event_s1_3 /// 
hr_s1_12 = hr_s1_12 hr_s1_13 = hr_s1_13 /// 
p_s1_12 = p_s1_12 p_s1_13 = p_s1_13 /// 
hr_s2_12 = hr_s2_12 hr_s2_13 = hr_s2_13 /// 
p_s2_12 = p_s2_12 p_s2_13 = p_s2_13 /// 
s1_flag = s1_flag /// 
trt_s2_1 = trt_s2_1 trt_s2_2 = trt_s2_2 trt_s2_3 = trt_s2_3 /// 
event_s2_1 = event_s2_1 event event_s2_2 = event_s2_2 event_s2_3 = 






* Look at the means for different s1_flags 
 
* First stage 
ci means trt_s1_1 trt_s1_2 trt_s1_3 event_s1_1 event_s1_2 event_s1_3 
event_s2_1 event_s2_2 
event_s2_3 hr_s1_12 hr_s1_13 p_s1_12 p_s1_13 
 
* Looking at both arms continues (s1_flag =1 ) 
ci means trt_s2_1 trt_s2_2 trt_s2_3 event_s2_1 event_s2_2 event_s2_3 
hr_s2_12 hr_s2_13 p_s2_12 
p_s2_13 if s1_flag==1 
 
* Looking at only arm 2 continues (s1_flag = 2) 
ci means trt_s2_1 trt_s2_2 event_s2_1 event_s2_2 hr_s2_12 p_s2_12 if 
s1_flag==2 
 
* Looking at only arm 3 continue (s1_flag = 3) 
ci means trt_s2_1 trt_s2_3 event_s2_1 event_s2_3 hr_s2_13 p_s2_13 if 
s1_flag==3 
 
* Assessing the simulations out of total simulations 
* Type 1 error under H0 and Type II error under H0 at stage 1 
 
count if hr_s1_12 <= 1.188 
count if hr_s1_13 <= 1.188 
* Type 1 error under H0 and Type II error under H0 at final stage 
count if hr_s2_12 <= 1.078 





DEVA NI Scenario 3 
* What: Generating sample sizes for DEVA NI trial with different alpha and 
power values 
 
* Set working directory 
 
cd "C:\Users\pmistry2\OneDrive - JNJ\PhD\3. Post PhD\Thesis\Chapter 
6\Analysis\DEVA" 
 
* Generate survival and event data, exponential distribution, 
* Control arm = 5 year OS 81.8%, lambda = log(0.818)/-5 
* Experimental 1 = 5 year OS 81.8 to test under H0 lambda = log(0.818)/-5 
=.04017859 





* Scenario 3 
* Alpha = 0.25, 0.05 
* Power = 0.9, 0.85 
 
nstage, nstage(2) alpha(0.25 0.05) omega(0.9 0.85) hr0(1.1878 1.1878) hr1(1 
1) accrue(845 845) arms(3 3) t(5 5) s(0.818 0.818) tstop(8) 
 
nstage, nstage(2) alpha(0.25 0.05) omega(0.9 0.85) hr0(1.1878 1.1878) hr1(1 
1) accrue(845 845) arms(3 2) t(5 5) s(0.818 0.818) tstop(8) 
 
/* 
Alpha = 0.25, 0.05 
Power = 0.9, 0.85 
Sample size in first stage = 5988 
Duration of the first stage including recruitment = 7.086 
 
Sample size in second stage = 772 
Total trial length (no arms dropped) = 10.154 
Total trial length 2 (1 arm dropped) = 9.985 
 
Critical HR at stage 1 = 1.119 
Critical HR at final stage = 1.069 
*/ 
 
program drop DEVA_3A2S_NI 
 
prog define DEVA_3A2S_NI, rclass 
 
* Simulate First stage of the trial 
clear 
 
local ss_s1 5988 // Set sample size in first stage 
local time_s1 7.086 // Set duration of first stage 
local lambda_trt1 0.04017859 // Lambda for the control arm 
local lambda_trt2 0.04017859 // Lambda for the first exp. arm (Same as 
control) 
local lambda_trt3 0.04765144 // Lambda forthe second exp. arm (Alternative 
hypothesis) 
local trial_length 10.154 // Total trial length if no arms are dropped 




local ss_s2 772 // Remaining number of patients to be randomised 
local trial_length2 9.985 // Total trial length if 1 arm dropped 
 
 
set obs `ss_s1' 
 
gen trt = runiformint(1,3) // Generate 3 treatment arms 
gen rectime = runiform(0, `time_s1') // Generate recruitment (uniform rate) 
from 0 to 5.912 
 
* Generate survival time for these patients till end of study, 13.527 years 
if arms continue to 
very end and if one arm is dropped then trial length will reduce to 12.586 
 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt == 3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
* Generate NEW survival variable for which events and patients are censored 
till time 5.912 - end 
of first stage 
 
* Censoring survival time 
gen stime_s1 = stime 
replace stime_s1 = `time_s1' - rectime if stime_s1+rectime > `time_s1' 
 
* Censoring survival events at stage 1 
gen event_s1 = event 
replace event_s1 = 0 if rectime+stime > `time_s1' 
 
* Storing number of patients on each arm at stage 1 
 
quietly: tab trt, matcell(trt_s) 
quietly: gen trt_s1_1 = trt_s[1,1] in 1 
quietly: gen trt_s1_2 = trt_s[2,1] in 1 
quietly: gen trt_s1_3 = trt_s[3,1] in 1 
 
* Storing number of events on each arm at stage 1 
quietly: tab event_s1 trt if event_s1==1, matcell(event_s1_) 
quietly: svmat event_s1_ 
 
* Set survival data to perform analysis between arms 1 and 2 




* Perform cox regression (PH Assumption) pairwise comparison and store HR, 
p-value which obtained from LR test however it is equivalent to the log-
rank test  
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s1_12 (exp(_b[2.trt])) 
gen hr_s1_12 = `hr_s1_12' in 1 // store the HR 
sts test trt, logrank 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
gen p_s1_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_12 > 1 in 1 
replace p_s1_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
drop _* 
stset stime_s1 if trt==1 | trt==3, failure(event_s1 = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s1_13 (exp(_b[3.trt])) 
gen hr_s1_13 = `hr_s1_13' in 1 // store the HR 
sts test trt, logrank 
 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
gen p_s1_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_13 > 1 in 1 
replace p_s1_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_13 < 1 in 1 // 




* Generating a flag to indicate the outcome of the pairwise comparisons 
gen s1_flag = 1 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Both arms continue 
replace s1_flag = 2 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Arm 2 continue, Arm 3 stop 
replace s1_flag = 3 if hr_s1_12 > `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Arm 2 stop, Arm 3 continue 
replace s1_flag = 4 if hr_s1_12 > `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Both arm stop 
 
* Below shows the relevant calculations for each option 
 
if s1_flag == 1 in 1 { // Both arms continue 
 




set obs `ss_s2' // Remaining patients to be randomised 
gen trt = runiformint(1,3) // Both arms continue hence equally distributed 
between 3 arms 
gen rectime = runiform(`time_s1', 8) // recruitment time between 6.832 and 
8 years 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt ==1 
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replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt==3 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 




append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
drop _* 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 
Store p-value according to the value of HR 
if s1_flag == 2 in 1 { // Arm 2 continue, Arm 3 stop 
 
* Censoring survival time & events as arm dropped, trial length reduced and 
update to incorporate recruitment 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring all events on arm 3 
replace event = 0 if rectime+stime > `time_s1' & trt==3 
 




set obs `ss_s2' 
gen trt = runiformint(1,2) 




* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Cenosoring the survival time 





append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
gen p_s2_13 = . 




if s1_flag == 3 in 1 { // Arm 2 stops, Arm 3 continues 
 
* Censoring survival time as arm dropped and update to incorporate 
recruitment & 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
* Censoring all events on arm 2 





set obs `ss_s2' 
gen trt = runiformint(1,2) 
replace trt = 3 if trt==2 
gen rectime = runiform(`time_s1', 8) 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt==1 




gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring the survival time 





append using `file2' 
 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 
Store p-value according to the value of HR 
 
 
gen p_s2_12 = . 





if s1_flag == 4 in 1 { // Both arm stops 
 
gen hr_s2_12 = . 
gen p_s2_12 = . 
gen hr_s2_13 = . 





* Storing number of patients and events on each arm at stage 1 
* Patients 
quietly: tab trt, matcell(trt_s2_) 
quietly: gen trt_s2_1 = trt_s2_[1,1] in 1 
quietly: gen trt_s2_2 = trt_s2_[2,1] in 1 
quietly: gen trt_s2_3 = trt_s2_[3,1] in 1 
 
* Events 
quietly: tab event trt if event==1, matcell(event_s2_) 
 







* Simulate the data 100 times, show number of patients, treatment, hr and 
p-values 
set seed 130933 
simulate trt_s1_1 = trt_s1_1 trt_s1_2 = trt_s1_2 trt_s1_3 = trt_s1_3 /// 
event_s1_1 = event_s1_1 event event_s1_2 = event_s1_2 event_s1_3 = 
event_s1_3 /// 
hr_s1_12 = hr_s1_12 hr_s1_13 = hr_s1_13 /// 
p_s1_12 = p_s1_12 p_s1_13 = p_s1_13 /// 
hr_s2_12 = hr_s2_12 hr_s2_13 = hr_s2_13 /// 
p_s2_12 = p_s2_12 p_s2_13 = p_s2_13 /// 
s1_flag = s1_flag /// 
trt_s2_1 = trt_s2_1 trt_s2_2 = trt_s2_2 trt_s2_3 = trt_s2_3 /// 
event_s2_1 = event_s2_1 event event_s2_2 = event_s2_2 event_s2_3 = 








* Look at the means for different s1_flags 
 
* First stage 
ci means trt_s1_1 trt_s1_2 trt_s1_3 event_s1_1 event_s1_2 event_s1_3 
event_s2_1 event_s2_2 
event_s2_3 hr_s1_12 hr_s1_13 p_s1_12 p_s1_13 
 
* Looking at both arms continues (s1_flag =1 ) 
ci means trt_s2_1 trt_s2_2 trt_s2_3 event_s2_1 event_s2_2 event_s2_3 
hr_s2_12 hr_s2_13 p_s2_12 
p_s2_13 if s1_flag==1 
 
* Looking at only arm 2 continues (s1_flag = 2) 
ci means trt_s2_1 trt_s2_2 event_s2_1 event_s2_2 hr_s2_12 p_s2_12 if 
s1_flag==2 
 
* Looking at only arm 3 continue (s1_flag = 3) 




* Assessing the simulations out of total simulations 
 
* Type 1 error under H0 and Type II error under H0 at stage 1 
 
count if hr_s1_12 <= 1.119 
count if hr_s1_13 <= 1.119 
 
* Type 1 error under H0 and Type II error under H0 at final stage 
 
count if hr_s2_12 <= 1.069 






QUASAR2_NI Scenario 1 
* What: Generating sample sizes for QUASAR NI trial with different alpha 
and power values and simulating to check Type I & Power  
* Set working directory 
 
cd "C:\Users\pmistry2\OneDrive - JNJ\PhD\3. Post PhD\Thesis\Chapter 
6\Analysis\QUASAR" 
 
* Generate survival and event data, exponential distribution, 
* Control arm = 3 year OS 89.4%, lambda = log(0.894)/-3 = 0.03734983 
* Experimental 1 = 3 year OS 89.4 to test under H0 lambda = log(0.894)/-3 = 
0.03734983 






* Scenario 1 
* Alpha = 0.5, 0.025 
* Power = 0.95, 0.9 
 
nstage, nstage(2) alpha(0.5 0.025) omega(0.95 0.9) hr0(1.3046243 1.3046243) 
/// 
hr1(1 1) accrue(579 579) arms(3 3) t(3 3) s(0.894 0.894) tstop(5.5) 
 
* DROP ONE AT FIRST STAGE 
nstage, nstage(2) alpha(0.5 0.025) omega(0.95 0.9) hr0(1.3046243 1.3046243) 
/// 
hr1(1 1) accrue(579 579) arms(3 2) t(3 3) s(0.894 0.894) tstop(5.5) 
 
/* 
Alpha = 0.5, 0.025 
Power = 0.95, 0.9 
Sample size in first stage = 2755 
Duration of the first stage including recruitment = 4.759 
 
Sample size in second stage = 430 
Total trial length (no arms dropped) = 11.620 
Total trial length 2 (1 arm dropped) = 11.122 
 
Critical HR at stage 1 = 1.305 
Critical HR at final stage = 1.111 
*/ 
 
*program drop QUASAR2_3A2S_NI 
 
prog define QUASAR2_3A2S_NI, rclass 
 
* Simulate First stage of the trial 
clear 
 
local ss_s1 2755 // Set sample size in first stage 
local time_s1 4.759 // Set duration of first stage 
local lambda_trt1 0.03734983 // Lambda for the control arm 




local lambda_trt3 0.0487275 // Lambda forthe second exp. arm (Alternative 
hypothesis) 
local trial_length 11.620 // Total trial length if no arms are dropped 
local c_hr_s1 1.305 // Critical HR at stage 1 
 
local ss_s2 430 // Remaining number of patients to be randomised 
local trial_length2 11.122 // Total trial length if 1 arm dropped 
 
set obs `ss_s1' 
 
gen trt = runiformint(1,3) // Generate 3 treatment arms 
gen rectime = runiform(0, `time_s1') // Generate recruitment (uniform rate) 
from 0 to 5.912 
 
* Generate survival time for these patients till end of study, 13.527 years 
if arms continue to very end and if one arm is dropped then trial length 
will reduce to 12.586 
 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt == 3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
* Generate NEW survival variable for which events and patients are censored 
till time 5.912 – end of first stage 
 
* Censoring survival time 
gen stime_s1 = stime 
replace stime_s1 = `time_s1' - rectime if stime_s1+rectime > `time_s1' 
 
* Censoring survival events at stage 1 
gen event_s1 = event 
replace event_s1 = 0 if rectime+stime > `time_s1' 
 
* Storing number of patients on each arm at stage 1 
 
quietly: tab trt, matcell(trt_s) 
quietly: gen trt_s1_1 = trt_s[1,1] in 1 
quietly: gen trt_s1_2 = trt_s[2,1] in 1 
quietly: gen trt_s1_3 = trt_s[3,1] in 1 
 
* Storing number of events on each arm at stage 1 
quietly: tab event_s1 trt if event_s1==1, matcell(event_s1_) 
quietly: svmat event_s1_ 
 
* Set survival data to perform analysis between arms 1 and 2 




* Perform cox regression (PH Assumption) pairwise comparison and store HR, 
p-value which obtained from LR test however it is equivalent to the log-
rank test 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s1_12 (exp(_b[2.trt])) 
gen hr_s1_12 = `hr_s1_12' in 1 // store the HR 
sts test trt, logrank 
 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
gen p_s1_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_12 > 1 in 1 
replace p_s1_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
drop _* 
stset stime_s1 if trt==1 | trt==3, failure(event_s1 = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s1_13 (exp(_b[3.trt])) 
gen hr_s1_13 = `hr_s1_13' in 1 // store the HR 
sts test trt, logrank 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
gen p_s1_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_13 > 1 in 1 
replace p_s1_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_13 < 1 in 1 // 




* Generating a flag to indicate the outcome of the pairwise comparisons 
gen s1_flag = 1 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Both arms continue 
replace s1_flag = 2 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Arm 2 continue, Arm 3 stop 
replace s1_flag = 3 if hr_s1_12 > `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Arm 2 stop, Arm 3 continue 
replace s1_flag = 4 if hr_s1_12 > `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Both arm stop 
 
* Below shows the relevant calculations for each option 
 
if s1_flag == 1 in 1 { // Both arms continue 
 




set obs `ss_s2' // Remaining patients to be randomised 
gen trt = runiformint(1,3) // Both arms continue hence equally distributed 
between 3 arms 
gen rectime = runiform(`time_s1', 8) // recruitment time between 6.832 and 
8 years 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
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gen lambda = `lambda_trt1' if trt ==1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt==3 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 




append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
drop _* 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 





if s1_flag == 2 in 1 { // Arm 2 continue, Arm 3 stop 
 
* Censoring survival time & events as arm dropped, trial length reduced and 
update to incorporate recruitment 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring all events on arm 3 
replace event = 0 if rectime+stime > `time_s1' & trt==3 
 






set obs `ss_s2' 
gen trt = runiformint(1,2) 
gen rectime = runiform(`time_s1', 8) 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Cenosoring the survival time 





append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
gen p_s2_13 = . 




if s1_flag == 3 in 1 { // Arm 2 stops, Arm 3 continues 
 
* Censoring survival time as arm dropped and update to incorporate 
recruitment & 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
* Censoring all events on arm 2 
 






set obs `ss_s2' 
gen trt = runiformint(1,2) 
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replace trt = 3 if trt==2 
gen rectime = runiform(`time_s1', 8) 
 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt==1 
replace lambda = `lambda_trt3' if trt==3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring the survival time 





append using `file2' 
 
 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 
Store p-value according to the value of HR 
 
gen p_s2_12 = . 




if s1_flag == 4 in 1 { // Both arm stops 
 
gen hr_s2_12 = . 
gen p_s2_12 = . 
gen hr_s2_13 = . 





* Storing number of patients and events on each arm at stage 1 
* Patients 
quietly: tab trt, matcell(trt_s2_) 
quietly: gen trt_s2_1 = trt_s2_[1,1] in 1 
quietly: gen trt_s2_2 = trt_s2_[2,1] in 1 





quietly: tab event trt if event==1, matcell(event_s2_) 





* Simulate the data 100 times, show number of patients, treatment, hr and 
p-values 
set seed 130933 
simulate trt_s1_1 = trt_s1_1 trt_s1_2 = trt_s1_2 trt_s1_3 = trt_s1_3 /// 
event_s1_1 = event_s1_1 event event_s1_2 = event_s1_2 event_s1_3 = 
event_s1_3 /// 
hr_s1_12 = hr_s1_12 hr_s1_13 = hr_s1_13 /// 
p_s1_12 = p_s1_12 p_s1_13 = p_s1_13 /// 
hr_s2_12 = hr_s2_12 hr_s2_13 = hr_s2_13 /// 
p_s2_12 = p_s2_12 p_s2_13 = p_s2_13 /// 
s1_flag = s1_flag /// 
trt_s2_1 = trt_s2_1 trt_s2_2 = trt_s2_2 trt_s2_3 = trt_s2_3 /// 








* Look at the means for different s1_flags 
 
* First stage 
ci means trt_s1_1 trt_s1_2 trt_s1_3 event_s1_1 event_s1_2 event_s1_3 
event_s2_1 event_s2_2 
event_s2_3 hr_s1_12 hr_s1_13 p_s1_12 p_s1_13 
* Looking at both arms continues (s1_flag =1 ) 
ci means trt_s2_1 trt_s2_2 trt_s2_3 event_s2_1 event_s2_2 event_s2_3 
hr_s2_12 hr_s2_13 p_s2_12 
p_s2_13 if s1_flag==1 
 
* Looking at only arm 2 continues (s1_flag = 2) 
ci means trt_s2_1 trt_s2_2 event_s2_1 event_s2_2 hr_s2_12 p_s2_12 if 
s1_flag==2 
 
* Looking at only arm 3 continue (s1_flag = 3) 
ci means trt_s2_1 trt_s2_3 event_s2_1 event_s2_3 hr_s2_13 p_s2_13 if 
s1_flag==3 
 
* Assessing the simulations out of total simulations 
 
* Type 1 error under H0 and Type II error under H0 at stage 1 
 
count if hr_s1_12 <= 1.305 
count if hr_s1_13 <= 1.305 
 
* Type 1 error under H0 and Type II error under H0 at final stage 
 
count if hr_s2_12 <= 1.111 




QUASAR2_NI Scenario 2 
* What: Generating sample sizes for QUASAR NI trial with different alpha 
and power values and simulating to check Type I & Power 
 
* Set working directory 
 
cd "C:\Users\pmistry2\OneDrive - JNJ\PhD\3. Post PhD\Thesis\Chapter 
6\Analysis\QUASAR" 
 
* Generate survival and event data, exponential distribution, 
* Control arm = 3 year OS 89.4%, lambda = log(0.894)/-3 = 0.03734983 
* Experimental 1 = 3 year OS 89.4 to test under H0 lambda = log(0.894)/-3 = 
0.03734983 





* Scenario 2 
* Alpha = 0.5, 0.05 
* Power = 0.9, 0.9 
 
nstage, nstage(2) alpha(0.5 0.05) omega(0.9 0.9) hr0(1.3046243 1.3046243) 
/// 
hr1(1 1) accrue(410 410) arms(3 3) t(3 3) s(0.894 0.894) tstop(6.5) 
 
* DROP ONE AT FIRST STAGE 
nstage, nstage(2) alpha(0.5 0.05) omega(0.9 0.9) hr0(1.3046243 1.3046243) 
/// 
hr1(1 1) accrue(410 410) arms(3 2) t(3 3) s(0.894 0.894) tstop(6.5) 
 
/* 
Alpha = 0.5, 0.05 
Power = 0.9, 0.9 
Sample size in first stage = 1808 
Duration of the first stage including recruitment = 4.409 
 
Sample size in second stage = 857 
Total trial length (no arms dropped) = 11.872 
Total trial length 2 (1 arm dropped) = 10.018 
 
Critical HR at stage 1 = 1.305 
Critical HR at final stage = 1.124 
*/ 
 
*program drop QUASAR2_3A2S_NI 
 
prog define QUASAR2_3A2S_NI, rclass 
 
* Simulate First stage of the trial 
clear 
 
local ss_s1 1808 // Set sample size in first stage 
local time_s1 4.409 // Set duration of first stage 
local lambda_trt1 0.03734983 // Lambda for the control arm 




local lambda_trt3 0.0487275 // Lambda forthe second exp. arm (Alternative 
hypothesis) 
local trial_length 11.872 // Total trial length if no arms are dropped 
local c_hr_s1 1.305 // Critical HR at stage 1 
 
local ss_s2 857 // Remaining number of patients to be randomised 
local trial_length2 10.018 // Total trial length if 1 arm dropped 
 
 
set obs `ss_s1' 
 
gen trt = runiformint(1,3) // Generate 3 treatment arms 
gen rectime = runiform(0, `time_s1') // Generate recruitment (uniform rate) 
from 0 to 5.912 
 
* Generate survival time for these patients till end of study, 13.527 years 
if arms continue to very end and if one arm is dropped then trial length 
will reduce to 12.586 
 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt == 3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
* Generate NEW survival variable for which events and patients are censored 
till time 5.912 – end of first stage 
 
* Censoring survival time 
gen stime_s1 = stime 
replace stime_s1 = `time_s1' - rectime if stime_s1+rectime > `time_s1' 
 
* Censoring survival events at stage 1 
gen event_s1 = event 
replace event_s1 = 0 if rectime+stime > `time_s1' 
 
* Storing number of patients on each arm at stage 1 
 
quietly: tab trt, matcell(trt_s) 
quietly: gen trt_s1_1 = trt_s[1,1] in 1 
quietly: gen trt_s1_2 = trt_s[2,1] in 1 
quietly: gen trt_s1_3 = trt_s[3,1] in 1 
 
* Storing number of events on each arm at stage 1 
quietly: tab event_s1 trt if event_s1==1, matcell(event_s1_) 
quietly: svmat event_s1_ 
 
* Set survival data to perform analysis between arms 1 and 2 
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stset stime_s1 if trt==1 | trt==2, failure(event_s1 = 1) 
 
* Perform cox regression (PH Assumption) pairwise comparison and store HR, 
p-value which obtained from LR test however it is equivalent to the log-
rank test 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s1_12 (exp(_b[2.trt])) 
gen hr_s1_12 = `hr_s1_12' in 1 // store the HR 
sts test trt, logrank 
 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
gen p_s1_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_12 > 1 in 1 
replace p_s1_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
drop _* 
stset stime_s1 if trt==1 | trt==3, failure(event_s1 = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s1_13 (exp(_b[3.trt])) 
gen hr_s1_13 = `hr_s1_13' in 1 // store the HR 
sts test trt, logrank 
 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
gen p_s1_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_13 > 1 in 1 
replace p_s1_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_13 < 1 in 1 // 




* Generating a flag to indicate the outcome of the pairwise comparisons 
gen s1_flag = 1 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Both arms continue 
replace s1_flag = 2 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Arm 2 continue, Arm 3 stop 
replace s1_flag = 3 if hr_s1_12 > `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Arm 2 stop, Arm 3 continue 
replace s1_flag = 4 if hr_s1_12 > `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Both arm stop 
 
* Below shows the relevant calculations for each option 
 
if s1_flag == 1 in 1 { // Both arms continue 
 




set obs `ss_s2' // Remaining patients to be randomised 
gen trt = runiformint(1,3) // Both arms continue hence equally distributed 
between 3 arms 





* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt ==1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt==3 
gen stime = -log(u)/lambda 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 




append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
drop _* 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 





if s1_flag == 2 in 1 { // Arm 2 continue, Arm 3 stop 
 
* Censoring survival time & events as arm dropped, trial length reduced and 
update to incorporate recruitment 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring all events on arm 3 
replace event = 0 if rectime+stime > `time_s1' & trt==3 
 






set obs `ss_s2' 
gen trt = runiformint(1,2) 
gen rectime = runiform(`time_s1', 8) 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Cenosoring the survival time 





append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-valueaccording to the value of HR 
 
gen p_s2_13 = . 




if s1_flag == 3 in 1 { // Arm 2 stops, Arm 3 continues 
 
* Censoring survival time as arm dropped and update to incorporate 
recruitment & 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
* Censoring all events on arm 2 






set obs `ss_s2' 
gen trt = runiformint(1,2) 
replace trt = 3 if trt==2 
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gen rectime = runiform(`time_s1', 8) 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt==1 
replace lambda = `lambda_trt3' if trt==3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring the survival time 





append using `file2' 
 
 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 
Store p-value according to the value of HR 
 
 
gen p_s2_12 = . 





if s1_flag == 4 in 1 { // Both arm stops 
 
gen hr_s2_12 = . 
gen p_s2_12 = . 
gen hr_s2_13 = . 





* Storing number of patients and events on each arm at stage 1 
* Patients 
quietly: tab trt, matcell(trt_s2_) 
quietly: gen trt_s2_1 = trt_s2_[1,1] in 1 
quietly: gen trt_s2_2 = trt_s2_[2,1] in 1 





quietly: tab event trt if event==1, matcell(event_s2_) 





* Simulate the data 100 times, show number of patients, treatment, hr and 
p-values 
set seed 130933 
simulate trt_s1_1 = trt_s1_1 trt_s1_2 = trt_s1_2 trt_s1_3 = trt_s1_3 /// 
event_s1_1 = event_s1_1 event event_s1_2 = event_s1_2 event_s1_3 = 
event_s1_3 /// 
hr_s1_12 = hr_s1_12 hr_s1_13 = hr_s1_13 /// 
p_s1_12 = p_s1_12 p_s1_13 = p_s1_13 /// 
hr_s2_12 = hr_s2_12 hr_s2_13 = hr_s2_13 /// 
p_s2_12 = p_s2_12 p_s2_13 = p_s2_13 /// 
s1_flag = s1_flag /// 
trt_s2_1 = trt_s2_1 trt_s2_2 = trt_s2_2 trt_s2_3 = trt_s2_3 /// 









* Look at the means for different s1_flags 
 
* First stage 
ci means trt_s1_1 trt_s1_2 trt_s1_3 event_s1_1 event_s1_2 event_s1_3 
event_s2_1 event_s2_2 
event_s2_3 hr_s1_12 hr_s1_13 p_s1_12 p_s1_13 
* Looking at both arms continues (s1_flag =1 ) 
ci means trt_s2_1 trt_s2_2 trt_s2_3 event_s2_1 event_s2_2 event_s2_3 
hr_s2_12 hr_s2_13 p_s2_12 
p_s2_13 if s1_flag==1 
 
* Looking at only arm 2 continues (s1_flag = 2) 
ci means trt_s2_1 trt_s2_2 event_s2_1 event_s2_2 hr_s2_12 p_s2_12 if 
s1_flag==2 
 
* Looking at only arm 3 continue (s1_flag = 3) 




* Assessing the simulations out of total simulations 
 
* Type 1 error under H0 and Type II error under H0 at stage 1 
 
count if hr_s1_12 <= 1.305 
count if hr_s1_13 <= 1.305 
 
* Type 1 error under H0 and Type II error under H0 at final stage 
 
count if hr_s2_12 <= 1.124 
count if hr_s2_13 <= 1.124  
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QUASAR2_NI Scenario 3  
* What: Generating sample sizes for QUASAR NI trial with different alpha 
and power values and simulating to check Type I & Power 
 
* Set working directory 
 
cd "C:\Users\pmistry2\OneDrive - JNJ\PhD\3. Post PhD\Thesis\Chapter 
6\Analysis\QUASAR" 
 
* Generate survival and event data, exponential distribution, 
* Control arm = 3 year OS 89.4%, lambda = log(0.894)/-3 = 0.03734983 
* Experimental 1 = 3 year OS 89.4 to test under H0 lambda = log(0.894)/-3 = 
0.03734983 





* Scenario 3 
* Alpha = 0.25, 0.05 
* Power = 0.9, 0.85 
 
nstage, nstage(2) alpha(0.25 0.05) omega(0.9 0.85) hr0(1.3046243 1.3046243) 
/// 
hr1(1 1) accrue(579 579) arms(3 3) t(3 3) s(0.894 0.894) tstop(6) 
 
* DROP ONE AT FIRST STAGE 
nstage, nstage(2) alpha(0.25 0.05) omega(0.9 0.85) hr0(1.3046243 1.3046243) 
/// 
hr1(1 1) accrue(579 579) arms(3 2) t(3 3) s(0.894 0.894) tstop(6) 
 
/* 
Alpha = 0.25, 0.05 
Power = 0.9, 0.85 
Sample size in first stage = 3297 
Duration of the first stage including recruitment = 5.694 
 
Sample size in second stage = 177 
Total trial length (no arms dropped) = 8.244 
Total trial length 2 (1 arm dropped) = 8.176 
 
Critical HR at stage 1 = 1.191 
Critical HR at final stage = 1.109 
*/ 
 
*program drop QUASAR2_3A2S_NI 
 
prog define QUASAR2_3A2S_NI, rclass 
 
* Simulate First stage of the trial 
clear 
 
local ss_s1 3297 // Set sample size in first stage 
local time_s1 5.694 // Set duration of first stage 
local lambda_trt1 0.03734983 // Lambda for the control arm 




local lambda_trt3 0.0487275 // Lambda forthe second exp. arm (Alternative 
hypothesis) 
local trial_length 8.244 // Total trial length if no arms are dropped 
local c_hr_s1 1.191 // Critical HR at stage 1 
 
local ss_s2 177 // Remaining number of patients to be randomised 
local trial_length2 8.176 // Total trial length if 1 arm dropped 
 
 
set obs `ss_s1' 
 
gen trt = runiformint(1,3) // Generate 3 treatment arms 
gen rectime = runiform(0, `time_s1') // Generate recruitment (uniform rate) 
from 0 to 5.912 
 
* Generate survival time for these patients till end of study, 13.527 years 
if arms continue to very end and if one arm is dropped then trial length 
will reduce to 12.586 
 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt == 3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
* Generate NEW survival variable for which events and patients are censored 
till time 5.912 – end of first stage 
 
* Censoring survival time 
gen stime_s1 = stime 
replace stime_s1 = `time_s1' - rectime if stime_s1+rectime > `time_s1' 
 
* Censoring survival events at stage 1 
gen event_s1 = event 
replace event_s1 = 0 if rectime+stime > `time_s1' 
 
* Storing number of patients on each arm at stage 1 
 
quietly: tab trt, matcell(trt_s) 
quietly: gen trt_s1_1 = trt_s[1,1] in 1 
quietly: gen trt_s1_2 = trt_s[2,1] in 1 
quietly: gen trt_s1_3 = trt_s[3,1] in 1 
 
* Storing number of events on each arm at stage 1 
quietly: tab event_s1 trt if event_s1==1, matcell(event_s1_) 
quietly: svmat event_s1_ 
 
* Set survival data to perform analysis between arms 1 and 2 
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stset stime_s1 if trt==1 | trt==2, failure(event_s1 = 1) 
 
* Perform cox regression (PH Assumption) pairwise comparison and store HR, 
p-value which obtained from LR test however it is equivalent to the log-
rank test 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s1_12 (exp(_b[2.trt])) 
gen hr_s1_12 = `hr_s1_12' in 1 // store the HR 
sts test trt, logrank 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
gen p_s1_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_12 > 1 in 1 
replace p_s1_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
drop _* 
stset stime_s1 if trt==1 | trt==3, failure(event_s1 = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s1_13 (exp(_b[3.trt])) 
gen hr_s1_13 = `hr_s1_13' in 1 // store the HR 
sts test trt, logrank 
* Storing p-value according to HR - these differ based on hypothesis (sup 
or ni) 
gen p_s1_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s1_13 > 1 in 1 
replace p_s1_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s1_13 < 1 in 1 // 




* Generating a flag to indicate the outcome of the pairwise comparisons 
gen s1_flag = 1 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Both arms continue 
replace s1_flag = 2 if hr_s1_12 <= `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Arm 2 continue, Arm 3 stop 
replace s1_flag = 3 if hr_s1_12 > `c_hr_s1' & hr_s1_13 <= `c_hr_s1' in 1 // 
Arm 2 stop, Arm 3 continue 
replace s1_flag = 4 if hr_s1_12 > `c_hr_s1' & hr_s1_13 > `c_hr_s1' in 1 // 
Both arm stop 
 
* Below shows the relevant calculations for each option 
 
if s1_flag == 1 in 1 { // Both arms continue 
 




set obs `ss_s2' // Remaining patients to be randomised 
gen trt = runiformint(1,3) // Both arms continue hence equally distributed 
between 3 arms 
gen rectime = runiform(`time_s1', 8) // recruitment time between 6.832 and 
8 years 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
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gen lambda = `lambda_trt1' if trt ==1 
replace lambda = `lambda_trt2' if trt == 2 
replace lambda = `lambda_trt3' if trt==3 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at max FU time 
replace event = 0 if stime + rectime > `trial_length' 
 
* Cenosoring the survival time 
replace stime = `trial_length'-rectime if stime+rectime > `trial_length' 
 




append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
drop _* 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 





if s1_flag == 2 in 1 { // Arm 2 continue, Arm 3 stop 
 
* Censoring survival time & events as arm dropped, trial length reduced and 
update to incorporate recruitment 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring all events on arm 3 
replace event = 0 if rectime+stime > `time_s1' & trt==3 
 
 






set obs `ss_s2' 
gen trt = runiformint(1,2) 
gen rectime = runiform(`time_s1', 8) 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt == 1 
replace lambda = `lambda_trt2' if trt == 2 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Cenosoring the survival time 





append using `file2' 
 
* Set survival data to perform analysis 
stset stime if trt==1 | trt==2, failure(event = 1) 
 
* BETWEEN ARMS 1 AND ARM 2 
stcox i.trt // perform cox regression for arms 1 and 2 
local hr_s2_12 (exp(_b[2.trt])) 
gen hr_s2_12 = `hr_s2_12' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_12 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_12 > 1 in 1 
replace p_s2_12 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_12 < 1 in 1 // 
Store p-value according to the value of HR 
 
gen p_s2_13 = . 




if s1_flag == 3 in 1 { // Arm 2 stops, Arm 3 continues 
 
* Censoring survival time as arm dropped and update to incorporate 
recruitment & 
replace stime = `trial_length2'-rectime if stime+rectime > `trial_length2' 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring all events on arm 2 






set obs `ss_s2' 
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gen trt = runiformint(1,2) 
replace trt = 3 if trt==2 
gen rectime = runiform(`time_s1', 8) 
 
* Generate survival data for these patients 
gen u = runiform(0,1) 
gen lambda = `lambda_trt1' if trt==1 
replace lambda = `lambda_trt3' if trt==3 
 
gen stime = -log(u)/lambda 
 
* Generate variable for events 
gen event = 1 
 
* Censoring number of events at 12.914 years as trial length has reduced 
replace event = 0 if stime + rectime > `trial_length2' 
 
* Censoring the survival time 





append using `file2' 
 
 
stset stime if trt==1 | trt==3, failure(event = 1) 
 
* BETWEEN ARMS 1 & ARM 3 
stcox i.trt // perform cox regression for arms 1 and 3 
local hr_s2_13 (exp(_b[3.trt])) 
gen hr_s2_13 = `hr_s2_13' in 1 // store the HR 
sts test trt, logrank 
gen p_s2_13 = (chi2tail(r(df), r(chi2)))/2 if hr_s2_13 > 1 in 1 
replace p_s2_13 = 1-((chi2tail(r(df), r(chi2)))/2) if hr_s2_13 < 1 in 1 // 
Store p-value according to the value of HR 
 
gen p_s2_12 = . 





if s1_flag == 4 in 1 { // Both arm stops 
 
gen hr_s2_12 = . 
gen p_s2_12 = . 
gen hr_s2_13 = . 





* Storing number of patients and events on each arm at stage 1 
* Patients 
quietly: tab trt, matcell(trt_s2_) 
quietly: gen trt_s2_1 = trt_s2_[1,1] in 1 
quietly: gen trt_s2_2 = trt_s2_[2,1] in 1 





quietly: tab event trt if event==1, matcell(event_s2_) 




* Simulate the data 100 times, show number of patients, treatment, hr and 
p-values 
set seed 130933 
simulate trt_s1_1 = trt_s1_1 trt_s1_2 = trt_s1_2 trt_s1_3 = trt_s1_3 /// 
event_s1_1 = event_s1_1 event event_s1_2 = event_s1_2 event_s1_3 = 
event_s1_3 /// 
hr_s1_12 = hr_s1_12 hr_s1_13 = hr_s1_13 /// 
p_s1_12 = p_s1_12 p_s1_13 = p_s1_13 /// 
hr_s2_12 = hr_s2_12 hr_s2_13 = hr_s2_13 /// 
p_s2_12 = p_s2_12 p_s2_13 = p_s2_13 /// 
s1_flag = s1_flag /// 
trt_s2_1 = trt_s2_1 trt_s2_2 = trt_s2_2 trt_s2_3 = trt_s2_3 /// 








* Look at the means for different s1_flags 
 
* First stage 
ci means trt_s1_1 trt_s1_2 trt_s1_3 event_s1_1 event_s1_2 event_s1_3 
event_s2_1 event_s2_2 
event_s2_3 hr_s1_12 hr_s1_13 p_s1_12 p_s1_13 
 
* Looking at both arms continues (s1_flag =1 ) 
ci means trt_s2_1 trt_s2_2 trt_s2_3 event_s2_1 event_s2_2 event_s2_3 
hr_s2_12 hr_s2_13 p_s2_12 
p_s2_13 if s1_flag==1 
 
* Looking at only arm 2 continues (s1_flag = 2) 
ci means trt_s2_1 trt_s2_2 event_s2_1 event_s2_2 hr_s2_12 p_s2_12 if 
s1_flag==2 
 
* Looking at only arm 3 continue (s1_flag = 3) 




* Assessing the simulations out of total simulations 
 
* Type 1 error under H0 and Type II error under H0 at stage 1 
 
count if hr_s1_12 <= 1.191 
count if hr_s1_13 <= 1.191 
 
* Type 1 error under H0 and Type II error under H0 at final stage 
 
count if hr_s2_12 <= 1.109 
count if hr_s2_13 <= 1.109 
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Appendix 9: Simulation results for DEVA_SUP 
Trial Scenario Stage 
Nstage Type I 
error  
Simulated Type I 
error 
Nstage 
Power Simulated Power 
Nstage Control arm 
events 
No. Control arm 
events 
DEVA_SUP 
1 1 0.50 0.498 (0.488 - 0.508) 0.950 96.1% (95.7% - 96.5%) 12 12 
Final* 0.024 0.028 (0.025 - 0.031) 0.880 89.0% (88.4% - 89.6%)  35 34 
2 1 0.05 0.051 (0.047 - 0.055) 0.900 90.6% (90.0% - 91.2%) 7 7 
Final* 0.044 0.050 (0.046 - 0.054) 0.844 84.6% (83.9% - 85.3%) 29 29 
3 1 0.25 0.256 (0.247 - 0.265) 0.900 90.6% (90.0% - 91.2%) 14 14 
Final* 0.044 0.054 (0.050 - 0.058) 0.823 82.3% (81.6% - 83.0%) 24 23 





Appendix 10: Results from the sample size calculation for DEVA_NI and QUASAR 
2_NI MAMS trials.  
Trial Results 
3A2S 4A3S 5A4S 
Stage Stage Stage 





    
0.021 
      
0.021 
Pairwise Power 0.87 0.86 0.85 
Critical HR 1.188 1.070 1.188 1.13 1.07 1.188 1.13 1.107 1.07 
Time  5.9 7.6 5.6 8.0 12.3 4.6 6.6 8.0 9.5 
Sample Size 4995 6760 7043 10087 10120 10505 15005 18236 18240 
CA Patients 1665 2253 1761 2522 2530 2101 3001 3647 3648 






    
0.021 
      
0.021 
Pairwise Power 0.87 0.86 0.85 
Critical HR 1.305 1.111 1.305 1.208 1.111 1.305 1.208 1.169 1.111 
Time  4.8 11.6 4.6 6.5 9.9 4.3 6.1 7.3 8.7 
Sample Size 2755 3185 3828 5459 5460 5105 7276 8811 9000 
CA Patients 918 1062 957 1365 1365 1021 1455 1762 1800 




Appendix 11: MAMS designs with strong control of the FWER applied with 
different absolute NI margins 
2% absolute NI margin 
 end of do-file
. 
END OF NSTAGE
 ** Events are for the same outcome at all 3 stages
    for those arms to which patients are still being recruited
 ** Events are cumulative across stages, but are only displayed
 *  Patients are cumulative across stages
                                    
Events**      2452      613     1839
Patients*    10500     2625     7875
Acc. rate     1500      375     1125
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 3         
Events**      1188      297      891
Patients*    10485     2621     7864
Acc. rate     1500      375     1125
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 2         
Events**       599      149      450
Patients*     7340     1835     5505
Acc. rate     1500      375     1125
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 1         
Sample size and number of events
     expressed in cumulative periods.
     assumes survival times are exponentially distributed. Time is
 **  Length (duration of each stage) is expressed in  periods and
 *   All alphas are one-sided
Note: patient accrual stopped at time  7.000
                                                                             
Familywise Error Rate (SE)   0.0443 (0.0004)
Pairwise Error Rate          0.0171              Pairwise Power   0.8562
                                                                             
3           0.0200    0.900    1.210    1.000    1.076    4.154   11.144
2           0.2500    0.950    1.210    1.000    1.145    2.098    6.991
1           0.5000    0.950    1.210    1.000    1.210    4.893    4.893
                                                                             
Stage  Alpha(LOB)*    Power    HR H0    HR H1  Crit.HR Length**   Time**
                                                                             
Operating characteristics
Median survival time: 19.7 time units
Note: I outcome and D outcome are identical
                                                                 
(2019) Clinical Trials 16(2)
based on Royston et al. (2011) Trials 12:81 and Blenkinsop et al.
Sample size for a 4-arm 3-stage trial with time-to-event outcome
                                                                 
n-stage trial design                    version 4.0.1, 2 Nov 2018
> ) accrue(1500 1500 1500) arms(4 4 4) t(3 3) s(0.9 0.9) tstop(7)










 ** Events are for the same outcome at all 3 stages
    for those arms to which patients are still being recruited
 ** Events are cumulative across stages, but are only displayed
 *  Patients are cumulative across stages
                                    
Events**      1156      289      867
Patients*     4971     1243     3728
Acc. rate      710      178      533
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 3         
Events**       560      140      420
Patients*     4952     1238     3714
Acc. rate      710      178      533
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 2         
Events**       287       71      216
Patients*     3487      872     2615
Acc. rate      710      178      533
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 1         
Sample size and number of events
     expressed in cumulative periods.
     assumes survival times are exponentially distributed. Time is
 **  Length (duration of each stage) is expressed in  periods and
 *   All alphas are one-sided
Note: patient accrual stopped at time  7.000
                                                                             
Familywise Error Rate (SE)   0.0441 (0.0004)
Pairwise Error Rate          0.0171              Pairwise Power   0.8572
                                                                             
3           0.0200    0.900    1.320    1.000    1.113    4.134   11.110
2           0.2500    0.950    1.320    1.000    1.218    2.066    6.976
1           0.5000    0.952    1.320    1.000    1.320    4.910    4.910
                                                                             
Stage  Alpha(LOB)*    Power    HR H0    HR H1  Crit.HR Length**   Time**
                                                                             
Operating characteristics
Median survival time: 19.7 time units
Note: I outcome and D outcome are identical
                                                                 
(2019) Clinical Trials 16(2)
based on Royston et al. (2011) Trials 12:81 and Blenkinsop et al.
Sample size for a 4-arm 3-stage trial with time-to-event outcome
                                                                 
n-stage trial design                    version 4.0.1, 2 Nov 2018
> ) accrue(710 710 710) arms(4 4 4) t(3 3) s(0.9 0.9) tstop(7)
. nstage, nstage(3) alpha(0.5 0.25 0.02) omega(0.95 0.95 0.9) hr0(1.32 1.32) hr1(1 1
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 ** Events are for the same outcome at all 3 stages
    for those arms to which patients are still being recruited
 ** Events are cumulative across stages, but are only displayed
 *  Patients are cumulative across stages
                                    
Events**       696      174      522
Patients*     3010      752     2258
Acc. rate      430      108      323
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 3         
Events**       340       85      255
Patients*     3004      751     2253
Acc. rate      430      108      323
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 2         
Events**       175       43      132
Patients*     2111      528     1583
Acc. rate      430      108      323
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 1         
Sample size and number of events
     expressed in cumulative periods.
     assumes survival times are exponentially distributed. Time is
 **  Length (duration of each stage) is expressed in  periods and
 *   All alphas are one-sided
Note: patient accrual stopped at time  7.000
                                                                             
Familywise Error Rate (SE)   0.0446 (0.0004)
Pairwise Error Rate          0.0172              Pairwise Power   0.8580
                                                                             
3           0.0200    0.900    1.430    1.000    1.147    4.075   11.059
2           0.2500    0.951    1.430    1.000    1.289    2.075    6.985
1           0.5000    0.952    1.430    1.000    1.430    4.910    4.910
                                                                             
Stage  Alpha(LOB)*    Power    HR H0    HR H1  Crit.HR Length**   Time**
                                                                             
Operating characteristics
Median survival time: 19.7 time units
Note: I outcome and D outcome are identical
                                                                 
(2019) Clinical Trials 16(2)
based on Royston et al. (2011) Trials 12:81 and Blenkinsop et al.
Sample size for a 4-arm 3-stage trial with time-to-event outcome
                                                                 
n-stage trial design                    version 4.0.1, 2 Nov 2018
> ) accrue(430 430 430) arms(4 4 4) t(3 3) s(0.9 0.9) tstop(7)
. nstage, nstage(3) alpha(0.5 0.25 0.02) omega(0.95 0.95 0.9) hr0(1.43 1.43) hr1(1 1
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 ** Events are for the same outcome at all 3 stages
    for those arms to which patients are still being recruited
 ** Events are cumulative across stages, but are only displayed
 *  Patients are cumulative across stages
                                    
Events**       480      120      360
Patients*     2065      516     1549
Acc. rate      295       74      221
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 3         
Events**       232       58      174
Patients*     2055      514     1541
Acc. rate      295       74      221
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 2         
Events**       123       30       93
Patients*     1461      365     1096
Acc. rate      295       74      221
Arms             4        1        3
           Overall  Control   Exper.
                    Stage 1         
Sample size and number of events
     expressed in cumulative periods.
     assumes survival times are exponentially distributed. Time is
 **  Length (duration of each stage) is expressed in  periods and
 *   All alphas are one-sided
Note: patient accrual stopped at time  7.000
                                                                             
Familywise Error Rate (SE)   0.0450 (0.0004)
Pairwise Error Rate          0.0172              Pairwise Power   0.8600
                                                                             
3           0.0200    0.902    1.540    1.000    1.181    4.139   11.104
2           0.2500    0.951    1.540    1.000    1.359    2.012    6.965
1           0.5000    0.954    1.540    1.000    1.540    4.953    4.953
                                                                             
Stage  Alpha(LOB)*    Power    HR H0    HR H1  Crit.HR Length**   Time**
                                                                             
Operating characteristics
Median survival time: 19.7 time units
Note: I outcome and D outcome are identical
                                                                 
(2019) Clinical Trials 16(2)
based on Royston et al. (2011) Trials 12:81 and Blenkinsop et al.
Sample size for a 4-arm 3-stage trial with time-to-event outcome
                                                                 
n-stage trial design                    version 4.0.1, 2 Nov 2018
> ) accrue(295 295 295) arms(4 4 4) t(3 3) s(0.9 0.9) tstop(7)
. nstage, nstage(3) alpha(0.5 0.25 0.02) omega(0.95 0.95 0.9) hr0(1.54 1.54) hr1(1 1
360 
 
Appendix 12: MAMS designs with strong control of the PWER applied with 
different absolute NI margins 
2% absolute NI margin  
361 
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